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Abstract
Central serotonergic neurones control reflex parasympathetic outflow to the heart, 
airways and bladder in a number of species, and different 5-HT receptor subtypes are 
involved in this effect. 5-HTja and 5 -HT3 receptors in the brainstem facilitate these 
reflexes, whilst 5-HTjb/id, 5-HT2 and 5 -HT4 receptors inhibit them. Recently, central 
5 -HT7 receptors have been implicated in bladder reflexes.
Experiments on anaesthetised rats showed that the selective 5-HT7 receptor 
antagonists SB-269970 and SB-656104, given intracistemally (i.e.), attenuated 
cardiopulmonary, baroreflex and chemoreflex bradycardias. Similarly, the selective 
5-HTia receptor antagonist WAY-100635 attenuated cardiopulmonary and 
chemoreflex (but not baroreflex) bradycardia, whilst robalzotan and (-)-pindolol 
(antagonists at 5-HT 1 a receptors) had no effect on cardiopulmonary and baroreflex 
bradycardias respectively.
Chemical stimulation of presumed^ serotonergic cell bodies in raphe magnus/pallidus 
evoked a bradycardia that could not be attenuated either by 5-HT receptor 
antagonists (given i.v.) or by prior 5-HT depletion. The latter did, however, 
significantly attenuate cardiovascular reflex sensitivity.
Activation of nucleus tractus solitarius (NTS) neurones by the vagus was inhibited 
by the iontophoretic AMPA receptor antagonist DNQX or by topical SB-269970. 
Subsequent histology suggested that 5-HT containing terminals do not make close 
appositions with these neurones.
Preliminary data demonstrate that SB-269970 (given i.e.) effectively attenuates the 
cardiopulmonary reflex in awake rats, but has variable effects on the chemoreflex.
The data suggest that 5-HT7 receptors in the NTS are crucially involved in the central 
transmission of reflex bradycardias, at least in rats. The role of the 5-HTia receptor is 
less clear-cut than in the rabbit, and may reveal a species difference. The origin of 5- 
HT activating these receptors is unlikely to be the medullary raphe neurones, but 
may be primary afferents terminating in the NTS. Since recent ultrastructural 
evidence shows 5-HT terminals and NTS cardiovascular neurones are often 
separated by astroglial leaflets, astrocytes may be involved in serotonergic- 
glutamatergic signalling.
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1. G e n e r a l  i n t r o d u c t i o n
1.1. The autonomic nervous system
Langley’s highly influential monograph entitled The Autonomic Nervous System 
(Langley, 1921) laid the foundation of our current understanding of the tandem 
sympathetic and parasympathetic systems controlling physiological processes, and 
was indebted to the prior works of Gaskell, Bayliss and Starling at the end of the 19th 
century. The autonomic nervous system is currently divided into three subdivisions: 
the sympathetic system and the parasympathetic system (both of which have 
neuronal cells bodies located in both the central (CNS) and peripheral nervous 
sytem), and the enteric system (whose neurones are located exclusively in the walls 
of the gut).
Both sympathetic and parasympathetic neurones provide a two-neurone motor output 
to various targets: a preganglionic neurone located in the CNS, and a postganglionic 
neurone, whose cell body is located in a ganglion, and whose axon innervates the 
target organ. Sympathetic ganglia are located in the paravertebral chains on either 
side of the spinal cord (levels T1 to L3), and are innervated by the preganglionic 
neurones in the intermediolateral (IML) cell columns of the spinal cord. In this 
system, the cell bodies of the postganglionic neurones are located close to those of 
the preganglionic neurones, and at a distance from the target organ. Conversely, 
parasympathetic ganglia are located on or close to the target organ, and are 
innervated by preganglionic neurones located in either the midbrain/brainstem 
(nuclei of cranial nerves III, VII, IX and X) or the sacral spinal cord (IML at levels 
S2 -  S4).
All preganglionic neurones communicate with postganglionic neurones by releasing 
acetylcholine, which acts primarily on nicotinic receptors. Sympathetic 
postganglionic neurones release noradrenaline onto a and p adrenoceptors in the 
target organs (except for sweat glands, where the innervation is cholinergic via 
muscarinic receptors). Parasympathetic postganglionic neurones release 
acetylcholine onto muscarinic receptors in the target organ. Additionally, other
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transmitters such as peptides and purines act as co-transmitters (see Bumstock, 1986; 
Lundberg & Hokfelt, 1986).
Sympathetic nerves innervate structures at many different levels, for example the 
heart and lungs via the superior cervical and stellate ganglia, the stomach via the 
coeliac ganglion, and the lower intestine via the inferior mesenteric ganglion. 
Similarly parasympathetic nerves innervate a range of structures: in the midbrain, 
the Edinger-Westphal nucleus innervates the ciliary ganglion of the eye via the IIIrd 
nerve. In die medulla, the salivatory nuclei innervate the lachrymal, nasal and 
parotid glands via the VIIth and IXth nerves, whereas the dorsal vagal nucleus (DVN) 
and nucleus ambiguus innervate the heart, lungs and gut via the Xth nerve. Finally
i.
the sacral IML innervates the colon, bladder and reproductive organs via the pelvic 
splanchnic nerve.
1.2. The cardiovascular system
The cardiovascular system is regulated by both peripheral and central neural 
structures, which are responsible for maintaining the internal environment of the 
body. Hence the central cardiovascular centres regulate the heart and vasculature, 
and work closely with the respiratory system. Together, these systems are under the 
control of various sets of sensory receptors, leading to a number of complex 
feedback loops known as cardiovascular and respiratory reflexes (see Spyer, 1990). 
Blood pressure (BP), cardiac output, blood volume, and blood gas tensions are 
regulated and constantly monitored by peripheral sensors, whose activation produces 
the appropriate neural or endocrine compensatory reponses. These receptors are 
broadly divided into mechanoreceptors and chemoreceptors. Mechanoreceptors 
detect mechanical force (usually stretch), such as arterial pressure (baroreceptors) in 
the aortic arch and carotid sinus; additionally, cardiac mechanoreceptors are located 
in the atria and ventricles and in the endings of great veins (see Spyer, 1990). 
Chemoreceptors are sensitive to the chemical environment, in particular to O2 and 
CO2 tensions and pH of arterial blood. These are located in the carotid body, and 
also on the ventral surface of the medulla, and together function to adjust ventilation 
and modulate cardiovascular variables accordingly (see Daly, 1997). These 
receptors relay information to the CNS where reflex responses are integrated. The
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interactions between reflexes should not be underestimated: in vivo, different sets of 
afferents are often activated simultaneously. Furthermore, the reflex response to one 
afferent often activates a secondary reflex.
1.2.1. Parasympathetic control of the heart
Parasympathetic (vagal) drive has powerful negative chronotropic and inotropic 
actions on the heart, which in mammals is under a low to moderate level of tonic 
vagal influence. Hence withdrawal of vagal tone in itself causes a small tachycardia, 
whilst enhancement can cause a profound bradycardia up to and including 
atrioventricular block.
The vagus (Xth) nerve is the longest nerve in the body, exiting from the medulla, and 
taking a characteristic ‘wandering’ course through many parts of the thoracic and 
abdominal viscera. It is a mixed nerve consisting primarily of afferent fibres (80 % 
in the cat, with cell bodies in the nodose ganglia) as well as efferent fibres, which are 
the axons o f parasympathetic (vagal) preganglionic neurones (see Daly, 1997).
Cardiac vagal preganglionic neurones 
The location of vagal preganglionic neurones was first investigated by analysis of 
retrograde degeneration following vagotomy, which located vagal preganglionic 
neurones in the nucleus ambiguus (Bunzl-Fedem, 1899) and DVN (Getz & Simes, 
1949). Later the horseradish peroxidase (HRP) technique allowed retrograde 
labelling of specific neurones projecting to the heart (cardiac vagal preganglionic 
neurones; CVPNs) in rats (Nosaka et a l, 1979; Stuesse, 1982), cats (Kalia & 
Mesulam, 1980) and dogs (Bennett et a l , 1981), which were organised in two main 
cell groups, the DVN and nucleus ambiguus, but with a number of neurones scattered 
between these areas, as if not fully migrated to the nucleus ambiguus. CVPNs were 
found in more ventral parts of the nucleus ambiguus, but not in the cell columns 
innervating the striated muscles of the oesophagus, larynx and pharynx (Bieger & 
Hopkins, 1987). In the DVN, which also contains numerous gastrointestinal vagal 
preganglionic neurones, the CVPNs retrogradely labelled from the heart are mostly 
found in the lateral parts of the nucleus (Nosaka et a l , 1979; Bennett et a l , 1981), 
but in mammals this is thought to be a smaller population, the chief cardiac 
parasympathetic innervation arising from the nucleus ambiguus.
20
Projections to the nucleus ambiguus, identified by microinjection of HRP into parts 
of the nucleus that slowed the heart, are mainly from the ipsilateral medial nucleus of 
the tractus solitarius (NTS), but also from the parabrachial complex, the 
paraventricular nucleus of the hypothalamus (PVN), and the contralateral nucleus 
ambiguus (Stuesse & Fish, 1984), and ultrastructural analysis has shown the 
projection from the NTS to be monosynaptic (Deuchars & Izzo, 1991). Additionally, 
CVPNs receive synapses from terminals containing y-aminobutyric acid (GABA) 
(Maqbool et a l, 1991), 5-hydroxytryptamine (5-HT, serotonin) (Izzo et al., 1993), 
and substance P (Massari et a l, 1994).
Electrophysiological identification of cat CVPNs via antidromic stimulation of the
i.
cardiac branch of the vagus found that DVN neurones almost exclusively give rise to 
small diameter unmyelinated (C-fibre) efferents, whilst nucleus ambiguus neurones 
have small diameter myelinated (B-fibre) efferents (McAllen & Spyer, 1976). 
Further investigation found that nucleus ambiguus CVPNs are excited by 
baroreceptors, whereas nearby vagal bronchoconstrictor neurones are not (McAllen 
& Spyer, 1978). In the rabbit, some B-fibres also project from the DVN, but only B- 
fibres project from nucleus ambiguus (Jordan et a l, 1982). Similarly, in the rat C- 
fibres originate from DVN, whilst B-fibres originate from nucleus ambiguus (Nosaka 
et al., 1982).
Rabbit and cat nucleus ambiguus CVPNs have a low spontaneous firing rate with a 
strong respiratory rhythm, firing during the post-inspiratory phase, and strongly 
inhibited during inspiration, which accounts for respiratory sinus arrthymia -  the 
variability of heart rate (HR) during the respiratory cycle (McAllen & Spyer, 1976; 
McAllen & Spyer, 1978; Jordan et a l, 1982; Gilbey et a l, 1984). These studies also 
confirmed the powerful excitation of these neurones from baroreceptors, hence their 
ongoing activity strongly correlates with arterial pressure pulses. However, 
baroreceptors (and chemoreceptors) can only excite cardiac vagal outflow if they are 
timed during expiration (Haymet & McCloskey, 1975; Davidson et a l, 1976b), 
demonstrating that baroreceptor modulation of CVPNs is itself respiratory 
modulated. This inspiratory inhibition is attenuated by iontophoresis of atropine, 
whilst acetylcholine reduces firing (Gilbey et a l, 1984) suggesting a muscarinic 
receptor mechanism.
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Figure 1.1 Central autonomic afferent and efferent systems
Schematic sagittal diagrams of rat brain (adapted from Saper, 2004) illustrating cell 
groups involved in central autonomic processing, and their main afferent and efferent 
connections.
Ascending: central cells groups receive afferent information either from the NTS 
(solid line) or indirectly via a relay in the parabrachial nucleus (dotted line)
Descending: Preganglionic cell groups (grey) receive direct innervation from various 
cells groups (solid line) and indirect inputs via premotor areas (dotted line).
A5 A5 noradrenaline group
Amyg Central nucleus of the amygdala
AV Anteroventral third ventricular area
BST Bed nucleus of the stria terminalis
DVN Dorsal vagal nucleus
ILC Infralimbic cortex
IML Intermediolateral cell column
Ins Insular cortex
LH Posterior lateral hypothalamus
nA Nucleus ambiguus
NTS Nucleus tractus solitarius
PB Parabrachial nucleus
PVN Paraventricular nucleus
Thai Ventroposterior parvocellular nucleus of the thalamus
VLM Ventrolateral medulla
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CVPNs in the DVN of rats and cats fire at a slow tonic rate that is not modulated by 
respiration or baroreceptors, but they are excited by cardiopulmonary afferents 
(Nosaka et a l, 1982; Nosaka, 1986; Jones et a l , 1998). A population of these 
neurones also receive a powerful and long lasting inhibition from cardiac afferents 
(Ford etal., 1990).
The role of this dual B- and C-fibre innervation of the heart remains unresolved. It 
was assumed that B-fibres have negative chronotropic, whilst C-fibres have negative 
inotropic and coronary blood flow effects, although the latter is difficult to 
demonstrate as chronotropic changes will induce changes in the other variables. 
However, C-fibre efferents can be selectively stimulated using a triangular pulse 
anodal block technique, because they conduct slower than B-fibres. Selective C-fibre 
stimulation causes a slowing of the heart in rats, rabbits and cats (Woolley et a l, 
1987; Jones et a l, 1995b), although this is smaller and slower in onset than the 
profound chronotropic effect due to B-fibre activation. It was later shown that C- 
fibre efferents also decrease atrioventricular conduction and contractility of the heart 
in rabbits (Garcia Perez & Jordan, 2001).
Cardiac vagal postganglionic neurones 
Cardiac vagal postganglionic neurones have been extensively examined anatomically 
in the dog (Randall & Ardell, 1985; Randall et a l, 1986; Randall et a l, 1987), 
revealing a number of different ganglia usually embedded in fat pads around the vena 
cava, right pulmonary vein, interarterial groove and septum. Removing the fat pad at 
the junction of the inferior vena cava and left atrium abolished atrioventricular block 
due to vagal stimulation (Randall et a l, 1986), whereas removal of the fat pad over 
the right pulmonary vein attenuated vagal bradycardia without affecting 
atrioventricular block (Randall et a l, 1987), suggesting differential innervation of 
cardiac nodes. Vagal bradycardias are generally blocked by atropine, but the C-fibre 
efferent-evoked bradycardia is resistant to ganglionic blockade with hexamethonium 
(Ford & McWilliam, 1986) and chlorisondamine (Jones & Jordan, 1993), 
demonstrating that muscarinic as well as nicotinic mechanisms are present at the 
ganglia.
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1.2.2. Sympathetic control of the vasculature
Sympathetic preganglionic neurones
Sympathetic preganglionic neurones (SPNs) are found predominantly in the IML of 
the spinal cord, where their cytoarchitecture was first described following their 
identification by rhizotomy (Petras & Cummings, 1972). SPNs are also found in the 
adjacent white matter of the lateral funiculus, in the intercalated cell columns 
between IML and the central canal, and dorsolateral to the central canal, also called 
the central autonomic nucleus (see Coote, 1988). SPNs tend to group together in 
clusters or ‘nests’ (Oldfield & McLachlan, 1981), with long dendrites extending 
mainly rostrocaudally (which ihay encourage entrainment of their rhythm with other 
spinal cord levels) but also laterally. The innervation of sympathetic ganglia was 
extensively studied using the retrograde fluorogold method, and found that each 
ganglion is innervated by several spinal cord segments, although one segment 
provides the principal innervation (Strack et a l, 1988) A separate investigation 
suggests that each SPN is specific to a particular ganglion (Appel & Elde, 1988). It 
is generally accepted that sympathetic outflows to different vascular beds are quite 
independent, and that each has its own functional properties (see Janig, 1988). This 
allows blood flow in different parts of the body to be separately adjusted without 
sympathetic outflow necessarily being globally modulated.
Sympathetic premotor neurones 
A variety of neurones have been identified as providing control of SPNs from the 
brainstem or forebrain, and these are generally termed sympathetic premotor 
neurones. Anatomical tracing reveals that these neurones are found predominantly in 
the rostral ventrolateral medulla (RVLM) and medullary raphe nuclei (Amendt et al., 
1979; Loewy, 1981; Strack et al., 1989), although the PVN and A5 noradrenaline 
cells also project to SPNs (Strack et al., 1989). The role of raphe nuclei is described 
in 1.5.2 below.
The RVLM was first implicated in BP control when transections of the medulla or 
spinal cord at or below the RVLM were found to elicit a substantial fall in BP 
(Dittmar, 1873). Chemical inhibition of the RVLM via ventral surface applications
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causes a similar fall (Guertzenstein & Silver, 1974; Feldberg & Guertzenstein, 1976), 
suggesting that the maintenance of BP by SPNs depends on a tonic excitation from 
RVLM neurones. Chemical stimulation of the RVLM causes a profound 
hypertension in anaesthetised (Dampney et a l, 1985; McAllen, 1986) and awake 
animals (Bachelard et al., 1990). Neurones in the RVLM are organised 
topographically with respect to different vascular beds but not different body regions 
(McAllen & Dampney, 1990).
The RVLM is heavily innervated by the NTS (Loewy & Burton, 1978; Ross et a l, 
1985), forming a major reflex pathway, and also by the area postrema (Shapiro & 
Miselis, 1985; Ross et a l, 1985) which may relay information on circulating 
hormones to the RVLM. There are also major inputs to the RVLM from the 
periaqueductal grey (Carrive et a l, 1988), the PVN and lateral hypothalamic area 
(Dampney et a l, 1987), which are thought to be involved in reflex modulation and 
hypertension.
Single unit recordings reveal that there are many barosensitive neurones in the 
RVLM, which have a high rate of discharge ( 1 0 - 2 0  Hz), and these can be divided 
into Type 1 and Type 2, sending slow-conducting and fast-conducting axons to the 
spinal cord respectively (Brown & Guyenet, 1985). Type 1 are inhibited by 
iontophoresis of noradrenaline and the ai adrenoceptor agonist clonidine, whilst 
Type 2 are insensitive to these agents. This suggested that a population of RVLM 
neurones can be inhibited by a noradrenergic pathway, probably from the A5 cell 
group (Sun & Guyenet, 1986). RVLM barosensitive neurones fire in strong 
correlation with BP pulses, firing only during the BP trough; the lowest probability 
of firing was calculated to be -65 ms after the ECG R-wave, and ~25 ms after the 
discharge of a barosensitive NTS neurone, suggesting that this intramedullary 
pathway is very slow (-0.4 m s '1) (Moore & Guyenet, 1983), as was reported for the 
cardiac limb of the baroreflex (McAllen & Spyer, 1978). Barosensitive RVLM 
neurones have an intrinsic pacemaker discharge, which appears independent of 
external inputs. Intracistemal (i.e.) administration of the glutamate receptor 
antagonist kynurenic acid abolishes reflex changes in their firing rate, but their 
intrinsic rhythm persists, and it is also seen in vitro in the rat perfused bulb 
preparation (Sxmetal., 1988).
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input output
Figure 1.2 NTS microcircuitry
Schematic diagram of NTS (adapted from Spyer, 1994) based on intracellular 
recordings, illustrating some of the possible projections of primary afferents (input) 
to various NTS neurones (black circles and red circle which is an intrinsic 
GABAergic intemeurone) and their possible connectivity. Green projections are 
excitatory, red are inhibitory.
The postsynaptic potentials evoked by afferent stimulation are shown in each cell:
+ excitatory postsynaptic potential (EPSP)
-  inhibitory postsynaptic potential (IPSP)
± EPSP followed by IPSP
1.2.3. The nucleus tractus solitarius
The NTS is the principal site of termination of an array of visceral primary afferent 
fibres including arterial baroreceptors, chemoreceptors and lung stretch afferents (see 
Spyer, 1990). Together these provide moment to moment information on the 
pressure in arteries and great veins, and on the chemical composition of arterial 
blood. As such, the NTS is an essential integrator of cardiovascular reflexes, whose 
pathways are described in detail in 1.3 below.
The NTS is a sensory nucleus running longitudinally in the dorsomedial region of the 
medulla, and can be seen as the autonomic equivalent of the dorsal horn of the spinal 
cord. The NTS is centred around the level of the area postrema, and extends for a 
short distance caudally from the calamus scriptorius (caudal tip of the area postrema) 
and rostrally from the obex (caudal border of the IVth ventricle). Hence it is divided 
into three rostrocaudal portions: rostral (above the obex), intermediate (at the level of 
the area postrema), and caudal (below the calamus scriptorius). The intermediate 
NTS is just ventral to the dorsal column nuclei, and just dorsal to the DVN and 
hypoglossal nuclei. Vagal afferents terminate primarily in the caudal two-thirds of 
the NTS, whilst glossopharyngeal afferents terminate primarily in the rostral two- 
thirds. Mediolaterally it can also be divided into medial, commisural, and lateral 
segments. Lung stretch afferents terminate mainly in the medial and commisural 
NTS (Donoghue et al., 1982b). The termination of other afferents is discussed in 1.3 
below.
Extracellular and intracellular recordings have been used to assess the degree of 
convergence of different afferents onto NTS neurones (Donoghue et al., 1985). This 
study reported that the majority of NTS cells responding to aortic nerve, sinus nerve, 
or vagal stimulation, respond only to one input, although a low level of convergence 
was found, suggesting that generally a separate neuronal channel is used for each 
afferent type.
The NTS contains a variety of neurones involved in cardiovascular functions, as 
illustrated in Figure 1.2. Second order neurones are innervated by primary afferent 
fibres, and these project to higher order NTS neurones for further processing prior to
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leaving the NTS. A number of intemeurones may also be involved, but this is 
difficult to characterise. These pathways are generally excitatory, although a 
population of intrinsic GABAergic intemeurones are found in the NTS (Izzo et a l, 
1992), which receive primary afferents, as well as projecting to various second order 
neurones (see Spyer, 1994). Hence pathways through the NTS may be influenced by 
a number of excitatory and inhibitory inputs (quite apart from the wealth of 
neurochemical messengers discussed in 1.4 below), resulting in various 
electrophysiological phenotypes. Some neurones display excitatory postsynaptic 
potentials (EPSPs) when afferents are stimulated, some display inhibitory 
postsynaptic potentials (IPSPs), and some displaying an initial EPSP followed by an 
IPSP (Figure 1.2). A frequent problem with single unit recording studies is that the 
NTS neuronal type (second or higher order) is difficult to identify except by 
analysing the varibility of the latency, or by paired pulse activation. These 
techniques yield some information on whether a neurone is mono- or 
polysynaptically activated, but identification is not unequivocal. Therefore, 
microinjections are likely to activate all of these neurones, including inhibitory 
intemeurones. There is much less information on higher order neurones in the NTS: 
there is thought to be some limited convergence via polysynaptic interactions (see 
Jordan & Spyer, 1986), which are under continuing investigation.
The NTS also contains two kinds of respiratory-related neurones: firstly P cells 
(Berger, 1977), which burst fire in phase with lung inflation, and are 
monosynaptically activated by slowly adapting lung stretch afferents (Berger & 
Dick, 1987). Secondly, Ip cells are a subclass of dorsal respiratory group inspiratory 
neurones in the ventrolateral NTS. They are activated when the lungs are held 
inflated during expiration; the cells adapt and are excited by gasping, suggesting 
activation by rapidly adapting lung stretch afferents, but they are also innervated by 
slowly adapting lung stretch afferents (Averill et al., 1984; Backman et al., 1984).
Apart from primary afferents, the NTS receives inputs from all brain levels. These 
include, based on anatomical work, the periaqueductal grey (Bandler & Tork, 1987), 
PVN (van der Kooy et a l, 1984; Patel & Schmid, 1988), amygdala (Schwaber et al.,
1982), frontal cortex (Terreberry & Neafsey, 1983), and raphe (Thor & Helke, 1987; 
Schaffar et al., 1988). Only some of these connections have been functionally
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investigated. NTS neurones are excited by stimulation of the amygdala (Cox et al.,
1986). Stimulation of the parabrachial nucleus causes bradycardia via neurones in 
the commisural NTS (Hamilton et al., 1981), and modulates carotid sinus nerve 
inputs to the NTS (Felder & Mifflin, 1988). Stimulation of the area postrema excites 
NTS neurones (Hay & Bishop, 1991), and stimulation of PVN excites 20 % of NTS 
neurones orthodromically, 2.5 % antidromically, and inhibits 6 % (Kannan & 
Yamashita, 1985). Conversely, stimulation of the hypothalamic defence area inhibits 
most NTS cells, and attenuates carotid sinus nerve inputs (Mifflin et al., 1988). 
Stimulation of the RVLM also inhibits aortic nerve inputs to NTS neurones (Wang & 
Li, 1988) suggesting a reciprocal connection between these nuclei. Anatomical 
projections from the NTS to the parabrachial nucleus (Herbert et al., 1990), the 
hypothalamus and amygdala (Ricardo & Koh, 1978; Riche et al., 1990) have also 
been described, suggesting similar reciprocal connectivity.
1.2.4. The respiratory network
Normal ventilation consists of inspiration and expiration mediated by neuronal 
control of the diaphragm, thorax and abdominal wall, and these neuronal events fall 
into three respiratory phases: inspiration, post-inspiration, and expiration (see Richter 
et al., 1992). The main generators of the respiratory rhythm are located in the 
brainstem, consisting of the ventral respiratory group in the ventrolateral medulla, 
and the dorsal respiratory group in the region of the NTS. The ventral respiratory 
group is considered to contain the premotor neurones that provide most of the 
efferent control of the respiratory muscles (Richter et al., 1992). Neurones in the 
intermediate part of the ventral respiratory group retain respiratory-like activity even 
after blockade of excitatory transmission, suggesting they are pacemaker cells 
(Onimaru et al., 1988). Further pacemaker cells are found in a respiratory related 
area known as the pre-Botzinger complex (Smith et al., 1991). In cats the dorsal 
respiratory group is thought to have a role in transmission of inspiratory drive to 
motor neurones via other groups of respiratory neurones, but in rats the existence of a 
dorsal respiratory group remains controversial, and NTS neurones are believed to 
make a weak contribution to respiratory drive (Bianchi et a l, 1995). In both species, 
however, inspiratory and post-inspiratory neurones form a complex network 
modulating cardiovascular variables (see Figure 1.4).
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1.2.5. Other CNS structures
A variety o f other CNS structures contribute to cardiovascular regulation (see Figure 
1.1). A detailed description of these pathways is beyond the scope of this thesis, but 
they have been recently reviewed in depth (see Saper, 2004), as summarised below.
The parabrachial nucleus is a relay station between the NTS and higher areas, and in 
addition to autonomic afferents, it is involved in nociceptive processing. It is the only 
cardiovascular area to communicate with the thalamus. Various cardiovascular 
effects are evoked by stimulating this nucleus, depending on the area.
The A 5 noradrenaline cells are the origin of the chief descending noradrenergic 
innervation of spinal cord SPNs. Stimulating the A5 area causes hypotension.
The hypothalamus has many autonomic and homeostatic roles. The anteroventral 
third ventricular region participates in functions such as thermoregulation and 
drinking. The PVN has diverse functions including secretion of releasing hormones 
but also has various projections to cardiovascular areas. Stimulating the PVN can 
increase or decrease BP. The lateral hypothalamic area has a sympathoexcitatory 
role, and stimulation causes hypertension and tachycardia.
The central nucleus o f  the amygdala contains neurones that are barosensitive via a 
parabrachial input. Various responses are elicited by amygdala stimulation, but it is 
clearly involved in the conditioned cardiovascular fear response.
Little is known of the cardiovascular functions of the bed nucleus o f  the stria 
terminalis, but there is some evidence that it contains neurones that are sensitive to 
certain cardiovascular stimuli. Stimulation increases gastric motility.
Stimulating the insular cortex can produce hypotension with bradycardia or 
hypertension with tachycardia depending on the area stimulated.
The infralimbic cortex may be a type of visceral motor cortex: stimulation affects 
gastric motility via a hypothalamic relay.
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Figure 1.3 Cardiovascular reflex pathways
Schematic diagrams of rat medulla (at 2 levels) and thoracic spinal cord, illustrating 
main pathways o f reflex responses to baroreceptor and chemoreceptor stimulation. 
Green are excitatory and red are inhibitory pathways. The output at the end organs 
(heart or vasculature) is indicated in terms or a rise ( |)  or fall (f) in heart rate (HR) 
or blood pressure (BP).
CVLM: caudal ventrolateral medulla, nA: nucleus ambiguus, NTS: nucleus tractus 
solitarius, IML: intermediolateral cell column, RVLM: rostral ventrolateral medulla.
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1.3. Cardiovascular reflexes
1.3.1. The baroreflex
Signals from the arterial baroreceptors in the aortic arch and carotid sinuses reflexly 
modulate heart rate, sympathetic vasomotor activity and vasopressin release. As 
such, it is a crucial reflex responsible for maintaining appropriate perfusion of tissues 
by keeping arterial pressure within normal limits. Baroreflex dysfunction is thought 
to be one cause of hypertension, and therefore associated with considerable 
morbidity. At normal BP, baroreceptor afferents fire at a tonic, pulse-related rate, 
allowing reflex changes to occur if the afferent firing rate changes in either direction. 
Similarly, cardiac vagal efferents and sympathetic vasoconstrictor efferents fire at a 
tonic rate, allowing reflex increases or decreases to occur (see Spyer, 1990). When 
BP is elevated, baroreceptor afferents increase their firing rate through stretch 
activation, consequently cardiac vagal fibres increase their firing to lower HR, 
whereas vasoconstrictor fibres slow down. The consequent drop in cardiac output 
and total peripheral resistance helps return BP to baseline. Conversely, when arterial 
pressure drops (also called baroreceptor unloading) baroreceptor afferents slow 
down, vagal drive diminishes and sympathetic tone increases, causing tachycardia 
and vasoconstriction.
Experimentally, baroreflex responses can be elicited by artificially modulating BP. 
This is usually done with vasoactive substances, such as the vasoconstrictor 
phenylephrine, and the vasodilator sodium nitroprusside. Brief mechanical 
manipulations are also possible, such as occlusion of the abdominal aorta, which 
raises BP, or occlusion of the common carotid arteries, which unloads carotid sinus 
baroreceptors. The problem with these techniques is that changing BP can itself 
modulate respiration, alter the perfusion of the brain, and cause local cardiac 
reflexes. A more elegant technique is the electrical stimulation of afferent nerves, 
particularly the aortic nerve (Sapru et a l, 1981), which in the rat has mainly 
baroreceptor afferents, although recently some chemoreceptor afferents have been 
identified (Brophy et a l, 1999).
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In the rabbit and cat, mapping of aortic nerve baroreceptor afferents using retrograde 
labelling from the nodose ganglion and antidromic mapping found that they project 
to the ipsilateral medial, lateral and ventrolateral NTS in the cat, and to the medial 
and lateral NTS in the rabbit (Donoghue et al., 1982a). This study identified only 
myelinated fibres. Subsequent mapping of carotid sinus baroreceptor fibres with cell 
bodies in the petrosal ganglion reported that they project to the ipsilateral lateral NTS 
rostral to the obex via both myelinated and unmyelinated fibres (Donoghue et al., 
1984). Previously baroreceptor afferents had been characterised as both myelinated 
(A-fibres) and unmyelinated (C-fibres) (Coleridge & Coleridge, 1980), the latter 
(from the aortic wall) having a threshold of activation of 30 -  50 mmHg higher than 
A-fibres, a lower maximum discharge rate, and as such probably important for 
responses to sudden large pressure changes, whilst A-fibres regulate pressure under 
normal conditions (Thoren & Jones, 1977; Coleridge & Coleridge, 1977). Single 
carotid baroreceptor afferent fibres also consist of two types: Type I and Type II 
(Seagard et a l, 1993). Type I (A-fibres) have a high threshold for activation over a 
narrow range; Type II (C-fibres) have a low threshold, and operate over a wide range 
of pressures. Some myelinated Type II fibres also exist.
Baroreceptor resetting is a mechanism reported to occur in hypertension, 
characterised by an increase in the threshold and a reduction in the sensitivity and 
maximum frequency of impulses of baroreceptor fibres (Coleridge & Coleridge,
1980). More resetting was reported to occur in A-fibres than C-fibres (Jones & 
Thoren, 1977), and greater resetting occurs during chronic hypertension (Jones, 
1977), highlighting the importance of early treatment. A reduced flexibility of 
arterial walls at least partly accounts for reduced baroreceptor responsiveness in 
chronic hypertension, although more complex transductional and indeed central 
mechanisms are also thought to contribute.
The central pathways of the baroreflex involve medullary and spinal structures (see 
Figure 1.3). Midline electrolytic lesions in the medulla had no effect on baroreflex 
function, nor did decerebration or lower pontine transection, whilst DVN and nucleus 
ambiguus lesions abolished the bradycardia (Lee et al., 1972). This suggests that 
neither the medullary raphe nor more rostral brainstem or forebrain structures are 
involved in this reflex per se, although various supraspinal areas can modulate the
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baroreflex. The cardiac component of the baroreflex may involve a monosynaptic 
pathway from NTS to nucleus ambiguus (Deuchars & Izzo, 1991). DVN neurones 
are not barosensitive, and therefore not involved in baroreflex bradycardia (Jones et 
al., 1998). The symathetic component of the baroreflex involves an excitatory 
pathway from NTS to the caudal ventrolateral medulla (CVLM), followed by an 
inhibitory projection from CVLM to RVLM (Guyenet et al., 1987; Terui et al., 1990; 
Masuda et al., 1991). Hence baroreflex sympathoinhibition involves switching off 
the tonic activity of RVLM, and consequently IML neurones, whereas baroreflex 
sympathoexcitation (during baroreceptor unloading) involves inhibition of the tonic 
brake imposed by the CVLM.
Within the NTS, glutamate is thought to be the primary neurotransmitter. 
Micro injection of glutamate (Talman et al., 1980; Leone & Gordon, 1989) or NMDA 
(Kubo & Kihara, 1988b) into the NTS causes bradycardia and hypotension in 
anaesthetised rats, and bilateral microinjections of non-selective glutamate receptor 
antagonists strongly inhibit the baroreflex (Talman et al., 1981; Guyenet et al., 1987; 
Leone & Gordon, 1989). Interestingly, these researchers report hypertension after 
blockade of NTS glutamate receptors, illustrating the importance of the NTS in 
maintaining normal BP. In awake rats, both AMP A and NMDA receptors in the 
NTS (Machado, 2001) but not metabotropic glutamate receptors (Antunes & 
Machado, 2003) contribute to the baroreflex. Iontophoresis of selective antagonists 
onto NTS neurones excited by aortic nerve afferents found that AMPA receptors are 
located at the primary synapse between afferent and second order neurone, whilst 
NMDA receptors are only found on higher order neurones receiving polysynaptic 
inputs (Zhang & Mifflin, 1997; Zhang & Mifflin, 1998). As the NMDA receptor is 
involved in synaptic plasticity, this proposed a role in long-lasting changes in these 
higher order neurones, although this has not been confirmed. Indeed, recent evidence 
points to NMDA receptors on second order barosensitive NTS neurones (GA Jones 
& D Jordan, unpublished data). Another likely central mechanism for hypertension is 
increased inhibition of NTS barosensitive neurones via GAB A receptors (see Mifflin, 
2001).
There only appears to be a low degree of convergence of different afferents onto 
NTS neurones with respect to baroreceptor afferents (Donoghue et al., 1985), but a
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recent study demonstrated that lung stretch afferents tend to converge onto second 
order barosensitive NTS neurones, but not higher order neurones (Jones & Jordan, 
2003).
Respiratory modulation in cardiovascular reflexes is the the process by which the 
reflex output is modulated by the activity of the respiratory network. The baroreflex 
bradycardia is subject to respiratory modulation (Haymet & McCloskey, 1975; Neil 
& Palmer, 1975; Davidson et a l, 1976a). Baroreflex changes in the activity of 
CVPNs (i.e. increases in vagal drive to the heart) cannot be elicited during 
inspiration. This is also seen in the chemoreflex (see 1.3.3), but not the 
cardiopulmonary reflex (see 1.3.2). The modulation seems to occur at the level of 
the nucleus ambiguus, via inhibition by inspiratory neurones (see Figure 1.4). 
Furthermore, stimulation of the hypothalamic defence area attenuates the baroreflex, 
but enhances the chemoreflex (Coote et al., 1979), suggesting that under certain 
emergency situations it is desirable for the body to suppress the baroreflex.
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Chemoreceptors BaroreceptorsHDA
NTS NTS
Figure 1.4 Reflex modulation
Schematic diagram (adapted from Spyer, 1994) illustrating synaptic influences of 
both the respiratory network (IN: inspiratory neurone, PI: post-inspiratory neurone) 
and higher centres (HDA: hypothalamic defence area) on the transmission of 
chemoreceptor (left) and baroreceptor (right) reflexes through the NTS and nucleus 
ambiguus (nA). Green denotes an excitatory and red an inhibitory pathway, neither 
of which is necessarily monosynaptic.
The chief mediators of respiratory modulation are the inspiratory neurones, which 
inhibit nucleus ambiguus neurones, probably via an inhibitory intemeurone. Post- 
inspiratory neurones may provide an additional drive to nucleus ambiguus neurones 
during the post-inspiratory phase.
37
1.3.2. The cardiopulmonary reflex
First described by von Bezold and Hirt in 1867, and further characterised by Jarisch 
and Richter, the cardiopulmonary reflex has also been termed the von Bezold-Jarisch 
reflex or the pulmonary chemoreflex, although the von Bezold-Jarisch reflex refers 
specifically to the reflex evoked by C-fibre afferents in the coronary circulation 
(Dawes & Comroe, 1954). The cardiopulmonary reflex is physiologically stimulated 
when pulmonary capillary pressure rises, for example during pulmonary congestion 
(see Paintal, 1969).
The cardiopulmonary reflex can be elicited by injection of veratum alkaloids or 
other substances such as phenylbiguanide (PBG) or capsaicin into the 
cardiopulmonary circulation, although the latter compounds selectively activate C- 
fibre afferents in the heart and lungs, without activating mechanoreceptors 
(Coleridge & Coleridge, 1980). The action of PBG is mediated by 5 -HT3 receptors 
on the peripheral C-fibre terminals (Kay & Armstrong, 1990). The reflex response is 
a characteristic triad of bradycardia, hypotension and either apnoea or rapid shallow 
breathing (see Thoren, 1979), although additionally reflex bronchoconstriction and 
airway secretion can occur (see Coleridge & Coleridge, 1994).
Pulmonary C-fibres throughout the lungs were originally termed J-receptors, and 
reported to evoke the pulmonary depressor chemoreflex, whereas cardiac C-fibres 
located in the left ventricular wall, but also in the atria, evoked the cardiac 
chemoreflex (see Coleridge & Coleridge, 1979). The cardiac endings do not 
consistently respond to changes in BP, suggesting no role in the regulation of BP as 
such (Coleridge et al., 1973), but they do respond to prostaglandins and bradykinin, 
which can be endogenously released from the myocardium, for example during 
hypoxia, ischaemia, and increased preload (Needleman, 1976). Indeed, the 
cardiopulmonary reflex is thought to be activated in myocardial ischaemia, and 
during the injection of contrast media for coronary angiography (Mark, 1983). 
During experimental stimulation via injections into the jugular vein or right atrium, 
reflex responses to pulmonary C-fibres can only be usefully distinguished from 
cardiac receptors in larger species (e.g. in the cat, where the pulmonary circulation
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time is around 5 s) (Daly, 1991), so in small rodents it is more realistic to refer to the 
stimulated afferents as ‘cardiopulmonary C-fibres.’
Unmyelinated cardiopulmonary afferents project to the NTS via the vagus nerve, and 
antidromic mapping in the cat has found that they terminate in the medial NTS 
rostral to the obex, and in the dorsal commisural NTS caudal to the obex (Kubin et 
al., 1991) -  a pattern that was confirmed in the rat and rabbit by c-fos expression 
following repetitive PBG injection (Gieroba et al., 1995). Transmission within the 
NTS is thought to be glutamatergic, as microinjection of the non-selective glutamate 
receptor antagonist kynurenic acid into the NTS abolished the reflex (Verbeme & 
Guyenet, 1992; Vayssettes-Courchay et al., 1997). An iontophoretic study reported 
that NTS neurones are excited by cardiopulmonary afferents via AMPA receptors 
(Wilson et al., 1996), although microinjections into the NTS also implicate NMDA 
receptors (Chianca & Machado, 1996) or both (Vardhan et al., 1993). One possible 
explanation is that AMPA receptors are involved at the afferent synapse onto second 
order neurones, whereas NMDA receptors are located on higher order intemeurones 
within the NTS (see Andresen et al., 2004).
Whilst in the awake rat the depressor response to cardiopulmonary afferent 
stimulation is entirely atropine sensitive, hence secondary to the fall in cardiac output 
(Chianca & Machado, 1996), in the anaesthetised animal it is accompanied by a 
strong sympathoinhibition, which is thought to utilise the same pathway as the 
baroreflex. Micro injection of kynurenic acid into the CVLM, or of bicuculline into 
the RVLM attenuate the sympathoinhibition (Verbeme & Guyenet, 1992) suggesting 
that the sympathetic component involves an excitatory glutamatergic projection from 
NTS to CVLM, followed by an inhibitory GABAergic projection from CVLM to 
RVLM (as for the baroreflex). The lateral tegmental field of the medulla has also 
been reported to contain sympathoexcitatory neurones projecting to the RVLM and 
sympathoinhibitory neurones projecting to the medullary raphe, which are activated 
by the cardiopulmonary reflex and may be involved in the integration of the 
sympathetic component, at least in the cat (Vayssettes-Courchay et al., 1997). 
Earlier lesion experiments, however, suggested that only the NTS/DVN, 
ventrolateral medulla, and IML are involved in cardiopulmonary reflex function (Lee 
etal., 1972).
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In the cat, the cardiopulmonary reflex is not respiratory modulated (Daly & Kirkman, 
1988), and this has also been demonstrated in the rabbit and rat (Jones, 1993). 
Stimulation of cardiopulmonary afferents activates CVPNs in the DVN (Jones et al., 
1998), and since these do not have respiratory rhythm, it was thought that the lack of 
respiratory modulation meant only DVN neurones are involved in the bradycardia. 
However, this cannot be the case, since selective stimulation of the cardiac C-fibre 
efferents of DVN neurones only causes a small bradycardia (Jones et al., 1995b). 
Therefore the nucleus ambiguus CVPNs (with B-fibre axons) must contribute the 
larger part of the total bradycardia. Since these neurones have strong respiratory 
rhythm, the lack of respiratory modulation in this reflex could be explained by 
combined B-fibre and C-fibre outflow to the heart. Possibly the C-fibres uncouple 
the respiratory and sinoatrial node oscillators, suppressing the respiratory modulation 
caused by the B-fibres. Whether this is processed centrally or peripherally at cardiac 
ganglia remains somewhat mysterious. However, recordings from CVPNs in the 
nucleus ambiguus of the cat demonstrated that these neurones can be excited by 
cardiopulmonary afferents at various phases of the respiratory cycle (Wang et al., 
2000a).
1.3.3. The chemoreflex
The chemoreflex modifies ventilation according to the requirements of the body, and 
has additional complex cardiovascular effects. In the 1920s, JF and C Heymans 
reported first that the aortic and later that the carotid bodies were sensitive to 
asphyxia, hypoxia, hypercapnia and acidaemia, as part of a reflex control of 
breathing (see Daly, 1997). Chemical agents such as cyanide and nicotine also 
mimicked these effects. Later single fibre recordings from the carotid body or the 
sinus nerve were performed, and it is now established that a single fibre in this 
pathway can be sensitive to a decrease in arterial O2 tension (Pa0 2 ), and increase in 
PaCC>2, and an increase in plasma [H+]. Furthermore, the relationship between fibre 
discharge and PaC>2 is exponential, whereas the relationship to PaCC>2 is linear 
(Biscoe et al., 1970; Fitzgerald & Parks, 1971). When both stimuli (hypoxia and 
hypercapnia) are applied simultaneously, the respiratory response is greater than the 
sum of both stimuli (Lahiri et al., 1981). Taken together, these findings impute a
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complex system of transduction mechanisms which is under continuing 
investigation.
The greatest chemoreceptive response in vivo is generally accepted to arise from the 
carotid bodies (Lahiri et al., 1981). Experimentally these can be stimulated by 
injection of small volumes of either a cyanide salt or CCVsaturated saline to the 
vicinity of the carotid bifurcation, for example into the lingual artery (Hilton & 
Marshall, 1982). However, bolus doses of cyanide (NaCN or KCN) are frequently 
given systemically (into the femoral vein), producing chemoreflex effects that are 
abolished by sinus nerve transection (Franchini & Kreiger, 1993) or carotid body 
artery ligation (Barros et al., 2002), suggesting selective stimulation of carotid bodies 
even through this route. Cyanide is thought to activate carotid body chemoreceptors 
by temporarily inhibiting tissue respiration and causing histotoxic hypoxia.
Early investigations using anaesthetised free-breathing dogs reported increased 
ventilation and bradycardia in response to intracarotid injection of chemical agents 
(Heymans & Bouckart, 1941). However, responses to chemoreceptor stimulation 
can vary between different animals, or in the same animal depending on 
experimental conditions, which caused confusing and conflicting responses. For 
example, the finding of Heymans & Bouckart (1941) conflicted with an earlier 
observation in an anaesthetised dog, in which the carotid bodies were vascularly 
isolated and perfused with CC>2-saturated Ringer’s solution, causing hyperventilation 
and tachycardia (Heymans et al., 1930). Variable changes were also seen by later 
researchers (Daly & Scott, 1958; Daly & Scott, 1963) who reported hyperventilation 
plus either an increase, a decrease, or no change in heart rate. Another study 
reported tachycardia unless respiration was held constant with a ventilator pump, in 
which case the response was bradycardia (Bemthal et al., 1951). Daly & Scott 
(1958) showed that hypoxic blood delivered to the carotid bodies causes a sudden an 
intense hyperventilation and immediate tachycardia, which later slows down. Also, 
bradycardia tends to occur when the hyperventilatory response is smaller. In the cat, 
mainly bradycardic responses are reported (Macleod & Scott, 1964), whilst in the 
seal only bradycardia is seen (Eisner et al., 1977). In free-breathing anaesthetised 
rats, a bradycardia followed by a tachycardia was seen, and under neuromuscular 
blockade this became a bradycardia only (Marshall, 1987).
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The present consensus is that chemoreflex changes in respiration cause a subsequent 
change in the effectiveness of incoming chemoreceptor signals, as shown by the 
relationship between changes in ventilation and changes in heart rate (see Daly,
1997). Lung stretch afferents also interfere strongly with the bradycardic response to 
chemoreceptor stimulation (see Marshall, 1994), and for these reasons it is useful to 
clamp ventilation during chemoreflex experiments. A third influence on chemoreflex 
responses is anaesthesia: the profoundly depressant barbiturate anaesthetics tend to 
blunt reflexes (Marshall, 1987), especially vagal bradycardias, whereas a-chloralose 
is favoured for its milder effect on cardiovascular reflexes. Anaesthetics also 
influence the activity of the hypothalamic defence area: under light Saffan 
(alphaxalone/alphadalone) anaesthesia, rats exhibit a defence reaction pattern of 
responses to chemoreceptor stimulation, which is not seen in either deep Saffan or 
pentobarbitone anaesthesia (Marshall, 1987). In awake rats, a profound bradycardia 
and hypertension are observed, together with some behavioural alerting (Haibara et 
al., 1995), and these latter responses may involve hypothalamic defence area 
participation.
Cell bodies of chemosensitive neurones in the petrosal ganglia were antidromically 
mapped and shown to project to the dorsal NTS rostrally, and to the medial and 
commisural NTS caudally, via unmyelinated fibres (Donoghue et al., 1984). These 
projections were chiefly ipsilateral, although some contralateral collaterals were 
identified. Myelinated chemoreceptor afferents are also thought to exist (Fidone & 
Sato, 1969), but researchers have consistently failed to record from them. Further 
investigation found that the commisural NTS receives unmyelinated and probably 
also small myelinated carotid body chemoreceptor fibres (Izzo et al., 1987). 
Intracellular recordings from NTS cells monosynaptically activated by 
chemoreceptor afferents showed that these cells do not have respiratory rhythm, nor 
is the input modulated by the respiratory cycle or inflation of the lungs (Mifflin, 
1993a), suggesting that respiratory modulation does not occur at this early stage of 
the reflex pathway. However, simultaneous baroreceptor input does attenuate 
chemoreceptor input at the level of the NTS (Mifflin, 1993b). From the NTS, the 
bradycardic component of the chemoreflex is thought to project through the nucleus 
ambiguus as in the baroreflex.
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Stimulating chemoreceptors also increases BP, which is preceded by excitation of 
RVLM vasomotor neurones, which are subsequently inhibited by the rise in BP (Sun 
& Spyer, 1991). RVLM neurones excited by chemoreceptors were most likely to fire 
during the postinspiratory phase, demonstrating respiratory modulation of the 
sympathetic response (Koshiya et al., 1993). Micro injection of kynurenic acid into 
the RVLM inhibits the chemoreflex sympathoexcitation, but not the baroreflex 
sympathoinhibition, whilst microinjection into CVLM caused the reverse (Koshiya et 
a l,  1993), suggesting that the sympathetic components of these two reflexes take 
different pathways. Chemoreflex sympathoexcitation is probably integrated by a 
population of convergent NTS neurones that are excited by chemoreceptor afferents 
and the hypothalamic defence area, and inhibited by baroreceptor afferents (Silva- 
Carvalho et al., 1995), but it is unlikely that a direct NTS-RVLM projection is the 
only pathway mediating this sympathoexcitation. In anaesthetised rats, 
microinjection of kynurenic acid into the NTS abolishes the chemoreflex pressor 
response (Zhang & Mifflin, 1993), but in awake rats kynurenic acid and DNQX into 
the NTS only reduce the pressor response, although abolishing the bradycardia 
(Haibara et al., 1999). Similarly, blockade of NTS NMDA receptors inhibits the 
bradycardia but not the hypertension in awake rats (Haibara et a l, 1995), but the 
latter effect is attenuated by electrolytic lesions of the PVN (Olivan et al., 2001). 
Furthermore, kynurenic acid microinjected into the RVLM did not alter the pressor 
response in awake rats (Mauad & Machado, 2001), but micro injection of lignocaine 
into the parabrachial nucleus did attenuate it (Haibara et al., 2002). Together these 
data suggest that the established glutamatergic circuits through the NTS and RVLM 
are not the only pathways taken by the sympathetic chemoreflex: either different 
transmitters, or different nuclei are involved, and the data would suggest that both are 
likely.
The probable pathways of the bradycardic and sympathetic components of the 
chemoreflex are illustrated in Figure 1.3. Modulation of chemoreflex signal is also 
illustrated in Figure 1.4, showing that inputs from the hypothalamic defence area 
enhance reflex responses by stimulating the NTS, as well as enhancing respiratory 
modulation, which is thought to occur via rhythmical excitation of CVPNs in the 
nucleus ambiguus by post-insiratory neurones (see Spyer, 1994)
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1.4. Neuropharmacology of the NTS
The NTS contains an extensive range of endogenous transmitters and their receptors, 
many of which are involved in cardiovascular control. Whilst a comprehensive 
description of their physiology and pharmacology is beyond the scope of this thesis, 
the basic effects of locally applied agonists and antagonists is outlined below, with 
particular reference to reflex control.
y-Aminobutyric acid
The NTS is known to contain large amounts of GAB A (Dietrich et al., 1982). 
Bilateral micro injection of GAB A into the NTS causes an immediate hypertension 
and baroreflex inhibition via GABAa receptors (Catelli et a l, 1987; Kubo & Kihara, 
1988a), and selective activation of GABAb receptors also has this effect (Lalley, 
1980; Catelli et al., 1987). GABAa receptors tonically inhibit baroreflex 
transmission, as micro injection of bicuculline potentiates aortic nerve evoked 
responses (Kubo & Kihara, 1988a). The finding that spontaneously hypertensive rats 
have a higher density of GABAb receptors in the NTS suggests a role in 
hypertension (see Mifflin, 2001). The majority of GABAergic effects at this level are 
believed to be mediated by intrinsic intemeurones.
Glycine
Microinjection of glycine into the NTS can produce hypertension (Kubo & Kihara,
1987), or hypotension and bradycardia (Talman & Robertson, 1989), but the 
antagonist strychnine had no effect on the baroreflex (Talman & Robertson, 1989) 
suggesting that glycine is not part of the reflex arc. However, the depressor effects of 
glycine were blocked by micro injection of atropine (Talman et al., 1991), suggesting 
that the glycine receptor is modulating acetylcholine release.
Acetylcholine
Cholinesterase is found in a population of NTS neurones (Helke et al., 1983), and 
acetylcholine, like glycine, elicits bradycardia and hypotension when micro injected 
into the NTS, which is inhibited by atropine (Criscione et al., 1983). Interestingly, in 
this study atropine alone attenuated the baroreflex when bilaterally micro injected, so 
a muscarinic receptor mechanism may be involved in the reflex itself. Vagotomy
44
reduced Mi receptor binding sites in the NTS, suggesting a presynaptic location 
(Reynolds et al., 1994). Microinjection of nicotine also reduces BP and HR (Tseng 
et a l, 1993), proposing an additional cardiovascular role for nicotinic receptors.
Nitric oxide
Nitric oxide synthase is found in the NTS (Vincent & Kimura, 1992), and 
microinjection of nitrosocysteine, a nitric oxide donor, into the NTS produces 
immediate bradycardia and hypotension via soluble guanylate cyclase activation 
(Lewis et al., 1991b). Nitric oxide may also aid the transduction of cardiopulmonary 
afferent information (Lewis et al., 1991a), suggesting release from afferents. 
However, in vivo microdialysis suggests nitric oxide increases glutamate efflux in the 
NTS (Lawrence & Jarrott, 1993), hence is a modulator rather than transmitter. Nitric 
oxide also appears to interact with other transmitters, for example angiotensin II, 
which inhibits the baroreflex in the NTS via release of endothelial nitric oxide (Paton 
et al., 2001). On the single neurone level, the predominant effect of nitric oxide is to 
inhibit NTS neuronal discharge (Ma et al., 1995; Wang & Jordan, 1998).
Adenosine
The highest density of adenosine uptake sites in the brain is found in the NTS 
(Bisserbe et al., 1985). Microinjection of adenosine causes bradycardia and 
hypotension. A selective Ai receptor agonist causes the same responses, whilst a 
selective A2 receptor agonist causes hypertension (Barraco & Phillis, 1991). 
Antagonists of adenosine receptors such as caffeine inhibit baroreflex bradycardia 
(Mosqueda-Garcia et al., 1989), so the baroreflex may require adenosine as an 
endogenous transmitter. A2 receptor activation has also been shown to potentiate the 
bradycardia and reduce the hypotension evoked by the cardiopulmonary and 
baroreflexes (Carey & Jordan, 1998; Carey & Jordan, 1999).
Noradrenaline
The NTS receives innervations from noradrenaline-containing neurones in the locus 
coeruleus (McBride & Sutin, 1976) and from the A2 cell group within the NTS 
(Levitt & Moore, 1979). Dysfunction of these noradrenergic neurones may account 
for age-related loss of cardiovascular control and hypertension (Itoh et al., 1992). 
Whether noradrenaline has a reflex role, however, is not entirely clear. 6-
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hydroxydopamine induced noradrenergic lesions did not affect the baroreflex (Itoh et 
a l, 1992; Healy et a l, 1981), but NTS microinjection of the ai adrenoceptor 
antagonists yohimbine and idozoxan caused hypertension and baroreflex inhibition 
(Sved et a l, 1992). Lowering BP with glyceryl trinitrate enhances noradrenaline 
efflux in the NTS (Yamazaki & Ninomiya, 1993) supporting a reflex role for 
noradrenaline, although the action of nitric oxide produced by glyceryl trinitrate 
cannot be ruled out.
Dopamine
A population of dopamine containing neurones are found in the A2 cell group of the 
NTS (Armstrong et a l, 1982), and microinjection of dopamine into the NTS causes 
bradycardia and hypotension (Zandberg et a l, 1979), although high doses cause 
tachycardia and hypertension (Granata & Woodruff, 1982). Central administration of 
the D2 receptor antagonist sulpiride has no effect on cardiovascular reflexes (Bogle et 
a l, 1990; Dando, 1995). During severe hypoxia, however, dopamine efflux 
increases in the NTS, which is preventable by carotid sinus nerve transection (Goiny 
et a l, 1991). This does not occur in mild hypoxia, suggesting an emergency role.
5-hydroxy tryptamine
The cardiovascular roles of 5-HT are discussed in detail in 1.6 with respect to the 
individual receptor subtypes involved.
Peptides
The NTS contains a variety of peptide transmitters, many of which cause 
cardiovascular changes when locally applied. These include substance P, 
neuropeptide Y, angiotensin II, vasopressin, cholecystokinin, bradykinin, 
somatostatin, opioid peptides, endothelin and neurotensin (see Lawrence & Jarrott, 
1996).
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Figure 1.5 Central 5-HT containing cell groups
Midline sagittal diagram of rat brain illustrating position of various 5-HT containing 
cell groups, and their major established projections. Colours are arbitrary, but yellow 
areas are the least understood.
Note: the size and shape of the cortex at this midline level has been expanded for 
illustration of projections, but the remainder is to scale (bar = 2 mm).
3V: Third ventricle
4 V: Fourth ventricle
AP: Area postrema
CL: Caudal linear nucleus
Do: Dorsal raphe nucleus
HTh: Hypothalamic 5-HT containing neurones
Ip: Raphe interpositus nucleus
Me: Median raphe nucleus
Mg: Raphe magnus nucleus
Ob: Raphe obscurus nucleus
Pa: Raphe pallidus nucleus
Po: Raphe pontis nucleus
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1.5. The central serotonergic system
Terminology
A point of terminology should be clarified before attempting to describe this highly 
complex system. Neurotransmission mediated via release of 5-HT onto 5-HT 
receptors is termed 5-hydroxytryptaminergic, or serotonergic for simplicity. The 
term serotonergic will be used to describe neuronal pathways that are functionally 
characterised as involving 5-HT neurotransmission. Conversely, cell groups, fibres 
and terminals that are anatomically identified on the basis of 5-HT content (e.g. 
immunoreactivity or histofluorescence) will be termed 5-HT containing when there 
is no supporting functional data.
5-hydroxy tryptamine
The existence of a serum-borne factor affecting the tonus of blood vessels had been 
known for some time, hence the original name of serotonin (Rapport et al., 1948). 
An unknown substance found in the gut, where it affected motility, was called 
enteramine. Later these were both identified as 5-HT (Amin et al., 1954). 5-HT was 
located in varying amounts in different CNS structures, proposing its role as a 
neurotransmitter: an interesting proposition was that 5-HT and noradrenaline might 
serve as opposing central transmitters, much as acetylcholine and noradrenaline in 
the periphery (Brodie & Shore, 1957).
Peripherally, 5-HT is found in platelets and enterochromaffin cells throughout the 
body, as well as in the gastrointestinal tract, urinary system, kidneys, liver and heart. 
It is rapidly broken down by monoamine oxidase to produce 5-hydroxyindoleacetic 
acid, which in the periphery occurs primarily in the endothelial cells of the lungs and 
liver (Verbeuren, 1989).
5-HT is synthesised from the amino acid tryptophan, which is converted to 5- 
hydroxytryptophan by tryptophan hydroxylase (the rate limiting step), and then to 5- 
HT by 5-hydroxytryptophan decarboxylase.
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1.5.2. 5-HT containing neurones
Anatomy
The location of 5-HT containing neurones was first demonstrated by the Falck- 
Hillarp histochemical fluorescence technique (Dahlstrom & Fuxe, 1961), revealing 
that the majority were in cell groups of the midline seam {raphe), first described in 
detail by Cajal in 1911 and characterised in detail thereafter (Cajal, 2000; Taber et 
al., 1960). None of these authors had suspected that these neurones shared a 
common transmitter. Although 5-HT containing neurones comprise only a very 
small proportion of CNS neuroiies, in the rat it is estimated that there are about 6 * 
106 5-HT containing varicosities per mm3 of cortex (Audet et al., 1989).
The atlas of Paxinos & Watson (1998) provides a general consensus on the anatomy 
of rat raphe nuclei, and the delineations are shown in Figure 1.5. The caudal linear 
nucleus is the most rostral group of 5-HT containing neurones, extending from the 
rostral tip of the dorsal raphe nucleus to the dorsal aspect of the interpeduncular 
nucleus. At its caudal end it is bordered ventrally by the decussation of the superior 
cerebellar peduncles. The caudal linear nucleus contains small to medium sized 
neurones, with the largest proportion of 5-HT containing neurones in the caudal 
portion (Steinbusch & Nieuwenhuys, 1983), although many dopamine-containing 
neurones belonging to the A10 cell group are also found in the caudal linear nucleus 
(Swanson, 1982).
The dorsal raphe is the largest raphe nucleus, and has received the most research 
interest. It extends from the level of the pons to the oculomotor nucleus, and the 
majority of its neurones are in the midbrain, dorsal to the median longitudinal 
fasciculi, but also ventrally between these fibre tracts. Laterally the dorsal raphe 
nucleus is difficult to differentiate from the periaqueductal grey. Various neuronal 
types have been characterised in dorsal raphe: small spherical, medium fusiform and 
large multipolar (Danner & Pfister, 1980), later arranged into Type 1, 2 and 3 
neurones depending on their morphology -  a classification that applied to other raphe 
areas too (Holzel & Pfister, 1981). Whilst dorsal raphe contains about half of all
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central 5-HT containing neurones, it is estimated that only 40 -  50 % of dorsal raphe 
neurones contain 5-HT (Wiklund et al., 1981; Descarries et al., 1982). 
Noradrenaline containing neurones are found in the caudolateral part (Steinbusch,
1981), and dopamine containing neurones near the midline (Ochi & Shimizu, 1978). 
GABA-containing neurones are found throughout dorsal raphe, which can be divided 
into those sensitive to the serotonergic neurotoxin 5,7-dihydroxytryptamine (5,7- 
DHT), and those that are insensitive, suggesting that one population is colocalised 
with 5-HT (Nanopoulos et al., 1982; Belin et a l, 1983). A number of peptides are 
also found in dorsal raphe, such as substance P which coexists with 5-HT (Hokfelt et 
al., 1978), and cholecystokinin in an independent neuronal population (Innis et al., 
1979).
The median raphe nucleus is found ventrally and caudally to dorsal raphe, and runs 
between the tectospinal tracts, with the raphe pontis nucleus at its caudal end. Only a 
minority of neurones contain 5-HT (Wiklund et al., 1981). Three types of neurone 
with similar morphological characteristics to dorsal raphe are found in median raphe 
(Holzel & Pfister, 1981). Raphe pontis is a small nucleus continuing caudally from 
median raphe to the level of the raphe magnus nucleus, and its cells are not well 
differentiated from those of the underlying reticular tegmental nucleus.
Raphe magnus is a long and wide nucleus, forming a characteristic triangular lateral 
extension into the gigantocellular reticular nucleus and ventrolateral medulla, and 
contains a seemingly random scattering of additional 5-HT containing neurones, 
although the majority of raphe magnus 5-HT neurones are close to the midline. 
Raphe magnus extends from the facial nucleus rostrally, and joins into the raphe 
obscuras nucleus caudally, with the raphe pallidus nucleus running along most of its 
ventral surface, between the pyramids. Raphe magnus cytoarchitecture is different 
from the rostral raphe, as the cells are larger and more loosely distributed, with many 
neurones arranged at right angles to the midline, their dendrites extending far into the 
surrounding reticular formation. Approximately 50 % of raphe magnus neurones 
contain 5-HT, whilst 25 % are positive for substance P and thyrotropin releasing 
hormone; in some cases all three transmitters coexist in the same neurone (Johansson 
et al., 1981). Other peptides located in raphe magnus include enkephalin (Hokfelt et
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al., 1979), somatostatin (Finley et al., 1981) and cholecystokinin (Kubota et a l, 
1983).
Raphe obscurus continues from raphe magnus caudally in two paramedian columns 
remaining very close to the midline, and reaching the greatest dorsoventral height at 
the level of the obex. Raphe obscurus is flanked by reticular formation and by the 
inferior olive ventrally. The majority of neurones contain 5-HT, and are medium to 
large in size, with dendrites extending both along the midline and laterally 
(Steinbusch & Nieuwenhuys, 1983). Other transmitters such as substance P, 
thyrotropin releasing hormone and cholecystokinin are found here as is raphe 
magnus. ^
Raphe pallidus is a thin column of cells on the ventral surface of the medulla, flanked 
by the pyramids. It makes contact with raphe obscurus caudally and raphe magnus 
rostrally, and is sometimes interpreted as a continuation of these cell groups (Taber, 
1961), although raphe pallidus neurones are very compactly arranged, consisting of 
small, medium and large cells. 5-HT containing neurones are amongst the medium 
and large type (Steinbusch & Nieuwenhuys, 1983), and again various peptides 
coexist.
Cell bodies in the hypothalamus capable of accumulating 5-HT that had been 
injected intracerebroventricularly (i.c.v.) were described some time ago (Fuxe & 
Ungerstedt, 1968). 5-HT immunoreactive neurones in the dorsomedial hypothalamic 
nucleus was subsequently confirmed (Frankfurt et al., 1981), but only in rats 
pretreated with both L-tryptophan and the monoamine oxidase inhibitor pargyline. 
These neurones are small in size and in number, and their connections are unknown. 
They may be a group of small local neurones, and whilst they are difficult to reveal, 
their existence may explain why the 5-HT content of the hypothalamus is only 
reduced but not abolished by surgical lesioning of its brainstem afferents (Palkovits 
etal., 1977).
A small scattering of 5-HT containing neurones is found lateral to raphe magnus, and 
also in the vicinity of the locus coeruleus, the dorsal tegmental nucleus, and the 
interpeduncular complex (Steinbusch, 1981). In the area postrema on the dorsal
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surface of the medulla is a further population of very small 5-HT containing 
neurones, although little is known of their connections (Steinbusch, 1981). Finally, 
there is one report of a population of 5-HT immunoreactive neurones in the medial 
nucleus of the rat NTS (Calza et al.y 1985) but only in i.e. colchicine pretreated 
animals. Also, older (24 month old) animals showed greater numbers of these 
neurones. The implications are unclear, nor has the observation been confirmed 
elsewhere.
Connections
The major ascending projections from dorsal and median raphe have been clearly 
demonstrated to project to nearly all rostral brain areas ipsilaterally via the medial 
forebrain bundle, where they travel parallel to numerous noradrenaline containing 
fibres (Takagi et al., 1980a). This bundle contains both myelinated and 
unmyelinated 5-HT immunoreactive fibres in the rat and monkey, with more 
myelination in the monkey (25 % vs\ 1 % in the rat) (Azmitia & Gannon, 1983). 
The hippocampus receives afferents from dorsal and median raphe, the latter 
travelling in the cingulum bundle and fornix (Azmitia & Segal, 1978b). The 
hypothalamic medial preoptic area, suprachiasmatic nucleus and anterior area 5-HT 
content was reduced by dorsal but not median raphe lesions, whereas anterolateral 
and arcuate nucleus 5-HT content was also reduced by dorsal raphe lesion (Van De 
Kar & Lorens, 1979). Both dorsal and median raphe also project to various parts of 
the thalamus (Azmitia & Segal, 1978a), septum (Swanson & Cowan, 1979), and 
midbrain (Steinbusch, 1981) whereas the main projection to the caudate-putamen is 
from dorsal raphe (Jacobs et al., 1978). Dorsal and median raphe also project to pial 
blood vessels, suggesting a role in the pathogenesis of migraine (Edvinsson et al.,
1983)
Early studies failed to find clear ultrastructural evidence of synapses between 
monoamine-containing fibres and cortical neurones, and described the mode of 
transmission as diffuse and non-specific (Descarries et al., 1975; Beaudet & 
Descarries, 1976), fitting with an older concept of the brain as a neuroendocrine 
organ, where neurosecretion modulated general brain activity. Since then, however, 
specific synaptic connections have been well established (see Pamavelas & 
Papadopoulos, 1989), with axons selectively innervating certain types of cat cortical
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neurones (Mulligan & Tork, 1988). In monkey visual cortex, 5-HT containing fibres 
preferentially innervate layer IV, whilst noradrenaline containing fibres are 
predominantly in layers V and VI (Morrison et al., 1982).
In the hindbrain, the locus coeruleus receives afferents from many raphe areas 
including dorsal, median and raphe magnus (Cedarbaum & Aghajanian, 1978; 
Morgane & Jacobs, 1979). Brainstem motor nuclei, especially the facial and 
trigeminal motor nuclei, receive 5-HT containing synapses (Aghajanian & McCall, 
1980; Schaffar et al., 1984), although retrograde labelling failed to find a projection 
from any raphe areas (Travers & Norgren, 1983). The RVLM is also innervated by 
5-HT containing neurones fropi dorsal raphe (Underwood et al., 1999). The 
cerebellum receives a sparse innervation of 5-HT containing fibres (Takeuchi et al.,
1982).
The caudal or medullary raphe (magnus, obscurus, pallidus) have predominantly 
descending projections that are well-characterised. 5-HT immunoreactivity is found 
in the rat spinal cord (chiefly in substantia gelatinosa and IML); injection of HRP 
into the spinal cord retrogradely labels neurones in all medullary raphe areas, many 
of which contain 5-HT; lesion of the dorsolateral funiculus inhibits raphe labelling 
(Bowker et al., 1982). Many 5-HT containing neurones in raphe magnus and 
pallidus projecting to the spinal cord also express enkephalin (Millhom et al., 1989), 
and in the guinea pig either somatostatin, substance P, enkephalin or thyrotropin 
releasing hormone (Chiba & Masuko, 1989). Anterograde transport of phaesolus 
vulgaris leucoagglutinin from rat raphe magnus/pallidus also labelled the C l to C3, 
A l and A2 catecholamine cell groups, with close appositions of 5-HT containing 
varicosities at neurones of the Cl group (Nicholas & Hancock, 1990), supporting a 
body of evidence for the interaction of monoamine systems.
The density of 5-HT containing fibres in the NTS has been widely reported 
(Steinbusch, 1981; Maley & Elde, 1982; Pickel et al., 1984). Retrograde labelling 
reveals 5-HT containing neurones in dorsal raphe and raphe magnus (Schaffar et al.,
1988) as well as in raphe obscurus and pallidus that project to the NTS (Thor & 
Helke, 1987). Some of the 5-HT containing fibres in the NTS, however, are the
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terminals of primary afferents from the nodose ganglia (Gaudin-Chazal et a l, 1982; 
Nosjean et a l, 1990; Sykes et al., 1994).
5-HT and substance P immunoreactive fibres form a dense network around 
respiratory muscle motoneurones in the nucleus ambiguus, and the ventral 
respiratory group receives an innervation from the medullary raphe (Holtman, 1988; 
Holtman et al., 1990a). Further examination found clear and frequent synaptic 
contacts between 5-HT containing terminals and phrenic motoneurones in the cat 
(Pilowsky et al., 1990; Holtman et al., 1990b).
Of the numerous other anatomical connections of the raphe, raphe obscurus projects 
to pudendal motoneurones (Hermann et al., 1998), suggesting a role in pelvic floor 
autonomic and motor functions, and raphe magnus also projects to the septum, and 
together with raphe obscurus (but not pallidus) to the hypothalamus (Takagi et al., 
1980b). However others report that raphe pallidus has a reciprocal connection with 
the dorsal hypothalamus, which contains asymmetrical (excitatory) synapses from 
raphe pallidus (Hosoya, 1985; Hosoya et al., 1989). In fact, the majority of afferents 
to the medullary raphe come from the dorsal hypothalamus and periaqueductal grey 
(Hermann etal., 1997).
The area postrema sends a 5-HT containing projection to the parabrachial area in rats 
(Lanca & van der Kooy, 1985), as well as to the NTS, DVN and nucleus ambiguus 
(Shapiro & Miselis, 1985), suggesting it may modulate the processing of visceral 
afferent information.
Functions
The neuronal activity of dorsal raphe is believed to play a critical role in regulating 
mood, sleep, learning and memory (see Graeff et a l, 1996); some of the effects of 
manipulating rostral raphe neuronal activity on these functions is discussed in 1.6 
below. On the autonomic side, electrical stimulation of dorsal or median raphe 
increases BP in anaesthetised rats, which was attenuated by pretreatment with the 5- 
HT synthesis inhibitor para-chlorophenylalanine (p-CPA) (Kuhn et al., 1980). 
Electrical or chemical stimulation (with DL-homocysteic acid; DLH) of dorsal raphe 
reduces carotid blood flow in cats (Goadsby et al., 1985). Furthermore, electrical
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stimulation of rostral dorsal raphe reduces cerebral blood flow, whereas stimulation 
of the caudal part of the nucleus increases cerebral blood flow (Underwood et al., 
1992) Electrical stimulation of any raphe area must be interpreted with care, as it is 
possible to activate fibres of passage, many of which cross at the midline. Hence 
chemical stimulation is often used to confirm that cell bodies are activated. 
Chemical stimulation with kainate but not glutamate increased cerebral blood flow 
(Underwood et al., 1995).
The medullary raphe have a number of established roles, especially the control of 
descending antinociception by raphe magnus (see Mason, 2001), although raphe 
obscurus may also be involved pi this function (Dantas et al., 1990). Raphe magnus 
and pallidus also control skin blood flow (Nalivaiko & Blessing, 2001), and the 
activity of raphe neurones is modulated by skin temperature (Dickenson, 1977; 
Rathner et al., 2001). An autonomic role of the medullary raphe was first described 
in the 1970s (Coote & Macleod, 1974), and reported evoking a sympathoinhibition. 
Depletion of endogenous 5-HT, however, caused no change in BP or sympathetic 
nerve activity, suggesting that 5-HT is not crucially required (Coote et al., 1978).
Since then, the autonomic roles of the medullary raphe have received much attention, 
although there is considerable disagreement. In cats, electrical stimulation causes a 
rise or fall in BP depending on which area is stimulated, although there was little 
clear pattern (Adair et al., 1977). In rabbits there were similarly varied responses to 
electrical stimulation, with a pressor responses accompanied by tachycardia at dorsal 
sites, and a pressor/bradycardic response at ventral sites, the bradycardia being 
mainly reflexive (Haselton et al., 1988). The concurrent bradycardia was also seen 
in cats (Lalley, 1986) and rats (from raphe obscurus) (Dreteler et al., 1991). 
Chemical stimulation, however, can cause pressor (Dreteler et al., 1991) or depressor 
(Bernard, 1998) responses without heart rate changes, or depressor with bradycardia 
(Coleman & Dampney, 1995) in rats. Effects on the sympathetic system are also 
varied: the raphe can mediate sympathoexcitation in anaesthetised rats (Nalivaiko & 
Blessing, 2001; Zhou & Gilbey, 1995), and rabbits (Blessing et al., 1999), and 
sympathoinhibition in anaesthetised cats (Coote et al., 1987; Gilbey et al., 1981) and 
rats (Coleman & Dampney, 1995).
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The caudal raphe also modulate central respiratory drive: raphe stimulation increases 
(Holtman et al., 1986c; Haxhiu et al., 1998) or decreases (Lalley et al., 1997) phrenic 
nerve firing in cats, and increases it in rats (Bernard, 1998; Dreteler et al., 1991). The 
raphe may also be involved in chemosensing in piglets (Dreshaj et al., 1998) and rats 
(Bernard et al., 1996).
Few studies have concentrated on parasympathetic raphe roles: medullary raphe 
stimulation reduces parasympathetic outflow to the airways in cats (Haxhiu et a l,
1998). Also electrical and chemical stimulation of raphe obscurus increases gastric 
motility in anaesthetised rats (McCann et al., 1989), which is thought to occur via 
raphe activation of vagal preganglionic neurones in the DVN; another study reports 
that electrical stimulation of raphe obscurus augments distal bowel motility in 
anaesthetised rats via direct activation of sacral spinal parasympathetic neurones 
(Holmes et al., 1997). As concerns cardiovascular reflexes, chemical stimulation of 
raphe pallidus can attenuate the cardiopulmonary reflex in anaesthetised rats 
(Edwards & Paton, 2000), whereas chemical stimulation of raphe obscurus attenuates 
chemoreflex bradycardia in conscious rats (BH Machado, unpublished data).
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5A
Figure 1.6 Evolution o f 5-HT receptors
Dendrogram (adapted from Barnes & Sharp, 1999) illustrating evolutionary 
relationship between different 5-HT (1A -  7) receptor amino acid sequences (all 
from human except 5A and 5B, which are murine in origin).
58
1.6. 5-HT receptors
1.6.1. Classification
The effects of 5-HT are mediated by a variety of receptors, only one of which is a 
ligand-gated ion channel (5 -HT3), and the rest comprise a superfamily of at least 13 
G protein-coupled receptors (see Figure 1.6). 5-HT receptors were first divided into 
M and D receptors by Gaddum & Picarelli (1957), and later into 5-HT] and 5 -HT2 
receptors by Peroutka & Snyder (1979). In 1986, the M receptor was renamed 5 -HT3 
by Bradley and colleagues. During the next few years the 5-HT] receptor began to 
be subdivided, whilst other putative 5-HT receptors were discovered and variously 
named, leading to the generally^ accepted reclassification by the International Union 
of Pharmacology in 1994 (Hoyer et a l, 1994). The molecular, functional, and 
pharmacological properties of 5-HT receptors continue to be regularly and 
extensively reviewed (see Barnes & Sharp, 1999; Hoyer et a l, 2002).
5-HT receptors are often classified as autoreceptors or heteroreceptors, referring to 
the neurochemical phenotype of the neurone expressing them. Autoreceptors are 
located on serotonergic neurones, and heteroreceptors on non-serotonergic neurones. 
Either type of receptor can be found either presynaptically, modulating transmitter 
release, or post-synaptically, modulating somatic membrane potential.
Whilst a comprehensive review of 5-HT receptors is beyond the scope of this thesis, 
the receptors targetted in later chapters are described in some detail, whilst other 
receptors are given an overview appropriate to their known contribution to 
autonomic functions.
1.6.2. Binding of 5-HT to its receptors
5-HT binds to its receptors with varying affinities. In human cloned receptors, 5-HT 
receptors can be grouped as follows. Receptors with relatively low affinity for 5-HT 
(pK[ 6 - 7 )  are 5 -HT2A, 5 -HT3, 5 -HT4, 5-htsA and 5-HT6. Receptors with moderate 
affinity (pK[ 7 - 8 )  are 5-ht]E> 5-HT]F, 5-HT2b and 5-HT2c- Receptors with higher 
affinity (pKi 8 - 9 )  are 5-HTia, 5-HTib, 5-HT1d and 5-HT7 (Roberts et a l, 2001b; 
Kilpatrick et a l, 1989). These variations suggest a hierarchy of different roles, with
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some receptors active during normal and some only during high concentrations of 5- 
HT.
1.6.3. 5-HT1A receptor
Molecular biology
Prior to its full molecular characterisation, the existence of the 5-HTia receptor was 
first inferred in a study describing two populations of 5-HT receptors in the rat brain, 
one with high affinity for spiperone in the cortex, and one with low affinity in the 
striatum (Pedigo et al., 1981), later identified as 5-HTia and 5-HTib receptors 
respectively. Since then, the 5-HTia receptor has become the most intensively 
studied of all 5-HT receptors. An intronless gene with similarity to the p2 
adrenoceptor was first identified when the human genome was screened with a p2 
clone (Kobilka et al., 1987), located on human chromosome 5 (ql 1.2 -  13), and later 
named as the 5-HTia receptor gene (Fargin et al., 1988). Subsequently the receptor 
was cloned in the rat, as a 422 amino acid protein comprising 7 transmembrane 
spanning domains with sites for glycosylation and phosphorylation, having 89 % 
sequence homology with the human form (Albert et a l, 1990). Activation of the 
cloned receptor reduced cyclic adenosine monophosphate (cAMP) production. Also, 
3 different messenger ribonucleic acid (mRNA) products of the gene were described 
in the rat (but not in the human), suggesting that different transcriptional or 
polyadenylation start sites might exist in the rat gene (Albert et a l, 1990).
The 5-HTja receptor is negatively coupled to adenlyate cyclase (Albert et al., 1990; 
Pauwels et a l, 1993); agonist-induced inhibition of cAMP accumulation rapidly 
desensitises (van Huizen et al., 1993). The receptor is also thought to couple directly 
to K+ channels without a soluble intracellular messenger, at least in the hippocampus 
(Andrade et al., 1986). The Gia protein itself can directly activate inwardly rectifying 
K+ channels independent of lowered cAMP (Codina et al., 1987), so this direct 
coupling may be a significant in vivo signalling method.
Distribution
The 5-HTja receptor was first pharmacologically characterised as a binding site for 
the archetypal agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT)
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(Middlemiss & Fozard, 1983), and brain distribution of 5-HTia receptors was first 
described using [3H]-8-OH-DPAT (Gozlan et al., 1983), with the highest signal in 
the hippocampus. mRNA expression is highest in septum and hippocampus (Albert 
et al., 1990). High mRNA is also described in subiculum, entorhinal cortex, raphe, 
dorsomedial and ventromedial hypothalamus, with lower signal in all layers of 
cerebral cortex, NTS, hypoglossal nucleus, spinal trigeminal nucleus, and the least 
signal in thalamus and cerebellum (Wright et al., 1995). Combined
immunocytochemistry, in situ hybridisation and radioligand binding describes all 3 
signals in entorhinal cortex, dorsal raphe and hippocampus, with less intensity in the 
cortex (Miquel et al., 1991). Many older papers describe 5-HTi binding sites, most of 
which correspond to known 5-,HTia receptor sites: high density binding sites are 
found in the rat hippocampus, septum, dorsal raphe, with less in amygdala, substantia 
nigra, hypothalamus, and some in cortex, thalamus, basal ganglia, NTS, spinal 
trigeminal nucleus, nucleus ambiguus, and spinal cord. Virtually no binding is 
reported in cerebellum (Pazos & Palacios, 1985). Within the brainstem of the cat, 8- 
OH-DPAT binding sites have reported in NTS, DVN, nucleus ambiguus, and 
medullary raphe (Dashwood et al., 1988).
In the human brain, highest densities are reported in layer II of cortex and area CA1 
of hippocampus (Hoyer et al., 1986). Autoradiography has also been performed 
using the more selective radioligand [3H]WAY-100635 (therefore not necessitating 
masking compounds for non-selective bindings, as is required with [3H]-8-OH- 
DPAT); in the human brain, [3H]WAY-100635 has been useful in characterising 
cloned receptors (Khawaja et al., 1997) and in confirming high receptor densities in 
hippocampus, raphe, neocortex, amygdala and septum, and low density in brainstem 
and cerebellum (Hall et al., 1997). This distribution has been confirmed in the human 
brain in vivo using positon emission tomography (PET) with n [C]-WAY-100635 
(Pike e ta l ,  1995).
5-HTia receptors in the dorsal raphe are thought to be somatodendritic autoreceptors 
with a high receptor reserve (Meller et a l, 1990), causing inhibition of raphe 
neuronal firing (Aghajanian et a l, 1968; Blier & de Montigny, 1987), whereas in the 
hippocampus the receptors are postsynaptic, with no such receptor reserve (Yocca et 
al., 1992). This is supported by serotonergic lesions with 5,7-DHT abolishing
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receptor expression in the dorsal raphe but not the hippocampus (Miquel et al., 
1992), indicating that raphe 5-HTja receptors are autoreceptors.
Pharmacology
5-HT binds to 5-H T ja receptors with a pATj of 8.8 in rat and human cortex (Hoyer et 
al., 1985b; Hoyer et al., 1986). Of the substituted tryptamines, 5-
carboxamidotryptamine (5-CT) binds with a \>KX of 8 (Lovenberg et al., 1993a) 
Several other classes of agonists for the 5-H Tja receptor have been synthesised: the 
aminotetralins, including the archetypal agonist 8-OH-DPAT, with a pJKj of 8.5 in rat 
(Mellin et a l, 1991) and cloned human receptors (Millan et a l, 2000), although this 
also binds to 5-H T jb/id and 5 -HT7 receptors (see 1.6.4 and 1.6.11 below). Another 
common full agonist is flesinoxan (pATj 8.1) (Boess & Martin, 1994). The 
arylpiperazines are a class of partial agonists, of which the best known is buspirone, 
which has p £ jo f 7.6 in rat cortex (Gozlan et al., 1988) but also binds to dopamine D2 
and aj adrenoceptors with a \)K\ of 7.4 and 6.2 respectively (see van Wijngaarden et 
a l, 1990). Similar drugs with comparable affinities are ipsapirone, tandospirone and 
zalospirone (Abou-Gharbia et al., 1988; Hamik et al., 1990).
Various non-selective antagonists have been used, including (with p.Ki in rat brain) 
the antipsychotics spiperone (7.6) (Hoyer et al., 1985b) and methiothepin (7.4) 
(Fozard et a l, 1987) and the (3 adrenoceptor antagonists (-)-pindolol (7.8) (Hoyer et 
a l,  1985b) and propranolol (6.6) (Gozlan et a l, 1988), although both spiperone and 
methiothepin display inverse agonist properties (McLoughlin & Strange, 2000). 
More recently, a number of selective arylpiperazine antagonists have been 
developed, including NAN-190 (pATj 9.2; rat hippocampus) (Millan et a l, 1993), 
which also blocks dopamine D2 and aj adrenoceptors, and NAD-299 (robalzotan; pK\ 
9.2; rat hippocampus) with pATj of only 6.6 at aj adrenoceptors (Johansson et al.,
1997). Perhaps the most widely used selective antagonist is WAY-100635 (Forster et 
al., 1995), with a p£j of 9.6 at rat cortical 5-HTjA receptors, and of 7.3 and 7.1 at aj 
and D2 respectively (Johansson et al., 1997).
General physiology
In brain slices, activation of 5-H T ja receptors causes hyperpolarisation of neuronal 
membranes in all areas studied, including hippocampus (Andrade & Nicoll, 1987;
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Van den Hooff & Galvan, 1991), prefrontal cortex (Araneda & Andrade, 1991a), 
septum (Van den Hooff & Galvan, 1992) and dorsal raphe (Haj-Dahmane et al.,
1991). In anaesthetised rats, dorsal raphe neuronal firing was first reported to be 
inhibited by iontophoretic lysergic acid diethylamide (LSD) (Aghajanian et al., 1972; 
Haigler & Aghajanian, 1974), and then by 8-OH-DPAT, which was blocked by (-)- 
propranolol (Sprouse & Aghajanian, 1986) and WAY-100635 (Wang et al., 1995). 
Intravenous (i.v.) 8-OH-DPAT also inhibits dorsal raphe firing in awake cats, an 
effect which is blocked by spiperone, which by itself increases firing (Fomal et al.,
1994), suggesting that 5-HTiA autoreceptors are tonically activated. This was also 
seen in anaesthetised rats, using WAY-100635 given iontophoretically (Wang et al.,
1995) or systemically (Gartside(et al., 1995), albeit to a lesser extent than in awake 
animals (Fomal et al., 1996). Hence systemic 5-HTiA receptor agonists would be 
expected to have a dual effect: firstly by inhibiting raphe firing and hence decreasing 
release at terminals; secondly by activating 5-HTjA receptors on non-serotonergic 
neurones. Antagonists on the other hand should facilitate 5-HT release.
Systemic administration of non-selective 5-HT receptor agonists tends to produce a 
cluster of behavioural signs in rats (Jacobs, 1976) known as 5-HT syndrome or 5-HT 
related stereotyped behaviour. Typically this includes many of the following: lower- 
lip retraction, flat body posture, hindlimb abduction, forepaw treading, head weaving 
and wet dog shakes. Of these, lower lip retraction is the behaviour most closely 
attributed to activation of 5-HTjA receptors, although a delicate interaction of other 
5-HT receptor subtypes is also thought to be involved (Berendsen et al., 1989). A 
further behaviour linked to 5-HTiA receptor activation is feeding, since 8-OH-DPAT, 
at lower doses than those that cause head weaving and other behavioural 
disturbances, induces feeding (Dourish et al., 1985a; Dourish et al., 1985b). 
Likewise, microinjection of 8-OH-DPAT into dorsal raphe increased feeding 
(Bendotti & Samanin, 1986; Fletcher & Davies, 1990), again pointing to the 
autoreceptor as the mediator of this physiological role.
There has been considerable interest in 5-HTiA receptor ligands in the treatment of 
depression and anxiety: learned helplessness -  an animal model of depression -  is 
reversed by 8-OH-DPAT and buspirone (Martin et al., 1990) via activation of 5- 
HTjA receptors in the septum, but not the dorsal raphe. Conversely, the anxiolytic
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effects of buspirone relate to its actions on raphe neuronal firing, which is also 
inhibited by anxiolytic doses of benzodiazepines (Trulson et al., 1982): 
microinjection of buspirone (Carli et a l, 1989) or 8-OH-DPAT (File et al., 1996) 
into the median raphe has anxiolytic effects. However, in dorsal hippocampus 8-OH- 
DPAT has anxiogenic effects (File et al., 1996), and the same results are reported 
elsewhere for microinjecting into dorsal raphe (Romaniuk et al., 2001). Suffice it to 
say that anxiolysis appears autoreceptor-mediated, whereas anxiogenesis is 
heteroreceptor-mediated, and this may account for idiosyncratic anxiety caused by 
buspirone in some patients, at least initially.
A variety of antidepressant drugs (paroxetine, venlafaxine and clomipramine) inhibit 
dorsal raphe activity in anaesthetised rats, which is reversed by WAY-100635 
(Gartside et al., 1997). Since the efficacy of serotonergic antidepressants is thought 
to relate to their ability to increase extracellular concentrations of 5-HT, there has 
been some interest in adjunctive treatment with a 5-HTia receptor antagonist, to 
prevent the initial inhibition of raphe activity caused by antidepressants, and possibly 
reduce the latency of the therapeutic effect (see Kinney et al., 2000). Clinical trials 
with an antidepressant plus pindolol have not, however, produced clear results (Isaac 
et a l, 2003; Perry et al., 2004).
5-HTia receptors have various influences on neurotransmitter release. Firstly, using 
in vivo microdialysis, activation of 5-HTja receptors decreases efflux of 5-HT in the 
forebrain, probably via activation of raphe autoreceptors (Sharp & Hjorth, 1990; 
Hjorth et a l, 1995; Sharp et a l, 1996). Conversely, 5-HTja receptor antagonists 
have been demonstrated to facilitate the ability of 5-HT reuptake inhibitors 
(Invemizzi et al., 1992; Hjorth & Sharp, 1993; Gartside et al., 1995), monoamine 
oxidase inhibitors and tricyclic antidepressants (Romero et al., 1996; Artigas et al.,
1996), to increase 5-HT efflux in the forebrain. Again, this is thought to reflect the 
antidepressant-evoked inhibition of raphe firing by increased synaptic concentrations 
of 5-HT in these nuclei, and the blockade by antagonists of these autoreceptors, 
removing the antidepressant-evoked inhibition.
Secondly, 8-OH-DPAT also increases the efflux of acetylcholine in the cortex of rats 
(Consolo et al., 1996) and guinea pigs (Bianchi et al., 1990; Wilkinson et a l, 1994).
64
5-HTja receptors are expressed in cholinergic cell bodies in the septum - an area that 
projects to the cortex. But given that these are inhibitory receptors, it is not yet 
understood how they increase release. Thirdly, 8-OH-DPAT also increases efflux of 
noradrenaline in hypothalamus (Suzuki et al., 1995), ventral tegmental area (Chen & 
Reith, 1995), and hippocampus (Done & Sharp, 1994), and this effect is sensitive to 
WAY-100635 (Hajos-Korcsok & Sharp, 1996), but insensitive to 5,7-DHT lesions or 
5-HT depletion with p-CPA (Suzuki et al., 1995; Hajos-Korcsok et al., 1999), 
suggesting that 5-HTja heteroreceptors mediate the modulation of noradrenergic 
transmission.
Autonomic functions
In respect of autonomic functions, systemic 8-OH-DPAT causes hypotension and 
vagal bradycardia with sympathoinhibition in anaesthetised cats (Fozard & Ramage, 
1984; McCall et al., 1987; Ramage & Fozard, 1987), but the antagonist WAY- 
100802 alone had no effect (Ramage & Mirtsou-Fidani, 1995), indicating that these 
5-HTja receptors are not tonically activated. A similar bradycardia and hypotension 
is reported in normal and spontaneously hypertensive rats (Gradin et al., 1985; 
Martin & Lis, 1985; Fozard et al., 1987), rabbits (Hof & Fozard, 1989; Shepheard et 
al., 1990) and conscious dogs (Di Francesco et al., 1988). The hypotensive effects in 
awake animals are thought to be less profound due to behavioural alerting. Repeated 
doses of 8-OH-DPAT do not produce tolerance to the hypotensive effect (Kolbasa et 
al., 1991). The agonist flesinoxan is also hypotensive, and the i.e. or intra-vertebral 
arterial route of administration produce greater hypotension than the i.v. route 
(Wouters et al., 1988); furthermore i.e. administration is more hypotensive than i.c.v. 
(Mir & Fozard, 1987; Wouters et al., 1988), and together these data point to a 
medullary location of sympathoinhibitory 5-HTjA receptors. Also, 5,7-DHT lesions 
abolish the hypotensive effect, whereas depletion of 5-HT stores does not (Mir & 
Fozard, 1987), suggesting that intact serotonergic fibres, but not 5-HT stores, are 
required for this effect. Pretreatment with the antagonist idazoxan also confirmed 
that (*2 adrenoceptors are not involved in the hypotensive effect of 8-OH-DPAT (Mir 
& Fozard, 1987). Investigation of the site of action tested microinjection of 8-OH- 
DPAT and flesinoxan into raphe obscurus, which actually produced a pressor 
response, as did glutamate (Dreteler et al., 1991). The preferred site of action is the 
RVLM, as supported by ventral surface application (Gillis et al., 1989) and
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microinjection (Laubie et a l, 1989) of 8-OH-DPAT. Pressor effects, however, are 
also seen when 5-HTia receptors are activated via the i.c.v. route, producing 
sympathoexcitation (Anderson et al., 1992), possibly by activating raphe obscurus 
autoreceptors, although in this case a hypothalamic target such as the preoptic area 
(Szabo et a l,  1998) is more likely, as it is within quickest reach of i.c.v. injection.
The parasympathetic role of central 5-H T ia receptors has also been widely 
investigated. Originally it was noted that LSD increases vagal drive in cats (Cervoni 
et a l, 1963). It is likely that this was due to 5-H T ja receptor activation in the 
medulla, since 8-OH-DPAT administered into the IVth ventricle causes a profound 
vagal bradycardia in cats (Shepfyeard et a l, 1994). The receptors are now thought to 
be located primarily in the vicinity of CVPNs in the nucleus ambiguus, as 
microinjection of 8-OH-DPAT (Izzo et a l, 1988) into this area produces a vagal 
bradycardia in the cat. However, they may also be located in the DVN, where 
microinjection of 8-OH-DPAT and flesinoxan produces a vagal bradycardia in the rat 
(Sporton et a l, 1991). A number of iontophoretic studies have compared 5-H T ja 
receptors in the DVN and nucleus ambiguus: iontophoresis of 5-HT onto rat DVN 
neurones excited at low currents and inhibited at high currents. The excitation was 
blocked by WAY-100635 and pindolol. Iontophoretic 8-OH-DPAT inhibited the 
majority of neurones and excited some; only this excitation could be blocked by 
WAY-100635. By itself, WAY-10063 5 was inhibitory at most neurones, whilst 
exciting a few, and had an additive inhibitory effect with 8-OH-DPAT (Wang et a l, 
1995). In cat CVPNs of the nucleus ambiguus, however, WAY-100635 by itself did 
not affect activity, posing the question of either a species difference or a 
pharmacological difference between DVN and nucleus ambiguus neurones. In 
agreement with DVN, however, 8-OH-DPAT inhibited at low currents and excited at 
high currents, and this excitation was WAY-100635 sensitive (Wang & Ramage, 
2001).
The fact that these inhibitory receptors are activating neurones that cause bradycardia 
proposes an interesting mode of action, probably involving disinhibition. Indeed, 
microinjection of bicuculline into the nucleus ambiguus causes a vagal bradycardia 
(DiMicco et a l,  1979). Also, NTS-evoked inhibitory synaptic currents in DVN 
neurones in vitro were diminished by 5-H T ja receptor activation, and this effect was
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bicuculline sensitive (Browning & Travagli, 1999). Hence it is likely that 5-HTiA 
receptors are located on GABAergic terminals presynaptic to CVPNs, which evokes 
excitation.
The triad of hypotension, bradycardia and sympathoinhibition caused by activating 
medullary 5-H T ia receptors resembles the responses evoked by stimulating 
cardiopulmonary afferents, and this prompted the question of whether these receptors 
serve a reflex function. If they are not tonically involved in cardiovascular 
regulation, as shown by the lack of effect of antagonists on baseline variables, they 
may be activated in certain circumstances. This was first demonstrated in the 
anaesthetised rat, using the nop-selective antagonists spiperone, methiothepin, and 
(±)-pindolol, which all attenuated cardiopulmonary reflex bradycardias when given 
i.e. (Bogle et al., 1990). Additionally, buspirone caused an attenuation, whereas the 
5 -HT2, ai adrenoceptor and D2 receptor antagonists BW-501C67, alfuzosin and (-)- 
sulpiride were without effect, suggesting that 5-H T ia receptors in the medulla are 
involved.
Later it was also found that reflex bronchoconstriction caused by inhaled capsaicin 
was attenuated by i.e. methiothepin, (-)-pindolol and WAY-100635, and potentiated 
by 8-OH-DPAT in the anaesthetised cat (Bootle et al., 1996). Similarly, in the 
anaesthetised guinea pig, reflex bronchoconstriction was attenuated by i.e. (-)- 
pindolol and WAY-100635, and potentiated by buspirone, 8-OH-DPAT, and 
fluoxetine (Bootle et al., 1998). In anaesthetised rabbits, the bradycardia evoked by 
stimulation of the upper airways with smoke was attenuated by i.e. (-)-pindolol and 
WAY-100635, and potentiated by buspirone (Dando et al., 1998). In this study, 
however, 8-OH-DPAT failed to potentiate the bradycardia (indeed it attenuated it via 
5-H T ib/id receptor activation; see 1.6.4 below). This attenuation was previously 
observed (Futuro-Neto et a l, 1993), pointing to a possible species difference in the 
roles of these receptor subtypes. Further work in the anaesthetised rabbit confirmed 
the crucial role of the 5-H T ja receptor in cardiovascular reflex transmission: 
cardiopulmonary, aortic nerve and chemoreceptor afferent-evoked bradycardias were 
all potentiated by i.e. buspirone and attenuated by WAY-100635, with the exception 
of the chemoreflex, which was potentiated by buspirone but not significantly 
attenuated by WAY-100635 (Skinner et al., 2002). Here the sympathetic
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components of these reflexes were also potentiated by buspirone and, in the case of 
the cardiopulmonary reflex, both the sympathetic and the respiratory components 
were attenuated by WAY-100635. This raised the possibility of the receptors being 
located in the NTS, where afferent inputs are distributed to the respective targets of 
the different components of the reflex, and receptor blockade would influence all 
components. Functional 5-H T ia receptors have been located in the rat NTS (Wang et 
al., 1997) using iontophoretic 8-OH-DPAT (but not confirmed with an antagonist); 
however, a reflex role has not been established within this nucleus. In the cat nucleus 
ambiguus, however, functional 5-H T iA receptors are clearly demonstrated in the 
vicinity of CVPNs, and the excitation of these neurones by cardiopulmonary 
afferents is inhibited by iontophoretic WAY-100635 (Wang & Ramage, 2001). 
Whether this is specific to the cat remains to be seen, but the observation supports 
the direct facilitation of CVPNs by 5-H T ja receptors in their vicinity, independent of 
NTS processes.
Additional to these cardiovascular reflex functions, 5-H T ja receptors have been 
identified as a major player in bladder reflexes. In anaesthetised rats, the supraspinal 
micturition reflex was facilitated by 8-OH-DPAT given i.v., i.c.v, or intrathecally 
(i.t.; at the level of the sacral spinal cord), but not topically onto the bladder (Lecci et 
al., 1992). Later studies found that WAY-100635 prevented reflex bladder 
contractions when given i.v. (Testa et al., 1999; Conley et al., 2001) or i.t. (Kakizaki 
et al., 2001); additionally, WAY-100635 interferes with micturition when given 
either i.c.v. or i.t. in anaesthetised rats (Seeker et al., 2002). Hence the role of the 5- 
H T ja in parasympathetic drive to the bladder is well documented, but the location is 
complex and poorly defined. The efficacy of i.c.v. as well as i.t. compounds suggests 
that functional receptors are located both supraspinally, possibly in the pontine 
micturition centre, and spinally. A spinal location in the vicinity of sacral 
parasympathetic preganglionic neurones would be comparable to the location in the 
nucleus ambiguus of the cat (Wang & Ramage, 2001), but this remains to be tested.
One further and no less complex parasympathetic role for 5-H Tja receptors is in the 
outflow to the iris: in conscious mice (Prow et al., 1996) and anaesthetised rats (Yu 
et a l, 2004), systemic 8-OH-DPAT produces pupillary dilatation, which is sensitive 
to 5-H Tja and <X2 adrenoceptor antagonists, but unchanged by sympathetic nerve
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section in the rat (Yu et al., 2004), suggesting that 5-H T ja receptors cause an 
inhibition of parasympathetic tone to the iris, via activation of noradrenergic 
neurones acting on 012 adrenoceptors. Interestingly, this action seems to be specific to 
rodents, as buspirone causes pupillary constriction in humans via sympathetic nerves 
(Fanciullacci et al., 1995) although parasympathetic tone may also be involved 
(Phillips et al., 1999).
These observations support the fact that both multiplicity of effects and species 
differences are characteristics of the comparative physiology of the 5-HTia receptor, 
and as such any roles do not necessarily extend to other brain regions or other 
species. ^
1.6.4. 5-HTib and 5-HTiD receptors
Molecular biology
The [3H]-5-HT binding site in the rat striatum with low affinity for spiperone (Pedigo 
et a l, 1981) was later named the 5-H Tjb binding site, whereas another [3H]-5-HT 
binding site in the bovine brain was termed the 5-H T id binding site on account of its 
different pharmacological profile (Heuring & Peroutka, 1987). Subsequent molecular 
discoveries led to considerable debate and revision of the nomenclature of these 
receptors, due to the existence of both intraspecies receptor subtypes and interspecies 
receptor homologues (see Hartig et al., 1992; Hartig et al., 1996).
The first clone of this receptor pair was of the 5-HT id receptor gene, then simply 
called RDC4 -  an unassigned sequence from a canine thyroid cDNA library (Libert 
et al., 1989). Although its homology to the 5-H T ja receptor sequence was noted, it 
was only later identified as the canine 5-H Tjd receptor gene (Zgombick et al., 1991). 
It was thought that rodent 5-H T jb and non-rodent 5-H T jd receptors were species 
homologues, based on their distribution and pharmacology (Hoyer & Middlemiss, 
1989). This was confirmed by cloning of the rat 5-H T jb receptor (Voigt et al., 1991; 
Hartig et al., 1992) with the pharmacological profile of the 5-H T jb binding site. Very 
soon afterwards, however, an orthologous gene was isolated from the human 
genome, and this had a different pharmacological profile -  namely that of the 5-H T jd
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receptor (Weinshank et a l, 1992; Levy et al., 1992; Veldman & Bienkowski, 1992). 
The human 5-H Tjd receptor appeared to be a composite of 2 subtypes, encoded by 
different genes, which were then defined as 5-H T jdo and 5-HTjop (Hartig et al.,
1992). The human 5-HTjDp has 96 % sequence homology to the rat 5-H T jb receptor 
(Jin et al., 1992), and their pharmacological difference has been attributed to a single 
amino acid substitution (Metcalf et a l, 1992). These differences are summarised in 
Figure 1.7, using the old nomenclature (5-HTjDa etc.), which has now been revised to 
take into account these homologies: hence 5-HTjop is now known simply as 5-H T jb, 
and 5-HTjDa has reverted to 5-H T jd-
Both rat and human cloned 5 -H J jb receptors (Adham et al., 1992; Levy et al., 1992; 
Weinshank et a l, 1992) and 5-H T jd receptors (Hamblin et al., 1992; Weinshank et 
al., 1992) inhibit forskolin-induced cAMP accumulation, suggesting negative 
coupling to adenylate cyclase.
intraspecies subtypes
human 5-HT,0o human 5-HT1()S!
species
homologues
species
homologues
canine 5-HTt0 rat 5-HT18
(RDC4)
interspecies subtypes
Figure 1.7 5-H T jb/id  receptors
Diagram illustrating relationships between species differences
in 5-H T ib/id receptors (adapted from Hartig, 1992)
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Distribution
Mapping of differential tissue distributions of 5-HTib and 5-HTid receptors using 
radioligands poses some difficulties due to the lack of 5-HTid selective ligands. In 
the rat, the 5-HTib/id receptor radioligand [125I]GTI, alone or in the presence of CP- 
93129 to mask 5-HTjb receptors, reveals densest 5-HTjb binding sites in the basal 
ganglia (globus pallidus, substantia nigra pars reticulata, nucleus accumbens and 
subthalamic nucleus), and 5-HTjd binding sites in a very similar distribution, but 
with only a fraction of the intensity (Bruinvels et al., 1993). The same researchers 
reported the highest 5-HTjb receptor mRNA expression in the rat olfactory cortex, 
subthalamic nucleus, and hippocampal CA1, with lower signal in nucleus 
accumbens, caudate-putamen, and cerebellar Purkinje cells, and lowest expression in 
the amygdala, hypothalamus, thalamus, cortex and pons. Likewise, very weak 5- 
HTjd receptor mRNA was present in olfactory cortex, nucleus accumbens, caudate- 
putamen, dorsal raphe and pons (Bruinvels et al., 1994). Interestingly, they also 
found 5-HTjb receptor mRNA in rat posterior communicating artery but not basilar 
artery.
Researchers focussing on the cellular location of 5-HTjb receptors report mRNA in 
dorsal root ganglia, cerebral cortex layer IV, cerebellar Purkinje cells, and neurones 
of the dorsal and median raphe. These latter two signals are greatly reduced by 5,7- 
DHT lesion, suggesting 5-HTjb autoreceptors in these raphe nuclei (Doucet et al., 
1995). Another in situ hybridisation study described highest 5-HTjb receptor signal 
in caudate-putamen, olfactory tubercle, CA1 and cerebellar Purkinje cells, with less 
in cortex (layer IV), thalamus, dorsal raphe and spinal cord (Boschert et al., 1994). 
However, additional autoradiography in this investigation showed that areas with 
high receptor mRNA have few binding sites and vice-versa, although the areas to 
which the mRNA-rich structures project are high in binding sites. Together with the 
previous lesion study, this suggests that 5-HTjb receptors are located predominantly 
on axon terminals. Interestingly, inhibitory 5-HTjd receptors are also located on 
raphe cell bodies (Bonaventure et al., 1998), and these are colocalised with 5-HTjb 
receptors, at least in the mouse (Evrard et al., 1999).
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With respect to the brainstem and spinal cord, binding sites were identified in human 
tissue using [ H]-sumatriptan, plus ketanserin to differentiate between 5-H Tjb and 5- 
H Tjd (Castro et al., 1997). Both binding sites were detected in (rank order of 
density) spinal trigeminal nucleus, substantia gelatinosa, NTS, and periaqueductal 
grey, although 5-H T jb binding sites were between 3 and 20 fold denser in all these 
regions. The expression in these areas indicates a possible role in the processing and 
modulation of sensory and autonomic afferent information.
Pharmacology
5-H T jb/id receptor binding is fraught with idiosyncrasies, and the following 
examples will illustrate such problems. Binding of common ligands at 5-H T jb 
receptors in rat frontal cortex (Millan et al., 2002) and guinea pig striatum (Audinot 
et al., 1997) is as follows (pATj rat vs. pK\ guinea pig). Agonists include 5-HT (9.1 vs. 
8.6), 5-CT (9.5 vs. 9.1), L-694247 (10.4 vs. 10.1), CP-93129 (8.4 vs.< 6), and 
sumatriptan (7.4 vs. 6.8). Antagonists include GR-125743 (9.4 vs. 9), GR-127935 
(8.2 vs. 8.4), (-)-pindolol (7.6 vs. 5.8), (-)-propranolol (7.4 vs. 5.6), methiothepin (7 
vs. 8) and methysergide (6.5 vs. 6.7). These reveal that CP-93129 and the [3-blockers 
are more selective for the rat receptor. Interestingly (-)-pindolol binds to rat cortical 
5-H Tjb receptors with a pKi of 7.1 (Hoyer et al., 1985a), and to human cortical 5- 
H Tjd receptors with a pK\ of 5.1 (Peroutka et al., 1989). Also, (-)-propranolol binds 
to cloned rat and cloned human 5-H T jb receptors with a pK\ of 8.3 and 6.2 
respectively (Hamblin et al., 1992). Conversely, sumatriptan has pK\s of 7.3 and 8.7 
respectively on cloned rat and human 5-H T jb receptors (Hamblin et al., 1992), and 8 
and 8.4 respectively on cloned rat and human 5-H Tjd receptors (Hamblin & Metcalf, 
1991; Hamblin et al., 1992), whereas on cloned dog 5-H T jd receptors it has a pK\ of
8.8 (Boess & Martin, 1994). This illustrates some of the variations shown in Figure 
1.7 -  human 5-H Tjb/id and dog 5-H T jd receptors have similar affinities, whereas rat 
5-H T jb is pharmacologically distinct, although genetically related.
Compative binding (pATj) to cloned human 5-H Tjb and 5-H T jd (i.e. 5-H T jdo and 5- 
HTjop) receptors (Weinshank et a l, 1992) using [3H]-5-HT, was reported as follows: 
5-HT (8.4 vs. 8.4), 5-CT (8.8 vs. 9.1), 8-OH-DPAT (6.6 vs. 6.9), sumatriptan (8.1 vs.
8.5), methysergide (7.6 vs. 8.4), spiperone (< 5 vs. 6). In a different study, again 
using [3H]GR-125743 (Domenech et al., 1997), the affinities (pICso) at human
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cloned 5-H T ib v s . 5-H T id receptors were: 5-HT (7.4 vs. 8.5), 5-CT (7.9 vs. 8.6), 8- 
OH-DPAT (6.1 vs. 7.3), sumatriptan (7.2 vs. 8.1), methiothepin (8.2 vs. 8.2), GR- 
127935 (9.4 vs. 8.7) and naratriptan (8 vs. 8.8). Therefore within the human species 
there tend to be less discrepancies between these subtypes than there are between the 
same receptor amongst different species. As such, the guinea pig is favoured over the 
rat as a species with comparable affinities to the human receptors.
For the most part, it remains difficult to distinguish between 5-H T ib and 5-HT id 
receptors, especially in functional assays, so compounds are often referred to as 
acting on 5-H T ib/id receptors, for the sake of simplicity. The most selective 
antagonists for 5-H T ib/id receptors over other 5-HT receptors are GR-127935 
(Skingle et a l , 1996) and GR-125743 (Millan et al., 2002), although recently several 
highly potent and selective 5-H T ib receptor antagonists have been developed, 
including SB-216641 (Price et a l, 1997) and SB-236057 (Roberts et al., 2000).
General physiology
Inhibitory 5-H T jb autoreceptors on serotonergic terminals are believed to fine tune 5- 
HT release at various CNS structures. For example, it has been demonstrated that 
these receptors limit the increased forebrain efflux of 5-HT caused by selective 
serotonin reuptake inhibitors (SSRIs) (Malagie et al., 2001). On the other hand, 5- 
H Tjb receptors have been reported to facilitate dopamine efflux in the striatum 
(Galloway et al., 1993), acetylcholine efflux in the hippocampus (Maura et a l, 
1989), and to inhibit GABAergic transmission onto dopamine containing neurones 
(Morikawa et a l, 2000), so their effects on other transmitter systems are potentially 
very wide ranging. Functional roles in vivo have been described in the regulation of 
mood (Sipes & Geyer, 1996; Saudou et a l, 1994), reward (Fletcher & Korth, 1999; 
Belzung et al., 2000), sleep (Boutrel et al., 1999), locomotor activity (Chaouloff et 
al., 1999), appetite (Lucas et al., 1998), and cognition (Boulenguez et al., 1998; 
Meneses, 1999). Due to the lack of selective ligands, 5-H T jb receptor (-/-) knockout 
mice have been useful in differentiating 5-H T ib from 5-HT id receptor mediated 
effects. There is no dramatic knockout phenotype, although they do display various 
behavioural differences, such as increased aggression (Saudou et a l, 1994) and 
increased paradoxical sleep (Boutrel et al., 1999). Fenfluramine-induced anorexia is
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abolished (Lucas et al., 1998), and SSRI-induced 5-HT efflux is enhanced (Malagie 
et al., 2001).
By far the most useful application of 5-H T ib/id receptor agonists is in the treatment 
of migraine (see Goadsby, 1998; De Vries et al., 1999; Tepper et al., 2002). The 
effect of these agonists is thought to be spread across a number of targets: firstly, by 
constricting cerebral blood vessels via 5-H T ib receptors (see Villalon et al., 2002); 
secondly by inhibiting the release of inflammatory mediators; and thirdly, by 
reducing the excitability of sensory neurones (see Goadsby, 1998). This latter effect 
is demonstrated by iontophoresis of the agonists sumatriptan and zolmitriptan, which 
inhibit the excitation of second (.order trigeminal neurones by nociceptor afferents in 
anaesthetised cats (Storer & Goadsby, 1997).
Autonomic functions
Peripherally, 5-H T ib/id receptor agonists cause internal carotid vasoconstriction in 
anaesthetised dogs, probably via smooth muscle 5-H T ib receptors (Centurion et al.,
2001), although these receptors also mediate external carotid vasodilatation, possibly 
via a presynaptic sympathoinhibitory mechanism (Villalon et a l, 2001). In 
anaesthetised cats the inhibition of sympathetic ganglionic transmission by 5-HT and 
5-CT was attributed to 5-H T ib/id receptors (Jones et al., 1995a).
Reflex activation of cardiac vagal and renal sympathetic outflow by stimulation of 
the upper airways with smoke in anaesthetised rabbits was attenuated by i.e. 
sumatriptan (Dando et al., 1998), indicating that 5-H Tjb/id receptor activation has 
the same effect as 5-H T ja receptor blockade, possibly reflecting inhibition of 5-HT 
release onto 5-H T ia receptors. GR-127935 had no effect, so 5-H T ib/id receptors in 
the medulla are not involved in reflex transmission per se. Similar results were found 
in the micturition reflex in anaesthetised rats, which was inhibited by sumatriptan 
and 5-CT, but not in the presence of GR-127935 (Read et al., 2004). Within the 
NTS, iontophoresis of sumatriptan tended to inhibit ongoing neuronal firing, and this 
effect was inhibited by 5-H T id selective, and potentiated by 5-H T ib selective 
antagonists. Also, the 5-H T iB receptor selective agonist CP-39129 increased 
baseline, vagus-evoked, and cardiopulmonary afferent-evoked firing, whilst the latter
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was reduced by sumatriptan (Jeggo et a l, 2000a; Jeggo, 2003). These data point to 
differential roles of these receptors within the NTS, with 5-H T iB increasing, and 5- 
HTjd decreasing neuronal excitability. Consequently, sumatripan is likely to 
attenuate autonomic reflexes via 5-H Tjd receptor activation. As such, the effects of 
non-selective 5-HTi receptor agonists must be treated with care.
1.6.5. 5-ht1E and 5-HTiF receptors
5-htiE  receptor
Little is known about the 5-htiE receptor due to a lack of selective ligands, and it 
remains in lower case (5-ht) due to the lack of functional characterisation to date. 
The receptor was first characterised in human brain as having low affinity for 5-CT 
and ergotamine (Leonhardt et a l, 1989), distinguishing it from other 5-HTi 
receptors. The human receptor was cloned, with 64 % sequence homology to the 
human 5-H T ib/id receptors, and shown to inhibit forskolin-induced cAMP 
accumulation (Zgombick et a l, 1992). In situ hybridisation signal was detected in 
human and monkey caudate nucleus and putamen, parietal, visual and entorhinal 
cortex, and medial hypothalamus (Bruinvels et a l, 1994).
Various non-selective ligands bind to the cloned human 5-htin receptor, and their 
rank order of potencies is reported as: 5-HT > methysergide > ergotamine > 8-OH- 
DPAT > 5-CT > ketanserin (Zgombick et a l, 1992). Comparative binding of 
common ligands to human cloned 5-htiE (Zgombick et a l, 1992) and 5-H T if 
receptors (Adham et a l, 1993) (p£i) was as follows: 5-HT (8 vs. 8), 5-CT (5.1 vs. 
6.1), methiothepin (6.7 vs. 6.2), methysergide (6.6 vs. 7.5), and sumatriptan (5.6 vs.
7.6), suggesting that 5-htiE receptors tend to have lower affinities for known 5-HT] 
ligands, and especially that sumatripan binding is particularly selective for 5-HT if 
receptors.
5-HT if receptor
The 5-H T if receptor was the fifth human 5-HT] receptor to be cloned, also 
negatively coupled to adenylate cyclase (Adham et a l, 1993). In situ hybridisation 
revealed prominent receptor mRNA in guinea-pig frontal, olfactory, parietal,
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entorhinal and cingulate cortices (layer V), and moderate signal in hippocampus, 
amygdala, pons, claustrum, and spinal trigeminal nucleus (Bruinvels et a l, 1994). In 
the human brainstem and spinal cord, [3H]-sumatriptan in the presence of 5-CT 
revealed differential 5-H T ib, 5-H T id and 5-H T if receptor binding sites in the 
following rank order: NTS and spinal trigeminal nucleus (5-H T ib > 5-H T iF > 5- 
H T id ), substantia gelatinosa (5-H T if >  5-H T ib > 5-HTm) (Castro et al., 1997).
Common 5-HT] receptor ligands including 5-CT, methysergide and sumatriptan have 
comparable affinities for the cloned human and rat 5-HT if receptors (Adham et al., 
1993; Lovenberg et a l, 1993b) suggesting that species variation is not an important 
factor as in the 5-HTib/id receptor. Sumatripan, zolmitriptan and naratriptan all have 
high and similar affinities (pKi 7.6 -  9) for 5-HTib/id/if receptors (see Barnes & 
Sharp, 1999) . A selective agonist, LY-334370, has also been developed, with a pK\ 
of 8.8 at the cloned 5-HT if receptor and 100-fold selectivity over 5-HTib/id receptors 
(Phebus et a l, 1997).
LY-334370 has been demonstrated to inhibit neurogenic dural inflammation in the 
guinea pig (Johnson et a l, 1997), and to inhibit the activation of second order 
trigeminal neurones by dural stimulation in the rat (Shepheard et a l, 1999). This 
suggests that the antimigraine effects of compounds such as sumatriptan may be 
mediated by 5-H T if in addition to 5-H T jb/id receptors. Due to their distribution in 
areas such as hippocampus and cortex, there may be roles for the 5-H T if receptor in 
certain behavioural states, although systemic LY-334370 does not produce 5-HT 
stereotypical behaviour (see Barnes & Sharp, 1999).
1.6.6. 5-HT2 receptors
The three 5-HT2 receptor subtypes share a 46 -  50 % overall sequence identity, and 
couple preferentially to Gq leading to increased hydrolysis of phosphoinositide and a 
rise in intracellular Ca2+ concentration (see Hoyer et a l, 2002). The 5-HT2a receptor 
was originally termed the D receptor (Gaddum & Picarelli, 1957), later renamed the 
5-HT2 receptor (Peroutka & Snyder, 1979). The 5-HT2b receptor, firstly located in rat 
fundus, was previously known as the 5-HT2f (fundus) receptor. The 5-HT2c receptor
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was previously known as the 5-HTic receptor, and reclassified by the International 
Union of Pharmacology in 1994 (see Hoyer et a l ,  1994).
5-HT2A receptor
The 5-HT2A receptor was first cloned from a rat brain cDNA library, with high 
affinity for spiperone, ketanserin and mianserin, and low affnity for 8-OH-DPAT 
(Pritchett et al., 1988). Cloning of the human counterpart showed an 87 % sequence 
homology with the rat receptor (Saltzman et al., 1991). Receptor autoradiography 
using [125I]-DOI or [3H]-MDL-100907 combined with in situ hybridisation found 
receptor expression with good agreement in neocortex (layer V), caudate-putamen,
and various brainstem nuclei (pontine, trigeminal motor and facial nuclei) (Mengod
1.
et al., 1990b; Lopez-Gimenez et al., 1997). This confirms an earlier in situ 
hybridisation study, which additionally found lower signal in various areas including 
CA3, entorhinal cortex, amygdala, substantia nigra, and lowest signal in various 
brainstem areas including NTS and raphe (Pompeiano et al., 1994). Others have 
reported high levels of mRNA in rat DVN and nucleus ambiguus (Wright et a l ,
1995). Peripherally, Northern blotting reveals highest levels of receptor mRNA in the 
liver and spleen (Bonhaus et al., 1995).
5-HT2B receptor
The receptor mediating 5-HT-evoked contraction of the rat stomach fundus was 
cloned from the mouse (Foguet et a l ,  1992) and rat (Kursar et al., 1992), and termed 
the 5 -HT2B receptor. Originally, it was thought to be only peripherally expressed. 
Northern blotting identified mRNA in rat kidney, pancreas and liver, but not in 
whole brain (Bonhaus et al., 1995). Immunocytochemistry localised the receptor not 
only to longitudinal and circular smooth muscle of rat stomach fundus, but also to 
Purkinje cells of the cerebellum, the lateral septum, dorsal hypothalamus and medial 
amygdala, and to fibres but not cell bodies of the frontal cortex and spinal cord 
(Duxon et al., 1997a). This distribution correlates well with mRNA expression in the 
rat brain (Flanigan et al., 1995).
5-HT2C receptor
The 5 -HT2C receptor was cloned in the rat (Julius et al., 1988), mouse (Yu et al., 
1991) and human (Saltzman et al., 1991), and is X-linked (human chromosome
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Xq24). Although mRNA has been detected in rat heart, kidney and liver (Bonhaus et 
al., 1995), this receptor it thought to be almost exclusive to the brain, where its 
mRNA is highly expressed in hippocampus, subiculum and subthalamic nucleus, 
moderately expressed in amygdala, lamina V of the spinal cord, and substantia nigra. 
Lower expression was found in NTS, nucleus ambiguus, raphe, and various 
hypothalamic and thalamic nuclei (Molineaux et a l, 1989; Wright et al., 1995). A 
later study confirmed a similar distribution, including NTS, plus moderate levels in 
parts of cortex and septum, basal ganglia and locus coeruleus, but no signal in raphe 
(Pompeiano et al., 1994). Additional to these sites, the choroid plexus is a very rich 
source of 5-HT2C receptors (Mengod et al., 1990a).
Pharmacology o f 5-HT2 receptors 
A lot of pharmacological characterisation has been performed in cloned 5-HT2 
receptor subtypes. Importantly, there are no overt difference in the affinities of 
common ligands to human and rat cloned, and to human cloned and native 5 -HT2 
receptors (Bonhaus et al., 1995)
A wide variety of compounds non-selectively activate 5 -HT2 receptors, but there are 
no highly selective (> 100-fold) agonists; pharmacological characterisation has relied 
on antagonists. 5-HT activates all subtypes with comparable potency (pEC50 of 7.7,
8.9 and 8 at human cloned 5 -HT2A, 5-HT2B and 5 -HT2C receptors respectively); m- 
CPP is selective for 5-HT2A/C (pECso of 6.7, < 5 and 7), DOI is poorly selective for 5- 
HT2A (pECso of 8.2, 7.5 and 7) (Jerman et al., 2001), whereas a-methyl-5-HT is 
selective for 5-HT2B (pECso of 7.4, 8.7, 7.9) and DOB and quipazine are non- 
selective (Porter et al., 1999) LSD is a partial agonist with similar potency at all 3 
subtypes, and lisuride a 5 -HT2A selective partial agonist (Porter et al., 1999).
The antagonists methiothepin and mianserin have similar high affinities for all 5 -HT2 
receptors, whereas ketanserin is 5 -HT2A selective (pXs at cloned human receptors of 
8.7, 6 and 7 respectively), SB-204741 is 5 -HT2B selective (j>Kb of 5.8, 6.7 and 6.2) 
mesulergine is 5 -HT2C selective (pXs of 7.4, 8.9 and 9.5) (Jerman et al., 2001). With 
the exception of SB-204741, all these compounds have effects on other 5-HT and 
non-5-HT receptors. In this respect, cinanserin is a useful 5 -HT2A selective 
antagonist (pKv of 8.3, 5.8, 6.7) with negligible ai adrenoceptor, histamine or
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muscarinic receptor affinity (van Wijngaarden & Soudijn, 1997). More selective 
antagonists continue to be developed, including MDL-100907 for 5-HT2a (Sorensen 
et a l, 1993), RS-127445 for 5-HT2B (Bonhaus et a l, 1999), and SB-242084 for 5- 
HT2c (Kennett et a l, 1997b).
General physiology
Activation of 5-HT2 receptors causes depolarisation of neuronal membranes in a 
number of different brain areas, but whether the excitation (reduced K+ conductance) 
depends upon phosphoinositide signalling is uncertain. In rat piriform cortical slices, 
5-HT has excitatory effects via 5-HT2a receptors on intemeurones, and 5-HT2c 
receptors on pyramidal cells (Sheldon & Aghajanian, 1991; Marek & Aghajanian, 
1994). The effects of hallucinogenic and antipsychotic drugs (such as LSD and 
clozapine) which bind to these receptors are thought to be mediated by these cortical 
mechanisms. Excitatory 5-HT2 receptors are also described in slices of nucleus 
accumbens (North & Uchimura, 1989), dentate gyms (Piguet & Galvan, 1994) and 
prefrontal cortex (Araneda & Andrade, 1991b). In vivo, systemic 5-HT2 receptor 
activation decreases noradrenaline efflux in the hippocampus (Done & Sharp, 1992; 
Done & Sharp, 1994), via indirect inhibition of locus coemleus neurones, possibly 
involving other brainstem afferents (Gorea et a l , 1991).
Systemic administration of 5-HT2 receptor agonists produces various behavioural 
signs such as head twitches, which are thought to be mediated by 5-HT2a receptors. 
There is also a close correlation between the hallucinogenic properties of drugs in 
humans, and their affinity for 5-HT2a receptors (Glennon, 1990), where they are 
thought to act as agonists or partial agonists. Additionally, atypical antipsychotics 
such as clozapine, olanzapine and risperidone have high affinity for 5-HT2a 
receptors, suggesting a role in schizophrenia (Leysen et a l, 1993). Other effects of 
5-HT2a receptor activation include hyperthermia (Gudelsky et a l, 1986), and 
neuroendocrine secretion (Fuller, 1996). There is little evidence for a behavioural 
role for the 5-HT2B receptor, which is poorly expressed in the CNS, with the 
exception of the amygdala. Indeed, microinjection of the selective 5-HT2B receptor 
agonist BW-723C86 into the amygdala has an anxiolytic effect (Duxon et a l, 
1997b), making it an interesting target in the treatment of anxiety. A number of 
behavioural responses are also attributed to 5-HT2c receptor activation, including
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hypolocomotion, hypophagia, anxiety, penile erections and hyperthermia (see Koek 
et al., 1992), and the advent of new and highly selective ligands is allowing many 
formerly generalsed 5 -HT2 receptor mechanisms to be re-evaluated.
Autonomic functions
Systemic administration of DOI raises BP in rats via a combination of direct and 
angiontensin II-mediated vasoconstriction (Alper, 1990), as well as by a central 
mechanism: in cats i.v. DOI and quipazine also increases sympathetic nerve 
discharge (McCall et al., 1987; Vayssettes-Courchay et al., 1991) , which was 
prevented by pretreatment with ketanserin but not prazosin (McCall & Harris, 1988). 
Ketanserin itself decreased baseline sympathetic activity, but this was probably 
mediated by ai adrenoceptor blockade (Ramage, 1985). In rats, i.c.v. cinanserin does 
not affect baseline sympathetic activity (Knowles & Ramage, 1999), suggesting that 
these central receptors are not tonically activated. In the anaesthetised cat, however, 
i.v. cinanserin can cause a fall in blood pressure (Ramage, 1988).
Iontophoretically applied DOI had no effect on sympathetic preganglionic neurones 
that were excited by i.v. DOI (Clement & McCall, 1990), suggesting that the 
receptors are located supraspinally. Application of DOI to the ventral medulla of 
cats raised BP (without altering HR), suggesting the receptors are located in the 
RVLM (Mandal et al., 1990). Additionally this study found that the pressor response 
to central DOI was reduced by i.v. propranolol or stellate ganglionectomy, 
suggesting that central sympathoexcitatory 5 -HT2 receptors have a cardiac inotropic 
but not chronotropic effect, i.e. that they are located on sympathetic premotor 
neurones controlling outflow to the ventricles but not nodal regions of the heart, 
hence increasing contractility and cardiac output, but not rate. This was supported by 
the observation that i.c.v. DOI increased cardiac nerve activity but not HR, and did 
not increase renal nerve activity (Anderson et al., 1995). However, in the definitive 
experiment, where BP and HR were held constant in an anaesthetised cat, DOI onto 
the ventral medulla failed to increase cardiac contractility, although it did increase 
hindlimb resistance (Ramage & Daly, 1998), which nevertheless confirms that 
RVLM premotor neurones to the heart respond differently from those to other 
targets.
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In rats, 5-HT2A receptors regulate vasopressin release (Anderson et al., 1992), and 
stimulation of 5-HT2A receptors with i.c.v. agonists causes a tachycardia and rise in 
BP due in part to vasopressin release; additionally, this vasopressin release causes a 
secondary reduction in sympathetic nerve activity via 5-HT2B receptors (Knowles & 
Ramage, 1999), although 5-HT2B receptors can themselves excite sympathetic 
outflow to the kidney (Knowles & Ramage, 2000). These receptors are believed to be 
involved in central regulation of blood volume.
Vagally-activated NTS neurones are either excited or inhibited by iontophoretic DOI 
(Wang et al., 1997). Further investigation found that second-order neurones in the 
NTS are more likely to be inhibited, whilst higher-order neurones tend to be excited 
by 5 -HT2 receptors (Sevoz-Couche et al., 2000b), and these effects were probably 
mediated by 5-HT2C (inhibition) and 5 -HT2A/B (excitation) receptors respectively.
1.6.7. 5-HT3 receptor
It was first demonstrated that 5-HT can cause neuronal depolarisation and the release 
of acetylcholine in the guinea pig ileum, which was attributed to the activation of the 
M receptor (Gaddum & Picarelli, 1957), thus termed because it interfered with the 
effects of morphine on gut contractions. Several decades later this was reclassified 
as the 5 -HT3 receptor (Bradley et al., 1986).
Molecular biology
The 5 -HT3 receptor is a fast-conducting ligand-gated ion channel (Derkach et al., 
1989). Electron microscopic imaging of the 5 -HT3 receptor protein revealed a 
pentameric structure arranged around a central aperture which forms the ion channel, 
similar to the neuronal nicotinic receptor (Boess et al., 1992). The 5 -HT3A subunit 
was first cloned from a neuroblastoma expression library (Maricq et al., 1991), 
where it showed approximately equal sequence similarity to the neuronal nicotinic, 
GABAAbi and glycine receptors. An alternative murine splice variant with a 6 amino 
acid deletion in the cytoplasmic loop was also cloned (Hope et al., 1993). The 5- 
HT3 receptor causes fast depolarisation of neuronal membranes, and is selective for 
Na+ and K+ with near equal permeability. It is also prone to rapid desensitisation 
(see Peters et al., 1992; Jackson & Yakel, 1995). In vitro, promiscuous co­
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assemblies of 5 -HT3 and neuronal nicotinic subunits can be formed, which are Ca2+ 
permeable (van Hooft et al., 1998), but whether these exist in vivo remains to be 
seen. Some 5 -HT3 receptor agonists have also been reported to increase 
phosphoinositide hydrolysis (Edwards et a l ,  1991), so further versions of the 
receptor may be naturally occurring.
Distribution
■2
Receptor autoradiography with [ H]-GR-65630 reveals the highest density of 5 -HT3 
binding sites in the cat NTS, DVN, nucleus ambiguus, and spinal trigeminal nucleus 
(Reynolds et al., 1991), and a similar distribution is found in the rat and human 
brainstem using tritiated selective ligands (Barnes et al., 1990; Waeber et a l ,  1989). 
Outside of the brainstem, however, density is much lower, with highest binding in 
hippocampus and amygdala, moderate binding in several cortical and limbic regions, 
and virtually no binding in pons, cerebellum, or basal ganglia (Barnes et al., 1990; 
Waeber etal., 1989).
Another important location of 5 -HT3 receptors is on peripheral terminals of many 
sensory afferents. 5-HT applied to a blister base causes pain in humans, which is 
sensitive to 5 -HT3 receptor antagonists (Richardson et a l ,  1985). 5 -HT3 receptors 
are thought to be responsible particularly for the peripheral transduction of 
chemically-induced pain (Giordano & Dyche, 1989). Centrally in the dorsal horn of 
the rat spinal cord, 5 -HT3 binding sites are reduced by capsaicin treatment (Hamon et 
al., 1989) suggesting the receptors are located on C-fibre terminals. They have also 
been found electrophysiologically in the rat dorsal root ganglion (Todorovic & 
Anderson, 1990). High receptor densities are found in autonomic nerves and their 
ganglia, especially the nodose ganglia and along the length of the vagus in the cat 
(Hoyer et a l ,  1989). Lesion of the cervical vagus in the mouse (Waeber et al., 
1988) or of the nodose ganglion in the rat (Pratt & Bowery, 1989) reduces binding 
sites in the NTS, suggesting a presynaptic location on primary afferent terminals, as 
in the spinal cord. Many of these afferents, however, may be abdominal, as 
subdiaphragmatic vagotomy abolishes 5 -HT3 binding sites, at least in the ferret 
(Leslie et al., 1990).
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Pharmacology
Pharmacological characterisation of 5 -HT3 receptors has been greatly facilitated by a 
wealth of selective ligands, especially when compared with other 5-HT receptors. 5- 
HT has a comparatively low affinity (pKj 6.8) for rat 5 -HT3 receptors (Kilpatrick et 
al., 1989; Barnes et al., 1990). Full agonists include (with pKi in rat brain) 
quipazine (9), 2-methyl-5-HT (6.9) (Kilpatrick et al., 1989) and PBG (7.1) (Barnes 
et al., 1990). Selective antagonists include zacopride (9.4), ICS-205930 (9.1), 
granisetron (8.7), ondansetron (8.6), MDL-72222 (7.9), and clozapine (7) (Barnes et 
al., 1990). Binding affinities of granisetron at central (cortex) and peripheral (vagus) 
sites are quite similar (pKx 9.2 vs 8.7) (Kilpatrick et al., 1989), and also at rat and 
human brain receptors (8.6) (Bames et al., 1988a; Barnes et al., 1988b). However, 
interspecies differences in pharmacology have been reported. For example, PBG and 
MDL-72222 have low affinities for the guinea pig receptor (Kilpatrick & Tyers, 
1992; Lankiewicz et al., 1998).
General physiology
The 5 -HT3 receptor has been researched within the framework of a number of 
different physiological functions and pathological conditions. The 5 -HT3A subunit 
knockout mouse displayed anxiolytic behaviour (Kelley et al., 2003), and antagonists 
have a similar anxiolytic effect on the startle response (Nevins & Anthony, 1994). 
Furthermore, cocaine-induced behaviour (Herges & Taylor, 2000), dopamine efflux 
in the nucleus accumbens by drugs of abuse (Carboni et al., 1989), and dopamine- 
induced locomotor behaviour (Costall et al., 1990) are all sensitive to 5 -HT3 receptor 
antagonists. 5 -HT3 receptor activation caused dopamine efflux in the striatum in 
vitro (Blandina et al., 1989) and in the nucleus accumbens in vivo (Chen et a l ,
1991). Thus the 5 -HT3 receptor is implicated in anxiety, reinforcement, and 
possibly in aspects of schizophrenia.
5 -HT3 receptors mediate the vomiting reflex, probably via actions at the NTS and 
area postrema, and this is very efficiently inhibited by 5 -HT3 receptor antagonists 
(Miner & Sanger, 1986), which also inhibit radiation- and cytotoxic drug-induced 
emesis (Miner et al., 1987; Bermudez & Sanger, 1994). Indeed, ondansetron and 
granisetron are widely used in the clinic for this reason. Additionally, the antagonist
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tropisetron is clinically effective in the treatment of fibromyalgia (Farber et al., 
2001).
Autonomic functions
Central autonomic functions of 5 -HT3 receptors appear to relate to their ability to 
modulate glutamate release: DVN vagal preganglionic neurones are excited by 
iontophoretic PBG, and this excitation is sensitive to 5 -HT3, AMPA and NMDA 
receptor antagonists, and to inhibition of neurotransmitter release with Mg2+ (Wang 
et al., 1996), suggesting that presynpatic 5 -HT3 receptors potentiate the release of 
glutamate onto these neurones. In NTS neurones activated by vagal afferents, a 
similar effect has been observed: both PBG- and cardiopulmonary afferent-evoked 
excitation are inhibited by granisetron, the NMDA receptor antagonist AP-5, and 
Mg2+ (Jeggo et al., 2000b; Jeggo et a l, 2001). This further proposes a reflex 
function -  that 5 -HT3 receptors in the NTS tonically contribute to reflex 
transmission, at least for the cardiopulmonary reflex -  which is supported by the 
effects of i.e. or microinjected (into the NTS) granisetron, which inhibits both 
cardiopulmonary reflex bradycardia and hypotension in the anaesthetised rat (Pires et 
al., 1998). Microdialysis in the NTS has shown increased glutamate efflux during 
local infusion of PBG (Ashworth-Preece et al., 1995), supporting the gluatamergic 
mechanism of action. However, micro injection of 5-HT or 1 -(m-chloro)-PBG into 
the NTS had also been shown to attenuate cardiopulmonary reflex bradycardia 
(Sevoz et al., 1996), and chemoreflex bradycardia (Sevoz et al., 1997), which were 
prevented by pretreatment (microinjection) with zacopride or ondansetron, and by 
bicuculline in the latter study, suggesting that 5 -HT3 receptor stimulation can also 
activate a GABAergic brake, which in these experiments overrides any glutamatergic 
effects.
1.6.8. 5-HT4 receptor
Prior to its molecular characterisation, the 5 -HT4 receptor was identified in the 1980s 
(see Bockaert et al., 1992). The receptor sequence was subsequently cloned in the 
rat (Gerald et al., 1995), consisting of two splice variants, a short (5-HT4S) and a 
long (5-HT4l) version, later renamed 5-HT4(a) and 5-HT4(b) (Hoyer & Martin, 1997). 
The human gene was mapped to chromosome 5 (q.31 -  q.33), sharing 94 % sequence
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homology with the rat and mouse (Claeysen et a l ,  1997). Further human splice 
variants (5-HT4(C) to 5-HT4(h)) have since been described (see Hoyer et a l ,  2002). 
The 5 -HT4 receptor couples positively to adenylate cyclase to increase cAMP 
production (Gerald et al., 1995), and this causes neuronal depolarisation via 
phosophorylation and inactivation of the inwardly rectifying K+ channel (Fagni et al.,
1992).
Reverse transcriptase polymerase chain reaction found 5-HT4(a) receptor signal in rat 
striatum, ileum, colon, and cardiac atria, and 5-HT4(b) receptor signal in striatum, 
olfactory bulb, hippocampus and brainstem, as well as in ileum and colon (Gerald et 
al., 1995). Autoradiography with [3H]-GR-113808 located 5 -HT4 binding sites in 
guinea pig brain, in the rank order striatum > olfactory tubercle > globus pallidus > 
hippocampus > substantia nigra, and in the rat brain in the rank order olfactory 
tubercle > globus pallidus > striatum > substantia nigra > superior colliculus > 
hippocampus (Grossman et al., 1993). The same radioligand revealed binding sites 
in the human brain in the rank order caudate nucleus > globus pallidus > putamen > 
hippocampus (Reynolds et al., 1995). Interestingly, the 5-HT4(d) isoform was 
detected only in the gut in humans, whereas 5-HT4(a-c) were also in brain and atrium 
(Blondel etal.,  1998).
5-HT binds to cloned rat 5 -HT4 receptors with a pK\ of 6.8 (Gerald et al., 1995). 
Several compounds have comparable binding affinities in the guinea pig striatum and 
hippocampus, including (with pK\ at striatum) the full agonists GR-67333 (8.7) 
(Eglen, 1997) 5-HT (7.3) and 5-methoxytryptamine (6.5), the partial agonists BMU- 
8 (7.9), cisapride (7.5), zacopride (6.8) and metoclopramide (6.3), and the highly 
selective antagonists GR-113808 (9.5) (Grossman et a l ,  1993), RS-39604 (9.1) 
(Hegde et al., 1995), and SB-204070 (10.2) (van den Wyngaert et al., 1997). 8-OH- 
DPAT, LSD, 5-CT and sumatriptan do not bind (pifi < 5) (Gerald et a l ,  1995).
A variety of neuromodulatory functions is ascribed to the 5 -HT4 receptor, especially 
acetylcholine release in the myenteric plexus of the gut (Tonini et al., 1989; Craig & 
Clarke, 1990), which is the basis of cisapride treatment for constipation-predominant 
irritable bowel syndrome. Subsequently, 5 -HT4 receptor activation with i.c.v. BMU- 
8 was also shown to increase acetylcholine efflux in rat frontal cortex (Consolo et al.,
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1994), possibly from cholinergic neurones in the septum -  an area which contains 
some 5 -HT4 receptor mRNA (Ullmer et al., 1996). This promoted interest in a 
cognitive role. Indeed, human post-mortem Alzheimer’s disease brains were reported 
to have lower 5 -HT4 receptor densities in the hippocampus compared to age-matched 
controls (Reynolds et al., 1995). In rats, the agonist GR-67333 reverses atropine- 
induced cognitive deficits (Fontana et al., 1997), and similar memory improving 
effects are described elsewhere in rats (Letty et al., 1997) and monkeys (Terry et a l,
1998).
Other roles of the 5 -HT4 receptor include facilitation of dopamine release in the rat 
striatum (Bonhomme et al., 1995; Steward et al., 1996), anxiolysis (caused by 
receptor antagonism) in the rat (Kennett et al., 1997a), and tachycardia in the pig 
(Villalon et al., 1990; Villalon et al., 1991). This latter effect is attributed to 5 -HT4 
receptors in the right atrium, which mediate 5-HT induced positive chronotropic 
effects, although positive inotropic effects are also reported, which are not thought to 
reflect the existence of ventricular 5 -HT4 receptors (Saxena et al., 1992). There are 
notorious species differences in the 5-HT receptors mediating tachycardia (see 
Saxena & Villalon, 1991), so it is interesting to note that in human atrial tissue, 5- 
HT4 receptors cause a positive chronotropic and inotropic effect (Blondel et al.,
1997). More recently, 5 -HT4 receptor stimulation has been shown to elicit atrial 
arrhythmias in man (see Kaumann, 1994). Cisapride, the only selective 5 -HT4 
receptor (partial) agonist to be marketed, has now been withdrawn due to side effects 
of QT prolongation and ventricular arrhythmias (Wysowski et al., 2001).
Although 5 -HT4 receptors are not involved in cardiovascular reflex transmission per 
se, a cAMP-dependent attenuation of the cardiopulmonary reflex was linked to 5- 
HT4 receptor activation (Edwards & Paton, 1999), i.e. microinjection of 5- 
methoxytryptamine (a non-selective agonist) into the NTS of anaesthetised rats 
attenuated cardiopulmonary reflex bradycardia and tachypnoea, which was prevented 
by pretreatment (microinjection) with RS-39604, which by itself had no effect. 
Further investigation found that chemical stimulation of raphe pallidus attenuated the 
cardiopulmonary reflex unless RS-39604 was bilaterally microinjected into the NTS 
(Edwards & Paton, 2000), suggesting that serotonergic axons from raphe pallidus 
innervate 5 -HT4 receptors in the NTS, causing an attenuation of reflex bradycardia,
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probably via activation of GABAergic inhibition, and with the possible function of 
blocking reflexes in an emergency situation.
A final interesting respiratory role was recently demonstrated in rats, where 
respiratory depression with the opioid receptor agonist fentanyl was reversed by 5- 
HT4 receptor stimulation, without loss of analgesia (Manzke et al., 2003), which 
suggests that 5 -HT4 receptors located in the pre-Botzinger complex can counteract 
this major side effects of opioid therapy.
1.6.9. 5-ht5 receptor
The 5 -ht5 receptor molecular characteristics are well established, but no function has 
yet been reported. Two subtypes, 5-htsA and 5-htsB, have been identified in the rat, 
sharing a 6 8  % amino acid homology (Erlander et a l, 1993). In humans, however, 
only the 5-htsA receptor gene is functional (Schanen et al., 1996), whereas the 5-htsB 
receptor gene is interrupted by stop codons (Grailhe et al., 2001), suggesting the 
receptor was lost during evolution. In transfected glioma cells, the 5-htsA receptor 
reduces cAMP accumulation (Carson et al., 1996). It was later shown to couple to 
Gi/Go (Francken et al., 1998). Additionally, when expressed in Xenopus oocytes, the 
5 -ht5A receptor can couple to and activate the inwardly rectifying K+ channel (Grailhe 
et al., 2 0 0 1 ).
5 -ht5A receptor mRNA is found in rat hippocampal CA1, medial habenula, raphe, 
septum, and hypothalamus, whereas 5-htsB mRNA is found throughout the CNS 
(Erlander et al., 1993; Grailhe et al., 2001). No 5-htsA receptor mRNA is found in 
peripheral organs (Grailhe et al., 2001), although both mRNA and immunoreactivity 
are reported in the carotid body, petrosal and superior cervical ganglia (Wang et al., 
2000b), suggesting a role in the chemoreceptor pathway. 5-htsA receptor mRNA is 
also found in rat astroctyes, at least during development (Carson et al., 1996), 
proposing a possible role for serotonergic signalling in gliosis or other glial cell 
functions.
The human 5-htsA receptor has high affinities (piCj) for LSD (9.7) and 5-CT (8) 
(Grailhe et al., 2001), but no selective ligands have been identified. Several
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commonly used 5-HT receptor ligands have comparable binding affinities at human 
and mouse cloned 5-htsA receptors, including (with p^i at human receptor) 
methiothepin (8.5), ergotamine (8), 5-CT and ritanserin (7.6), 5-HT (6.7) and 
clozapine (6.5) (Grailhe et al., 2001). The low affinity for 5-HT is noteworthy, and 
might suggest a function as a back-up receptor, activated only by high concentrations 
of endogenous transmitter, and hence a possible emergency control mechanism. Of 
further note is the potential overlap of 5-ht5A receptor pharmacology with that of 
other 5-HT receptors. The overlap with 5-HTja is minimal, since 8-OH-DPAT has a 
pK[ of only 5.7 (Grailhe et al., 2001), and WAY-100635 has a pK[ of < 5 (Thomas et 
al., 2004) at the cloned human 5-htsA receptor. Significant overlap, however, exists 
with the 5 -HT7 receptor, not only in the binding of 5-CT and methiothepin, but of the 
selective antagonist SB-269970, which has a pK\ at the 5-htsA receptor of 7.2 
(human), 6.9 (guinea pig) and 7.8 (rat) respectively (Thomas et al., 2004).
Very little functional data is available. The 5-ht5a (-/-) knockout mouse displays 
increased exploratory behaviour without accompanying anxiolytic behaviour, as well 
as, conversely, a reduction of LSD-evoked exploratory behaviour (Grailhe et al., 
1999), which supports a further functional binding site for LSD, but offers no real 
insight into receptor function. Based on deduction using a range of antagonists, 5- 
htsA receptor activation may also account for the cardiac sympathoinhibition caused 
by i.v. 5-HT in the pithed rat (Sanchez-Lopez et al., 2003), but more selective 
ligands are required to characterise this and any other functions of this poorly 
understood receptor.
1.6.10. 5-HT6 receptor
The rat 5-HT6 receptor was identified by cloning, and found to increase cAMP 
production (Ruat et al., 1993a). Cloning of the human receptor found it to be similar 
to rat in molecular, transductional and pharmacological properties (Kohen et al.,
1996).
In the rat and guinea pig, receptor mRNA was detected by Northern blotting and in 
situ hybridisation in the striatum, olfactory tubercle, nucleus accumbens and 
hippocampus (Ruat et al., 1993a). Receptor immunoreactivity was demonstrated in
similar areas, plus frontal, entorhinal and piriform cortex, cerebellum, caudate- 
putamen, and some brainstem motor nuclei (Hamon et al., 1999). Human receptor 
distribution is comparable to the rat and guinea pig, most noteably in the caudate 
nucleus (Kohen et al., 1996). 5,7-DHT lesions did not affect 5-HT6 receptor mRNA 
expression, suggesting it is not an autoreceptor (Gerard et al., 1996).
Non-selective agonists at the human cloned 5-HT6 receptor include (with \>K\) 5- 
methoxytryptamine (7.4), 5-HT (7.2), 2-methyl-5-HT (6.4) and 5-CT (6.1), and 
antagonists include methiothepin (9.4), mianserin (7.3) and methysergide (6.7) 
(Kohen et al., 1996). Recently, highly selective antagonists have been developed, 
such as Ro-650563 (pKj 7.9) (Slejght et al., 1998) and SB-357134 (8.8) (Stean et al.,
2002). EMDT has been described as a moderately (10-fold) selective agonist (pKj 
7.8) (Glennon et al., 2000). Several common antipsychotics also bind to 5-HT6 
receptors, including olanzapine (pKi 8.6), clozapine (8.4) and pimozide (7.2) (Roth et 
al., 1994).
Treatment with selective antagonists has produced a behavioural syndrome of 
stretching, yawning and chewing in rats (Sleight et al., 1998), which was also found 
when i.c.v. antisense oligonucleotides were given (Bourson et al., 1995), although a 
separate group instead reported an anxiogenic effect of i.c.v. antisense (Hamon et al.,
1999). The main current interests in this receptor are for the treatment of 
schizophrenia and cognitive decline (see Branchek & Blackburn, 2000). There are 
no reports or indications that the receptor may have any autonomic functions.
1.6.11. 5-HT7 receptor
The 5 -HT7 receptor is the most recently identified 5-HT receptor, and has attracted a 
fair amount of pharmaceutical research interest, much of which has been recently 
reviewed (see Vanhoenacker et al., 2000; Glennon, 2003; Thomas & Hagan, 2004; 
Hedlund & Sutcliffe, 2004). Prior to its classification in 1993, the 5 -HT7 was 
described as an as yet unidentified receptor different from other 5-HT receptors. 5- 
HT induced relaxation of the porcine vena cava was antagonised by methysergide 
(Trevethick et al., 1984) suggesting a novel 5-HT receptor mediating vasodilatation. 
This receptor was further characterised as being positively coupled to adenylate
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cyclase, and activated by 5-CT (Sumner et a l, 1989), making it different from any 
other 5-HT receptor known. A similar unidentified 5-HT receptor was found on the 
canine coronary artery (Cushing & Cohen, 1992) and in the vicinity of SPNs in the 
rat spinal cord (Lewis & Coote, 1990).
Molecular biology
In 1993 a novel nameless 5-HT receptor was cloned from a rat cDNA library 
(Meyerhof et al., 1993), and then also from a human library and described as the 5- 
HT7 receptor (Bard et al., 1993). Then in quick succession it was also cloned from 
mouse (Plassat et al., 1993), rat (Lovenberg et al., 1993a) and guinea pig (Tsou et 
al., 1994), and later from pig (Bhalla et al., 2002). The 5 -HT7 receptor gene has been
1,
localised to chromosome 10 of the human genome (q23.3 -  q24.4) (Gelemter et al., 
1995). Alternative splicing has been described in rat and human, consisting of splice 
variants 5-HT7(a) and 5-HT7(b), which are homologous in both species, and a third 
splice variant termed 5-HT7(C) in rats and 5-HT7(d) in humans (see Vanhoenacker et 
al., 2000). All 3 isoforms are functionally active: 5-HT7(a) is the most abundant in the 
brain, accounting for 55 % of 5 -HT7 mRNA in the human hippocampus, and 80 % in 
the rat (Heidmann et a l, 1997). The 5-HT7b isoform is the second most abundant in 
both species, and the 5-HT7C (rat) and 5-HT7(d) (human) isoforms account for less 
than 4 % of mRNA (Heidmann et a l, 1997). The splice variants display similar 
binding characteristics. In the human splice variants, however, different numbers of 
phosphorylation sites and different C terminus lengths have been found, which might 
lead to differences in desensitisation and trafficking properties, even if gross 
pharmacology is similar.
The 5 -HT7 receptor is positively coupled to adenylate cyclase (Bard et al., 1993), 
presumably via Gs. The 5-HT7(a) isoform couples to the Ca -calmodulin sensitive 
isoforms of adenylate cyclase (AC1 and AC8), which are neurone specific, leading to 
an increase in intracellular Ca2+, both of which imply a role in neuronal excitability 
(Baker et a l, 1998). Indeed, activation of 5 -HT7 receptors increases neuronal 
excitability by suppressing the Ca2+-activated K+ current causing slow 
afterhyperpolarisation following a spike discharge, which has been demonstrated in 
brain slices containing hippocampal CA3 (Bacon & Beck, 2000) and midline 
thalamus (Goaillard & Vincent, 2002). This appears to be due to direct inhibition of
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the Ca2+ activated K+ channel, which also causes an increase in burst firing in CA3 
(Gill et al., 2002). This 5-CT induced firing was absent in slices of 5 -HT7 receptor 
(-/-) knockout mice (HI Choudhury et a l, in press). In vivo, the increase in firing of 
CA1 neurones evoked by the SSRI fluvoxamine is abolished by 5 -HT7 receptor 
antagonists, which by themselves do not affect population spike activity (Matsumoto 
et al., 2002) confirming a role for the 5 -HT7 receptor in neuronal activity in vivo, 
albeit not a tonic one.
Distribution
Receptor distribution has been reported in a wide range of CNS structures, mainly 
using autoradiography with [3H]-5-CT or other compounds, in situ hybridisation, and 
rarely immunocytochemistry. Combined autoradiography and in situ hybridisation 
found overlapping binding and mRNA signals in rat superficial neocortex, lateral 
septum, hypothalamus, dorsal/midline thalamus, amygdala and hippocampus, as well 
as weaker signals in dorsal raphe, periaqueductal grey, pontine nuclei, NTS, and 
dorsal horn of the spinal cord (Gustafson et al., 1996). The same technique in the 
guinea pig revealed overlapping signals in thalamus, hippocampus, hypothalamus, 
neocortex and amygdala, and weak binding in dorsal raphe, NTS and the reticular 
formation (To et al., 1995). An antibody to the 5 -HT7 receptor was raised, binding 
and overlapping with mRNA expression in rat superficial neocortex, olfactory 
tubercle, septal nuclei, hippocampus, amygdala, thalamus and hypothalamus 
(Neumaier et al., 2001). In this study, agonist induced (8-OH-DPAT in the presence 
of WAY-100635) c-fos expression was shown in neurones, demonstrating the effect 
of the 5 -HT7 receptor on neuronal excitability. Another study has also reported 5- 
HT7 receptor immunoreactivity in the rat cerebellum, confined to Purkinje cells 
(Geurts et al., 2002), and on hippocampal pyramidal cells (Bickmeyer et a l, 2002). 
More recently, the selective antagonist [3H]-SB-269970 has been used to radiolabel 
5 -HT7 receptors in the neocortex of the rat, pig, guinea pig, marmoset, and human 
(Thomas et al., 2002). Hence it is clear that 5 -HT7 receptors are predominantly 
expressed in limbic areas of the brain, but also in the NTS of both the rat and guinea 
Pig-
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Pharmacology
The pharmacological profile of the 5 -HT7 receptor has redefined the classification of 
agonists and antagonists previously thought to be selective for other receptors. No 
selective agonists have been found to date, but the agonist with the highest affinity is 
5-CT, with a \>KX of 9.1 at human 5-HT7(a) and of 8.8 at guinea pig cortex (Hagan et 
al., 2000). 8-OH-DPAT is also an agonist with moderate affinity, having a p^i of 6.6 
at both human and guinea pig receptors (Hagan et al., 2000), while 5-HT has a pK\ of 
8.2 and 8 respectively (Hagan et al., 2000). In the original cloned human receptors, 
the affinity of 5-CT (pKx) was 9, 5-HT was 8.1, and 8-OH-DPAT was 6.3 (Bard et 
al., 1993). Compared to 5-CT, 8-OH-DPAT has an efficacy of 0.73 or 0.87 
depending on which G protein adapter type is transfected (Wood et al., 2000). Both 
5-CT and 8-OH-DPAT also have affinities for 5-HT ia, 5-H T ib and 5-HTJD receptors. 
Reported affinities of 5-CT (pATj) include 8 at 5-HT ia (Lovenberg et al., 1993a), 7.9 at 
5-HT jb, and 8.6 at 5-HT id (Domenech et a l, 1997), whilst affinities of 8-OH-DPAT 
include 7.6 at 5-HT ia (Lovenberg et a l, 1993a), 6.2 at 5-HTiB and 7.3 at 5-H T jd 
(Domenech et al., 1997).
Many non-selective antagonists that were previously used to generate data on other 
receptor systems have affinities for the 5 -HT7 receptors including (with pK\ at 
guinea pig cortex): methiothepin (7.4), mesulergine (6.9) and clozapine (6.5) (Hagan 
et al., 2000). Affinities of many antagonists were also described at the cloned human 
5-HT7 receptor (with pKx): methiothepin (8.4), metergoline (8.2), mesulergine (7.7), 
ritanserin (7.3), methysergide (7.1) and spiperone (7) (Bard et al., 1993). Ritanserin 
and mesulergine, for example, were previously thought to be selective for the 5 -HT2 
receptor. Various other commonly used drugs are also reported to bind to 5 -HT7 
receptors, including the antipsychotics pimozide (pKi 9.3), risperidone (8.9), 
chlorpromazine (7.7), loxapine (7.4), olanzapine (7) and haloperidol (6.6) (Roth et 
al., 1994); the antidepressants mianserin (7.2) and clomipramine (6.9), and the 
hallucinogen LSD (8) (Ruat et al., 1993b).
The first antagonist with high (100-fold) selectivity for 5 -HT7 over other 5-HT 
receptors was the aryl sulphonamide SB-258719 (Thomas et a l, 1998a), although its 
affinity was only moderate. Variations on this structure led to the synthesis of
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compounds with higher affinity, including SB-258741 and SB-269970 (Lovell et al.,
2000), the latter having a pK[ of 8.9 at cloned human 5-HT7(a) receptors and 8.3 at 
guinea pig cortex, and 100-fold selectivity over other 5-HT receptors except the 5- 
htsA receptor (50-fold selectivity) (Hagan et al., 2000). SB-269970 is CNS penetrant 
(with a brain:blood steady state of 0.83:1 in rats) but is rapidly cleared, with no 
compound detectable in the brain 1 hour after a 3 mg kg’1 intraperitoneal (i.p.) dose 
(Hagan et al., 2000). Further structural modifications led to the development of SB- 
656104, with a p£j of 8.7, which is orally active, and has a half-life of 1.4 hr 
following a 10 mg kg'1 i.p. injection, leading to a plasma concentration of ~1 pM 
(Thomas et al., 2003). SB-656104 binds to other receptors moderately, with the 
following relative selectivity for the 5 -HT7 receptor: 5-HT id (20-fold), dopamine D2 
(70-fold), 5-HT ia (150-fold).
General physiology
The high level of receptor expression in the hypothalamus proposed a role for the 5- 
HT7 receptor in temperature regulation (Gustafson et al., 1996); indeed, the ability of 
new compounds to inhibit i.c.v. 5-CT induced hypothermia has become a reliable 
pharmacodynamic assay of 5 -HT7 receptor antagonism in vivo. This model has 
demonstrated the 5 -HT7 receptor antagonism of SB-269970 (Hagan et al., 2000) and 
SB-656104 (Thomas et a l, 2003) in the guinea pig. In the mouse, 5-CT induced 
hypothermia was attenuated by the 5 -HT7 receptor antagonists SB-269970 and SB- 
258719, but not by the 5-HT iA or 5-HT ib/id receptor antagonists WAY-100635 or 
GR-127935 (Guscott et al., 2003), confirming the 5 -HT7 receptor mediated 
mechanism. 5-CT induced hypothermia is also absent in 5 -HT7 receptor (-/-) 
knockout mice (Hedlund et al., 2003), although in this study oleamide still caused 
hypothermia. Oleamide is an endogenous lipid that is thought to be an allosteric 
modulator of 5 -HT7 (as well as 5-HT ja and 5-HT2a/c) receptor function (Hedlund et 
al., 1999). It induces sleep, and accumulates during sleep deprivation (Basile et al., 
1999; Thomas et al., 1998b). Furthermore, neurones of the thalamus and 
hypothalamus that express c-fos in response to oleamide tend to express 5 -HT7 
receptors (Thomas et al., 1999b).
Within the hypothalamus, 5 -HT7 receptors are highly expressed in the 
suprachiasmatic nucleus (SCN) (Lovenberg et al., 1993a) -  a cell group involved in
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circadian rhythms. In vitro, a 5 -HT7 receptor-induced phase shift of SCN neurones 
has been demonstrated, which is sensitive to transcription and translation inhibitors, 
suggesting that 5 -HT7 receptors contribute to circadian rhythms via protein synthesis 
(Jovanovska & Prosser, 2002). In vivo, both SB-269970 (Hagan et al., 2000) and SB- 
656104 (Thomas et al., 2003) modulate sleep architecture, the latter increasing the 
latency of rapid eye movement (REM) sleep and reducing the time spent in REM 
sleep. These effects have stimulated pharmaceutical interest for the treatment of 
depression. Disturbed sleep is a common symptom of unipolar depression: in 
humans, sleep cycles and circadian rhythms interact to influence mood (Boivin et al.,
1997), and unipolar depression commonly involves reduced sleep efficiency, time, 
and latency, combined with increased amount of REM sleep (Brunello et a l, 2000). 
Conversely, SSRIs modify sleep architecture in healthy and depressed patients 
(Schlosser et al., 1998; Trivedi et al., 1999). Hence the ability of 5 -HT7 receptor 
antagonists to mimic the sleep modulating profiles of antidepressants raised the 
possibility that this could be a good predictor of antidepressant efficacy. It is 
interesting to note that a number of antidepressants including fluoxetine and 
imipramine are reported to increase c-fos expression in SCN neurones via 5 -HT7 
receptor activation, and also to downregulate these receptors with chronic treatment 
(Mullins etal., 1999).
A role for 5 -HT7 receptors in anxiety is under preliminary investigation, based on the 
assumption that inhibition of ascending dorsal raphe neurones has an anxiolytic 
effect, as is seen with the 5-HTia receptor agonists (see Menard & Treit, 1999), 
which subsequently decrease 5-HT efflux in raphe terminal fields (Sharp et a l, 
1993). In rat dorsal raphe slices, SB-269970 was originally reported as not affecting 
local 5-HT efflux (Roberts et al., 2001a), but a subsequent adjustment of the protocol 
showed that SB-269970 does cause a bicuculline-sensitive decrease in 5-HT efflux, 
suggesting that 5 -HT7 receptors are located on GABAergic intemeurones in this 
nucleus (Roberts et al., 2004b). Whether these effects extend to other brain areas, or 
correlate to behaviour, remains to be established.
Additional to its role in the treatment of depression, there has been interest in the 5- 
HT7 receptor’s role in the treatment of psychotic illness, due to its affinity for 
clozapine (Plassat et al., 1993). The antagonist SB-258719 was tested on 3 animal
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models of the positive symptoms of schizophrenia, but its only effect was to 
normalise phencyclidine-disrupted prepulse inhibition, with no effect on the other 
models (Pouzet et al., 2002). Amphetamine induced locomotion was reduced in this 
study, but so was basal locomotor activity, so the results are unclear. Suffice it to say 
that this antagonist does not display the typical profile of an antipsychotic drug.
There has also been some interest in the 5 -HT7 receptor’s role in learning and 
memory. In contrast to the 5-HT6 receptor, 5 -HT7 receptor activation may enhance 
memory, since the beneficial effects of 8-OH-DPAT on learning consolidation in rats 
was blocked by the non-selective 5 -HT7 receptor antagonists ritanserin and LY- 
215840 (Meneses & Terron, 2001). Although in this study the role of the 5 -HT7 
receptor is not unequivocal, recent research with 5-HT7 receptor (-/-) knockout mice 
describes an impaired contextual fear conditioning, together with reduced long-term 
potentiation in hippocampal CA1 (Roberts et al., 2004a), but no other differences 
compared to (+/+) wild-type littermates on a battery of behavioural tests including 
locomotion, rotarod, light-dark transfer, tail flick analgesia, Barnes maze, and 
operant food conditioning. Further research, using selective antagonists, will be 
necessary for full characterisation of the behavioural functions of the 5 -HT7 receptor.
Autonomic functions
Very little has been reported on the autonomic roles of the 5 -HT7 receptor. Various 
peripheral functions have been described, including dilatation of canine coronary 
artery (Cushing & Cohen, 1992) and carotid artery (Centurion et al., 2000; Villalon 
et al., 2001). Additionally, 5-HT induced tachycardia is thought to be caused by 
cardiac 5 -HT7 receptors in the cat (Villalon et al., 1997), although there is a marked 
species difference in this effect (see Saxena & Villalon, 1991).
Prior to the characterisation of the 5 -HT7 receptor, it was reported that 5-CT applied 
iontophoretically to rat sympathetic preganglionic neurones caused excitation that 
could not be blocked by selective antagonists, hence pointed to a novel (5-HT 1-like) 
receptor (Lewis & Coote, 1990). In retrospect, the 5 -HT7 receptor would be a strong 
candidate. Since then, this receptor has been implied in the transmission of spinal 
reflexes evoked by stimulation of the sural nerve in the decerebrate rabbit: in this
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respect, reflex facilitation due to 8-OH-DPAT was inhibited by ritanserin (Ogilvie et 
al., 1999), hence suggesting but not confirming 5 -HT7 receptor involvement.
Supraspinally, the 5 -HT7 receptor has been implicated in the control of micturition 
in anaesthetised rats: both SB-269970 and SB-656104 inhibit reflex-evoked bladder 
contractions when given i.c.v., but not when given i.t. (Read et al., 2003). Also i.c.v. 
5-CT, in the presence of GR-127935, causes spontaneous bladder contractions (Read 
et al., 2004). Together these results suggest an important physiological role for 
supraspinal 5 -HT7 receptors in the control of bladder function, and raised the 
question of whether other parasympathetic functions also utilise this receptor.
I
1.6.12. 5-HT transporter
The 5-HT transporter, often referred to as SERT (serotonin transporter) is the 
principal mechanism of inactivation of released 5-HT, removing it from the 
extracellular space, back into neurones where it can be either repackaged into 
vesicles, or degraded by monoamine oxidase. SERT belongs to a large family of 
transporters, other members of which selectively sequester other monoamines 
(noradrenaline and dopamine), amino acids (glutamate, GABA, glycine), and other 
molecules (see Amara & Kuhar, 1993). The monoamine transporters constitute a 
distinct subfamily on the basis of their high amino acid homology, and their affinities 
for various antidepressants, amphetamine analogues, and cocaine.
SERT was cloned from the rat (Blakely et a l, 1991; Hoffman et a l, 1991), where it 
is a Na+-dependent transporter (i.e. Na+ is a co-factor co-transported with 5-HT), with 
12 transmembrane spanning domains, highly expressed in raphe areas, and sensitive 
to a variety of antidepressants. The human cloned transporter shares 92 % of its 
sequence with the rat (Ramamoorthy et a l, 1993). Autoradiography with tritiated 
uptake inhibitors reveals dense binding in the raphe, and moderate binding 
throughout all their projection areas in humans (Cortes et al., 1988) and rats (Hrdina 
et al., 1990; Hensler et al., 1994). A similar pattern of SERT immunoreactivity is 
found (Qian et al., 1995), and the SERT antibody is a popular tool for staining 5-HT 
containing structures in general.
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A variety of SSRIs and tricyclic antidepressants bind to cloned human SERT and rat 
cortical SERT with comparable affinities (Owens et a l, 1997). Of the SSRIs, the 
most potent is paroxetine, with a pKx (human cloned SERT) of 10, compared with 7.1 
at the human cloned noradrenaline transporter. The most selective with respect to 
this latter transporter is citalopram (p£j 8.8 vs. 5.1), just ahead of fluoxetine (9 vs. 
6.1) (Owens et al., 1997). An example of a SERT-selective tricyclic is clomipramine 
(p£i 9.8 vs. 7.3) (Millan et al., 2001), whereas a non-selective tricyclic is 
amitriptyline (pK\ 8.6 vs. 7.7) (Owens et a l, 1997). Additionally, a number of 
compounds such as MDMA (‘ecstasy’) and fenfluramine require SERT to gain entry 
to neurones, (Hekmatpanah & Peroutka, 1990; Wichems et al., 1995) causing non- 
vesicular release (retrotransport) of 5-HT, again via SERT.
SERT is regarded as the primary site of action of many antidepressants. Although 
their mode of action is complex, their initial effect is to increase synaptic 
concentrations of 5-HT. At first this would decrease raphe neuronal firing by 
autoreceptor activation, but chronic treatment is thought to desensitise autoreceptors, 
thus enhancing serotonergic transmission at the heteroreceptors (Blier et al., 1990). 
This would account for the several week delay in therapeutic effect. The many roles 
of SERT and its ligands in the pathogenesis and treatment of affective and other 
disorders have been extensively reviewed (Lesch, 1997; Stanford, 1999).
Whilst older tricyclic antidepressants are renowned for cardiovascular side-effects 
(due to peripheral muscarinic and ai adrenoceptor antagonism, and Type 1A 
antiarrhythmic action), central autonomic effects of selective compounds are rarely 
reported. From the mode of action of SSRIs, they should be able to enhance certain 
serotonergic functions. Indeed, i.e. fluoxetine augments reflex bronchoconstriction 
in the anaesthetised guinea pig (Bootle et al., 1998). Repeated (4 day) fluoxetine 
treatment also enhances baroreflex control of the sympathetic system in rats (Moffitt 
& Johnson, 2004), which may account for its success in the treatment of orthostatic 
intolerance. Similarly, human post traumatic stress disorder patients tend to display 
decreased heart rate variability, which is reversed with fluoxetine treatment (Cohen 
et a l, 2000). Other researchers report no effect of SSRIs on heart rate variablity in 
depressed patients (Sattler et a l, 2000) or in healthy volunteers (Siepmann et al.,
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2003), although in this latter study the SSRI sertraline did lower baseline HR and 
skin conductance, possibly due to sympathoinhibition.
1.7. Aims of the thesis
The aims of this thesis are to characterise the serotonergic control of cardiovascular 
reflexes in rats with reference to the 5-HT receptor subtypes involved, the central 
pathways innervating these receptors, and the synaptic mechanisms responsible for 
interaction between serotonergic and glutamatergic reflex transmission in the 
medulla. These investigations ar6 divided into the following parts:
1. To characterise which 5-HT receptors in the brainstem are involved in the 
transmission of the cardiopulmonary reflex, baroreflex and chemoreflex in 
anaesthetised rats, using new highly selective antagonists. The aim is to confirm 
previous findings on the role of the 5-HTi a receptor in the rabbit, to spot any 
species differences, and also to investigate the possible role of the 5 -HT7 
receptor, which has recently been implicated in bladder reflex control. This 
study will also re-examine previous findings of the role of 5-HT 1 a receptors in 
cardiopulmonary reflex control in anaesthetised rats, in which no sympathetic or 
respiratory variables were measured, and in which non-selective 5-HT receptor 
antagonists were used.
2. To investigate which central 5-HT containing cell groups may be responsible for 
the effects observed in 1. above. Initially this will involve electrically and 
chemically stimulating areas of the medullary raphe to locate any areas affecting 
cardiac vagal outflow. Subsequently, the role of endogenous 5-HT and 5-HT 
receptors in these responses will be evaluated. One of these techniques (5-HT 
depletion) will also allow the role of endogenous 5-HT in cardiovascular reflex 
function to be assessed. Additionally, an attempt will be made to reconcile the 
conflicting previous reports on sympathetic and respiratory roles of the raphe by 
careful topographical analysis of the roles of these nuclei.
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3. To examine the site of action of intracistemally applied compounds characterised 
in 1. above, using extracellular single unit recordings from dorsal medullary 
nuclei. Additionally, the role of glutamatergic transmission in the NTS will be 
studied (using iontophoretically applied drugs) to assess the interactions between 
glutamatergic and serotonergic signalling in reflex pathways, with particular 
attention to higher order neurones in the NTS. Neurones will also be labelled by 
the juxtacellular technique, and subsequent 5-HT immunocytochemistry will be 
performed to assess the apposition of 5-HT containing terminals with these 
physiologically characterised neurones.
4. Having characterised the roles and mechanisms of 5-HT receptor contribution to 
cardiovascular reflexes in anaesthetised rats, a brief study will be carried out to 
confirm that these mechanisms are functioning in awake animals.
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2. G e n e r a l  m e t h o d s
The methods outlined below describe the general methods used for the preparation of 
anaesthetised animals and the collection of data presented in this thesis. These have 
been divided as shown in Table 2.1. The specific protocols used will be outlined 
within the methods section of each chapter, for clarity. Additionally, the full 
methods for the preparation of the awake rats used in Chapter 6 are described in that 
chapter.
Table 2.1 Methods separated according to anaesthesia and techniques
Table illustrating different methods described in this chapter, depending on 
anaesthetic protocol (A or B), and how these are used in different chapters. The 
variables measured in each chapter are also shown (MAP: mean arterial pressure, 
ECG: electrocardiogram, IRNA integrated renal nerve activity, IPNA: integrated 
phrenic nerve activity, Cell: single unit extracellular potential, HR: heart rate).
Anaesthesia Chapter Techniques used Variables
A a-chloralose 3 Reflex pharmacology MAP
a-bungarotoxin ECG
atenolol 4 Raphe stimulation IRNA
5-HT depletion IPNA
B pentobarbitone 5 Single unit electrophysiology MAP
gallamine Iontophoresis ECG
Topical applications IPNA
juxtacellular labelling Cell
C None 6 Reflex pharmacology MAP
(awake rats) HR
See Ch 6
for methods
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2.1. Preparation of rats
Experiments were performed on adult male Sprague-Dawley rats (280 -  450 g) under 
a personal and project licence from the UK Home Office. At the end of experiments, 
animals were euthanased with pentobarbitone sodium (60 mg i.v.) All rats were 
obtained from a colony at the Comparative Biology Unit, Royal Free & University 
College Medical School.
Induction o f  anaesthesia
Animals were placed in a perpex induction chamber and anaesthetised with 
isoflurane (5 % in 100 % O2), then placed supine on a homeothermic heating blanket 
(Harvard Apparatus), the isoflurane transferred to a face-mask (Fluovac), and the 
concentration reduced to 1.5 -  2.5 %. Core body temperature was maintained 
between 37 and 38°C. by means of a rectal temperature probe attached to the 
homeothermic system (Harvard Apparatus).
Cannulation o f blood vessels
The left femoral vein was cannulated (Portex non-sterile tubing, ED 0.96 mm, ID 
0.58 mm) and the cannula attached to a three-way valve for administration of drugs 
and fluids. The left femoral artery was cannulated (Portex non-sterile tubing, ED 
0.96 mm, ID 0.58 mm); the tubing contained heparinised 0.9% saline (10 IU ml'1), 
and was connected to a pressure transducer (Statham model P23XL) and amplifier 
(Grass Instruments 7PI). The cannula was used for continuous recording of arterial 
blood pressure and periodical collection of arterial blood samples. The skin incision 
was closed with stainless steel suture clips.
Maintenance o f anaesthesia
Once intravenous access and blood pressure recordings were established, isoflurane 
was switched off, and anaesthesia was continued with a-chloralose (80 mg kg'1 i.v.) 
given over 1 min. Throughout the surgery the depth of anaesthesia was assessed by 
the absence of a withdrawal reflex in reponse to a noxious pinch, and supplementary 
doses of a-chloralose (10 mg kg'1 i.v.) were given if required.
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2.1.2. Anaesthesia for single unit electrophysiology
For single unit electrophysiological experiments, animals were anaesthetised with 
pentobarbitone sodium (Sagatal®; 60 mg kg'1 i.p.). This provides greater stability of 
cardiovascular reflexes, and consequently greater stability of the brainstem and 
recording electrode. Once intravenous access was established, anaesthesia was 
maintained with supplementary doses of pentobarbitone sodium as required (approx. 
20 mg kg'1 h '1 i.v.).
2.1.3. General surgical preparation
Cannulation o f the trachea 
A midline skin incision was made in the throat and the underlying salivary glands 
sprayed with Xylocaine® (lignocaine in 10 mg metered doses). The trachea was 
exposed by blunt dissection, and cannulated using a stainless steel tube (ED 1.8 mm) 
to enable connection to a ventilator (Harvard Apparatus model 683). A branch of the 
ventilator tubing was connected to a pressure transducer (Statham model P23XL) and 
amplifier (Grass Instruments 7PI) for measurement of tracheal pressure. Mechanical 
ventilation with oxygen-enriched room air was commenced once the animal was in 
the stereotactic frame, as described below.
Cannulation o f the bladder
A 1 cm skin incision was made in the lower abdomen and sprayed with lignocaine. 
The abdomen was opened and the bladder was pulled to the surface, emptied by 
gentle digital pressure, and cannulated at the apex using a polythene tube (ED 1.6 
mm, ID 1.0 mm). This allowed urine to drain freely, preventing any reflex effects 
from bladder distention. The abdomen and skin were closed with stainless steel 
suture clips.
Cannulation o f the right atrium and cardiopulmonary reflex 
The right external jugular vein was exposed following tracheal cannulation, and a 
polythene cannula (ED 0.8 mm, ID 0.4 mm) advanced 3 cm into the vein so that the 
tip lay within or close to the right atrium. This cannula was connected to a 100 pi 
Hamilton syringe and pre-filled with 0.05 mg ml'1 phenylbiguanide (PBG), which 
acts on 5 -HT3 receptors to activate cardiopulmonary afferents (Kay & Armstrong, 
1990). The cardiopulmonary reflex was stimulated by injection of 1 -  5 pg PBG per
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animal (20 -  100 pi) over 2 s. The dose of PBG was adjusted to evoked a 
submaximal bradycardia (40 -  100 bpm). At least 5 min was allowed to elapse 
between PBG injections to prevent tachyphylaxis. The skin incision was closed with 
stainless steel suture clips. In a few animals correct cannula placement was 
confirmed post mortem.
Intravenous injection o f sodium cyanide 
In experiments involving the arterial chemoreflex, a cannula (Portex non-sterile 
tubing, ED 0.96 mm, ID 0.58 mm) was inserted into the right femoral vein. This 
cannula was connected to a 100 pi Hamilton syringe and pre-filled with 0.5 mg ml’1 
NaCN in 0.9 % saline. The chemoreflex was elicited by injection of 25 -  50 pg 
NaCN per animal (50 -  100 pi) over 2 s. The dose of NaCN was adjusted to evoke a 
submaximal bradycardia (30 -  100 bpm). To ensure a bradycardia rather than 
tachycardia in response to NaCN injection, arterial PaC>2 was maintained at 85 -  100 
mmHg. At least 5 min was allowed to elapse between NaCN injections to prevent 
tachyphylaxis.
Intravenous injection o f phenylephrine
In some experiment a cannula was inserted into the right femoral vein as described 
above, and pre-filled with the a-adrenoceptor agonist phenylephrine (0.1 mg ml'1 in 
0.9 % saline). The baroreflex was elicited by injecting a bolus of 3 -  8 pg 
phenylephrine per animal (30 -  80 pi). The dose was adjusted to increase MAP by ~ 
50 mmHg.
Positioning in stereotaxic frame 
The animal’s head was placed in a stereotaxic frame (Royal Free Medical 
Engineering) using ear and incisor bars, with the head ventroflexed at 20°. The body 
was placed on an adjustable stage, which was lowered so that the forelimbs were just 
clear of the stage. A midline skin incision was made over the back of the head and 
continued laterally over the right scapula. The nuchal muscles were dissected from 
the occipital bone and removed by cautery to reveal the atlanto-occipital membrane.
Cannulation o f the cisterna magna and intracisternal injection
In experiments involving i.e. injection, a 23 gauge needle was used as a guide 
cannula. It was held in a Narashige micromanipulator at an angle of 20 - 40° from
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the vertical and inserted through the atlanto-occipital membrane until its tip lay 
within the cistema magna, as shown by the emergence of cerebrospinal fluid.
Test solutions for i.e. injection were drawn into a 25 pi glass syringe (Hamilton) 
attached via a short length of polythene tubing to a 25 gauge steel cannula. This was 
inserted into the cistema magna via the guide needle. Test solutions were injected 
over 20 s, and the cannula left in place for 5 min to ensure diffusion.
Exposure o f  the phrenic nerve
A phrenic nerve was exposed by reflecting the right scapula laterally and removing 
the overlying connective tissue. The nerve was dissected and desheathed, crushed 
distally to block afferent traffic, and placed on a bipolar silver hook electrode. The 
nerve and electrode were covered in polyvinylsiloxane dental impression material 
(Super Dent®, Carlisle Laboratories). This prevented the nerve from drying out or of 
excess fluid short-circuiting the electrode. Whole nerve activity was amplified 
(Digitimer NL 104; gain 1 0 - 2 0  K), filtered (Digitimer NL 125; 500 -  5000 Hz), 
and displayed on an oscilloscope (Tektronix 5103N), and as audio output (Royal 
Free Medical Electronics). The signal was also passed through a solid state electronic 
integrator (Royal Free Medical Electronics), which quantified activity in 5 s bins 
above background noise. The resulting peaks are a measure of both frequency and 
size of burst firing.
Exposure o f  the aortic depressor nerve 
In some experiments, the aortic depressor nerve was exposed following dissection of 
the phrenic nerve. The nerve was carefully dissected free from the cervical vagus and 
the sympathetic trunk, placed on a bipolar silver hook electrode, and insulated with 
polyvinylsiloxane dental impression material. The electrode was connected to a 
constant current stimulator box (Digitimer DS2) triggered by a digital programmer 
(Digitimer D4030). 5 s trains of 40 Hz pulses (0.1 ms pulse duration, 0 . 1 - 1  mA) 
were delivered and the current adjusted to evoke a submaximal bradycardia (40 -  
100 bpm). The identity of the aortic depressor nerve was confirmed by the 
bradycardia, hypotension and renal nerve inhibition resulting from its stimulation.
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Exposure o f  the renal nerve
In all but the single unit electrophysiolocial experiments, the animal’s hindquarters 
were turned, with the legs both facing left. A lumbar skin incision was made just left 
of the midline, the lumbodorsal fascia cut and the retroperitoneum opened by 
dissecting through the underlying muscle. A retractor exposed the renal artery and 
part of the abdominal aorta. A renal sympathetic nerve was dissected from the 
surrounding tissue where it crosses the junction of aorta and renal artery, placed on a 
bipolar platinum hook electrode, and insulated with polyvinylsiloxane dental 
impression material. Whole nerve activity was amplified (Digitimer NL 104; gain 20 
K), filtered (Digitimer NL 125; 100 -  500 Hz), and displayed on an oscilloscope 
(Tektronix 5103N) and as audio output above noise (Digitimer D130 Spike 
Processor). ^
Recording o f electrocardiogram 
ECG leads were attached to the front right and back left paw (ECG lead II) via 
needles inserted under the skin. The signal was amplified (Digitimer NL 104; gain 20 
K), filtered (Digitimer NL115; 10 -  100 Hz) and displayed on an oscilloscope 
(Tektronix 5103N, Guernsey Ltd). The R wave was discriminated using a spike 
processor (Digitimer NL 201).
2.1.4. Additional preparation: raphe stimulation
Using an electric drill (RS Biotech Ltd) a rectangular occipital crainiotomy was 
performed from the atlanto-occipital membrane to the lambdoid suture. The 
crainiotomy was extended rostrally using microrongeurs, taking care not to damage 
the venous sinuses. The dura was cut and reflected laterally. For optimal exposure of 
the IVth ventricle above the raphe, the overlying cerebellar lobules were removed by 
aspiration using a medical suction pump (MG Electronic Ltd) connected to a glass 
pipette. Any bleeding was controlled with haemostatic gauze (Surgicel®, Ethicon 
Sari). The exposed brain was covered with a saline-moistened cotton swab.
2.1.5. Additional preparation: single unit electrophysiology
A small unilateral thoracotomy was performed to create a pneumothorax, and light 
traction was put on the base of the tail to straighten the spine. End-tidal tracheal 
pressure was held at 1 cnftLO to prevent collapse of the lungs.
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A small crainiotomy was performed to gain access to the medulla, and the atlanto- 
occipital membrane was removed. Just prior to the beginning of the experiment, the 
dura and arachnoid were cut and reflected laterally.
After isolation of the phrenic nerve, the cervical vagus nerve was also dissected away 
from the sympathetic trunk and aortic depressor nerve, and placed on a bipolar hook 
electrode, connected to a power supply and stimulus generator. A test stimulus of 50 
Hz (1 ms pulse duration, 0.5 mA, 1 s train) producing an immediate maximal 
bradycardia confirmed a viable vagus. In some experiments the aortic depressor 
nerve was also identified and placed on a bipolar electrode. Nerves were insulated 
with polyvinylsiloxane. '
2.2. Neuromuscular blockade and stabilisation
Once surgery was completed, animals were neuromuscularly blocked with a- 
bungarotoxin (75 pg per animal i.v.) to ensure mechanical stability and to control 
respiratory afferent activity. An intravenous infusion was commenced (6 ml kg*1 h '1; 
Gilson Minipuls 2) consisting of 50 % Gelofusine plasma substitute and 50 % 
distilled water containing 100 mM NaHCOs and 10 mM glucose. This helped 
maintain blood volume and prevented metabolic acidosis. At regular intervals, 
arterial blood samples were collected in heparinised capillary tubes, and analysed 
using a pH/blood gas analyser (Ciba Coming 238).
Blood gases were maintained at PaC>2 90 -  120 mmHg, PaCC>2 40 -  50 mmHg, and 
pH at 7.3 -  7.4, by adjusting the rate and/or stroke volume of the ventilator, or by 
giving 1 mmol NaHCC>3 by slow intravenous injection. A PaCCh range of slightly 
higher than physiological norms was chosen to ensure that phrenic nerve discharge 
was entrained to the ventilator cycle. The preparation was left to stabilise for at least 
30 min. During neuromuscular blockade, depth of anaesthesia was continuously 
assessed by monitoring pupil diameter, the stability of blood pressure, heart rate and 
phrenic nerve activity, and the absence of cardiovascular response to noxious stimuli.
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Neuromuscular blockade for single unit electrophysiology 
In single unit electrophysiological experiments, neuromuscular blockade was 
commenced with gallamine triethiodide (initially 30 mg kg'1 i.v., followed by 6 mg 
kg’1 h '1 maintenance). This drug was selected because of its vagolytic properties, 
which prevent sudden changes in cardiac output due to reflex stimulation, thus 
reducing movement of the brainstem during these challenges. Accordingly, a dose of 
PBG that evoked a submaximal bradycardia was selected just prior to gallamine 
administration.
2.2.2. Cardiac sympathoadrenal blockade with atenolol
At the beginning of the protocol, animals were pretreated with the selective pi 
adrenoceptor antagonist atenolol (1 mg kg'1 i.v.) to block sympathoadrenal drive to 
the heart, so changes in heart rate could be assumed to reflect changes in cardiac 
vagal outflow. This drug has been chosen because it poorly penetrates the central 
nervous system (Street et a l, 1979) and has little or no affinity for 5-HT receptors 
(Middlemiss et al., 1977). It also has a long duration of action, making it suitable for 
our protocol of approximately 1 hour. Atenolol was not given to animals where 
single unit electrophysiology was performed.
2.3. Raphe stimulation
2.3.1. Stereotaxic microinjections
3-barrel glass micropipettes were constructed from borosilicate glass (1.5 mm OD, 
0.86 mm ID, Harvard Apparatus) bonded within brass collars (Royal Free Medical 
Engineering) using epoxy resin. These were pulled on a Narashige multibarrel 
electrode puller, and the tips broken back to 30 -  40 pm under microscopic guidance. 
The barrels were back-filled with 50 mM DL-homocysteic acid (DLH; in 0.9 % 
saline) for chemical stimulation, pontamine sky blue dye (2 % in 0.9 % saline) for 
marking of microinjection sites, and 0.9 % saline as a volume and pH control. All 
solutions were adjusted to pH 7.3 -  7.4. Each barrel was connected to a 3-way valve 
via a length of polythene tubing, and a 10 ml syringe used to apply positive pressure. 
A volume of 50 nl was injected by visualising the fluid meniscus via a binocular
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operating microscope (Leica M651) fitted with an eyepiece graticule. In some 
experiments the saline barrel was filled instead with a 1:1 mixture of Wood’s metal 
and indium for electrical stimulation. An indifferent electrode was also attached to 
the neck musculature, and electrical stimuli (0.2 ms pulses, 1 0 - 5 0  Hz, 50 -  100 pA, 
5 -  15 s) were delivered via a stimulus generator (Digitimer D4030) attached to an 
isolated constant current stimulator (Digitimer DS2).
The micropipette was held vertically in a Narashige micromanipulator, and the tip 
zeroed at the calamus scriptorius (caudal tip of the area postrema). Distinct areas of 
the medullary midline were serially stimulated with reference to a stereotaxic atlas 
(Paxinos & Watson, 1998). The most ventral point on any micropipette penetration 
was marked by depositing 50 nl pontainine for subsequent histological verification.
2.4. Depletion of 5-HT stores with para-chlorophenylalanine
In a separate set of experiments, the effects of depleting stores of 5-HT were 
investigated using the brain-permeable tryptophan hydroxylase inhibitor para- 
chlorophenylalanine methyl ester (p-CPA), which depletes both the CNS as well as 
peripheral organs of 5-HT (Koe & Weissman, 1966)). p-CPA was dissolved as 100 
mg ml"1 in sterile saline. Animals were given either p-CPA (350 mg kg'1 i.p.) or 
saline (3.5 ml kg'1 i.p.) on two consecutive days, and experiments performed 24 
hours after the second dose. This dosing regimen has been reported to deplete 5-HT 
stores by 95 % in the hippocampus (Chaput et al., 1990) and has previously been 
used to investigate whether an evoked response involved serotonergic transmission 
(Zhu & McNaughton, 1994). A single-blind design was adopted, in which the 
solutions were prepared by a technician, and their identity only revealed after data 
analysis and histology.
2.5. Single unit electrophysiology
2.5.1. Recording single unit activity
Single barrel recording electrodes were pulled from borosilicate glass and the tip 
broken against a glass rod to a diameter of ~1 pm. These were filled with 1M NaCl, 
resulting in an in vitro impedance of 5 -  15 MQ. Electrodes were held in a headstage 
(AxoClamp HS-2A) connected to an amplifier (AxoClamp 2B). An indifferent
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electrode was attached to the neck musculature. After dissection of the overlying pia 
mater, electrode penetrations were made along the edge of the area postrema, from 
0.2 mm caudal to 0.8 mm rostral to the calamus scriptorius, and 0.1 to 0.6 mm lateral 
to the midline. Electrodes were lowered through the medulla in 1 pm steps, using a 
micromanipulator (Inchworm, Burleigh).
Neurones responding to stimulation of the ipsilateral vagus (1 Hz, 1 ms pulse, 0.1 — 
1 mA) were recorded within the NTS at a depth of 350 -  900 pm, or in the DVN at a 
depth of 500 -  1100 pm. DVN (vagal efferent) neurones were distinguished from 
NTS neurones by the fact that they fire only a single evoked spike with no jitter 
(variability of latency), which is sensitive to the collision test, i.e. a vagal stimulus, 
triggered to fire at the same time as a spontanous spike, abolishes the evoked spike 
due to collision of the simultaneous afferent and efferent impulses.
Peri-stimulus time histograms (PSTHs; 1 ms bins) were plotted from 50 pulses 
(sweeps) of vagal stimulation at twice the latency of the evoked response. This 
characterised NTS neurones (according to the jitter of the evoked spikes) as 
receiving a monosynaptic or polysynaptic input.
Neurones were also functionally characterised with intra-atrial PBG, to test whether 
they receive cardiopulmonary afferent input (indicated by a burst of spikes within 2 s 
of PBG injection). In some experiments, neurones were also characterised as 
barosensitive or -insensitive depending on whether they fire in response to raising BP 
by 20 -  30 mmHg with i.v. phenylephrine ( 1 - 3  pg).
In some experiments, dorsal column (gracile nucleus) neurones were characterised as 
responding only to light touch (with a cotton bud) of the skin or fur of the ipsilateral 
hindquarters, and not responding to vagal stimulus. These neurones were found at a 
depth of 100 -  500 pm.
2.5.2. Pharmacology I: Iontophoresis
In some experiments, compound electrodes were constructed, consisting of a single 
recording electrode bonded to a 5 barrelled iontophoresis electrode (tip diameter 5 -
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10 pm; borosilicate glass, 1.5 mm OD, 0.86 mm ID bonded within brass collars with 
cyanoacrylate). The separation of the recording and iontophoresis tips was <10 pm.
Iontophoresis barrels were filled with a selection of: PBG (10 mM, pH 10.5), AMPA 
HBr (20 mM, pH 8.5), NMDA (20 mM, pH 8.5), DNQX (2.5 mM, pH 8.5) and 
DNQX vehicle (2.5 % DMSO, pH 8). All drugs were dissolved in 0.9 % saline 
except DNQX which was dissolved in DMSO and diluted in saline. Each barrel was 
connected via a silver wire to an iontophoresis pump (Neurophore). Drugs were 
ejected using a negative current (5 -3 0 0  nA). Between ejections, a positive retaining 
current of 15 nA was kept on the barrels to prevent leakage of drugs. To prevent 
artefacts due to current ejection, one barrel was filled with 2M NaCl and connected 
to the automatic current balancing module of the iontophoresis pump.
2.5.3. Pharmacology II: topical applications
In some experiments, the effect of test solutions, applied topically to the surface of 
the medulla, were tested on the baseline and evoked firing rate of NTS, DVN and 
dorsal column (gracile) neurones. In these experiments the medulla was 
conservatively exposed so that topical solution would remain over the obex region. 
Excess moisture was removed from the brain surface before each electrode 
penetration, but over the time taken to obtain a stable neuronal recording (10 -  20 
min) a layer of CSF forms over the surface, so topical solution is added to and 
diluted by this CSF (akin to i.e. administration).
2.5.4. Juxtacellular labelling
In some experiments, the recording electrode was filled with 1M NaCl containing 
2.5% (w/v) neurobiotin tracer for juxtacellular labelling (Pinault, 1996). Following 
electrophysiological characterisation of a neurone (with a spike amplitude of at least 
400 pV at 10 MQ impedance, suggesting juxtacellular placement of the electrode), 
positive current pulses (200 ms, 2.5 Hz) were applied to the electrode, starting at 0.5 
nA. Neurobiotin is positively charged in 1M NaCl solution, and so is 
iontophoretically ejected by positive current pulses. Current was carefully increased 
in 0.1 nA steps until the neurone began to fire regular spikes in response to the pulse 
(entrainment). Current was adjusted where necessary to keep neuronal activity 
between 3 - 8  spikes per pulse. This entrainment was maintained for 2 -  10 min. A
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maximum of 3 neurones were labelled on each side of the brain, separated by at least 
300 pm in the rostrocaudal axis to prevent overlap.
2.6. Histological processing
2.6.1. Confirmation of microinjections
At the end of raphe microinjection experiments, the animals were killed with an 
overdose of pentobarbitone. The background noise of the nerve recordings were 
verified. Brains were removed and fixed in 4 % formaldehyde in 0.1 M phosphate 
buffered saline for at least 72 hours. 100 pm coronal sections were cut on either a 
freezing microtome or a vibrating microtome, mounted, stained with 1 % neutral red, 
and coverslipped. The position of poiftamine marks were reconstructed on coronal 
stereotactic diagrams (Paxinos & Watson, 1998).
2.6.2. Immunocytochemistry of 5-HT containing neurones
At the end of experiments involving pretreatment with p-CPA (or saline), animals 
were deeply anaesthetised with pentobarbitone (30 mg kg'1 i.v.) and transcardially 
perfused with 300 ml heparinised saline followed by 500 ml 4 % formaldehyde in 0.1 
M phosphate buffered saline. The brains were removed and post-fixed for at least 72 
hours, then cut at 100 pm on a vibrating microtome. Sections were washed (3 x 10 
min) in tris-phosphate buffered saline (TPBS: 10 mM Tris, 0.9% NaCl, 0.05% 
thimerosal in 10 mM phosphate buffer, pH 7.4) containing 0.3 % Triton X-100, and 
incubated in 10 % normal horse serum (NHS; in TPBS-Triton) for 1 hour to block 
non-specific antibody binding sites, followed by primary antibody (rabbit anti-5-HT, 
Biogenesis, Poole; 1:4000 in 5 % NHS in TPBS-Triton) and left to incubate 
overnight. The following day sections were washed in TPBS (5 X 10 min) and 
incubated overnight with biotinylated secondary antibody (1:500 donkey anti-rabbit 
immunoglobulin; (Jackson ImmunoResearch Laboratories, West Grove PA). On the 
third day sections were washed in TPBS (3 x 10 min) and incubated overnight with 
ExtrAvidin® conjugated to horseradish peroxidase (1:1000 in TPBS-Triton). On the 
fourth day sections were washed in TPBS (3 x1 0  min) and processed for the nickel- 
diaminobenzidine (Ni-DAB) reaction as follows: sections were incubated in Ni-DAB 
solution (20 ml consisting of 5 ml 0.4 M phosphate buffer, 13.8 ml distilled water, 
0.2 ml 20 % glucose solution, 0.8 ml 1 % nickel ammonium sulphate solution, and
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10 mg DAB in tablet form). After 10 min incubation period, glucose oxidase solution 
(final concentration 250 units ml'1) was added to start the reaction. When optimum 
staining was observed, the reaction was stopped by washing with TBPS (2 x quickly 
and 2 x 1 0  min) and placing in distilled water. Sections were mounted on gelatinised 
slides, dehydrated, and coverslipped.
In some sections, the extent of background staining was confirmed by omitting the 
primary antibody from the protocol as a negative control.
2.6.3. Neurobiotin/5-HT double labelling
When juxtacellularly labelling was performed, at least 30 min was allowed to elapse 
after the last entrainment, to allow neurobio tin to diffuse throughout the neurone. 
Then animals were deeply anaesthetised, transcardially perfused, and the brains 
removed and post-fixed as described in 2.6.2 above.
50 pm coronal sections of medulla were cut on a vibrating microtome, and processed 
as follows, at room temperature and on a shaker. The sections were initially exposed 
to 1 % hydrogen peroxide (in distilled water) for 20 min to block endogenous 
perioxidase activity in red blood cells. Subsequently the sections were washed 3><10 
min in TPBS-Triton as described above (see 4.2.3), and exposed to 10% normal 
horse serum (NHS) in TPBS-Triton for at least 30 min before incubation in primary 
antibody. Primary antibodies were diluted with 10% NHS in TPBS-Triton and 
secondary antibodies, with 1% NHS in TPBS-Triton. Sections were washed 3 x 1 0  
min in TPBS after each exposure to an immunoreagent.
The sections were incubated for 2-3 days in 1:250 ExtrAvidin-horseradish 
peroxidase (Sigma) plus 1:7,500 rabbit anti-serotonin (Biogenesis). After washing, 
juxtacellularly labelled neurons were visualized via the imidazole-intensified 
diamidobenzidine (DAB-imidazole) reaction, peroxide being generated by glucose 
oxidase.
Sections were incubated in 20 ml DAB-imidazole solution, which was made up as 
follows: 10 ml of 100 mM Tris-HCl (pH 7.6), 200 pi of 1 M imidazole (w/v in 
distilled water), 200 pi of 0.4% NH4CI2 and 200 pi of 20% D-glucose (in 0.05%
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sodium azide). This was made up to 20 ml with distilled water, a 10 mg DAB tablet 
added and dissolved by stirring, filtered, and added to the sections.
After 10 min incubation, glucose oxidase solution (final concentration 250 units ml"1) 
was added to start the reaction. When optimum staining was observed, the reaction 
was stopped by washing with TBPS (2 x quickly and 2 x1 0  min).
The sections were then incubated overnight in 1:500 biotinylated donkey anti-rabbit 
immunoglobulin (Jackson ImmunoResearch Laboratories), followed by a 4 -  6 hr 
incubation in 1:1500 ExtrAvidin-HRP diluted with TPBS-Triton. Finally, 5-HT 
immunoreactive fibres were revealed with the nickel-DAB reaction, as described 
above (see 4.2.3.). This process visualises juxtacellularly labelled neurones in brown 
and 5-HT containing fibres in black. Processed sections were mounted on gelatinised 
slides, dehydrated and coverslipped.
2.7. Data Capture
All recorded variables were recorded onto computer hard disk using a CED 1401+ 
interface and Spike2 (version 4.1) software (Cambridge Electronic Design). In all 
experiments, BP, TP, raw phrenic nerve activity and ECG were captured as 
waveforms. HR was recorded as a digital input corresponding to R waves of the ECG 
(from the spike processor) and converted to instant frequency by Spike2 (bpm). BP 
and TP were displayed as mmHg and cmHiO respectively, and the pressure 
transducers were calibrated regularly. A keyboard input was used to annotate the 
traces with text and stimulus marks. A digital output from the stimulus programmer 
was also displayed as a TTL pulse to record the timing of nerve stimuli.
2.7.1. Whole nerve electrophysiology
Phrenic and renal nerve activities were captured as raw signal (sampled at 1 and 2 
kHz respectively), which was subsequently rectified and smoothed offline, using 
Spike2 functions. The time constants selected for the smoothing were 0.1 s for 
phrenic and 1 s for renal nerve, which. This form of processing is used for all 
illustrations of nerve activity, and is referred to as integrated phrenic and renal nerve
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activity (IPNA and IRNA) in figures to reflect the fact that it has been rectified and 
smoothed.
Additionally, both raw nerve activities were passed through solid state integrators 
(Royal Free Medical Electronics), which were calibrated at the beginning of each 
experiment to quantify nerve activity above background noise. The time constant 
selected was 5 s, i.e. the integrator quantifies activity in 5 s bins (displayed as 
arbitrary units). In figures, this are referred to as IPNA units and IRNA units.
2.7.2. Single unit electrophysiology
Extracellular neuronal activity was reporded as a waveform (sampled at 5 kHz). 
Additionally, extracellular spikes were discriminated using a spike processor 
(Digitimer D130) and recorded as a Spike2 event channel. Vagus nerve stimuli were 
also recorded in this way. Spike activity was displayed as a continuous rate meter in 
1 s bins (spikes s’1, unless otherwise stated). If there was any question of the 
accuracy of the spike discrimination window, spikes were redescriminated offline 
using Spike2 spike sorting functions.
Each channel of the iontophoresis pump provided a waveform output to display the 
timing and amplitude (nA) of iontophoresis currents in Spike2.
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2.8. Data analysis
2.8.1. Analysis of baselines and reflexes
Quantification
Annotated traces illustrating methods of measurement are shown in Figures 2.1 and 
2.2. All baseline variables were calculated from the 30s period prior to the 
stimulation of a reflex. Control baselines were averaged from the 3 30s periods 
preceding the 3 control reflexes, and post-drug or vehicle baselines were measured 
from the 30s periods preceding each subsequent reflex.
Baseline mean arterial pressure (MAP; calculated as diastolic pressure+(pulse 
pressured) was measured over the 30s before a reflex using best-fit horizontal 
cursors. Then MAP at the peak response following a reflex was measured, and 
absolute changes in MAP (peak response MAP-baseline MAP) were calculated for 
each reflex.
Baseline HR was measured in beats per min (bpm) over the 30s before a reflex using 
best-fit horizontal cursors. Then HR at the peak response following a reflex was 
measured. Since Spike2 only displays our discriminated R waves as bpm, HRs were 
converted to R-R interval (calculated as 60000-HHR; ms). This was done because R-R 
interval is linearly related to cardiac vagal outflow, therefore a more appropriate 
measure (see Daly, 1997, Appendix 1). From these calculations the absolute change 
in R-R interval (peak R-R interval-baseline R-R interval) was obtained. If during 
cardiopulmonary reflex stimulation there were 2 or 3 arrhythmic beats after PBG 
injection, these were discounted (as they can reflect movement of the cannula tip 
against the atrial wall) and the R-R interval immediately following them was 
measured.
Baseline IRNA (rectified and smoothed) was measured by bracketting the 30s prior 
to a reflex with vertical cursors, and averaging the waveform using Spike2 cursor 
functions. Then the peak change after a reflex was measured using a horizontal 
cursor, and calculated as the absolute fall for the cardiopulmonary reflex, and as the 
absolute rise within 10 s of NaCN injection for the chemoreflex.
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Baseline IPNA (from the solid state integrator) was calculated by measuring the 
height of the 6 5s bins prior to a reflex, using a horizontal cursor, and taking the 
mean. For the chemoreflex, peak change was measured as the largest bin within 10 s 
of NaCN injection. For the cardiopulmonary reflex, phrenic changes were not 
consistent enough to be usefully quantified. For aortic depressor nerve stimulations, 
nerve activities were not measured due to frequent electrical interference.
Since the absolute values of both phrenic and renal integrated nerve activity vary 
substantially between animals, the baseline prior to each stimulation was normalised 
to 100 %, and changes expressed as % of control (calculated as (peak 
activity^-baseline activityxlOO). At the termination of each experiment with 
pentobarbitone (60 mg i.v.) the noise level of the neurograms was verified, and the 
position of zero adjusted accordingly in subsequent analysis (see Figures 2.1 and 
2 .2).
In a separate series of experiments the baroreflex was elicited by raising MAP with a 
bolus dose of the vasoconstrictor phenylephrine (3 -  15 pg kg'1 i.v.) to provide 
additional data on this reflex, namely reflex gain and reflex changes in integrated 
renal nerve activity (IRNA). Absolute changes in MAP and HR were measured as 
for the cardiopulmonary reflex. Changes in IRNA (rectified and smoothed) were 
measured as follows: baseline was averaged over the 30 s prior to phenylephrine, as 
for the cardiopulmonary reflex. Reflex-evoked change was taken as the mean of the 
60 s after phenylephrine injection, this being a measure of both amplitude and 
duration of inhibition.
Reflex gain was quantified as described previously (Su et al., 1992). An illustration 
of the method is shown in Figure 2.3. Using an in-house Spike2 script (see 
Appendix), the section of the experimental trace beginning with the phenylephrine- 
evoked rise in BP and ending with the trough of the reflex bradycardia was converted 
into beat-by-beat MAP values and their corresponding R-R intervals. These were 
displayed as an X-Y plot (SigmaPlot 8.0) and a regression line fitted through the 
points, measuring slope and correlation coefficient (r). In their raw form, the points 
have poor correlation because of the delay (~ 1 s) of the reflex bradycardia. In order 
to achieve the maximum correlation between the points (r > 0.8), the MAP values
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were advanced (staggered) with respect to their corresponding R-R intervals, one 
beat at a time, and the correlation measured each time.. Typically MAPs would be 
staggered by about 10 beats to achieve the maximum correlation coefficient, and the 
slope would then be taken as the gain (in ms mmHg'1) -  a measure of reflex 
sensitivity.
Statistics
Raw data were collated and expressed as mean ± standard error of the mean (s.e.m.). 
Statistical analysis was performed using a 2-way analysis of variance (ANOVA) to 
compare a drug-treated experimental groups to its time-matched vehicle control 
group. Subsequent analysis was performed using the least significant difference 
(LSD) test, to calculate significant differences between means of drug and saline 
treated groups at specific time points.
In addition to the comparisons of drug and vehicle groups, the vehicle treated groups 
in themselves were analysed using 1-way ANOVA with repeated measures, followed 
by the Tukey test, or (non-parametrically) with 1-way ANOVA on ranks, followed 
by the Dunnett test. This compared the averaged control baselines and control 
reflexes with the baselines and reflexes at various time points after vehicle or drug 
injection.
For all statistical analysis, differences between groups were considered significant 
when P<  0.05.
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Figure 2.1 Cardiopulmonary reflex measurements
Sample trace illustrating method of analysing baseline and cardiopulmonary afferent- 
evoked changes (A) in mean arterial pressure (MAP), heart rate (HR -  converted to 
R-R interval), integrated renal (IRNA) and integrated phrenic (IPNA) nerve activity.
Baseline activity is averaged from the shaded area.
Reflex-evoked changes are maximum changes following afferent stimulation (PBG)
Termination of the experiment with pentobarbitone allows verification of IRNA and 
IPNA noise levels, and zero is set accordingly.
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Figure 2.2 Chemoreflex measurements
Sample trace illustrating method of analysing baseline and chemoreflex-evoked 
changes (A) in mean arterial pressure (MAP), heart rate (HR -  converted to R-R 
interval), integrated renal (IRNA) and integrated phrenic (IPNA) nerve activity.
Baseline activity is averaged from the shaded area.
Reflex-evoked changes are maximum changes following afferent stimulation with 
sodium cyanide (NaCN)
Termination of the experiment with pentobarbitone allows verification of IRNA and 
IPNA noise levels, and zero is set accordingly.
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Figure 2.3 Baroreflex gain calculation
Top: bolus injection of phenylephrine (PE) causes an elevation of blood pressure 
(BP) and a reflex drop in heart rate (HR). This area (shaded) is analysed by plotting 
each mean arterial pressure (MAP) point against the corresponding R-R interval and 
fitting a regression line (bottom left).
In its raw form, the correlation coefficient (r) tends to be poor. Hence the MAP 
points are advanced (staggered) one beat at a time with respect to the R-R interval 
points, until the maximum correlation coefficient is found (bottom right -  staggered 
by 11 beats).
The slope at this point (in ms mmHg'1) is taken as the baroreflex gain.
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2.8.2. Analysis of raphe stimulations
Quantification
All variables were measured as the baseline (from the 30s prior to a stimulation), and 
the peak change from baseline, as described in 2.8.1 above. MAP and HR were 
measured before a stimulus and at the peak response, and changes were calculated 
for each stimulus. As this was not a reflex study, HR was not converted to R-R 
interval. IRNA and IPNA were measured from the solid state integrators, and 
baselines were measured as the mean of the 6 bins immediately prior to stimulation. 
If there was a variation of over 20 %, no measurement could be made. After 
stimulation the bin showing the greatest change from baseline was measured. Since 
the absolute values of integrated nerve activity vary substantially between animals, 
the baseline prior to each stimulation was set at zero, and changes expressed as % 
change (calculated as (peak activity/baseline activityxl00)-100). In addition, the 
peak latency of each evoked response was calculated by measuring the time (s) from 
the stimulus mark to the peak of the response for each variable.
Statistics
Statistical analysis of raphe stimulations was performed using a paired Student’s t- 
test to compare baseline to peak BP and HR. Peak % change in IRNA and IPNA 
were analysed as a one-population t-test relative to 0.
For the analysis of receptor antagonist effects, evoked responses before and after the 
antagonist were compared to those before and after vehicle using 2-way ANOVA 
followed by the LSD test, to allow time-matched comparison of drug-induced 
changes with those of vehicle alone.
For comparison of the p-CPA and vehicle treated rats, peak changes were compared 
using an unpaired Student’s t-test.
For all statistical tests, differences were considered significant when P < 0.05.
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2.8.3. Analysis of single unit electrophysiological data
NTS and DVN neurones were characterised as shown in Figures 5.1, 5.2 and 5.3. 
The latency of the evoked spikes was measured by plotting a PSTH (in 1 ms bins) of 
50 sweeps of 1 Hz vagal stimuli. The position of the largest bar was taken as the 
mean latency, and the number of bars on either side of this bar was taken as the jitter 
(variability) of the latency. Neurones were characterised according to the criteria 
described previously (Sevoz-Couche et al., 2000b): neurones with < 3 ms jitter were 
Type 1 (second order neurones receiving monosynaptic input), those with jitter of 3 -  
5 ms were Type 2 (intermediate), and those with > 5 ms jitter were Type 3 (higher- 
order neurones receiving polysynaptic input).
2.8.4. Analysis of iontophoretic data
Quantification
Iontophoretic data were analysed as outlined in Figure 2.4. Baseline neuronal activity 
was averaged (i.e to spikes s'1) over a set period (equal to half the duration of the 
drug ejection) prior to the beginning of each drug ejection. Drug-evoked neuronal 
activity was averaged (spikes s'1) over a period equal to the duration of the drug 
ejection, but beginning halfway through the current application and continuing 
beyond its termination. This allows for the delay between drug ejection and neuronal 
response (due to the separation of the drug and iontophoresis barrels). Iontophoretic 
agonist-evoked effects were characterised as excitatory, inhibitory, or no effect, 
depending on their ability to change baseline neuronal activity by > 20 %, as 
described previously (Wang et al., 1995).
Vagus-evoked activity was measured in 20 s segments, as the total number of evoked 
spikes per 20 sweeps. Following DNQX, the 20 s segment corresponding to 
maximum inhibition was recorded.
Cardiopulmonary afferent-evoked activity was measured as the total number of 
spikes in the burst following PBG injection.
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Statistics
The effects of agonist alone were compared to those of agonist in the presence of 
DNQX (or vehicle) using the paired Student’s t-test (for parametric data) or the 
Mann-Whitney Rank Sum test (for non-parametric data).
Vagus-evoked effects during DNQX was compared to the mean of the 3 control 20 s 
segments using the Mann-Whitney Rank Sum test.
Cardiopulmonary afferent-evoked bursts during DNQX were compared to the mean 
of the control bursts using the paired Student’s t-test.
For all statistical tests, P < 0.05 was considered significant.
2.8.5. Analysis of topical applications during single unit 
recording
Quantification
Neuronal activity evoked by vagal stimulation was measured (as illustrated in Figure 
2.5) by plotting PSTHs for 50 sweeps (i.e. from 0 to 50 secs of each minute). Evoked 
spikes were counted from the PSTH, depending on the latency of the C-fibre evoked 
response (and its jitter) measured during initial neurone characterisation (i.e. for a 
neurone with latency of 30 ms and jitter of 2 ms, all evoked spikes of latency 29 -  31 
ms are counted throughout the protocol). Data are presented as spikes 50 sweeps'1, 
both before and after drug or saline. Hence 1 min after drug/saline refers to number 
of spikes in the opening 50 s of the 1st minute, etc.
Ongoing activity of DVN neurones was measured by calculating the mean 
spontaneous activity (spikes s'1) for each min before and after drug or saline 
administration. Hence 1 min after drug/saline refers to mean firing in the 1st minute, 
etc.
Ongoing activity of neurones in the gracile nucleus was measured (as illustrated in 
Figure 2.6) by calculating the mean spontanous activity (spikes s’1) during 30 s
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preceding a stimulus. Touch-evoked activity was measured by counting the number 
of spikes starting at the tracheal pressure peak corresponding to the first stimulus, 
and ending at the tracheal pressure trough after the last stimulus (i.e. number of 
spikes 10 stimuli'1). Data are presented as real values as well as being normalised (to 
% of control; control being the mean of the 3 pre-application values). This was to 
prevent variability within the samples from masking differences.
Statistics
The effect of test solutions on NTS, DVN and gracile neuronal data at each time 
point is compared to that of their vehicle at the equivalent time, using 2-way 
ANOVA, followed by the LSD test. Additionally, the time course of the vehicle 
group is analysed using 1-way ANOVA. P  < 0.05 is considered significant.
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Figure 2.4 Analysis o f iontophoretic data
Sample experimental trace illustrating method of analysing iontophoresis data. The 
trace shows extracellular neuronal activity (cell), the spike rate meter (s'1; 1 s bins) 
and the timing of iontphoretic currents of Drug 1 and Drug 2.
Baseline (Xi for Drug 1 and X2 for Drug 2) neuronal activity is averaged over 10 s 
prior to the beginning of the iontophoretic current of each drug. (10 s because this is 
half the duration of the iontophoretic current).
Drug-evoked neuronal activity is averaged over a period equal to the duration of the 
iontophoretic current (in this case 20 s) but beginning halfway through the current 
application. This allows for the delay in onset and termination of the drug effect due 
to the separation of the iontophoresis and recording barrels.
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Figure 2.5 Analysis o f NTS topical applications
Sample experimental trace illustrating method of analysing vagally-evoked NTS 
activity following topical applications. The trace shows extracellular neuronal 
activity (cell), the spike rate meter (s'1; 1 s bins) and the duration of 1 Hz vagal 
stimuli.
In each minute before and after a topical application, evoked activity is counted by 
plotting a PSTH (bottom) from the first 50 s of the minute (shaded areas; top). 
During the pre-application controls, the PSTH is analysed to set margins of the 
evoked response (shaded area; bottom). In this case the margins are from 31 to 38 ms 
post stimulus. The number of spikes within this region alone are counted throughout 
the protocol.
Counting the first 50 s only allows 10 s for the vagal stimulus to be switched off and 
PBG to be administered (top).
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Figure 2.6 Analysis o f gracile nucleus topical applications
Sample experimental trace illustrating method of analysing baseline and touch- 
evoked gracile neuronal activity following topical applications. The trace shows 
extracellular neuronal activity (cell), the spike rate meter (s'1; 1 s bins) and tracheal 
pressure (TP) which is used to time the touch (cotton bud) stimuli.
Stimuli are presented 10 times (arrows), 1 ventilator cycle (~ 1 s) apart, at the 
beginning of each minute before and after a topical application. Evoked activity is 
measured by counting the total spikes within this time (dark shaded area), i.e. 
between the 1st TP peak and the 10th TP trough.
Baseline neuronal activity is measured as the mean firing rate (s'1) over 30 s 
preceding each set of stimuli (light shaded area).
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2.9. Drugs and solutions
Dissolved in 0.9 % saline:
5-HT creatinine sulphate (Sigma, USA)
8-OH-DPAT hydrobromide (Sigma, UK)
AMPA hydrobromide (Tocris, UK)
Atenolol (Sigma, UK)
Atropine methylnitrate (Sigma, UK) 
a-bungarotoxin (Sigma, UK)
Cinanserin hydrochloride (a gift from Squibb, Princeton, USA)
DL-homocysteic acid (Sigma, UK) t 
DL-p-chlorophenylalanine methyl ester (Sigma, UK)
Evans blue (Sigma, USA)
Granisetron (a gift from GlaxoSmithKline, Harlow, UK)
Methiothepin mesylate (Sigma-RBI, UK)
NMDA (Tocris, UK)
Phenylbiguanide (Sigma, UK)
Phenylephrine (Sigma, UK)
Pontamine sky blue (BDH, UK)
SB-269970 (a gift from GlaxoSmithKline, Harlow, UK)
Sodium cyanide (BDH, UK)
Tribromoethanol (Sigma, USA)
WAY-100635, adjusted to pH. 6 with sodium bicarbonate (Sigma-RBI, UK) 
Dissolved in 1M saline:
Neurobiotin tracer (biotin ethylenediamine hydrobromide; Vector Laboratories)
Dissolved in acidified saline and adjusted to pH  6 with sodium bicarbonate: 
(-)-Pindolol (Sigma, UK)
Robalzotan (NAD-299; a gift from Pfizer, Sandwich, UK)
Dissolved in distilled water and salinated to 0.9 %:
SB-204070 (a gift from GlaxoSmithKline, Harlow, UK)
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Dissolved in dimethyl sulfoxide 
DNQX (Tocris, UK)
Dissolved in polyethylene glycol and dimethyl sulfoxide:
SB-656104 (a gift from GlaxoSmithKline, UK) was dissolved 0.6% (w/v) in a 
mixture of 50% polyethylene glycol and 50% dimethyl sulfoxide to form a stock 
solution. This was diluted with saline to yield 100 pg kg'1 in 10 pi (approx 55% stock 
and 45 % saline)
Dissolved in borax:
a-chloralose (Vickers Laboratories Ltd, UK) was dissolved (25 mg ml'1) in 0.9 % 
saline containing 2.5 % (w/v) sodium tetraborate (Borax; Sigma, UK) to improve 
solubility, and heated to 40 -  60°C until dissolved.
Other drugs and reagents:
Biotinylated donkey anti-rabbit immunoglobulin (Jackson ImmunoResearch, USA) 
D-glucose (BDH, UK)
Dimethyl sulfoxide (Sigma, UK)
ExtrAvidin® (Sigma, UK)
Gelofusine® (plasma substitute; Braun Medical Ltd, UK)
Glucose oxidase (Sigma, UK)
Isoflurane (Aerrane®; Baxter Healthcare Ltd, UK)
Lignocaine & noradrenaline (Lidostesin®; Probem, Brazil)
Lignocaine spray (Xylocaine®; AstraZeneca, UK).
Pentabiotico Veterinario (Fort Dodge Ltd, Campinas, Brazil)
Pentobarbitone sodium (Sagatal®; Rhone-Merieux Ltd, UK)
Polyethylene glycol (Sigma, UK)
Rabbit serotonin antibody (Biogenesis, UK)
Sodium bicarbonate (BDH, UK)
Thiopentone sodium (Thionembutal®; Abbott, Sao Paulo, Brazil)
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Figure 2.7 Chemical structures o f 5-HT receptor antagonists used
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HO
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HO NH
O
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NH.
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SB-204070
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3. T h e  r o l e s  o f  c e n t r a l  5-HT7 a n d  5-HT1a r e c e p t o r s  in  
THE REFLEX ACTIVATION OF CARDIAC VAGAL OUTFLOW
3.1. Introduction
3.1.1. Background
Central 5-HTiA receptors have been shown to contribute to the reflex activation of 
parasympathetic outflow in a number of species. Blockade of central 5-HTia 
receptors attenuates reflex parasympathetic outflow to the heart in rats (Bogle et al., 
1990) and rabbits (Dando et a l , 1998; Skinner et al., 2002), to the airways in guinea 
pigs (Bootle et al., 1998), and to the bladder in rats (Conley et al., 2001). More 
specifically, iontophoresis of the selective 5-HTja receptor antagonist WAY-10063 5 
onto cardiac vagal preganglionic neurones in the nucleus ambiguus of the cat 
attenuates their excitation by cardiopulmonary afferent stimulation (Wang & 
Ramage, 2001). The 5-HTia receptor is negatively coupled to adenylate cyclase, 
suggesting that their facilitatory action in the nucleus ambiguus is due to 
disinhibition (see Ramage, 2000). They may be located presynaptically on the 
terminals of fibres containing GABA or another inhibitory transmitter, as has been 
shown in DVN slices (Browning & Travagli, 2001). Functional 5-HTia receptors 
have been identified in the NTS (Wang et al., 1997) and DVN (Wang et al., 1995) in 
rats, but whether they are involved in reflex integration remains to be determined. 
Furthermore, central 5-HTiA receptors are not involved in all vagal reflexes: in 
rabbits, blockade of central 5-HTiA receptors attenuates reflex bradycardias evoked 
by stimulating cardiopulmonary and baroreceptor afferents, but not chemoreceptor 
afferents, although activation of 5-HTiA receptors potentiates chemoreflex 
bradycardia (Skinner et al., 2002).
5 -HT7 receptors, as the most recently discovered sub-type, are now known to be 
pharmacologically similar to 5-HTiA receptors. The archetypal agonist 8-OH-DPAT, 
for example, has a moderate affinity for the 5-HT7 receptor. Indeed it can have 
different effects on DVN cells when applied at low or high iontophoretic currents
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(Wang et al., 1995), possibly through activating these different receptors. Likewise 
the 5-HTj/2 receptor antagonist methiothepin has a strong affinity for the 5 -HT7 
receptor. Now that a number of highly selective 5 -HT7 receptor antagonists have 
become available, a re-examination of the complex area of 5-HT receptor control of 
parasympathetic outflow is possible.
Several observations of central importance to this study were made concerning 
parasympathetic outflow to the bladder: blockade of either supraspinal or sacral 5- 
HTia receptors strongly inhibits the micturition reflex in rats (Seeker et al., 2002). 
Additionally, blockade of supraspinal but not sacral 5 -HT7 receptors has the same 
effect (Read et al., 2003), suggesting that both 5-HTiAand 5 -HT7 receptor activation 
is necessary for successful reflex function. This posed the question of whether 5 -HT7 
receptors contribute to other parasympathetic reflexes, and a report of the receptor 
mRNA being expressed in the NTS (Gustafson et al., 1996) supported this 
possibility.
3.1.2. Aims of the study
The primary aim of this study was to investigate whether blockade of central 5 -HT7 
receptors modulates the reflex activation of vagal outflow to the heart in 
anaesthetised rats, and whether there are any differences between cardiopulmonary, 
baroreceptor, and chemoreceptor evoked reflexes. The selective and structurally 
distinct 5 -HT7 receptor antagonists SB-269970 (Hagan et al., 2000) and SB-656104 
(Thomas et a l, 2003) were used. Secondly, the role of 5-HTia receptors was re­
examined, to confirm previous findings in the rabbit using the selective antagonist 
WAY-100635 (Forster et al., 1995) and to compare its role to that of the 5 -HT7 
receptor. Additionally, the selective and structurally distinct 5-HTja receptor 
antagonist robalzotan (NAD-299) (Johansson et al., 1997) and the non-selective 
antagonist (-)-pindolol were used. For further comparison, the role of some receptors 
that are not believed to be involved in vagal reflexes per se -  the 5 -HT2 receptor 
family and the 5 -HT4 receptor -  were examined, using the selective 5 -HT2 receptor 
antagonist cinanserin and the selective 5 -HT4 receptor antagonist SB-204070 
(Wardle etal., 1994).
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3.2. Methods
3.2.1. Experimental protocols
After completion of surgery, animals were allowed to stabilise for at least 30 mins. 
Experiments were only performed in animals in which baseline variables were stable. 
Only animals in which stable control reflexes were obtained have been included in 
these studies.
At the start of each protocol, anaesthesia was supplemented by giving 15 mg kg'1 a- 
chloralose i.v. to ensure a stable level of anaesthesia during the protocol (which 
lasted a maximum of 80 min). Atenolol pretreatment (1 mg kg'1 i.v.) was also given 
at this time. 10 min were allowed to elapse before control reflexes were elicited. 
Schematic diagrams of the different protocols are shown in Figure 3.1.
Protocol 1
Protocol 1 was used to examine the effects of a selection of 5-HT receptor 
antagonists and their vehicles on the reflex responses evoked by stimulating 
cardiopulmonary afferents. 10 minutes after administering a-chloralose and atenolol, 
PBG was given intra-atrially every 10 mins until 3 stable control bradycardias had 
been obtained. A maximum of 4 control reflexes were obtained. 5 min after the final 
control, the test solution was administered i.e. PBG was then given 5, 15, 25, 35, and 
in some experiments 45 min after i.e. injection (i.e. until recovery was observed).
Protocol 1 was also used for the phenylephrine-evoked baroreflex, and phenylephrine 
was injected instead of PBG.
Protocol 2
Having identified compounds that significantly modulate the cardiopulmonary reflex 
in Protocol 1, Protocol 2 was used to compare the effect of these compounds on the 
reflex responses evoked by stimulating baroreceptor and chemoreceptor afferents. 10 
min after administering a-chloralose and atenolol, baroreceptor afferents were 
activated by electrically stimulating the right aortic depressor nerve. 5 min later, 
chemoreceptor afferents were activated by injecting NaCN i.v. Challenges were 
alternated every 5 min until 3 stable control bradycardias had been obtained. A
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maximum of 4 control reflexes were obtained. As soon as variables had returned to 
baseline after the final NaCN challenge (< 2 min), the test solution was administered 
i.e. Aortic nerve stimuli were given 5, 15, and 25 min after i.e. injection, and NaCN 
was given at 10, 20 and 30 min after drug or saline.
When using WAY-10063 5, which has a very short duration of action, chemoreceptor 
stimuli were delivered at 7, 17, and 27 min after test solution. In one supplementary 
experiment (illustrated in Figure 3.14) PBG was given instead of aortic nerve 
stimulation as a positive control.
Protocol 3
To reinvestigate the timescale of WAY-100635 at higher resolution, control reflexes 
(either NaCN injection or aortic nerve stimulation) were given every 10 min until 3 
stable controls were obtained. 10 mins after the last control, the test solution (WAY- 
100635 or saline) was injected i.e., and the reflex stimulus delivered at 2 and 5 min 
after the start o f the injection (which lasted 20 s).
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Figure 3.1 Experimental protocols
Schematic diagrams illustrating different experimental protocols for reflex 
pharmacology.
Protocol 1. To examine the effects of i.e. test solutions on phenylbiguanide (PBG) 
evoked cardiopulmonary reflex responses. (Also used for 
phenylephrine-evoked baroreflex).
Protocol 2. To examine the effects of i.e. test solutions on aortic depressor nerve 
(ADN) stimulation evoked baroreflex, and sodium cyanide (NaCN) 
evoked chemoreflex responses. The two reflexes are alternated.
Note: when WAY-100635 is given as a test solution, the NaCN 
challenges are given at 7, 17 and 27 min after injection, instead of 10, 
20 and 30 min.
Protocol 3. To re-examine the effects of test solutions on either sodium cyanide 
(NaCN) evoked chemoreflex, or aortic depressor nerve (ADN) evoked 
baroreflex, at 2 and 5 min after injection.
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3.3. Results
3.3.1. Effect of 5-HT receptor ligands on baseline variables
Effects o f saline on baseline variables 
Intracistemal administration of saline (10 pi i.e.; n = 5) at pH 5.8 (the average pH of 
SB-269970 in solution) had no significant effect on baseline MAP, IRNA or IPNA, 
but baseline R-R interval was significantly lower than control at all time points 
(Figure 3.2 and Table 9.1).
Effect o f SB-269970 on baseline variables
Central administration of the selective 5 -HT7 receptor antagonist SB-269970 (30, 
100 and 300 pg kg"1 i.e.; n = 5, all groups) had no significant effect on baseline 
MAP, R-R interval, or IRNA at any time point in the protocol, compared to i.e. 
saline (Figure 3.2, Tables 9.2, 9.3 and 9.4). However, baseline IPNA was 
significantly and dose-dependently attenuated at the middle and higher doses of SB- 
269970, with the greatest response 15 min after administration (88 ± 18 % of control 
after 100 jog kg'1 and 24 ± 12 % of control after 300 pg kg'1). In some experiments, 
the high dose (300 pg kg'1) caused a central apnoea. In a pilot study using this high 
dose in spontaneously breathing rats (n = 2), a central apnoea was also observed in 
both rats, requiring immediate mechanical ventilation.
Effects o f intravenous SB-269970 on baseline variables
Intravenous administration of SB-269970 (100 pg kg'1 i.e.; n = 3) had no significant 
effect on baseline MAP, R-R interval or IRNA, 5 min after injection compared to 
pre-drug controls (Table 9.5).
Effect o f  vehicle fo r  SB-656104 on baseline variables
Intracistemal administration of the vehicle for SB-656104 (45 % saline, 27.5 % 
DMSO, 27.5% PEG, 10 pi i.e.; n = 5) significantly raised baseline MAP at all time 
points after administration, but had no significant effect on baseline R-R interval, 
IRNA or IPNA (Figure 3.3, Table 9.6).
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Effects o f  SB-656104 on baseline variables 
Central administration of the selective 5 -HT7 receptor antagonist SB-656104 (100 pg 
kg'1 i.e.; n = 5) had no significant effect on baseline MAP, R-R interval, IRNA or 
IPNA at any time point in the protocol, compared to vehicle (Figure 3.3, Table 9.7).
Effects o f WAY-100635 on baseline variables 
Central administration of the selective 5-HTiA receptor antagonist WAY-100635 
(100 pg kg'1 i.e.; n = 5) had no significant effect on baseline MAP, R-R interval, 
IRNA, or IPNA at any time point in the protocol, compared to i.e. saline (Figure 3.4, 
Table 9.8).
Effects o f  robalzotan on baseline variables
Central administration of the selective 5-HTi a receptor antagonist robalzotan (100 pg 
kg'1 i.e.; n = 5) had no significant effect on baseline MAP, R-R interval, IRNA, or 
IPNA at any time point in the protocol (Figure 3.4, Table 9.9).
Effects o f (-)-pindolol on baseline variables
Central administration of the 5-HT ia receptor antagonist (-)-pindolol (100 pg kg'1 
i.e.; n -  5) had no significant effect on baseline MAP, IRNA or IPNA, but baseline 
R-R interval was significantly lower throughout the protocol (Figure 3.4, Table 
9.10).
Effects o f cinanserin on baseline variables
Central administration of the 5 -HT2 receptor antagonist cinanserin (100 pg kg'1 i.e.; n 
= 5) had no significant effect on baseline MAP or IPNA at any time point in the 
protocol, compared to i.e. saline (Figure 3.5, Table 9.11). However, it significantly 
increased baseline R-R interval 5 min after administration (194 ± 4 ms) and 
significantly increased IRNA 25 min after administration (131 ± 18 %).
Effects o f SB-204070 on baseline variables
Central administration of the selective 5 -HT4 receptor antagonist cinanserin (100 pg 
kg'1 i.e.; n -  5) had no significant effect on baseline MAP, R-R interval, or IRNA at 
any time point in the protocol (Figure 3.5, Table 9.12). However, it significantly 
increased baseline IPNA 5 min after administration (211 ± 14 % of control), 
returning to control after 15 min.
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Figure 3.2 Baseline graph: SB-269970
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n -  5), and SB- 
269970 30 pg kg'1 i.e. ( • ,  n = 5), 100 pg kg'1 i.e. (A , n = 5), and 300 pg kg'1 i.e. 
(T , n = 5), on baseline mean arterial pressure (MAP), heart rate (HR), integrated 
renal nerve activity (IRNA) and integrated phrenic nerve activity (IPNA) in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats.
* P <0.05,** P<  0.01, 2-way ANOVA followed by LSD test.
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Figure 3.3 Baseline graph: SB-656104
Graph showing the effects (mean ± s.e.m.) of 10 pi vehicle i.e. (□, n = 5), and SB- 
656104, 100 pg kg'1 i.e. ( • ,  n = 5) on baseline mean arterial pressure (MAP), heart 
rate (HR), integrated renal nerve activity (IRNA) and integrated phrenic nerve 
activity (IPNA) in anaesthetised, neuromuscular blocked and atenolol pretreated rats.
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Figure 3.4 Baseline graph: W AY-100635, robalzotan, (-)-pindolol
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), WAY- 
100635, 100 pg kg'1 i.e. ( • ,  n = 5), robalzotan, 100 pg kg'1 i.e. (A , n = 5), and (-)- 
pindolol, 100 pg kg'1 i.e. (T , n = 5), on baseline mean arterial pressure (MAP), 
heart rate (HR), integrated renal nerve activity (IRNA) and integrated phrenic nerve 
activity (IPNA) in anaesthetised, neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, ** P < 0.01, 2-way ANOVA followed by LSD test.
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Figure 3.5 Baseline graph: cinanserin, SB-204070
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), cinanserin, 
100 pg kg'1 i.e. ( • ,  n = 5), and SB-204070, 100 pg kg'1 i.e. ( A , n = 5), on baseline 
mean arterial pressure (MAP), heart rate (HR), integrated renal nerve activity 
(IRNA) and integrated phrenic nerve activity (IPNA) in anaesthetised, 
neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, ** P < 0.01, 2-way ANOVA followed by LSD test.
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3.3.2. Effect of 5-HT receptor ligands on cardiopulmonary reflex
Effects o f right atrial phenylbiguanide and saline
Taking as a group all experiments in Protocol 1 (n = 53), right atrial bolus 
administration of phenylbiguanide (PBG, 1 - 5  pg) evoked an increase in R-R 
interval of 50 ± 3 ms from a baseline of 184 ± 2 ms, a fall in MAP of 35 ± 2 mmHg 
from a baseline of 112 ± 2 mmHg, and a fall in IRNA of 43 ± 3 %. The IPNA 
response in this mechanically ventilated preparation was inconsistent -  either apnoea 
or tachypnoea was observed -  and therefore has not been quantified. These reflex 
changes usually occurred within 2 s of PBG administration, and returned to baseline 
within 15 -  30 s (Figure 3.6). 1
Right atrial bolus administration of the same volume of saline (20 -  100 pi; n = 5) 
had no significant effect on MAP, R-R interval, IRNA or IPNA.
Effects o f saline on cardiopulmonary reflex 
Saline (10 pi, i.e., pH 5.8; n = 5) had no significant effect on the reflex MAP or R-R 
interval changes evoked by PBG at any time point in the protocol when compared to 
controls. The reflex IRNA response, however, was significantly potentiated at all 
time points after saline (Figure 3.7, Table 9.13).
Effects o f SB-269970 on cardiopulmonary reflex 
Central administration of SB-269970 (30, 100 and 300 pg kg'1; n = 5 each group) 
significantly attenuated the response to stimulating cardiopulmonary afferents 
(Figures 3.6 and 3.7, Tables 9.14, 9.15 and 9.16). SB-269970 significantly and dose 
dependently attenuated the reflex increase in R-R interval compared to i.e. saline, 
with the greatest change after 15 min (24 ± 3 ms, 12 ± 3 ms, and 4 ± 2 ms 
respectively). Return to control reflex R-R interval (recovery) was observed after 25 
and 35 min in the 30 and 100 pg kg'1 groups, respectively, whilst in the 300 pg kg'1 
group, recovery took >45 min. SB-269970 had no significant effect on the reflex fall 
in MAP except at the high dose of 300 pg kg'1 (-1 ± 2 mmHg, 15 min after drug). 
Likewise the reflex renal sympathoinhibition was clearly attenuated only by 300 pg 
kg'1 SB-269970 (5 ± 2 % of control, 15 min after drug). However, the low and
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medium doses did cause some significantly attenuation which was not dose- 
dependent (Figure 3.7).
Effects o f intravenous SB-269970 on cardiopulmonary reflex 
Intravenous administration of SB-269970 (100 pg kg'1; n -  3) had no significant 
effect on changes in MAP, R-R interval or renal sympathoinhibition evoked by 
stimulating cardiopulmonary afferents, when compared to pre-drug controls (Table 
9.17).
Effects o f vehicle for SB-656104 on cardiopulmonary reflex
The vehicle for SB-656104 (45 % saline, 27.5 % DMSO, 27.5% PEG; 10 pi, i.e.; n = 
5) had no significant effect on the reflex MAP, R-R interval orl RNA changes 
evoked by PBG at any time point in the protocol when compared to controls (Figure 
3.8, Table 9.18).
Effects o f SB-656104 on cardiopulmonary reflex 
Central administration of SB-656104 (100 pg kg'1 i.e.; n = 5) significantly attenuated 
the reflex responses to stimulation of cardiopulmonary afferents (Figure 3.8, Table 
9.19). It significantly attenuated the reflex increase in R-R interval 5 min after 
administration (9 ± 5 ms), with no recovery observable within the time frame of the 
protocol. It also significantly attenuated the reflex fall in MAP (15 ± 5 mmHg) at 5 
min after drug administration, with recovery at 25 min. Reflex sympathoinhibition 
was not significantly affected.
Effects o f  WAY-100635 on cardiopulmonary reflex 
Central administration of WAY-100635 (100 pg kg'1 i.e.; n = 5) significantly 
attenuated the reflex responses to stimulation of cardiopulmonary afferents (Figures 
3.9 and 3.10, Table 9.20). WAY-100635 significantly attenuated the reflex increase 
in R-R interval only 5 min after administration (20 ± 3 ms), with no effect on the 
reflex fall in MAP or the reflex renal sympathoinhibition.
Effects o f  robalzotan on cardiopulmonary reflex
Central administration of robalzotan (100 pg kg'1 i.e.; n = 5) had no significant effect 
on the reflex increase in R-R interval, the reflex fall in MAP, or the reflex
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sympathoinhibition evoked by stimulation of cardiopulmonary afferents, compared 
to i.e. saline (Figure 3.11, Table 9.21).
Effects o f cinanserin on cardiopulmonary reflex 
Central administration of cinanserin (100 pg kg'1 i.e.; n = 5) had no significant effect 
on the reflex increase in R-R interval, or the reflex fall in MAP evoked by 
stimulation of cardiopulmonary afferents, compared to i.e. saline (Figure 3.11, Table 
9.22). However, cinanserin significantly attenuated the reflex sympathoinhibition 5 
min after administration (90 ± 7 %), returning to control after 15 min.
Effects o f SB-204070 on cardiopulmonary reflex
Central administration of SB-204070 (100 pg kg'1 i.e.; n = 5, and 300 pg kg'1 i.e.; n = 
3) had no significant effect on the reflex increase in R-R interval, the reflex fall in 
MAP, or the reflex sympathoinhibition evoked by stimulation of cardiopulmonary 
afferents, compared to i.e. saline (see Figure 3.11, Table 9.23).
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Figure 3.6 Cardiopulmonary reflex trace: SB-269970
Sample traces showing the effect of SB-269970 on heart rate (HR), blood pressure 
(BP), integrated renal (IRNA) and integrated phrenic (IPNA) nerve responses evoked 
by stimulation of cardiopulmonary afferents with phenylbiguanide (PBG; 2 pg) in an 
anaesthetised, neuromuscular blocked and atenolol pretreated rat.
Neurograms are rectified and smoothed (time constants: IRNA 1 s, IPNA 0.1 s)
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Figure 3.7 Cardiopulmonary reflex graph: SB-269970
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n — 5), and SB- 
269970 30 pg kg'1 i.e. ( • ,  n = 5), 100 pg kg'1 i.e. (A,  n = 5), and 300 pg kg'1 i.e. 
(Y,  n = 5), on changes (A) in mean arterial pressure (MAP), R-R interval, and 
integrated renal nerve activity (IRNA) evoked by cardiopulmonary reflex stimulation 
with phenylbiguanide in anaesthetised, neuromuscular blocked and atenolol 
pretreated rats.
* P < 0.05, ** P  < 0.01, 2-way ANOVA followed by LSD test (compared to time- 
matched saline control).
t  P < 0.05, 1-way ANOVA followed by Tukey test (compared to pre-saline control).
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Figure 3.8 Cardiopulmonary reflex graph: SB-656104
Graph showing the effects (mean ± s.e.m.) of 10 pi vehicle i.e. (□, n = 5), and SB- 
656104, 100 pg kg'1 i.e. ( • ,  n = 5) on changes (A) in mean arterial pressure (MAP), 
R-R interval, and integrated renal nerve activity (IRNA) evoked by cardiopulmonary 
reflex stimulation with phenylbiguanide in anaesthetised, neuromuscular blocked and 
atenolol pretreated rats.
* P < 0.05, ** P < 0.01, 2-way ANOVA followed by LSD test.
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Figure 3.9 Cardiopulmonary reflex trace: W AY-100635
Sample traces showing effect of WAY-100635 on heart rate (HR), blood pressure 
(BP), integrated renal (INRA) and integrated phrenic (IPNA) nerve responses evoked 
by stimulation of cardiopulmonary afferents with phenylbiguanide (PBG; 2.5 pg) in 
an anaesthetised, neuromuscular blocked and atenolol pretreated rat.
Neurograms are rectified and smoothed (time constants: IRNA 1 s, IPNA 0.1 s)
162
150-
BP
mmHg
50 
350 n
HR
bpm
250-
Control way-100635 5  m jn 15 min
100 ng kg i.e.
i
A^v^VOrrVs*#.* , . . '«W kS1vA V , 'i. ,»:N*A*V'■. „v»v'VA‘-
IRNA
Figure 3.10 Cardiopulmonary reflex graph: W AY-100635
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), and WAY- 
100635 100 pg kg'1 i.e. ( • ,  n = 5), on changes (A) in mean arterial pressure (MAP), 
R-R interval, and integrated renal nerve activity (IRNA) evoked by cardiopulmonary 
reflex stimulation with phenylbiguanide in anaesthetised, neuromuscular blocked and 
atenolol pretreated rats.
* P < 0.05, ** p <  0.01, 2-way ANOVA followed by LSD test.
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Figure 3.11 Cardiopulmonary reflex graph: robalzotan & cinanserin
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), robalzotan 
100 pg kg'1 i.e. ( • ,  n = 5), and cinanserin 100 pg kg'1 i.e. (A , n = 5) on changes 
(A) in mean arterial pressure (MAP), R-R interval, and integrated renal nerve activity 
(IRNA) evoked by cardiopulmonary reflex stimulation with phenylbiguanide in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, 2-way ANOVA followed by LSD test.
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3.3.3. Effects of 5-HT receptor ligands on chemoreflex
Effects o f intravenous sodium cyanide and saline
Bolus injection of NaCN (25 -  50 pg kg'1 i.v.; n = 25) evoked an increase in R-R 
interval of 29 ± 2 ms from a baseline of 178 ± 3 ms , a fall in MAP of 31 ± 2  mmHg 
from a baseline of 110 ± 2 mm Hg, a rise in IRNA of 74 ± 11 %, and a rise in IPNA 
of 262 ± 45 % (Figure 3.12). These reflex responses began within 2 s of NaCN 
administration, peaked within 10 (except IRNA and IPNA, which sometimes 
continued to rise for another 10 s) and usually returned to baseline within 30 -  60 s 
(except IPNA which took up to 2 min to recover). Vehicle administration (0.1 ml 
saline i.v.) had no measurable effect. To control for possible direct cardiac effects of 
NaCN, atropine methonitrate (1 mg kg'1 i.v.; n = 2) administered at the end of a 
protocol, abolished the reflex increase in R-R interval resulting from NaCN injection.
Effects o f saline on chemoreflex
Using Protocol 2, intracistemal administration of saline (10 pi, i.e., pH 5.8; n = 5) 
had no significant effect on the reflex MAP or IPNA changes evoked by NaCN at 
any time point in the protocol when compared to controls. The reflex R-R interval 
increase, however, was slightly potentiated at 10 and 20 min after saline 
administration, and the IRNA response was potentiated at 10 and 30 min (Figure
3.13, Table 9.24).
Using Protocol 3, saline (10 pi, i.e., pH 5.8; n — 5) had no significant effect on the 
reflex MAP, R-R interval, IRNA or IPNA changes evoked by NaCN at either 2 or 5 
min after saline, when compared to controls (Figure 3.17, Table 9.27).
Effects o f SB-269970 on chemoreflex 
Central administration of SB-269970 (100 pg kg'1 i.e., n = 5) significantly attenuated 
components of the response to stimulating chemoreceptor afferents (Figure 3.12 and
3.13, Table 9.25). It significantly reduced the reflex increase in R-R interval, with the 
greatest response after 10 min (11 ± 2 ms). Control reflex R-R interval recovered 30 
min after drug administration. SB-269970 had no significant effect on the fall in 
MAP, or on the reflex increase in IPNA. However, the reflex sympathoexcitation
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was significantly attenuated 10 min after drug administration (46 ± 6 % of control), 
with recovery at 20 min.
Effects ofWAY-100635 on chemoreflex
Central administration ofWAY-100635 (100 pg kg'1; n = 5) had no significant 
effect on the reflex increase in R-R interval, the reflex drop in MAP or the reflex 
increase in IPNA evoked by stimulating chemoreceptor afferents (Figure 3.14 and 
3.15, Table 9.26). However, 7 min after drug administration WAY-100635 
significantly attenuated the reflex sympathoexcitation (93 ± 9 % of control) with 
recovery 17 min after drug administration.
Further investigation using Protocol 3 to test NaCN challenges at 2 and 5 min after 
WAY-10063 5 found that the drug does indeed attenuate responses to chemoreceptor 
stimulation, but only at 2 min (Figure 3.16 and 3.17, Table 9.28). The reflex increase 
in R-R interval was significantly attenuated compared to i.e. saline (18 ± 7 3 6 ± 8
ms; n = 5), and the reflex renal sympathoexcitation was also significantly attenuated 
(101 ± 8 vs. 193 ± 4 0  % of control). There were no significant changes in reflex 
hypotension or phrenic excitation.
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Figure 3.12 Chemoreflex trace: SB-269970
Sample traces showing the effect of SB-269970 on heart rate (HR), blood pressure 
(BP),integrated renal (IRNA) and integrated phrenic (IPNA) nerve responses evoked 
by stimulation of chemoreceptor afferents with sodium cyanide (NaCN; 50 pg) in an 
anaesthetised, neuromuscular blocked and atenolol pretreated rat.
Neurograms are rectified and smoothed (time constants: IRNA 1 s, IPNA 0.1 s)
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Figure 3.13 Chemoreflex graph : SB-269970
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), and SB- 
269970, 100 pg kg'1 i.e. ( • ,  n = 5), on changes (A) in mean arterial pressure 
(MAP), R-R interval, integrated renal nerve activity (IRNA), and integrated phrenic 
nerve activity (IPNA) evoked by chemoreflex stimulation with sodium cyanide in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats.
** P < 0.01, 2-way ANOVA followed by LSD test.
172
Q-<
< 1
xa>M—<D
O)
X
E
E
i
cr
<1>
saline
SB-269970
10
E
(D 4U -  
£
-2 2 0 -  c
200
S' 150-
o's
0  <  100 -
o5 22 a  50-
<1
Control 10 20
time after injection (min)
30
173
F igure 3.14 Chemoreflex trace: WAY -10063 5
Sample traces comparing effect of WAY-100635 on heart rate (HR), blood pressure 
(BP), integrated renal (IRNA) and integrated phrenic (IPNA) nerve responses evoked 
by stimulation of cardiopulmonary afferents with phenybiguanide (PBG; 1.5 pg), 
and chemoreceptor afferents with sodium cyanide (NaCN; 50 jig) in an 
anaesthetised, neuromuscular blocked and atenolol pretreated rat.
Neurograms are rectified and smoothed (time constants: IRNA 1 s, IPNA 0.1 s)
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Figure 3.15 Chemoreflex graph: WAY-100635
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), and WAY- 
100635, 100 pg kg'1 i.e. ( • ,  n = 5), on changes (A) in mean arterial pressure 
(MAP), R-R interval, integrated renal nerve activity (IRNA), and integrated phrenic 
nerve activity (IPNA) evoked by chemoreflex stimulation with sodium cyanide in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, 2-way ANOVA followed by LSD test (comparing treated animals at 7, 
17 and 27 min with saline conrols at 10, 20 and 30 min).
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Figure 3.16 Chemoreflex trace (Protocol 3): W AY-100635
Sample trace illustrating effect of WAY-100635 at 2 and 5 min after injection on 
heart rate (HR), blood pressure (BP), integrated renal (IRNA) and phrenic (IPNA) 
nerve responses evoked by stimulation of chemoreceptor afferents with sodium 
cyanide (NaCN; 50 pg) in an anaesthetised, neuromuscular blocked and atenolol 
pretreated rat.
Neurograms are rectified and smoothed (time constants: IRNA 0.1 s, IPNA 0.1 s)
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Figure 3.17 Chemoreflex graph (Protocol 3): W AY-100635
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n — 5), and WAY- 
100635, 100 |ig kg'1 i.e. ( • ,  n = 5), on changes (A) in mean arterial pressure 
(MAP), R-R interval, integrated renal nerve activity (IRNA), and integrated phrenic 
nerve activity (IPNA) evoked by chemoreflex stimulation with sodium cyanide in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, 2-way ANOVA followed by LSD test.
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3.3.4. Effects of 5-HT receptor ligands on aortic nerve 
stimulation
Effects o f aortic nerve stimulation
5 s trains of constant current stimulation (40 Hz, 0.1 ms pulse, 0.2 -  1 mA) of the 
right aortic depressor nerve (n = 26) evoked an increase in R-R interval of 58 ± 6 ms 
from a baseline of 175 ± 2 ms , and a fall in MAP of 29 ± 2 mmHg from a baseline 
of 106 ± 2 mmHg. These reflex responses began within 0.5 s of electrical 
stimulation, peaked within 5 s and usually returned to baseline within 20 s (Figure 
3.18).
Effects o f  saline on aortic nerve stimulation
Saline (10 pi, i.e., pH 5.8; n = 5) had no significant effect on the reflex MAP or R-R 
interval changes evoked by aortic depressor nerve stimulation at any time point in the 
protocol when compared to controls (Figure 3.19, Table 9.29).
Effects o f SB-269970 on aortic nerve stimulation
Central administration of SB-269970 (100 pg kg'1; n = 5) significantly attenuated the 
response to stimulating the aortic depressor nerve (Figures 3.18 and 3.19, Table 
9.30). SB-269970 significantly attenuated the reflex increase in R-R interval 
(compared to i.e. saline) 5 min after drug administration (24 ± 6 ms), with recovery 
at 15 min post drug. SB-269970 had no significant effect on the reflex fall in MAP.
Effects o f WAY-100635 on aortic nerve stimulation
Central administration of WAY-100635 (100 pg kg'1 i.e.; n = 5) had no significant 
effect on the response to stimulation the aortic depressor nerve at 5, 15, or 25 min 
after drug administration (Figure 3.20, Table 9.31). On further investigation using 
Protocol 3, it was found that giving the aortic nerve stimulus at 2 min after drug 
delivery (100 pg kg'1; n = 6) also had no significant effect (Figures 3.21 and 3.22, 
Table 9.32). However, administration of a second dose in the same animals (200 pg 
kg'1; n = 6, 20 min after first dose) significantly attenuated the reflex increase in R-R 
interval at 2 min after drug administration (25 ± 8 ms, compared to control) with 
recovery at 3 min. Also the reflex hypotension was significantly attenuated at 2, 3
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and 4 min after drug administration, with the greatest attenuation at 2 min (-16 ± 4 
mmHg).
Effects o f  (-)-Pindolol on aortic nerve stimulation 
Central administration of (-)-pindolol (100 pg kg'1 i.e.; n — 5) had no significant 
effect on the response to stimulation the aortic depressor nerve at 5, 15, or 25 min 
after drug administration (Figure 3.20, Table 9.33).
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Figure 3.18 Aortic nerve stimulation trace: SB-269970
Sample trace illustrating the effect of SB-269970 on heart rate (HR), blood pressure 
(BP), integrated renal (IRNA) and integrated phrenic (IPNA) nerve responses evoked 
by electrical stimulation (40 Hz) of the right aortic depressor nerve in an 
anaesthetised, neuromuscular blocked and atenolol pretreated rat. For clarity, 
stimulus artefacts have been removed from the phrenic neurogram.
Neurograms are rectified and smoothed (time constants: IRNA 1 s, IPNA 0.1 s)
184
BP
mmHg
HR
bpm
150-i
50* 
400*
300-
IRNA
IPNA
Control SB-269970 5  n iin
100 j,ig kg1 i.e.
40 Hz 40 Hz 15 s
185
Figure 3.19 Aortic nerve stimulation graph: SB-269970
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), and SB- 
269970, 100 pg kg'1 i.e. ( • ,  n = 5), on changes (A) in mean arterial pressure (MAP) 
and R-R interval evoked by electrical stimulation of the right aortic depressor nerve 
in anaesthetised, neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, 2-way ANOVA followed by LSD test.
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Figure 3.20 Aortic nerve stimulation graph: W AY-100635 & pindolol
Graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), WAY- 
100635, 100 pg kg'1 i.e. ( • ,  n = 5), and (-)-pindolol, 100 pg kg'1 i.e. (▼, n = 5) on 
changes (A) in mean arterial pressure (MAP) and R-R interval evoked by electrical 
stimulation of the right aortic depressor nerve in anaesthetised, neuromuscular 
blocked and atenolol pretreated rats.
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Figure 3.21 Aortic nerve stimulation graph (Protocol 3): W AY-100635
Graph showing the effects (mean ± s.e.m.) of WAY-100635 (100 and 200 pg kg'1 
i.e.; n = 6) on changes (A) in mean arterial pressure (MAP) and R-R interval evoked 
by electrical stimulation of the right aortic depressor nerve (■) in anaesthetised, 
neuromuscular blocked and atenolol pretreated rats. Dotted line indicates s.e.m. of 
pre-drug control.
* P < 0.05, 1-way ANOVA followed by Tukey test.
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Figure 3.22 Aortic nerve stimulation trace (Protocol 3): W AY-100635
Sample trace illustrating the effect of 200 pg kg"1 i.e. WAY-100635 (administered 
20 min after the initial dose of 100 pg kg"1, on heart rate (HR), blood pressure (BP), 
and integrated renal nerve (IRNA) responses evoked by electrical stimulation (40 
Hz) of the right aortic depressor nerve in an anaesthetised, neuromuscular blocked 
and atenolol pretreated rat.
IRNA neurogram is rectified and smoothed (time constant 1 s)
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3.3.5. Effects of 5-HT receptor ligands on baroreflex
Effects o f intravenous phenylephrine
Bolus injection of phenylephrine (3 -  15 pg kg'1, n = 10) caused an increase in MAP 
of 77 ± 3 mmHg from a baseline of 98 ± 5 mmHg and a reflex increase in R-R 
interval of 22 ± 3 ms from a baseline of 184 ± 4 ms. The baroreflex gain calculated 
from plotting beat-by-beat changes in MAP and R-R interval was 0.24 ± 0.03 ms 
mmHg'1. When MAP was raised IRNA was immediately switched off, but when 
averaged over 60 s following phenylephrine, IRNA reflexly dropped to 44 ± 6 % of 
control (Figure 3.23).
Effects o f saline on baroreflex
Following saline (10 pi, i.e., pH 5.8; n = 5) the phenylephrine-evoked increase in 
MAP was significantly smaller at 25 min after saline, compared to control (64 ± 4 vs. 
74 ± 4 mmHg), and the baroreflex gain was significantly greater at 5 min after saline 
(0.25 ± 0.04 vs. 0.34 ± 0.06 ms mmHg'1). However, saline had no significant effects 
on the reflex increase in R-R interval or the reflex renal sympathoinhibition (Figures 
3.24 and 3.25, Table 9.34).
Effects o f SB-269970 on baroreflex
Central administration of SB-269970 (100 pg kg'1; n = 5) significantly attenuated the 
reflex responses to raising MAP with phenylephrine (Figures 3.23, 3.24, 3.25 and 
Table 9.35). It significantly attenuated the reflex increase in R-R interval (compared 
to i.e. saline) with the greatest effect 15 min after drug administration (9 ± 1 ms) and 
recovery at 25 min. It also significantly attenuated baroreflex gain (to 0.1 ± 0.03 ms 
mmHg'1, 15 min after drug administration). Reflex renal sympathoinhibition was 
unchanged until 25 min after drug administration, when it was significantly 
attenuated to 87 ± 10 % of control (compared to i.e. saline).
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Figure 3.23 Baroreflex trace: SB-269970
Sample trace illustrating changes in blood pressure (BP), heart rate (HR), and 
integrated renal nerve (IRNA) evoked by phenylephrine (PE; 3 pg i.v.), both before 
(control) and after SB-269970 (100 pg kg'1 i.e.) in an anaesthetised, neuromuscular 
blocked and atenolol pretreated rat.
IRNA neurogram is rectified and smoothed (time constant 1 s)
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Figure 3.24 Baroreflex gain: SB-269970
Sample plot illustrating phenylephrine-evoked baroreflex gain (regression line) both 
before (•, control) and 15 min after SB-269970 (T , 100 pg kg'1 i.e.) in an 
anaesthetised, neuromuscular blocked and atenolol-pretreated rat.
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Figure 3.25 Baroreflex graph: SB-269970
Opposite: graph showing the effects (mean ± s.e.m.) of 10 pi saline i.e. (□, n = 5), 
and SB-269970, 100 pg kg'1 i.e. ( • ,  n = 5), on changes (A) in mean arterial pressure 
(MAP) and reflex changes in R-R interval, baroreflex gain, and integrated renal 
nerve activity (IRNA), evoked by intravenous phenylephrine in anaesthetised, 
neuromuscular blocked and atenolol pretreated rats.
* P < 0.05, ** P < 0.01, 2-way ANOVA followed by LSD test.
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3.3.6. Intracisternal injection of pontamine sky blue dye
To examine the potential diffusion and possible sites of action of intracistemally 
administered drugs, 10 pi pontamine sky blue dye (2.5 % in saline) was 
administered i.e. at the end of an experiment in several animals. After 15 min (the 
time at which the maximum response to SB-269970 was observed) the animals were 
deeply anaesthetised with pentobarbitone (30 mg kg'1 i.v.), transcardially perfused 
with 100 ml heparinised saline followed by 100 ml 4 % formal saline, and the brain 
removed and photographed (Figure 3.26).
The heaviest staining was seen on the dorsal surface of the medulla, near the tip of 
the intracisternal cannula, but considerable staining was also seen around the ventral 
surface of the medulla and pons. Light staining continued rostrally along the ventral 
surface as far as the optic chiasm, and caudally to approximately C2. No staining was 
seen in cerebellar or cortical areas, or in more caudal parts of the spinal cord.
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Figure 3.26 Intracisternal pontamine sky blue
Photographs illustrating staining of rat brain 15 min after intracisternal injection of 
pontamine sky blue dye (10 pi).
Left: dorsal view 
Right: ventral view
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Table 3.1 Summary of drug effects
Effects of different 5-HT receptor antagonists on bradycardic (R-R) and sympathetic 
(IRNA) components of reflexes, j  attenuation, o no effect (t at 100 fig kg'1 dose).
Drug Cardiopulmonary Chemoreflex Baroreflex
SB-269970 |R-R  ?|IRNA 4R-R 4IRNA 4 R-R oIRNA
SB-656104 |R-R oIRNA
WAY-10063 5 |R-R oIRNA 4R-R |IRNA oR-Rf
Robalzotan oR-R oIRNA
(-)-Pindolol oR-R
Cinanserin oR-R 4 IRNA
SB-204070 oR-R oIRNA
Table 3.2 Maximum % inhibition
Comparison of the maximum % inhibition of reflex-evoked increases in R-R interval 
caused by different drugs, and different reflexes (PBG: cardiopulmonary, NaCN: 
chemoreflex, ADN: aortic depressor nerve stimulation. Changes are relative to pre­
injection controls. Asterisks indicate that the true values are significantly different 
from vehicle (* P < 0.05, ** P < 0.01).
Time of maximum inhibition (min) in parentheses. All drug doses are 100 fig kg'1.
Drug PBG NaCN ADN
SB-269970 70 ± 6  (15)** 72 ± 5  (10)** 59 ± 11 (5)*
SB-656104 87 ± 6  (15)**
WAY-10063 5 58 ± 2  (5)** 49 ± 10(2)* 26 ± 16(2)
Robalzotan -6 ± 20 (5)
(-)-Pindolol 27 ± 17(15)
Cinanserin 11 ±7(5)
SB-204070 37 ± 5  (5)
Saline 7 ± 6 (5) -24 ± 18 (10) 12 ± 16(25)
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3.4. Discussion
3.4.1. Main findings
These experiments demonstrate, for the first time, that central 5 -HT7 receptors are 
involved in the reflex activation of parasympathetic outflow to the heart in 
anaesthetised rats. Intracisternal injection of the selective 5 -HT7 receptor antagonist 
SB-269970 (Hagan et al., 2000) dose-dependently attenuated the vagally mediated 
cardiac slowing evoked by cardiopulmonary afferent fibres, arterial baroreceptor and 
chemoreceptor afferents. This effect is most likely due to blockade of 5-HT7 
receptors and not compound specific, as SB-656104, another selective 5-HT7 
receptor antagonist (Thomas et al., 2003), also strongly attenuated the bradycardic 
component of the cardiopulmonary reflex. SB-656104, although from the same 
chemical series, is sufficiently distinct in terms of structure and selectivity profile as 
to rule out this latter possibility. These effects are most likely due to actions on 5- 
HT7 receptors located within the brainstem, since the same dose of SB-269970 given 
i.v. was without effect.
The role of brainstem 5-HTia receptors is more ambiguous. Although the selective 
5-HTia antagonist WAY-100635 attenuated the bradycardic component of the 
cardiopulmonary reflex, the structurally different selective antagonist robalzotan 
failed to have any effect on this reflex. WAY-10063 5 also failed to attenuate the 
bradycardic component of the chemoreflex, which confirms previous experiments 
performed on rabbits (Skinner et al., 2002). On further investigation, however, it was 
found that WAY-100635 does attenuate the bradycardic component of the 
chemoreflex, but only at 2 min after drug administration. Finally, the bradycardic 
response to aortic nerve stimulation was not attenuated by either WAY-10063 5 
(including at the 2 min time point) or by the 5-HT ia receptor antagonist (-)-pindolol.
These data suggest that the role of 5-HT ja receptors in these reflexes is far less clear 
that the role of the 5 -HT7 receptor, at least in the rat. Possibly a compound-specific 
mechanism is revealed, with its most important role in the cardiopulmonary reflex, a 
lesser role in the chemoreflex, and no role in the aortic nerve-mediated baroreflex.
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Blockade of brainstem 5 -HT2 and 5 -HT4 receptors with the selective antagonists 
cinanserin and SB-204070 had no effect on the bradycardic component of the 
cardiopulmonary reflex. Finally, the antagonists used generally had no effect on 
baseline variables, although SB-269970 dose-dependently diminished central 
respiratory drive.
3.4.2. Selectivity of antagonists
The chief compounds used, SB-269970, SB-656104, and WAY-10063 5, are thought 
to be highly selective for the 5 -HT7 and 5-HTia receptor respectively, based on 
binding data principally from human cloned receptors, as summarised in Table 3.3. 
These human cloned data, however,, may not necessarily be the same at rat receptors. 
Various species differences in 5-HT receptor binding are reported, as discussed in 
1.6 above. SB-269970, however, has a similar binding affinity at 5 -HT7 receptors in 
a variety of species (Thomas et al., 2002).
In general, both SB-269970 and SB-656104 are very selective for the 5 -HT7 
receptor, although SB-656104 has 5-HTjd receptor affinity, which SB-269970 has 
not. Both drugs have negligible (SB-269970) or low affinity (SB-656104) for the 5- 
HTia receptor. The only possible non-5-HT7 receptor affinity that these drugs have 
in common is at the 5-htsA receptor. WAY-10063 5 is highly selective for the 5-HTiA 
receptor, but also has moderate affinity for the 5 -HT7 receptor.
Further comments on the selectivity of the antagonists used will be made in reference 
to the reflexes and protocols on which they were used.
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Binding affinity (p/fi)
Receptor SB-269970 SB-656104 WAY-100635
5-HT1A <5.0 6.3 9.0
5-HT1b 6.0 6.2 <5.5
5-HT1d 5.8 7.6 6.7
5-HTje <5.2 <5.3 <5.3
5-HTjf <5.5 <5.7 <5.3
5-HT2a <5.5 7.2 6.2
5-HT2B 5.0 7.0 7.3
5-HT2C <5.0 l 6.6 6.2
5-HT4 5.9 5.7 <4.3
5-ht5A 7.2 6.7 <5.0
5-HT6 5.2 6.1 <5.1
5-HTt 8.9 8.7 6.9
CtlB <5.0 6.7 7.4*
D2 6.5 7.0 7.1
D3 5.6 6.5 7.2
Table 3.3 Binding affinities at human cloned receptors 
Binding affinities at human cloned 5-HT receptors, a\ adrenoceptors and dopamine 
receptors. Data for SB-269970 are taken from Lovell et al. (2000), data for SB- 
656104 from Thomas et al. (2003), and data for WAY-10063 5 from Roberts et al. 
(2001b) and Johansson et al. (1997). * Data from rat cortical a\ adrenoceptors.
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3.4.3. Sites of action
Administration of pontamine suggests that a 10 pi i.e. injection has the greatest 
effects at the dorsal surface of the medulla at the level of the obex, but also 
significantly diffuses to the ventral surface. Over time, further diffusion is expected 
both rostrally and caudally, so effects seen late in the protocol are cautiously 
interpreted. The most likely site of action for the antagonists here used is the NTS, 
for the following reasons. Firstly it is the most accessible cardiovascular structure for 
an i.e. injection, secondly it is the main integrative nucleus for cardiovascular 
reflexes, with a high level of neurochemical complexity (Lawrence & Jarrott, 1996), 
thirdly it is also the only medullary structure where 5-HT7 receptor distribution has 
been reported (To et al., 1995; Gustafson et al., 1996), as well as containing 5-HTia 
receptors (Wright et al., 1995; Dashwood et al., 1988). However, 5-HTjA receptors 
are also located in the nucleus ambiguus, at least in the cat (Dashwood et al., 1988), 
where they are involved in cardiopulmonary reflex bradycardia (Wang & Ramage, 
2001), so it is possible that i.e. drugs are also diffusing into the nucleus ambiguus at 
sufficient concentrations. Experiments to investigate the site of action of SB-269970 
are described in Chapter 5.
3.4.4. Baseline variables
The general lack of effect of 5-HT receptor antagonists on baselines confirms that 5- 
HT per se has no clear tonic role in cardiovascular regulation in the anaesthetised rat. 
It should be noted, however, that i.e. injection of saline produced a small but 
significant lowering of baseline R-R interval (corresponding to an increase in HR of 
13 ± 4 bpm after 15 min), which might seem surprising. Since there were no 
significant differences between saline and drug-treated groups, however, these 
changes could be caused either by the volume of the injection, or by its pH, or by 
time. Without a separate control in which no solution was injected, it cannot be 
unequivocally concluded that time alone was the factor causing the change. 
However, if either volume or pH caused the changes, other phenomena would be 
expected. For example, sufficiently acidic solutions would be expected to increase 
central respiratory drive via activation of medullary chemoreceptors, but as the saline 
solution used here was not sufficiently acidic (pH 5.8) to cause such changes, the R- 
R interval changes are unlikely to be due to this. Also, the volume of 10 pi is
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unlikely to cause significant pressure changes; after injection the guide cannula was 
unobstructed, allowing cerebrospinal fluid pressure to equilibrate with atmospheric 
pressure. The likely cause of the decreased R-R interval is time, which could be due 
to atenolol wearing off. This is unlikely, since the protocol has been extensively used 
before (Bogle et al., 1990; Dando et al., 1998; Skinner et al., 2002), and this dose of 
atenolol shown to be sufficient for the duration of the protocols. In the present 
experiments, a further dose of atenolol at the end of the protocol did not further 
decrease HR, suggesting adequate lasting pi adrenoceptor blockade. Therefore the 
cause of the decreased R-R interval is likely to be a reduction in vagal drive to the 
heart, possibly as a consequence of the level of anaesthesia slowly changing. For this 
reason, the same supplementary dose of anaesthetic was given at the beginning of 
each protocol, and the comparison with time-matched vehicle controls can take such 
changes into account.
The vehicle for SB-656104 itself caused an increase in MAP which was no different 
from that caused by SB-656104 alone, and this effect was not seen in the saline 
group. This suggests that the vehicle alone causes this pressor response, which is not 
surprising considering it consists of about 25 % DMSO and 25 % PEG. SB-656104 
is not commercially available and was supplied pre-dissolved in DMSO and PEG for 
these experiments, hence there was no choice but to use this rather severe 
concentration. DMSO in particular is thought to increase the permeability of 
neurones and thus increase their excitability (as is shown in Chapter 5, Figure 5.6). 
A possible mechanism, therefore, is that the vehicle is centrally raising MAP by, for 
example, activating sympathoexcitatory neurones in the RVLM. The fact that no 
decrease in baseline R-R interval is seen in this vehicle group may be because the 
pressor response is causing a reflex increase in baseline R-R interval which is 
counteracting the presumed time-related decrease in R-R interval.
Neither SB-269970 nor SB-656104 significantly increase baseline MAP. This is an 
important observation, supporting a modulatory role for central 5 -HT7 receptors 
involved in cardiovascular reflexes. Blockade of glutamate receptors in the NTS, for 
example, raises MAP (Talman et al., 1981; Guyenet et al., 1987) as does blockade of 
012 adrenoceptors in the NTS (Sved et al., 1992). Both these effects were associated 
with a baroreflex inhibition. In the present experiments, baroreflex inhibition is
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associated with normal resting MAP, suggesting that when central 5 -HT7 receptors 
are blocked, there is no loss of control of baseline MAP. Possibly the continuing 
activity of other neurochemical systems, such as the major glutamatergic pathways, 
is responsible for this.
The effect of SB-269970 on central respiratory drive was also surprising. At the 
highest dose, the drug immediately (in < 5 min) reduced IPNA, but at the medium 
dose it took 15 min, and the low dose was without effect. The failure of SB-656104 
to affect IPNA raises doubts over the role of the 5 -HT7 receptor in this effect. 
Furthermore, the fact that only the higher doses have an effect would support the 
notion that a different receptor is involved. The affinity of SB-269970 for the 
dopamine D2 receptor (pA^ j 6.5) (Lovell et al., 2000) is unlikely to be the cause, as the 
D2 receptor antagonist sulpiride had no effect on central respiratory drive when given 
i.e. to anaesthetised rabbits (Dando, 1995). Based on its affinity, a possible 
mechanisms is via the 5-htsA receptor, but this is purely speculative as no 
information on its respiratory functions is available.
The lack of effect of WAY-10063 5 and robalzotan on baseline variables confirms 
earlier findings (Dando et a l, 1998; Skinner et al., 1997; Seeker, 2004), illustrating 
the lack of tonic effect of 5-HTia receptors in the medulla on cardiovascular 
regulation. The ability of (-)-pindolol to cause a significant reduction in baseline R-R 
interval also confirms previous findings (Bogle et al., 1990; Dando et al., 1998), and 
is probably due to its partial agonist activity at the (3 adrenoceptor (Hicks et al., 
1987). It is unclear whether the central actions involve a cardiac sympathoexcitation 
or a vagal inhibition. The atenolol pretreatment would be expected to prevent the 
former, although if it were sufficiently strong it could override the blockade.
The initial increase in IPNA caused by SB-204070 was surprising. Previous research 
found that activation of the 5-HT4 receptor reverses opioid-induced respiratory 
depression (Manzke et al., 2003), suggesting that the 5-HT4 receptor stimulates 
respiratory drive (although the effect of the agonist BIMU8 alone was not reported). 
The present experiments show that 5-HT4 receptor blockade augments respiratory 
drive, suggesting the 5-HT4 receptor is tonically dampening respiration. The effect is 
also very short-lived (only seen at 5 min). Hence, unless compensatory measures are
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activated to bring central respiratory drive back down (which is unlikely as the 
animals are ventilated) it is more likely that this is a non-selective effect of the drug.
The general lack of effects of cinanserin on baseline variables confirms the effects of 
i.c.v. cinanserin reported previously (Knowles & Ramage, 1999). However, at 5 min 
after cinanserin, R-R interval was slightly higher than saline, which was surprising. 
The control value for the cinanserin group, however, was slightly higher than the 
corresponding saline control value, so this may be an artefact caused by this 
difference. Furthermore, baseline IRNA was significantly higher at 25 min in the 
cinanserin group. There is no previous research to suggest that blockade of 5 -HT2 
receptors should cause sympathoexeitation, and the long latency of this effect would 
probably exclude 5 -HT2 receptors in the medulla, so this may reflect a change in 
stability of anaesthetic level at this later time in this group.
In general, it should be noted that this experimental design is not ideally suited to the 
study of baseline effects: the stimulation of cardiovascular reflexes by definition 
alters baselines, and these repeated challenges could have effects that have not been 
controlled for in these experiments. For this reason the baseline effects here reported 
are those from the groups in which only the cardiopulmonary reflex was elicited (or, 
in the case of (-)-pindolol, the aortic nerve mediated baroreflex). In these groups 
there was minimal perturbation of baselines, as the cardiopulmonary reflex changes 
are very short-lived.
3.4.5. The cardiopulmonary reflex
Intra-atrial PBG is a reliable tool for the study of the cardiopulmonary reflex, as it 
acts on the 5 -HT3 receptors located on the peripheral terminals of both cardiac and 
pulmonary vagal C-fibres (Kay & Armstrong, 1990). The latency of the bradycardia 
thus elicited is very rapid (< 2 s) and thus clearly within the circulation time of right 
atrium to left ventricle. Therefore there is no time for downstream (e.g. 
gastrointestinal) afferents to contribute to these effects. In the rabbit and cat the 
circulation time is sufficiently long (approximately 5 s) for the pulmonary afferent- 
evoked effect to be distinguished from the cardiac (Bezold-Jarisch) component, but 
in the rat these cannot be reliably distinguished. In these experiments the dose of 
PBG has been titrated to evoke submaximal bradycardias, to allow either attenuation
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or potentiation to be observed. The strength of the stimulation is therefore probably 
not great enough to cause consistent reflex apnoeas, hence the reflex changes in 
IPNA were variable. The pretreatment with atenolol means that changes in R-R 
interval will directly reflect changes in the activity of CVPNs.
5-HT7 receptors
SB-269970 dose-dependently and reversibly attenuated the bradycardic component 
of the cardiopulmonary reflex. The dose of 100 pg kg’1 i.e. was subsequently chosen 
as the most appropriate to use in other protocols, since it caused a moderate 
attenuation of the bradycardia. The same dose of SB-656104 also strongly attenuated 
the cardiopulmonary reflex bradycardia with a longer time-course, consistent with its 
longer plasma half-life (Thomas et al., 2003). Both drugs are selective for the 5 -HT7 
receptor, and their selectivity profiles are sufficiently different to conclude that their 
reflex effects reflect 5 -HT7 receptor blockade (see Table 3.3). Both drugs have been 
used to attenuate the micturition reflex in anaesthetised rats (Read et al., 2003). In 
that investigation, they were given by the i.c.v. route, and at a slightly lower dose (10 
-  100 pg kg'1 and 30 pg kg'1 respectively) and smaller volume (5 pi). However, since 
the target structures involved in the micturition reflex (probably the pontine 
micturition centre) are different, a comparison is meaningless. To date there have 
been no other studies using these compounds centrally in vivo (i.e. by the i.c or i.c.v. 
route), nor has the 5 -HT7 receptor previously been implicated in cardiovascular 
reflexes. However, the original report of the role of the 5-HTiA receptor in the 
cardiopulmonary reflex (Bogle et al., 1990) used two non-selective antagonists that 
also have affinities for the 5 -HT7 receptor, namely spiperone and methiothepin (Bard 
et al., 1993). At the time this was not known, but it may be significant to these 
findings.
In brain slices, SB-269970 is effective at nanomolar concentrations (Roberts et al., 
2004b), raising the question of whether the present dose of 100 pg kg'1 (26 nmol 
kg'1) is too high to have a selective effect. In the present experiments, the end 
concentration at the target neurones is nigh impossible to estimate, but the selectivity 
profiles of the drugs may give clues: SB-269970 has higher affinity at the 5-ht5A 
receptor than SB-656104 (see Table 3.3). Therefore it is unlikely that both drugs are 
attenuating the bradycardia via 5-htsA receptor blockade. The 5-HT id and 5-HT2A
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blocking properties of SB-656104 are also not expected to have an effect on the 
reflex (Jeggo, 2003; Bogle et al., 1990). SB-269970 has negligible affinity for the 5- 
HTja receptor, whereas SB-656104 has low affinity (pKi 6.25). The latter may 
contribute to the very strong attenuation of the bradycardia achieved with this drug, 
but the primary effect appears to be 5 -HT7 receptor mediated.
The effect of SB-269970 on cardiopulmonary reflex sympathoinhibition is more 
ambiguous. It should be noted that in the saline-treated group, the size of the 
sympathoinhibition grows larger over time. This is likely to be due to time rather 
than the saline injection. Whilst every care was taken to verify IRNA noise levels at 
the end of the experiment, these may also vary during the protocol. Although no 
changes in baseline IRNA were observed, various factors might cause a gradual 
increase in the reflex effect. Possibly a central mechanism is involved, by which 
successive reflex stimuli cause an increasingly efficient response. A possible 
candidate receptor for such an effect would be the NMDA receptor, which is known 
to be involved in cardiopulmonary reflex transmission in the NTS (Chianca & 
Machado, 1996). As such, the effect of SB-269970 (at the low and medium doses) is 
not to attenuate reflex sympathoinhibition, but to prevent its potentiation. This may 
be due to an interplay of glutamatergic and serotonergic mechanisms in the NTS. 
Only the high dose of 300 pg kg'1 clearly attenuated the reflex sympathoinhibition 
(and with it the reflex hypotension). Furthermore, there is no clear dose-depedency in 
this response.
If the 5 -HT7 receptor involved in this reflex are located in the NTS, where afferent 
information is integrated and distributed to the different limbs of the reflex, it is 
surprising that these components are not equally attenuated. Three possibilities 
should be considered: firstly, that the reflex sympathoinhibition has a different 
sensitivity from the reflex bradycardia; secondly, that it involves a different neuronal 
pathway, and thirdly that a different 5-HT receptor is involved. For the baroreflex, 
there is emerging evidence that the bradycardic and sympathetic components are 
physiologically quite different. For example, baroreflex sympathoinhibition is more 
sensitive and has a shorter latency than baroreflex bradycardia (Simms et a l, 2004). 
This may be due to the different properties of sympathetic and parasympathetic 
preganglionic neurones, but another hypothesis is that different afferents are
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involved. When the aortic nerves are cut in the rat, the baroreflex bradycardia is 
almost entirely abolished, but the sympathoinhibition remains fairly robust 
(Pickering et al., 2004), suggesting that the bradycardia preferentially uses the aortic 
nerve afferents, whilst the sympathoinhibition is maintained by the carotid sinus 
nerve afferents. As such, the present effects of SB-269970 on the cardiopulmonary 
reflex resemble the effects of cutting the aortic nerves on the baroreflex. Although 
the cardiopulmonary afferents all travel in the vagus nerve, as opposed to the 
baroreceptor afferents, which are both vagal (aortic nerve) and glossopharyngeal 
(carotid sinus nerve), there may be different types of afferent mediating the different 
components of reflexes. Like afferents terminating in the dorsal horn of the spinal 
cord (to which the NTS is often compared) these may terminate in very different and 
discrete parts of the NTS. These possibilities remain hypothetical, but raise the 
second question of a different 5-HT receptor being involved. The reflex sympathetic 
effects of SB-269970 (albeit unclear) are not confirmed by SB-656104. If the 5 -HT7 
receptor is indeed involved, this is unlikely to be a question of insufficient dose, as 
SB-656104 attenuates the bradycardia almost as strongly as the high dose of SB- 
269970 (which itself strongly attenuates the sympathoinhibition). Therefore it is 
possible that the effect of SB-269970 on reflex sympathoinhibition is non-selective, 
possibly via the 5-htsA receptor. The lack of effect of SB-656104 on reflex 
sympathoinhibtion, but its strong effect on reflex hypotension (comparable to that of 
the high dose of SB-269970) suggests that a large part of the reflex hypotension is 
vagally mediated. In awake rats it has been shown that the cardiopulmonary reflex 
hypotension is entirely vagal (Chianca & Machado, 1996) but in these anaesthetised 
rats some reflex hypotension remains after administration of atropine.
The major problem with interpreting 5 -HT7 receptor mechanisms is the lack of 
selective agonists to confirm the effect. The non-selective agonist 5-CT has been 
extensively used, but has its limitations. 5-CT induces hypothermia in guinea pigs, 
which is inhibited by SB-269970 (Hagan et al., 2000) or SB-656104 (Thomas et al., 
2003). Also 5-CT can evoke micturition in anaesthetised rats only when 5-HT ib/id 
receptors are masked with GR-127935 (Read et al., 2004). This latter approach could 
be used in the present experiments to confirm whether 5-CT can potentiate the reflex, 
although this would still not exclude possible effects at the 5-htsA receptor, for which 
5-CT has a high affinity.
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A final consideration is that SB-269970 is dose-dependently reducing central 
respiratory drive, which is known to modulate vagal bradycardias. Hence when 
IPNA is reduced, one would expect there to be less inhibition of CVPNs, causing an 
increase in reflex vagal outflow. In these cardiopulmonary reflex experiments, 
however, this is not an issue since the reflex bradycardia has been shown not to be 
respiratory modulated (Wang et al., 2000a).
5-HTja receptors
The attenuating effect of WAY-100635 on cardiopulmonary reflex bradycardia 
confirms the role of the 5-HTia receptor in this effect, as previously reported in the 
rat (Bogle et al., 1990), rabbit (Skinner et al., 2002) and cat (Wang & Ramage,
2001). The initial study in the rat did not use selective antagonists, nor look at reflex 
sympathoinhibition. The subsequent study in the rabbit, using the present dose of 
WAY-100635 given i.e., reported that all components of the cardiopulmonary reflex 
were attenuated (including sympathetic and respiratory components), suggesting that 
the receptors are located in the NTS, which mediates all components of the reflex. 
The study in the cat, however, found that reflex activation of CVPNs in the nucleus 
ambiguus was attenuated by iontophoretic WAY-100635, suggesting that the 
receptors are located here. Possibly the receptors are located in both nuclei. A further 
possibility is that WAY-10063 5 is acting at medullary raphe autoreceptors to 
increase firing, causing a release of 5-HT in the NTS, where it could inhibit reflexes. 
A possible pathway has been described from raphe pallidus to the NTS, which 
attenuates cardiopulmonary reflex bradycardia via 5 -HT4 receptors (Edwards & 
Paton, 2000). Raphe pallidus neurones on the ventral surface of the medulla could be 
rapidly reached by an i.e. injection. 5-HTid receptors in the NTS also attenuate 
activation of NTS neurones by cardiopulmonary afferents (Jeggo, 2003). Whether 
these receptors are innervated by a functional pathway from the raphe is not known, 
but illustrates that there are at least two 5-HT receptors that might inhibit reflexes if 
raphe neuronal firing increased.
WAY-100635 is considered a highly selective and potent 5-HT ia receptor 
antagonist, with almost 100-fold selectivity over the nearest 5-HT receptor (5-HT id). 
However, recently it has also been shown to have a moderate affinity for 5 -HT7
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receptors (see Table 3.3). The selectivity of the present dose (100 pg kg"1 i.e.) has not 
been verified: in the rabbit, this dose inhibited the potentiation of cardiovascular 
reflexes by i.e. buspirone, but it was only given intravenously (the dose itself having 
no effect on the reflex) (Skinner et al., 2002). The fact that buspirone potentiated the 
reflex but i.v. WAY-100635 had no effect can be explained by the relative difficulty 
of antagonising synaptic events with a systemic antagonist. However, these data do 
not exclude the possibility that this dose of WAY-100635, given i.e., has non- 
selective effects.
Robalzotan (NAD-299), on the other hand, is a highly potent and selective 5-H T iA 
receptor antagonist with a 5-HT ja binding affinity comparable to that of WAY- 
100635, but negligible affinity for the 5 -HT7 receptor (Johansson et al., 1997). 
Robalzotan i.e. had no effects on the cardiopulmonary reflex in these experiments, 
raising doubts over whether the effects of WAY-100635 are 5-HT ia receptor 
mediated. A set of experiments is described in Chapter 5, which investigate whether 
robalzotan can inhibit 8-OH-DPAT induced bradycardia (see 5.3.2). These found that 
an intravenous dose of 100 pg kg"1 of robalzotan was able to inhibit the bradycardia 
elicited by i.v. 8-OH-DPAT, suggesting adequate receptor occupancy when given 
systemically. Those data are presented in Chapter 5 to avoid confusing different 
anaesthetic protocols, and in those experiments robalzotan was not given i.e. because 
subsequent single-unit recordings were performed, which could be influenced by this 
pretreatment. Therefore robalzotan was given i.v. to ensure its rapid clearance from 
the body. This minor control is by no means unequivocal evidence, but it seems 
unlikely that the dose of robalzotan used i.e. in the present Chapter was insufficient 
to occupy medullary 5-H T ia receptors to a similar extent to WAY-100635. Similar 
doses of robalzotan and WAY-10063 5 increase bladder capacity in rats (Pehrson et 
al., 2002), suggesting similar potency when given centrally in vivo.
5-HT2 and 5-HT4 receptors 
The lack of effect of cinanserin and SB-204070 confirms that there is no tonic role of 
5 -HT2 and 5 -HT4 receptors in the cardiopulmonary reflex. 5 -HT2A, 5-HT2B and 5- 
HT2C receptors are found in the NTS, with 5 -HT2C receptors causing neuronal 
inhibition and 5 -HT2A/B causing excitation (Sevoz-Couche et a l, 2000b). Activation 
of 5 -HT4 receptors in the NTS also attenuates the cardiopulmonary reflex (Edwards
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& Paton, 1999). The present experiments are consistent with previous findings that 
the 5-HT2 receptor antagonist BW-501C67 given i.e. (Bogle et al., 1990) has no 
effect on the cardiopulmonary reflex. The present dose of cinanserin is marginally 
higher than the i.c.v. dose previously reported to block completely the effects of i.c.v. 
quipazine in rats (Knowles & Ramage, 1999), suggesting that it is a sufficient dose to 
occupy 5-HT2 receptors in the medulla. Cinanserin did, however, attenuate the reflex 
sympathoinhibition only at 5 min. This short-lasting effect is not consistent with the 
long duration of this antagonist when given i.c.v. (Knowles & Ramage, 1999), and 
therefore seems unlikely to be due to 5-HT2 receptor blockade. Although other 
components of the reflex in this group were stable, this could represent a change in 
the condition of nerve recording in a few animals, which has skewed the mean of this 
small group.
It has been previously shown that activation of 5 -HT4 receptors in the NTS attenuates 
the cardiopulmonary reflex (Edwards & Paton, 1999), but the 5-HT4 receptor 
antagonist RS-39604 alone had no effect. These present data demonstrate the lack of 
effect of another more potent 5-HT4 receptor antagonist, SB-204070, with a pK; of 
10.2 (van den Wyngaert et al., 1997). A 1 mg kg'1 i.p. dose of SB-204070 is 
sufficient to occupy striatal 5-HT4 receptors effectively (Porras et al., 2002), 
suggesting that the current dose of 100 pg kg'1 given i.e. is sufficient.
3.4.6. The chemoreflex
Bolus doses of i.v. cyanide were used to activate peripheral chemoreceptors in the 
carotid bodies. This mechanism has been previously verified: cutting of the carotid 
sinus nerves completely abolished the effect of i.v. cyanide in awake rats (Franchini 
& Kreiger, 1993). In the present experiments it was also found that atropine at the 
end of the experiment abolished cyanide-evoked bradycardias, indicating that the 
doses of cyanide used did not have direct cardioinhibitory effects. The chief effect on 
MAP in these experiments was a depressor response. Although a small initial 
increase in MAP was sometimes observed, the decrease in MAP was the dominant 
effect, and this was recorded. In awake animals the normal effect of chemoreceptor 
stimulation with cyanide is a marked pressor response, which turns into a depressor 
response when the animal is anaesthetised (Franchini & Kreiger, 1993), which may 
reflect the greater excitability of neurones in the unanesthetised state, and include
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some behavioural alerting. Also in the anaesthetised rabbit a pressor response is 
achieved when small doses of cyanide are applied locally to the carotid bodies via 
the lingual artery (Skinner et al., 2002), probably because with this method the doses 
of cyanide are not sufficient to cause peripheral vasodilatation by direct effects on 
the vasculature, which is probably what is causing the hypotension in the present 
experiments. The disadvantage in the lingual artery route is that only one carotid 
body is stimulated; in the present experiments the stimulation is bilateral. Another 
possibility is that the sympathoexcitation observed is either not of sufficient strength 
and duration to raise MAP, or is only restricted to certain targets (such as the 
kidney).
In the i.e. saline group, the reflex bradycardia was slightly potentiated with time, 
which was not seen in the cardiopulmonary reflex bradycardia, but was seen in the 
cardiopulmonary sympathoinhibition. As before, this may involve central 
mechanisms of increased synaptic efficacy, but is most likely due to changing 
anaesthesia level. However, it aids the interpretation of drug-evoked attenuation, as 
the normal tendency is for repeated stimuli to increase in size.
5-HT7 receptors
The medium dose of SB-269970 used in the cardiopulmonary reflex also caused a 
comparable attenuation of chemoreflex bradycardias. This illustrates for the first time 
the role of 5-HT receptors in chemoreflex transmission, as it was previously shown 
that 5-HTia receptors are involved in cardiopulmonary but not chemoreflex 
bradycardia in rabbits (Skinner et a l, 2002). From NTS neuronal recordings it was 
proposed that different reflexes use different neuronal channels in the NTS as well as 
different afferents (Donoghue et al., 1985), which would indicate an influence of 5- 
HT7 receptors on multiple channels, if in fact they are functioning within the NTS. 
The similar sizes of the cardiopulmonary and chemoreflex bradycardic attenuations 
(~ 70 %) suggest that the receptor has a similar role and importance in both reflexes.
The effect of SB-269970 on chemoreflex sympathoexcitation is a clear attenuation, 
not merely the prevention of potentiation seen in the cardiopulmonary reflex. 
Furthermore the effect follows the same time course as for the bradycardic 
attenuation, suggesting a similar site of action. This implies that in the chemoreflex,
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5 -HT7 receptors facilitate sympathoexcitation. The receptors could be located on or 
in the vicinity of NTS neurones projecting to the RVLM. The ability of the drug to 
attenuate this response, where it failed to have such a clear effect on 
cardiopulmonary reflex sympathoinhibition, could reflect a lower excitability of 
neurones mediating the effect. The control sympathoexcitation was an increase of 74 
± 1 1 % ,  which is comparatively small, and may reflect the depressant action of the 
anaesthetic. Hence it is not surprising that this effect is attenuated, whereas the huge 
reflex respiratory response (an increase of 262 ± 45 %) was unaffected. The 5-HT7 
receptors facilitating the sympathoexcitation could also be located on RVLM 
premotor neurones; the nature of the connection between NTS and RVLM in the 
chemoreflex is still under debate,^ and appears to be more complex than a simple 
glutamatergic projection (Mauad & Machado, 2001), possibly involving other 
transmitters. Hence 5-HT is another possible candidate, but there is no evidence of 
expression of 5-HT7 receptors in the RVLM.
The lack of effect on reflex increase in IPNA is interesting, and suggests that the 
neuronal channel mediating the respiratory response to chemoreceptor activation 
through the NTS is not facilitated by 5-HT7 receptors. Again this illustrates the 
differential role of the receptor in reflex integration. A similar effect was seen in the 
micturition reflex in anaesthetised rats, where SB-269970 reduced reflex bladder 
contractions, but did not affect reflex urethral dilatation (Read et al., 2003). The 
respiratory response to chemoreceptor stimulation (by simulated hypoxia in this 
case) is certainly the most important component of the reflex in terms of survival of 
the organism, so one would expect it to be more resistant to modulation.
Chemoreflex bradycardia is known to be respiratory modulated (Davidson et al., 
1976), so the lack of change in the reflex ventilatory response is advantageous to the 
interpretation of the bradycardic attenuation: the latter is unlikely to be affected, as 
the former has not changed. The baseline IPNA, however, is lowered by SB-269970, 
suggesting that cardiac vagal outflow is generally more excitable after the drug, due 
to reduced inspiratory drive to inhibit it. The fact that evoked bradycardias are still 
strongly attenuated even when IPNA is lowered confirms that the reduced 
bradycardia is not an artefact of altered respiratory modulation.
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5-HTja receptors
The same dose of WAY-10063 5 that attenuated cardiopulmonary reflex bradycardia 
5 min after injection had no effect on chemoreflex bradycardia at 7 min. This 
confirms previous findings in the rabbit (Skinner et al., 2002), where the same dose 
of WAY-10063 5 had no effect (at 5 min), although buspirone potentiated the 
bradycardia. This study, however, reported no attenuation of the sympathoexcitation 
at 5 min. This is at odds with the present data, which show that the 
sympathoexcitation is not diminished as such, but fails to be potentiated. In these 
experiments, the first chemoreceptor stimulus was given at 7 min after i.e. WAY- 
100635, as opposed to at 10 min after SB-269970 (and saline). This was because the 
inhibitory effect of WAY-100635 bn the cardipulmonary reflex was gone by 15 min, 
and previous experiments with WAY-10063 5 suggested a very short duration of 
action when given i.e. (Skinner et al., 2002). Subsequently it was considered that 
even 7 min might be too long, so a new protocol was designed, with stimuli given at 
2 and 5 min after WAY-100635 or saline. Here effects are compared with truly time- 
matched controls, rather than reflexes at 7 min being compared to those at 10 min in 
the saline group.
At 2 min after WAY-10063 5 the chemoreflex bradycardia was indeed attenuated, 
and the sympathoexcitation was again prevented from potentiating, as seen in the 
original protocol at 7 min. Both of these effects were gone at 5 min. This raises the 
question of whether the previously reported lack of effect in rabbits (Skinner et al.,
2002) was also due to the short duration of action rather than the lack of 5-HT ja 
receptor involvement. Such a short duration of action was very surprising, as WAY- 
100635 has a plasma half-life of ~15 min (Pfizer Ltd., personal communication). 
When given centrally, it may redistribute very rapidly, losing effective concentration 
in a much shorter time. Another possibility is a non-selective action. The selectivity 
of WAY-100635 for the 5-HT ia over the 5 -HT7 receptor has been reported to be 
between 75-fold (see Forster et al., 1995, discussion) and 100-fold (Roberts et a l, 
2001b). WAY-100635 appears to diffuse into the brain very rapidly following an i.e. 
injection, as it virtually abolished aortic nerve-mediated bradycardia in rabbits just 
90 seconds after administration (Skinner et al., 2002). The rat medulla is smaller, so 
the time to reach the target could be even less. It is conceivable that at this early time 
of 2 min after injection, the concentration of WAY-100635 at a relatively superficial
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structure such as the NTS could be high enough to occupy 5 -HT7 receptors. This 
could therefore be responsible for the very short-lived attenuation of chemoreflex 
bradycardia and sympathoexcitation. WAY-100635 also binds to a\ adrenoceptors, 
but there is no evidence for their involvement in the chemoreflex. Indeed ai 
adrenoceptor blockade has no effect on cardiopulmonary reflex bradycardia (Bogle 
et al., 1990).
3.4.7. The baroreflex
Electrical stimulation is an accepted and elegant way to activate the baroreflex 
(Sapru et al., 1981), as it directly stimulates the afferents without the need to change 
BP artificially. Therefore reflex hypotension as well as bradycardia can be observed. 
The disadvantage is that all the afferents are stimulated, and at the same time, rather 
than incrementally as would be the case with increasing BP. However, the aortic 
nerves in the rat have been shown to contain very few chemoreceptor afferents, and 
are the primary mediators of baroreflex bradycardia (Pickering et al., 2004). In the 
present experiments, stimulating of the right aortic nerve produced consistent 
bradycardias and hypotensions, though these were slightly less stable and 
reproducible than other reflexes. The use of constant current rather than constant 
voltage stimulation should overcome small changes in the impedance of the 
electrode-nerve preparation. However, as can happen with repeated electrical 
stimulation of neural tissue, there is some wind-down of the response. This may 
account for the slight downward trend in the saline group. Consistent 
sympathoinhibition was difficult to record in these experiments. In several animals 
there were stimulus artefacts in the renal nerve signal, possibly due to insufficient 
grounding. For this reason the baroreflex investigation was continued using the 
traditional method of raising MAP with phenylephrine. With this method, the real 
sensitivity of the baroreflex can be quantified. The method of plotting the 
phenylephrine-evoked MAP slope beat-by-beat against the corresponding R-R 
intervals, and staggering the two until the maximum correlation coefficient was 
reached (Su et al., 1992), was chosen because it takes into account the delay in the 
onset of the bradycardia, and shows the true linear relationship between MAP and R- 
R interval.
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5-HT7 receptors
SB-269970 again caused a significant attenuation of the aortic nerve-evoked 
bradycardia, with no effect on the evoked hypotension, which suggests that central 5 - 
HT7 receptors facilitate the cardioinhibitory but not the sympathoinhibitory 
component of the baroreflex. The size of the attenuation was not quite as great as that 
of the cardiopulmonary and chemoreflex bradycardias, nor did it reach the same level 
of significance with respect to saline control, which may reflect the tendency of the 
saline group to wind-down over time. For an initial investigation, however, the 
results are clear. In previous experiments, a variety of stimulus frequencies (1 0 - 8 0  
Hz) were delivered in the presence of buspirone, which has a long duration of action 
when given i.e. (Skinner et a l, 2002). However, in the presence of WAY-100635 
this was problematic due to its short duration of action, and the fact that at least 1.5 
min needed to elapse between each train of stimuli. If the drug is rapidly wearing off 
during a set of successive stimuli, the results become difficult to interpret. Therefore 
a single frequency of 40 Hz was chosen in this study.
SB-269970 also attenuated the absolute bradycardia evoked by phenylephrine 
injection, and flattened the slope, indicating a reduced gain or sensitivity of the 
reflex. This validates the aortic nerve experiments, and confirms that central 5 -HT7 
receptors facilitate bradycardias evoked by baroreceptors, as well as chemoreceptors 
and cardiopulmonary afferents. As suspected from the aortic nerve experiments, 
there was no effect on baroreflex sympathoinhibition until 25 min post drug, which 
was not attenuated per se, but presented from potentiating. As for the 
cardiopulmonary reflex sympathoinhibition, the effect on this component is 
inconsistent with the effect on the cardioinhibitory limb, and raises several alternate 
possibilities, including a distant site of action, a different receptor, or a change in the 
stability of the preparation at this late stage in the protocol.
5-HTia receptors
The role of the 5-HTia receptor in the baroreflex is even more ambiguous than its 
role in the chemoreflex. Surprisingly, neither WAY-10063 5 nor (-)-pindolol 
significantly affected the aortic nerve-evoked responses. In the rabbit, WAY-10063 5 
did inhibit baroreflex but not chemoreflex bradycardia (Skinner et a l, 2002) -  an 
effect which at the time was attributed possibly to the different afferents activated
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(aortic nerve afferents in the vagus and chemoreceptor afferents in the 
glossopharyngeal nerve), which might have different central circuitry and 
pharmacology. The present experiments suggest that if this is the case, there is a 
species difference from the rat, in which two different 5-HTiA receptor antagonists 
are inactive at the baroreflex.
The pindolol group appears to be slightly attenuated: of 5 animals 1 had a strongly 
attenuated bradycardia at 5 min only, but the remaining 4 were unaffected. The lack 
of effect was particularly surprising as the same dose of (±)-pindolol has been 
reported to attenuate cardiopulmonary reflex bradycardia in anaesthetised rats (Bogle 
et al,, 1990), and the same dose o f (-)-pindolol has been reported to attenuate smoke- 
induced bradycardia in anaesthetised rabbits (Dando et al., 1998). In the study of 
Bogle et al. (1990), (±)-pindolol was the only antagonist used that did not bind to 5- 
HT7 receptors, and in retrospect this drug provided the confirmation that the 5-HTia 
was involved. Subsequent to these present experiments, a brief investigation was 
made to reproduce the conditions in the study of Bogle et al. (1990), stimulating the 
cardiopulmonary reflex in spontaneously breathing anaesthetised rats. However, 
neither 100  pg kg' 1 i.e. (±)-pindolol (n = 2 ), nor the same dose of (-)-pindolol {n -  2) 
had much effect on cardiopulmonary reflex bradycardias.
After the findings that chemoreflex bradycardias were attenuated by WAY-10063 5 
only at 2  min, this protocol was tried on the aortic nerve-evoked baroreflex, but the 
attenuation was not as large as in the chemoreflex group, and not significant. 
Addition of a further 200 pg kg' 1 i.e. WAY-100635 (20 min after the first dose) then 
did attenuate the bradycardia between 2 and 3 min after drug, and the hypotension 
between 2 and 5 min. At such high doses one cannot expect a selective response, 
therefore these data were treated as minor observations and not supported with a 
vehicle control. From these experiments, however, it is clear that the role of the 5- 
HTia receptor in cardiovascular reflexes is not at all clear in rats, and that WAY- 
100635 has different potencies at different reflexes, the aortic nerve-evoked 
baroreflex being the most resistant to attenuation by this drug.
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3.4.8. Comparative receptor mechanisms
Species differences are regularly encountered in the serotonergic system. For 
example, in the mouse and rat 8-OH-DPAT induced hypothermia is WAY-100635 
sensitive, therefore was originally thought to be 5-HT[A receptor mediated (Forster et 
a l, 1995). On the other hand, in the guinea pig 5-CT induced hypothermia is 
sensitive to SB-269970 (Hagan et al., 2000) and SB-656104 (Thomas et a l,  2003), 
suggesting that in this species the effect is 5-HT7 receptor mediated. However, 
studies with 5-HT7 receptor knockout mice have shown that 8-OH-DPAT acts on 5- 
HT7 receptors at low doses, and at 5-HTjA receptors at higher doses, both producing 
hypothermia (Hedlund et al., 2004). In the guinea pig, activation of 5-HTib receptors 
can also cause hypothermia (Hagan et a l, 1997). Therefore what was previously 
thought to be a clear species difference of 5-HTiA receptors in rats and 5-HT7 
receptors in guinea pigs, now appears to be a more complex picture of multiple 
receptor mechanisms, possibly with different emphasis in different species. With 
respect to the present experiments, there was an early speculation that in the rabbit, 
reflex bradycardias might be 5-HT]A dependent, whilst in the rat the 5-HT7 receptor 
is dominant. This will remain purely hypothetical until 5-HT7 receptor effects are 
examined in other species, namely the rabbit and guinea pig. However, in the 
micturition reflex in the rat, the 5-HTjA receptor is clearly a major player (Testa et 
a l, 1999; Conley et a l, 2001; Pehrson et al., 2002), and this reflex is exquisitely 
sensitive to antagonists. WAY-100635 at doses as low as 1 pg kg'1 i.c.v. inhibits 
micturition (Seeker, 2004). This would suggest that 5-HTiA receptors do have a 
major parasympathetic reflex role in rats. The pharmacology of reflex micturition 
and reflex bradycardia are comparable, as 5-HTjA and 5-HT7 receptors facilitate 
whereas 5-HTib/id receptors inhibit (Dando et a l, 1998; Read, 2004). In the rat, 
however, it would appear that the 5-HTjA receptor is closely involved with 
micturition, but only a minor player in cardiovascular reflexes. One confounding 
factor in these experiments is that the micturition experiments in the rat (and indeed 
the cardiovascular reflex studies in the rabbit) were performed under urethane 
anaesthesia, whilst the rat cardiovascular experiments used a-chloralose. Therefore 
the different 5-HTjA effects could be anaesthesia-related.
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Both 5-HT ja and 5 -HT7 mechanisms co-operate in micturition (Read et al., 2003; 
Pehrson et al., 2002) and hypothermia (Hedlund et al., 2004). In the physiological 
context of micturition, blockade of either receptor inhibits the reflex. This suggests 
that they are located in series within the reflex arc, raising the question of how 
receptors with opposite effects on neuronal excitability (inhibition vs. excitation) can 
have the same effect. Some clues have come from hippocampal membranes, where 
5 -HT7 receptors stimulate cAMP production, and 5-H T ja receptors further fine tune 
(i.e. augment) this effect (Thomas et al., 1999a). This raised the possibility of a 
population of 5-HT ja receptors positively coupled to adenylate cyclase, but from that 
study using homogenised tissue it is uncertain whether the two receptors are located 
on the same neurone. In the cat nucleus ambiguus, 5-H T ja receptors are believed to 
inhibit a tonic GABAergic inhibition of CVPNs (Wang & Ramage, 2001), causing 
their excitation indirectly. An important experiment would be to test whether 
functional 5 -HT7 receptors are located in the cat NTS, as this would illustrate the 
hypothesis that 5 -HT7 and 5-HT ja receptors are in series (one in the sensory and one 
in the premotor nucleus). One must bear in mind that in the rat, 5-HT ja receptors 
involved in micturition are located both supraspinally and in the sacral spinal cord 
(Seeker, 2004), which is a comparable sensory and premotor distribution. It is likely 
that 5-HT ja receptors are found in the nucleus ambiguus of all mammals, as systemic 
agonists produce bradycardia in a variety of species (see Ramage, 2001). Therefore, 
if species differences exist in the 5-HT receptors involved in cardiovascular reflexes, 
the NTS may be the site involved.
3,4.9. Technical limitations
The use of anaesthesia and neuromuscular blockade allows a high level of control 
over confounding variables such as animal movement, changes in ventilation and 
associated afferent information, and blood gases. Whilst every care was taken to 
keep animals as stable and physiologically normal as possible, anaesthesia is a major 
limitation, but this is addressed in the awake experiments of Chapter 6.
A serious potential limitation of these studies is the small group size. Groups of 5 are 
often used in these types of experiments, and pose no problem when an effect is clear 
cut. Indeed in such a case small groups should be encouraged to reduce the number 
of animals required. However, in more variable responses (such as reflex effects on
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nerve activity) and more ambiguous effects (such as the 5-HTiA receptor role), a 
higher number (e.g. 8 per group) would give a clearer result. Within the limited time 
frame of this project, larger group sizes would have meant reducing the scope of the 
study.
Another possible confounding factor is the use of multiple reflexes in Protocol 2. 
This has been done previously in this laboratory in the rabbit (Skinner et al., 2002), 
and has the advantage of reducing the number of animals required for a study, as 
well as providing an internal control in the case of one drug having different actions 
on different reflexes. The problem is that the stimulation of one reflex might have an 
effect on the other, requiring further controls. In these experiments, the effect of 
WAY-100635 on aortic nerve and chemoreflex evoked changes (Protocol 2) was 
subsequently re-tested using Protocol 3, to confirm that the lack of effect on the 
chemoreflex was due to time, not due to the aortic nerve stimuli. Similarly, the 
effects of aortic nerve stimulation were similar in the presence and in the absence of 
chemoreflex stimluli. The effects of SB-269970 on the chemoreflex, however, were 
not confirmed in the absence of aortic nerve stimulation. The effects on the 
phenylephrine-evoked baroreflex were comparable to the effects on aortic nerve 
stimulation, suggesting that this latter effect was not influenced by the chemoreflex 
in the same protocol. Lastly, the effect on pindolol was tested on aortic nerve 
stimulation in the absence of chemoreflex stimulation, and as such is not entirely 
comparable to the effects of WAY-10063 5 (which was tested on both reflexes in the 
same protocol). As such, the mixing of different reflexes has been counterproductive 
in terms of reduction of animals, and would best be avoided in future.
3.4.10. Conclusion
In anaesthetised rats, the central 5 -HT7 receptor makes a major contribution to the 
activation of cardiac vagal outflow in response to a variety of peripheral stimuli, and 
these receptors are likely to be located in the medulla, possibly the NTS. Conversely, 
central 5-HTiA receptors have a questionable role: the antagonist WAY-100635 has 
an effect on reflex bradycardias in the rank order of cardiopulmonary reflex > 
chemoreflex > baroreflex, but this is not supported by other antagonists, so the 
possibility of a non-selective (e.g. 5 -HT7 receptor mediated) or compound-specific 
effect cannot be excluded. In terms of sympathetic components, 5 -HT7 receptors are
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clearly involved in chemoreflex sympathoexcitation, but sympathoinhibitions in 
response to other reflexes are ambiguous.
There are various clinical implications, as a number of commonly used drugs bind to 
these receptors. In particular, antipsychotic medications such as clozapine bind to 5- 
HT7 receptors, and whether the cardiovascular side-effects of such compounds relate 
to actions on reflexes is an interesting question. Changes in the efficacy of 
serotonergic neurotransmission may be involved in depressive disorders, and most 
commonly used antidepressants aim to restore this hypothetical functional deficit. In 
either case, reuptake inhibitors potentiate the action of endogenous 5-HT, so possible 
changes in cardiovascular reflex efficacy might be expected either in depression, or 
during antidepressant administration, or both. An interesting finding is that patients 
with depression have lower heart rate variability (Tulen et al., 1996; Stein et al., 
2000) and increased mortality after cardiac surgery than non-depressed patients 
(Baker et al., 2001; Blumenthal et al., 2003).
A major remaining question is which neurones are releasing 5-HT onto 5 -HT7 and 5- 
HTja receptors during these reflexes. This will be addressed during the following 2 
chapters.
3.4.11. Future experiments
The most important follow-up confirmation required for these experiments is of the 
mixed effects of 5-HTia receptor antagonists. This would best be approached using 
an old and a new antagonist (e.g. pindolol and robalzotan), given in several doses, 
and tested only against highly stable vehicle controls. The effects of 5 -HT7 receptor 
antagonists on reflex sympathetic activity should also be further evaluated, including 
the effect on sympathoexcitation evoked by stimulation of the upper airways with 
smoke, or by baroreceptor unloading with sodium nitroprusside. In such a study, a 
more detailed and elegant method of analysing reflex changes in sympathetic outflow 
could be used (Scheuer & Mifflin, 2001). A vital observation would also be the 
effect of these new 5 -HT7 antagonists on cardiovascular reflexes in other species, 
particularly the guinea pig and the rabbit.
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4. T h e  c o n t r ib u t io n  o f  5 -H T  c o n t a in in g  c e l l  g r o u p s  
TO AUTONOMIC BASELINES AND REFLEXES
4.1. Introduction
4.1.1. Background
Many brainstem cell groups involved in cardiovascular regulation are innervated by 
5-HT containing fibres. The NTS in particular receives a dense innervation. In the cat 
this consists of unmyelinated fibres with both varicosities and specialised synapses 
(Maley & Elde, 1982). The origin of these fibres is unclear, although some are likely 
to be 5-HT containing vagal afferents (Sykes et al., 1994) from the nodose ganglion 
(Gaudin-Chazal et al., 1982; Nosjean et al., 1990) or other peripheral sources. From 
retrograde tracing it would appear that a further source is neurones of raphe magnus 
and dorsal raphe (Schaffar et al., 1988). Thirdly it has been suggested that 
intemeurones within the NTS contain 5-HT (Calza et al., 1985). Whether or not 
these fibres serve a role in cardiovascular regulation is also not clear, but the growing 
body of evidence identifying roles for various 5-HT receptor subtypes in the NTS in 
cardiovascular control suggests that these are the fibres releasing 5-HT onto the 
relevant NTS neurones. Other autonomic cell groups receive a similar innervation: 
retrograde viral tracing discloses a projection from the caudal raphe to the DVN and 
nucleus ambiguus (Hadziefendic & Haxhiu, 1999). Such anatomical connections are 
not necessarily functional. The medullary raphe, however, are the cell groups of 
interest to this study, since they are reported to have predominantly descending 
projections, and a variety of functions which have been discussed in 1.5.1 above.
4.1.2. Aims of the study
The previous chapter suggests that 5-HT is released during cardiovascular reflexes. 
The aim of this study is to investigate the origin of this 5-HT. This took the form of 
an initial mapping study of the medullary raphe, paying particular attention to cardiac 
vagal outflow, but also monitoring central respiratory drive and sympathetic tone. 
Chemical and electrical stimulation were used to identify areas that mediate changes 
in baselines resembling autonomic reflexes. Particular areas of interest were then
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further characterised by attempting to block the responses using 5-HT receptor 
antagonists. Furthermore some animals were depleted of 5-HT to confirm firstly the 
findings of the antagonist study, and secondly that endogenous 5-HT is required for 
successful reflex function.
4.2. Methods
4.2.1. Protocols
Raphe mapping study
Distinct areas of the medullary midline were serially stimulated with reference to the 
calamus scriptorius (rostrocaudal axis) and the floor of the IVth ventricle 
(dorsoventral axis), using the stereotaxic deliniations of Paxinos and Watson (1998). 
In each animal up to four electrode penetrations were performed on the midline, 
between 0.5 and 4 mm rostral, and between 1 and 3 mm ventral. Individual 
stimulations were separated by 0.5 -  1 mm in the dorsoventral axis, and by 1 mm in 
the rostrocaudal axis. 10 min was allowed to elapse between chemical stimulations, 
and 5 min between electrical stimulations, to prevent tachyphylaxis, depolarisation 
block, or excitotoxic damage. In some experiments stimulations were made 1 mm 
lateral to the midline to control for the effect of drug diffusion or current spread. The 
most ventral point on any penetration was marked by depositing 50 nl pontamine sky 
blue dye for subsequent histological verification.
Pharmacology
When an area of interest had been characterised in the mapping study, the effects of 
5-HT receptor antagonists on the responses to stimulating this area with DLH were 
investigated. The following antagonists were used: methiothepin (broad spectrum 5- 
HT receptor antagonist; (Monachon et al., 1972) 1 & 3 mg kg’1), granisetron 
(selective 5 -HT3 receptor antagonist; (Bermudez et al., 1988) 0.3 mg kg'1) and SB- 
204070 (selective 5 -HT4 receptor antagonist; (Wardle et a l, 1994) 3 mg kg'1). Since 
the location of 5-HT release caused by raphe stimulation was not known, antagonists 
were given i.v., and comparisons were made between drug and saline pretreated 
groups.
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Only one raphe area was stimulated in each experiment. After micropipette 
placement, atenolol (1 mg kg'1 i.v.) and a-chloralose (15 mg kg'1 i.v.) were given. 10 
min were allowed to elapse, then control micro injections were commenced (2.5 nmol 
DLH) every 10 min. 5 min after the third control, the test solution was given i.v. in a 
volume of 1 ml kg'1, and a further microinjection performed at 5 min after injection.
Depletion o f 5-HT stores 
In a further set of experiments, the effect of depleting 5-HT stores with p-CPA were 
investigated on raphe-evoked responses and cardiovascular reflexes. A detailed 
protocol is shown in Figure 4.1. Serial micro injections were made at 6 distinct 
locations in the raphe, separated by 10 min. At the beginning and the end of the 
protocol, baroreflex sensitivity was tested by giving 10 pg phenylephrine i.v., and 
cardiopulmonary reflex sensitivity was tested by giving 2.5 pg PBG into the right 
atrium.
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Figure 4.1 Microinjection protocol for depletion study
Diagram of protocol for stimulating areas of medullary raphe at various positions
threlative to calamus scriptorius (rostral) and floor of the IV ventricle (depth) with 
DLH (2.5 nmol) in p-CPA or saline treated rats.
PE: phenylephrine 10 pg i.v.
PBG: phenylbiguanide 2.5 pg intra-atrial 
pont: pontamine sky blue (50 nl).
Inset: coronal diagrams of medulla illustrating sites of micro injection (relative to 
bregma in parentheses).
NTS: nucleus tractus solitarius 
ROb: raphe obscurus
RPa: raphe pallidus
RMg: raphe magnus
VII: facial nucleus.
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4.3. Results
4.3.1. Chemical stimulation of medullary raphe
Baseline variables
Microinjections were performed in anaesthetised, neuromuscular blocked and 
atenolol-pretreated rats {n = 12). Baselines at the beginning of the protocol were a 
MAP of 118 ± 2 mmHg and a HR of 362 ±10 bpm.
1.5 mm rostral (Bregma A -12.8, L 0, D 10.1-10.6)
Microinjection of DLH (2.5 nmol in 50 nl) into parts of raphe obscurus and pallidus
1.5 mm rostral to calamus scriptorius evoked the following changes: at 2 mm depth 
(n = 6) DLH significantly reduced baseline IRNA (-45 ± 8 %) and increased baseline 
IPNA (+116 ± 21 %), with no effect on baseline MAP or HR (Figures 4.2 and 4.3, 
Table 9.36).
At 2.5 mm depth (n = 5) DLH significantly reduced baseline IRNA (-40 ± 8 %) and 
increased baseline IPNA (+123 ± 46 %), with no effect on baseline MAP or HR.
Microinjection of saline at depth 2.5 mm (50 nl, pH 7.4; n = 3) had no observable 
effect on any variable (Table 9.36).
Lateral control microinjections of DLH (into gigantocellular reticular nucleus, Figure 
4.3; n = 3) had no significant effect on any variable (Table 9.36).
2.5 mm rostral (Bregma A -11.8, M  0, V 9.3-10.3)
Microinjection of DLH (2.5 nmol in 50 nl) into parts of raphe obscurus and pallidus
2.5 mm rostral to calamus scriptorius evoked the following changes: it significantly 
reduced baseline IRNA at all 3 depths tested: -35 ± 3 % at 1.5 mm depth (n = 9), -29 
± 8 % at 2 mm depth (n = 7), and -20 ± 9 % at 2.5 mm depth (n = 8). It had no 
significant effects on baseline MAP, HR, or IPNA at any depth (Figures 4.4 and 4.5, 
Table 9.37).
Lateral control microinjections of DLH (into gigantocellular reticular nucleus, Figure
4.5, Table 9.37; n = 4) significantly raised baseline MAP by 22 ± 3 mmHg (126 ± 5
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to 149 + 8 mmHg), and baseline IRNA (+36 ± 3 %), with no significant effect on 
baseline HR or IPNA.
3.5 mm rostral (Bregma A -10.8, L 0, V 10.0-10.5)
Microinjection of DLH (2.5 nmol in 50 nl) into parts of raphe magnus and pallidus
2.5 mm rostral to calamus scriptorius evoked the following changes: at 2 mm depth 
(,n = 6) it significantly reduced baseline HR by 30 ± 7 bpm (367 ± 16 to 340 ± 15 
bpm), increased baseline IRNA (+31 + 6 %) and reduced baseline IPNA (-53 ± 7 %), 
with no significant effects on baseline MAP (Figures 4.6 and 4.7, Table 9.38).
At 2.5 mm depth {n = 7) DLH significantly reduced baseline HR by 42 ± 6 bpm (378 
±10 to 338 + 8 bpm), increased baseline IRNA (+46 ± 6 %), and decreased baseline 
IPNA (-60 ± 6 %), with no significant effects on baseline MAP. Stimulation of the 
corresponding area 1mm further rostral (4.5 mm rostral to calamus scriptorius) 
consistently had no effect on any variable.
Microinjection of pontamine sky blue (50 nl, pH 7.4; n = 7) at depth 2.5 mm had no 
significant effect on any variable. The histological appearance of such a pontamine 
deposit is shown in Figure 4.9.
Lateral control microinjections of DLH (into gigantocellular reticular nucleus, Figure 
4.7; n = 5) significantly increased baseline MAP by 13 ± 1 mmHg (127 ± 5 to 139 ± 
6 mmHg), increased baseline IRNA (+33 ±10 %), and decreased baseline IPNA (-47 
+ 8 %), with no significant effect on baseline HR.
4.3.2. Electrical stimulation of medullary raphe
Electrical stimulation of the medullary raphe via a Wood’s metal/indium filled 
micropipette was attempted using various protocols (0.1 ms pulses at 1 0 - 5 0  Hz, 50 
- 1 0 0  pA, 3 — 15 s). The results of these stimulations were highly inconsistent and 
have not been quantified. In general, stimulation of raphe obscurus produced 
dramatic pressor or depressor responses with a high degree of variability between 
experiments. These effects were frequency dependent, with the greatest response at 
50 Hz, and no effect at 10 Hz. Occasionally a response was seen that resembled that 
evoked by chemical stimulation, as illustrated in Figure 4.8.
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Figure 4.2 Raphe obscurus stimulation trace: 1.5 mm rostral
Experimental trace illustrating effect of micro injecting DLH into a part of raphe 
obscurus (1.5 mm rostral, 1.5 mm depth) on baseline BP, HR, integrated renal 
(IRNA) and phrenic (IPNA) nerve activity in an anaesthetised, neuromuscular 
blocked and atenolol pretreated rat.
Nerve activities are presented as rectified and smoothed neurograms (time constants: 
IRNA 1 s, IPNA 0.1 s) as well as in 5 s bins (arbitrary units).
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Figure 4.3 Raphe stimulation histogram: 1.5 mm rostral
Top:
Bottom:
Histogram of mean (± s.e.m.) changes in baseline integrated renal 
nerve (IRNA) and phrenic nerve (IPNA) activity evoked by 
microinjection of DLH into raphe 1.5 mm rostral and at 1.5 and 2.5 
mm depth (n = 6, 5 respectively), and lateral control microinjection (n 
— 3) in anaesthetised, neuromuscular blocked and atenolol pretreated 
rats.
Coronal diagram of rat medulla illustrating position of microinjections 
reconstructed from pontamine sky blue deposits
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Figure 4.4 Raphe pallidus stimulation trace: 2.5 mm rostral
Experimental trace illustrating effect of microinjecting DLH into a part of raphe 
pallidus (2.5 mm rostral, 2.5 mm depth) on baseline BP, HR, integrated renal (IRNA) 
and phrenic (IPNA) nerve activity in an anaesthetised, neuromuscular blocked and 
atenolol pretreated rat.
Nerve activities are presented as rectified and smoothed neurograms (time constants: 
IRNA 1 s, IPNA 0.1 s) as well as in 5 s bins (arbitrary units).
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Figure 4.5 Raphe stimulation histogram: 2.5 mm rostral
Top:
Bottom:
Histogram of mean (± s.e.m.) changes in baseline IRNA and IPNA 
evoked by micro injection of DLH into raphe 2.5 mm rostral and at
1.5, 2.0 and 2.5 mm depth (n = 9, 7, 8 respectively), and lateral 
control microinjection (n = 4) in anaesthetised, neuromuscular 
blocked and atenolol pretreated rats.
Coronal diagram of rat medulla illustrating position of microinjections 
reconstructed from pontamine sky blue deposits.
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Figure 4.6 Raphe magnus stimulation trace: 3.5 mm rostral
Experimental trace illustrating effect of microinjecting DLH into a part of raphe 
magnus/pallidus (3.5 mm rostral, 2.5 mm depth) on baseline BP, HR, integrated renal 
(IRNA) and phrenic (IPNA) nerve activity in an anaesthetised, neuromuscular 
blocked and atenolol pretreated rat.
Nerve activities are presented as rectified and smoothed neurograms (time constants: 
IRNA 1 s, IPNA 0.1 s) as well as in 5 s bins (arbitrary units).
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Figure 4.7 Raphe stimulation histogram: 3.5 mm rostral
Top:
Bottom:
Histogram of mean (± s.e.m.) changes in baseline IRNA and IPNA 
evoked by microinjection of DLH into raphe 3.5 mm rostral and at 2.0 
and 2.5 mm depth {n = 6 , 7 respectively), and lateral control 
microinjection (n = 5) in anaesthetised, neuromuscular blocked and 
atenolol pretreated rats.
Coronal diagram of rat medulla illustrating position of microinjections 
reconstructed from pontamine sky blue deposits, including areas 
where DLH had no effect on any variable.
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Figure 4.8 Electrical stimulation o f raphe magnus
Experimental trace illustrating effect of electrical stimulation of raphe 
magnus/pallidus (3.5 mm rostral, 2.5 mm depth) at 10 -  30 Hz (0.1 ms pulses, 50 
pA, 5 s train) as well as chemical stimulation (DLH) on baseline HR, BP and IRNA 
in an anaesthetised, neuromuscular blocked and atenolol-pretreated rat.
IRNA is rectified and smoothed ( I s  time constant).
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Figure 4.9 Histological verification o f microinjection
Micrographs of coronal sections of rat medulla (3.5 mm rostral to calamus 
scriptorius) counterstained with neutral red, illustrating location of a 50 nl deposit of 
pontamine sky blue after chemical stimulation with DLH.
Left: Gross appearance (scale bar = 1 mm)
RMg: raphe magnus
RPa: raphe pallidus
pyr: pyramid
Gi: gigantocellular reticular nucleus
gVII: genu of the VIIth nerve
Right: Magnification of boxed area (scale bar =100 pm)
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4.3.3. Effects of 5-HT receptor antagonists on baselines
Intravenous injection of the 5-HT receptor antagonists methiothepin (1 and 3 mg 
kg'1; n = 5, 4), granisetron (0.3 mg kg'1; n = 2) and SB-204070 (3 mg kg'1; n = 2) had 
no effect on baseline MAP, HR, IRNA or IPNA when compared to i.v. saline, with 
one exception: HR in animals given 3 mg kg ' 1 methiothepin was significantly lower 
than in those given saline, although the pre-drug control HR was also significantly 
lower than the pre-saline controls (Table 9.39).
4.3.4. Effects of 5-HT receptor antagonists on raphe-evoked 
changes
To investigate the role of 5-HT receptors in the triad of responses (bradycardia, renal 
sympathoexcitation, phrenic inhibition) to raphe magnus/pallidus stimulation 
(Bregma A -10.8, L 0, V 10.5), various 5-HT receptor antagonists were given i.v. and 
compared to time-matched i.v. saline controls.
Saline (1 ml kg'1 i.v.)
Microinjection of DLH (2.5 nmol in 50 nl) into raphe magnus/pallidus evoked an 
increase in MAP of 5 ± 4 mmHg from a baseline of 122 ± 5 mmHg, a bradycardia of 
29 + 5 bpm from a baseline of 345 ± 4 bpm , a renal sympathoinhibition of +101 ± 
29 %, and a phrenic inhibition of -81 ± 5  %. Intravenous administration of saline (1 
ml kg'1; n -  5) had no significant effects on DLH-evoked responses 5 min after 
administration (Figure 4.11, Table 9.40).
Methiothepin (1 & 3 mg kg'1 i.v.)
Intravenous injection of the broad-spectrum 5-HT receptor antagonist methiothepin 
(1 mg kg'1; n = 5) had no significant effect on DLH-evoked responses 5 min after 
administration, compared to i.v. saline (Figure 4.11. Table 9.40).
Intravenous injection of 3 mg kg' 1 methiothepin (n = 4) significantly potentiated the 
renal sympathoexcitation evoked by DLH microinjection (+355 + 100 % vs. +80 ± 
29 %, 5 min after administration, Figures 4.10 and 4.11, Table 9.40). Methiothepin 
had no significant effects on other DLH-evoked responses.
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Granisetron (0.3 mg k g 1 i.v.)
Intravenous injection of the selective 5 -HT3 receptor antagonist granisetron (0.3 mg 
kg'1; n = 2) had no effect on DLH-evoked responses (Table 9.40).
SB-204070 (3 mg kg'1 i.v.)
Intravenous injection of the selective 5 -HT4 receptor antagonist SB-204070 (3 mg 
kg'1; n = 2) had no effect on DLH-evoked responses (Table 9.40).
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Figure 4.10 Raphe magnus trace: effects o f methiothepin
Experimental trace illustrating effects of micro injecting DLH into raphe 
magnus/pallidus (3.5 mm rostral and 2.5 mm depth) on baseline HR, BP, IRNA and 
IPNA before (control) and 5 min after methiothepin (3 mg kg' 1 i.v.) in an 
anaesthetised, neuromuscular blocked and atenolol pretreated rat.
Neurograms are rectified and smoothed (time constants: IRNA 1 s, IPNA 0.1 s)
250
Control
DLH
2.5 nmol
BP
mmHg
200-1
100-J
I
5 min after methiothepin 
(3 mg kg1 i.v.)
DLH
2.5 nmol
I
HR
bpm
350
300]
IRNA
Figure 4.11 Raphe magnus histogram: effects o f methiothepin
Histogram of mean (± s.e.m.) changes (A) in baseline HR, IRNA and IPNA evoked 
by micro injection of DLH into raphe magnus/pallidus before (control) and 5 min 
after i.v. saline (n = 5), 1 mg kg' 1 methiothepin (n = 5) and 3 mg kg' 1 methiothepin (n 
= 4) in anaesthetised, neuromuscular blocked and atenolol pretreated rats.
** P  < 0.01 (relative to saline, 2-way ANOVA followed by LSD test).
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4.3.5. Effects of 5-HT depletion
Baseline variables
Rats pretreated with p-CPA (350 mg kg' 1 i.p on 2 consecutive days; n = 7) had a 
significantly lower baseline MAP (8 6  ± 7  vs. 107 ± 5 mmHg) than rats pretreated 
with saline (3.5 ml kg' 1 i.p.; n = 7). Baseline HR was unchanged (321 ± 6  vs. 311 ± 5 
bpm; Table 9.42) . p-CPA pretreated animals did not show a marked behavioural 
difference from controls, although a few were more resistant to handling.
Cardiopulmonary reflex
Intra-atrial injection of a bolus dose of PBG (2.5 jig in 50 pi) evoked a significantly 
smaller increase in R-R interval in p-CPA pretreated rats compared to controls (38 ± 
1 vs. 130 ± 31 ms; n = 7, Figure 4.12, Table 9.42). The PBG-evoked hypotensions, 
however, were not significantly different (-27 ± 4  vs. -31 ± 6  mmHg).
Baroreflex gain
Intravenous administration of a bolus dose of phenylephrine (10 pg) evoked an 
increase in MAP of 11 ± 1  mmHg (from a baseline of 8 6  ± 8 mmHg; n — 5) in p- 
CPA treated animals, compared to an increase of 72 ±  6  mmHg (from a baseline of 
113 ± 2 mmHg; n — 5) in saline treated animals (Table 9.42). This hypertension was 
associated with an increase in R-R interval of 55 ± 12 ms in p-CPA treated animals 
and 82 ± 12 ms in saline treated animals. Neither the hypertensions nor the changes 
in R-R interval were statistically different. Analysis of the baroreflex gain, however, 
revealed that the baroreflex slope was significantly attenuated in the p-CPA group 
(0.19 ± 0.05 vs. 0.66 ± 0.07 ms mmHg"1; Figure 4.14). The correlation coefficients of 
MAP to R-R interval, and the rates of change of MAP, were not significantly 
different in p-CPA and saline groups (Table 9.42).
Raphe stimulation
3 micropipette penetrations were made in the medulla, at 1.5, 2.5 and 3.5 mm rostral 
to calamus scriptorius (-12.8, -11.8 and -10.8 mm from bregma). DLH (2.5 nmol in 
50 nl) was microinjected at 1.5 and 2.5 mm depth in each track (Figure 4.15, Table
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9.41). In the p-CPA pretreated group the DLH-evoked responses were not 
significantly different from those o f the saline pretreated group at any location, with 
the following exceptions: the DLH-evoked changes in MAP were significantly 
different at 2 locations in raphe obscurus: firstly at 1.5 mm rostral and 1.5 mm depth 
(-10 ± 3 mmHg (p-CPA) vs. 0 ± 2 mmHg (saline); n = 5), and also at 2.5 mm rostral 
and 1.5 mm depth (-3 ± 4 mmHg (p-CPA) vs. 11 ±  2 mmHg (saline); n -  5). 
Furthermore, in raphe pallidus at 2.5 mm rostral and 2.5 mm depth, the MAP 
increase was significantly larger in the depleted group (18 ± 1 vs. 1 ± 3 mmHg; n = 
5) and the renal sympathoinhibition was likewise significantly larger (-54 ± 5 vs. -8 ± 
11 %; n =  5).
Immunocytochemistry 
Immunocytochemical staining of rat brainstem sections, with a rabbit antibody for 5- 
HT followed by a donkey anti-rabbit secondary antibody, clearly revealed neuronal 
cell bodies belonging to the raphe cell groups. No staining of cell bodies was seen in 
cell groups outside of the raphe structures previously described (Tork, 1985). 
Additionally, the staining revealed a dense network of fibres in various cell groups, 
most notably the DVN and the NTS, which contained a marginally lower density of 
fibres than the DVN. Moderate density fibres were observed in structures including 
RVLM, nucleus ambiguus, gracile nucleus, and the spinal trigeminal nucleus. 
Sections treated with secondary antibody alone did not show any staining of cell 
bodies or fibres (Figure 4.16, F).
Medullary sections from rats pretreated with saline (n = 7) were indistiguishable 
from controls (no pretreatment -  data not shown), whereas medullary sections from 
rats pretreated with p-CPA (n = 7) displayed a dramatic reduction in the density of 
fibre staining, compared to saline-pretreated rats. The depletion was particularly 
clear in the NTS and DVN (Figure 4.16, A and B). Staining of cell bodies in the 
medullary raphe, however, was unchanged (Figure 4.16, C and D).
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Figure 4.12 Cardiopulmonary reflex trace: effects o f p-CPA
Experimental trace illustrating cardiopulmonary reflex elicited by 2.5 pg intra-atrial 
phenylbiguanide (PBG) in 2 anaesthetised, neuromuscular blocked and atenolol 
pretreated rats, pretreated with saline (3.5 ml kg' 1 i.p.) and p-CPA (350 mg kg' 1 i.p.) 
respectively, for 2  days.
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Figure 4.13 Cardiopulmonary reflex histogram: effects o f p-CPA
Mean (± s.e.m.) changes (A) in MAP and R-R interval evoked by stimulation of 
cardiopulmonary afferents with PBG in anaesthetised, neuromuscular blocked and 
atenolol pretreated rats pretreated with either saline {n = 7) or p-CPA (n = 7).
** P  < 0.01 relative to saline, Student’s impaired t-test.
-40 J
* 200 -,
E
Saline
258
Figure 4.14 Baroreflex graphs: effects o f p-CPA
Top:
Bottom:
Mean (± s.e.m.) changes (A) in MAP, R-R interval, and baroreflex 
slope evoked by phenylephrine in anaesthetised, neuromuscular 
blocked and atenolol pretreated rats treated with either saline (n = 5) 
or p-CPA (n = 5).
** P  < 0.001 relative to saline, Student’s unpaired t-test.
Phenylephrine (10 jug i.v.) evoked baroreflex slope analysis in 2 
anaesthetised, neuromuscular blocked and atenolol pretreated rats, 
pretreated with either saline (3.5 ml kg' 1 i.p.) or p-CPA (350 mg kg' 1 
i.p.) for 2  days.
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Figure 4.15 Raphe stimulation histogram: effects of p-CPA
Histogram of mean (± s.e.m.) changes in baseline MAP, HR, IRNA and IPNA 
evoked by microinjection of DLH into various raphe areas of anaesthetised, 
neuromuscular blocked and atenolol pretreated rats, pretreated with either saline (3.5 
ml kg' 1 i.p.; n -  5) or p-CPA (350 mg kg' 1 i.p.; n = 5) for 2 days.
Location of the microinjection (reconstructed from pontamine deposits) is shown in 
mm relative to calamus scriptorius (rostral) and brain surface (depth).
* P  < 0.05, ** P < 0.01 (unpaired Student’s t-test)
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Figure 4.16 5-HT immunocytochemistry: effects of p-CPA
Photomicrographs of coronal sections of rat medulla immunostained for 5-HT 
(except negative control in F), illustrating effects of pretreatment with saline or p- 
CPA.
A. 5-HT containing fibres in the caudal NTS/DVN of a saline pretreated rat
B. Caudal NTS/D VN in a p-CPA pretreated rat
C. 5-HT containing neurones in the raphe magnus of a saline pretreated rat
D. Raphe magnus in a p-CPA pretreated rat
E. 5-HT containing fibres in the rostral NTS of a saline pretreated rat
F. Negative control (using only secondary antibody) from rostral NTS in a
saline pretreated rat.
Scale bars: 200 pm
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4.4. Discussion
4.4.1. Main Findings
The data demonstrate that the medullary raphe can have both an excitatory or 
inhibitory influence on various cardiovascular and respiratory variables, depending 
on which area is stimulated. The most caudal areas of raphe obscurus and pallidus 
caused sympathoinhibition and increased respiratory drive; the more rostral areas of 
raphe obscurus and pallidus caused similar sympathoinhibition and either raised or 
lowered respiratory drive; finally the most rostral area (raphe magnus/pallidus) 
caused bradycardia, sympathoexcitation, and respiratory depression.
i.
Effects of electrical stimulation rarely matched those of chemical stimulation, 
indicating the unsuitability of passing current through these midline structures. They 
do, after all, contain many axons either crossing the midline or travelling 
longitudinally; if any of these fibres have a cardiovascular or respiratory role, the 
results would be uninterpretable.
The rostral area of raphe magnus/pallidus became the focus of further investigation 
because its influence on HR imputed a possible role in vagal reflexes. However, the 
bradycardia could not be attenuated by methiothepin (which is an antagonist at 5- 
HTi, 5 -HT2, 5 -ht5, 5-HT6 and 5 -HT7 receptors). In addition, the 5 -HT3 and 5 -HT4 
receptor antagonists granisetron and SB-204070 respectively were without effect, 
suggesting that the bradycardia does not involve the activation of 5-HT receptors. 
Methiothepin did, however, augment the sympathoexcitation evoked by raphe 
magnus/pallidus stimulation.
To investigate further the role of 5-HT in the transmission of the effects of raphe 
stimulation, rats were depleted of 5-HT using p-CPA. This had no effect on raphe- 
evoked reponses with the exception of augmenting renal sympathoinhibition in one 
caudal area. This confirms that the raphe magnus/pallidus evoked bradycardia is 
probably not 5-HT related. It also suggests that the other responses do not involve 5- 
HT, or that other transmitters are able to compensate in the absence of 5-HT.
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Depletion of 5-HT lowered baseline MAP with no corresponding elevation in 
baseline R-R interval. Cardiopulmonary reflex bradycardia was much smaller in 
depleted animals, as was the sensitivity of the baroreflex, demonstrating for the first 
time that endogenous 5-HT is required for the successful function of these reflexes.
In general these data propose that whilst vagal reflexes involve the release of 5-HT 
from fibres within the NTS or nucleus ambiguus, the neurones from which these 
fibres originate are unlikely to be located in the medullary raphe.
4.4.2. Raphe stimulation
The glutamate receptor agonist DLH was used in preference to glutamate because the 
distribution of 5-HT containing neurones in the medullary raphe is relatively sparse; 
DLH is not rapidly removed by a reuptake mechanism like glutamate, so is likely to 
activate a greater number of neurones. Unfortunately DLH is also likely to spread 
further and activate other neurones. Pontamine injections suggest that a 50 nl volume 
does not spread further laterally than 0.5 mm, however pontamine diffusion does not 
necessarily reflect DLH diffusion. Further control microinjections were performed at 
1 mm lateral to the raphe, and at die caudal areas these were different from the 
midline stimulations, suggesting that the renal sympathoinhibitory and phrenic 
excitatory responses are indeed mediated by raphe obscurus and pallidus. At the 
rostral locus, however, lateral injections elicited a smaller but still noticeable triad of 
responses (bradycardia, renal sympathoexcitation, phrenic inhibition). This would 
suggest that the responses involve neurones spread over some distance -  a 
distribution that is characteristic of this area of raphe. The other possibility is that the 
reticular area stimulated laterally happens to have a similar functional influence on 
the autonomic system although the neurones activated are different. One cannot 
exclude the possibility that DLH is activating neurones whose cell bodies are not in 
the vicinity of the micropipette, but whose dendrites extend a long distance.
The problem with many past raphe stimulation studies is that they offer no 
comprehensive functional topography of these nuclei with respect to their multiple 
cardiovascular, respiratory, and sympathetic roles. Therefore these experiments have
266
measured central sympathetic, parasympathetic, and respiratory drive 
simultaneously.
Blood pressure responses 
Stimulation of the medullary raphe had no significant effect on baseline MAP, 
therefore other variables (particularly central respiratory drive) are free from the 
confounding factor of MAP change. Previous research found that chemical 
stimulation of the medullary raphe (particularly raphe obscurus) in anaesthetised 
animals causes a small to moderate ( 1 0 - 3 0  mmHg) pressor response (Haselton et 
al., 1988; D'Amico et al., 1996; Dreteler et al., 1991). Numerous electrical 
stimulation experiments (e.g. Adair et al., 1977) report more pronounced pressor
i,
responses not unlike those found in the present experiments. However, since the 
present results of chemical and electrical stimulation rarely correspond, there is no 
reason for further analysis of the electrical stimulations.
Heart rate responses
Bradycardic responses to stimulation of raphe magnus/pallidus have not been 
previously described. Bradycardia with concurrent hypotension has been 
demonstrated in a more caudal raphe area (Coleman & Dampney, 1995), but not in 
an atenolol-treated animal. Considering the strong sympathoinhibition reported in 
that study, the small bradycardia may well be due to cardiac sympathoinhibition. An 
atropine-sensitive hypotension resulting from microinjection of 5-HTia receptor 
agonists into dorsal raphe (which would inhibit neuronal activity) has been reported 
(Connor & Higgins, 1990), suggesting that this area tonically inhibits vagal drive. 
Other raphe stimulation studies have occasionally reported bradycardias, which are 
secondary to an evoked pressor response (Haselton et al., 1988; Dreteler et al., 
1991).
The bradycardia in these present experiments was of interest because it might 
represent the serotonergic component of vagal reflexes. The triad of bradycardia, 
sympathoinhibition and apnoea resembled the diving response previously shown to 
involve 5-HTia receptors in rabbits (Futuro-Neto et al., 1993; Dando et al., 1998). 
Indeed, there is a projection from raphe magnus to NTS, and many of these neurones 
also contain 5-HT (Schaffar et al., 1988). It is unlikely that this is the case, however,
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for the following reasons: firstly, the bradycardia is too slow to participate in a fast 
reflex such as the cardiopulmonary reflex (it took up to 15 s to reach a maximum in 
these experiments, whilst the cardiopulmonary reflex bradycardia is almost 
instantaneous); secondly, it is not sensitive to a variety of 5-HT receptor antagonists; 
thirdly, it is not affected by 5-HT depletion. The lack of a role of the raphe in reflex 
bradycardias would agree with the midine lesion studies of Lee et al. (1972). Further 
investigation using reversible inhibition of the raphe (by micro injection of GAB A, 
cobalt chloride or similar) would be needed to conclude unequivocally that there is 
no reflex role in these areas.
A possibility is that the bradycardia is either caused or potentiated by the phrenic 
inhibition, resulting from respiratory modulation of CVPNs. This is unlikely for the 
following reasons: firstly, bradycardia was observed in several animals in the 
absence of any phrenic changes; secondly, the onset of bradycardia often preceded 
the onset of phrenic inhibition; thirdly, bradycardia size was unchanged when 
animals were put into central apnoea by hyperventilation. Respiratory modulation of 
HR is more likely to be seen during the strong increases of respiratory drive evoked 
by raphe obscurus stimulation. This was usually accompanied by a tachycardia of 3 -  
10 bpm, which one would expect to be due to respiratory inhibition of CVPNs.
It is unlikely that the raphe magnus-evoked bradycardia demonstrates the anatomical 
connection between raphe magnus and NTS (Schaffar et al., 1988). There is no 
evidence that the responses to raphe stimulation are due to a direct pathway: several 
other cell groups may well be involved, which might account for the slow responses. 
A further anatomical connection from the medullary raphe to nucleus ambiguus has 
been reported (Haxhiu et al., 1993), but these present data do not demonstrate such a 
functional connection. Single unit electrophysiology would be the most reliable way 
of demonstrating a functional connection between raphe and either NTS or CVPNs. 
Preliminary experiments in the cat were unable to find such a connection (Wang & 
Ramage, unpublished observations). Another possible connection could be between 
raphe and CVPNs in the DVN with C-fibre efferents. Selective stimulation of these 
efferents causes a relatively small and slow bradycardia (Jones et al., 1995b). The 
long time taken for this raphe-evoked bradycardia to reach a maximum was 
surprising at first. It was thought that this could be due to slowly reverberating
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activity in a network, but it could also be explained by its similarity to the C-fibre 
efferent-evoked bradycardia.
Sympathetic responses
The sympathetic changes evoked by raphe stimulation are the most widely reported. 
Some studies report sympathoexcitation and some sympathoinhibition. 
Sympathoexcitatory responses are reported due to both myelinated (Zhou & Gilbey, 
1995) and unmyelinated (Huangfu et a l, 1994; Morrison, 1993) direct projections 
from raphe obscurus and pallidus to spinal cord. As such these disagree with the 
present data. Increased sympathetic drive, as evidenced by reduced blood flow, has 
been reported in the rat tail after stimulation of raphe magnus/pallidus (Blessing & 
Nalivaiko, 2001), and whilst these effects were shown not to reflect global 
sympathoexcitation, they agree with the present renal sympathoexcitation evoked 
from the same area. Care must be taken in interpreting the effects on different 
sympathetic targets, as these are known to behave differently. Hence a report of 
decreased tail blood flow in one report does not necessarily support the increased 
renal nerve activity in another, or, for that matter, contradict a reduced mesenteric 
blood flow in another.
Many researchers have reported sympathoinhibition due to raphe stimulation, 
including in raphe of the cat (Gilbey et al., 1981), and raphe obscurus/pallidus of the 
rabbit (Coleman & Dampney, 1995; Coleman & Dampney, 1998) and raphe 
obscurus of rat (Verbeme et al., 1999). In the rabbit and the rat, these responses have 
been shown to be due to raphe-mediated inhibition of RVLM (Coleman & Dampney, 
1998; Verbeme et a l, 1999). In the cat, the sympathoinhibition was blocked by 
spinal LSD, suggesting a direct connection with spinal cord SPNs. Other earlier 
reports also suggest that the direct raphe-spinal pathway is sympathoinhibitory 
(Coote & Macleod, 1975) However, the majority of spinal cord SPNs are excited by 
iontophoretic 5-HT (Coote et al., 1981), so the role of 5-HT receptors in this effect is 
still unclear.
The present data demonstrate, for the first time, that the sympathoinhibitory response 
is limited to the caudal portion of the medullary raphe, and becomes a 
sympathoexcitation in the corresponding dorsoventral portion of raphe
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magnus/pallidus. This suggests different populations of raphe neurones with 
projections to sympathetic or presympathetic areas. These could be mediated by 
different receptors within the same structure (e.g the spinal cord, as suggested by the 
iontophoretic study of Lewis & Coote, 1990), or by different structures (the 
sympathoinhibition being indirect via RVLM inhibition, and the sympathoexcitation 
being a direct raphe-spinal pathway). This supposition warrants further investigation.
Respiratory responses
A variety of studies report increases or decreases in central respiratory drive when 
stimulating the raphe. Raphe obscurus stimulation in the cat caused an increase in 
respiratory drive (Holtman et al., 1986a; Holtman et al., 1987) which was reduced by 
the 5-HT receptor antagonist methysergide (Holtman et al., 1987). A separate group, 
however, reported decreased respiratory drive evoked from the same area (Lalley, 
1986; Lalley et al., 1997) which was prevented by the 5-HTiA receptor antagonist 
NAN-190 (Lalley et a l, 1997). One clear difference in these studies is that the first 
group used a-chloralose/urethane anaesthesia, and the second pentobarbitone. This 
could explain the different results. In the rat, chemical stimulation of raphe obscurus 
has been shown to increase respiratory drive (Dreteler et al., 1991; Bernard, 1998), 
and stimulation of raphe pallidus or magnus had a smaller effect (Bernard, 1998). In 
brain slices, raphe neurones increase their firing rate when PaC0 2  in the bath is 
lowered (Richerson, 1995), suggesting a role in chemosensing. In vivo it was found 
that some raphe sites respond to local acidosis by increasing repiratory drive 
(Bernard et al., 1996).
As seen in the sympathetic responses, the present data demonstrate for the first time 
that the phrenic nerve increases are limited to the caudal medullary raphe, especially 
raphe obscurus. Stimulation of the rostral part (magnus/pallidus) caused a strong 
inhibition of phrenic activity, often including apnoea. Whether these two functional 
populations have different projections remains to be determined. The excitatory 
population could project directly to phrenic motoneurones, which have been shown 
to receive 5-HT containing synaptic terminals (Holtman et al., 1990b; Pilowsky et 
al., 1990), but whether these are the synapses involved in this raphe-evoked response 
is disputed by the following evidence: firstly, the effects of electrical raphe 
stimulation are too rapid to be caused by slow-conducting raphe-spinal fibres
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(Holtman et al., 1986b; Lalley, 1986), secondly iontophoresis of 5-HT onto phrenic 
motoneurones had no effect on their activity (Lalley, 1986). Therefore the 
serotonergic innervation of phrenic premotor neurones or other components of the 
network may be responsible for this raphe-evoked effect. In the present data, raphe 
stimulation affected both amplitude and rate of phrenic nerve activity (see Figures 
4.2 and 4.6). However, discharge of the phrenic nerve was locked to the rhythm of 
the ventilator in a ratio of either 1:1 or 1 :2 , therefore changes in the rate of phrenic 
discharge typically presented as either doubling or halving of frequency. From these 
observations it would appear that the raphe-respiratory influence is not merely at the 
level of the phrenic motoneurones.
4.4.3. Pharmacology
Raphe-evoked responses are notoriously difficult to interpret because of the variety 
of neurotransmitters found within the somata (and therefore expected to be found in 
axon terminals), of which 5-HT generally makes up only about 50 % (see 1.5). 
Whilst 5-HT containing neurones can be distinguished electrophysiologically from 
their steady discharge rate, there is no technique to stimulate that population 
selectively. Therefore pharmacological tools were used to investigate the role of 5- 
HT in the raphe-evoked responses.
Methiothepin is an antagonist with a broad spectrum of action, especially at 5-HTi 
and 5 -HT2 receptors. Additionally it has a high affinity at 5 -HT7 receptors, and also 
at 5 -ht5 and 5-HT6 receptors, dopamine and a adrenoceptors (see 1.6). Hence many 
monoaminergic effects should be sensitive to methiothepin. The doses used in this 
study are high, and should be able to antagonise even synaptic effects (Chaput et al., 
1986; Terron, 1997), which are less antagonist-sensitive than exogenous agonist 
effects. In the present experiments, 1 mg kg' 1 methiothepin (i.v.) completely blocked 
the pressor effects of 5 pg phenylephrine (i.v.) for over 20 minutes, demonstrating 
that the a  adrenoceptor antagonist properties of methiothepin are potent and long- 
lasting.
271
Administration of i.v. saline, methiothepin (1 and 3 mg kg'1), granisetron and SB- 
204070 caused no significant changes in baseline variables, which is to be expected 
if 5-HT is not involved in resting cardiovascular variables. Methiothepin did cause 
an initial depressor response, probably due to peripheral ai adrenoceptor blockade, 
but this rapidly recovered. Additionally, the 3 mg kg' 1 methiothepin group has a 
lower control HR than the saline group, and following methiothepin this is reduced 
by approximately 5 bpm from control, which appears highly significant compared to 
the time-matched saline control, but is probably an artefact caused by that group 
having a lower starting HR.
Stimulation of raphe magnus/pallidus with DLH evoked changes comparable to 
those in the initial mapping study, and i.v. saline did not significantly affect the size 
of these responses. The tendency was for evoked responses to get smaller, as might 
be expected with repeated micro injections due to factors such as depolarisation 
block, excitotoxicity and mechanical damage. Hence in example traces it can appear 
that methiothepin is having an effect (e.g. Figure 4.10). Compared to the time- 
matched control, however, methiothepin had no effect on bradycardia or phrenic 
inhibition. This lack of effect of two high doses of methiothepin suggest that 5-HT 
receptors are not involved in the transmission of these responses. It cannot be ruled 
out, however, that this is a failure of the drug: it may be that antagonising multiple 5- 
HT receptors with opposing effects fails to dissect out the receptor of interest, or that 
the route of administration fails to provide a sufficient synaptic concentration of the 
drug, even at these high doses (McCall & Aghajanian, 1980). To exclude the 
possibility that the effects are mediated by 5 -HT3 or 5 -HT4 receptors, which 
methiothepin does not antagonise, granisetron and SB-204070 were used at doses 
greater than those previously shown to be peripherally effective (Bingham et al., 
1995). The dose of SB-204070 here used was particularly high. From preliminary 
experiments with two animals in each group, it seemed unlikely that these receptors 
were involved.
One clear results of methiothepin, however, was to potentiate the sympathoexcitation 
evoked from raphe magnus/pallidus. This suggests that the evoked 
sympathoexcitation is the net effect of an excitation with a concurrent inhibitory 
component via a 5-HT receptor. Therefore when this receptor is blocked, the full
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excitation is unmasked. As sympathoinhibitions are evoked from the more caudal 
raphe areas investigated, it is not unreasonable to consider that this area may have a 
mixed population of neurones. Considering the small group size, however, this was 
treated with caution, and further investigated using 5-HT depletion.
Within the raphe there are not only separate populations of neurones containing 
transmitters other than 5-HT (such as GABA and dopamine) but also peptides 
existing as co-transmitters with 5-HT, such as substance P, cholecystokinin, 
thyrotropin releasing hormone, enkephalin and somatostatin (see Tork, 1985). The 
relative contributions of these transmitters has not been established. It may be that 
blockade of the serotonergic component alone is not sufficient to abolish the effect of 
the co-transmitters.
In the past, various responses to raphe stimulation have been blocked or attenuated 
with 5-HT receptor antagonists. Phrenic inhibition is prevented by the 5-HT[A 
receptor antagonist NAN-190, at a dose of 24 pg kg' 1 i.v. (Lalley et al., 1997). 
Likewise raphe-evoked bronchodilatation was abolished by brainstem application of 
the broad-spectrum 5-HT receptor antagonist methysergide (Haxhiu et al., 1998), and 
sympathoinhibition was reduced by the partial agonist LSD, given i.v. or spinally 
(Gilbey etal., 1981).
4.4.4. 5-HT depletion
In order to verify the data obtained using 5-HT receptor antagonists, further 
experiments were performed on rats depleted of 5-HT using the synthesis inhibitor p- 
CPA. This technique was first described by Koe & Weissman (1966), who 
suggested that the drug inhibits tryptophan hydroxylase, causing a rapid depletion of 
5-HT stores throughout the body. Neurochemical analysis showed that doses of up to 
316 mg kg' 1 i.p. had no effect on brain noradrenaline or dopamine concentrations. 
Administration of 100 mg p-CPA per rat for 3 days similarly caused no change in 
brain noradrenaline, but a depletion of brain 5-HT of over 90 % (Ito & Schanberg, 
1975). Similar results have been confirmed (Chaput et al., 1990; Datla & Curzon, 
1996; Geranton et al., 2004), so in the present experiments no neurochemical assay 
was performed. Depletion was verified with immunocytochemistry.
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Immunocytochemistry
The 5-HT antibody used is highly selective for 5-HT, with minimal cross-reactivity 
with other catecholamines, 5-HT precursors, or metabolites (Wallace et a l 1982). 
Medullary sections showed dense staining in the areas expected to contain 
serotonergic fibres, such as the NTS, DVN, RVLM, facial nucleus and trigeminal 
complex. The density in the NTS in particular is well known (Steinbusch, 1981; 
Maley & Elde, 1982; Pickel et al., 1984). However, the present histology did not 
reveal 5-HT containing cell bodies in the NTS, meaning that this observation of 
Calza et al. (1985) remains unconfirmed. The only cell bodies stained by the 5-HT 
antibody were those in raphe obscurus, pallidus, and magnus in agreement with the 
descriptions of Tork (1985). This included a more diffuse scattering of 5-HT 
containing neurones lateral to the classical boundaries of raphe magnus, including 
some within the pyramids. Hence it is unlikely that a 50 nl midline DLH injection 
will activate all raphe neurones at this level, or at least not to the same degree.
After 2-day treatment with p-CPA, the staining of 5-HT containing fibres was almost 
entirely absent. This is thought to be simply due to absence of the transmitter; there 
is no evidence that p-CPA destroys fibres. Co-transmitters, therefore, are expected to 
remain. The pretreatment did not affect the staining of raphe cell bodies, which 
probably represents a non-releasable pool of 5-HT within the cell body that is 
unaffected by synthesis inhibition. A rough estimate by eye would suggest a 
depletion of approximately 90 % in fibres, in agreement with earlier neurochemical 
measurements (e.g. Ito & Schanberg, 1975). In one extra experiment, administration 
of p-CPA for 3 days instead of 2 did not further decrease staining, suggesting that the 
animals were maximally depleted.
Baseline variables
The finding that 5-HT depletion with p-CPA significantly lowered baseline MAP 
was surprising as 5-HT is not thought to be involved in the maintenance of MAP. In 
this thesis, a variety of 5-HT receptor antagonists given i.e. or i.v. have consistently 
failed to affect baseline MAP. It was considered that the lower MAP was due to 
some change in the condition of the depleted animals. The first possibility is that 5-
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HT depletion is potentiating the effect of the anaesthetic, as deeper anaesthesia 
typically presents as lowered MAP. Pretreatment with methiothepin potentiates the 
effect of general anaesthetics in rats (Dringenberg, 2000), suggesting a tonic role for 
5-HT at some level of consciousness. However, the effect of anaesthetics on 
consciousness is probably due to the exquisite sensitivity of the neuronal networks 
generating this phenomenon, whereas the effects of anaesthetics on the brainstem 
cardiovascular system is due to depressant actions on the neurones involved, which 
occurs at much higher doses of anaesthetic. As such, rate of loss of consciousness 
and rate of loss of cardiovascular control cannot be compared.
To shed some light on the master, a previous report found a comparable fall in 
baseline MAP in conscious rats after a single 400 mg kg' 1 i.p. p-CPA injection 
(Buckingham et a l , 1976) and this hypotension lasted 8 days. This suggests that the 
present results are not an artefact of anaesthetic. Similar lowered MAP is reported in 
the rabbit (Wing & Chalmers, 1974). Other studies have found no baseline MAP 
response to 100 mg kg*1 i.p. p-CPA for 3 days in pentobarbitone-anaesthetised rats 
(Smits et al., 1978) although that protocol did attenuate median raphe-evoked 
hypertension. A further study reports a rise in MAP due to 100 mg per rat for 3 days 
(Ito & Schanberg, 1975), but in a-chloralose/urethane anaesthetised rats, which were 
also vagotomised. As such the results are not directly comparable to the present data.
Cardiopulmonary reflex 
Comparison of the sensitivity of the cardiopulmonary reflex in different animals is 
difficult because of the inherent variability. From the reflex studies of Chapter 3 it 
was found that PBG doses need to be adjusted in each animal, at least to produce a 
submaximal bradycardia. From these experiments, a dose of 2.5 pg per animal was 
selected as the most appropriate. To ensure that the stimulation of cardiopulmonary 
afferents was similar in all animals, PBG was delivered at exactly the same rate (25 
pi s'1), and the intra-atrial cannula was always in the same place (3 cm into the 
jugular vein from the same point of insertion). The present data demonstrate, for the 
first time, that cardiopulmonary reflex bradycardia is smaller in p-CPA pretreated 
animals than in controls, but that cardiopulmonary reflex hypotension is unchanged. 
This is in direct agreement with the findings of Chapter 3, where central 5-HT7 
receptor blockade produced a similar effect (<cf. Figures 3.6 and 4.12), illustrating
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that either blockade of the receptor involved, or removal of the endogenous 
transmitter, selectively inhibits the reflex bradycardia.
The reduced bradycardia is unlikely to be a haemodynamic consequence of the 
lowered MAP. As this hypotension is not associated with a significant tachycardia, 
cardiac output should be lower in the depleted animals. Therefore intra-atial injection 
will be slower passing through lungs, which would cause, if anything, greater 
binding to receptors on cardiopulmonary afferents. Furthermore, the reduced reflex 
bradycardia does not always relate to reduced MAP. For example, in Figure 4.12 the 
baseline MAP in the saline-pretreated animal is actually lower than in the p-CPA 
pretreated animal, but the latter’s bradycardia is much smaller.
Baroreflex gain
10 pg phenylephrine caused a rise in MAP, evoking a clear baroreflex bradycardia in 
all animals. The hypertension is larger than ideal (75 ± 4 mmHg), and it is thought 
that vasoconstrictor-evoked increases in MAP of over 50 mmHg can cause direct 
cardiac reflexes. These, however, typically present as arrhythmic beats and profound 
bradycardias, which were not seen in the present experiments. In the depleted 
animals, the reflex bradycardia was smaller but not significantly different from 
controls, which is what was previously found in awake rats with serotonergic lesions 
(using 5,7-DHT) of the nodose ganglia or NTS (Orer et al., 1991). However, when 
the reflex gain was calculated with the more sensitive method of Su et a l (1992), it 
was found to be much smaller in the depleted group. This demonstrates for the first 
time that p-CPA pretreatment lowers the sensitivity of the phenylephrine-evoked 
baroreflex, and again confirms the findings of Chapter 3, albeit by removing the 
transmitter rather than blocking its receptor. A similar regimen of p-CPA 
pretreatment has previously been shown to inhibit the carotid sinus reflex in 
anaesthetised, vagotomised rats (Ito & Schanberg, 1975), i.e. to reduce the pressor 
response to carotid baroreceptor unloading (hence suggesting that 5-HT facilitates 
reflex sympathoexcitation). As the data of Chapter 3 demonstrate that 5-HT {via 5- 
HT7 receptors) facilitates chemoreflex sympathoexcitation, but did not test its role in 
baroreflex sympathoexcitation, this warrants further investigation.
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Again the possibility that the lowered resting MAP is a confounding factor must be 
considered. Baroreceptors are sensitive to change as well as rate of change, and the 
present data demonstrate no significant difference between either absolute change or 
rate of change in different groups (see Table 9.42). Furthermore, in the p-CPA group 
the correlation between MAP and R-R interval is no different from the saline group.
Raphe-evoked changes
The data demonstrate that this protocol of p-CPA administration is sufficient to cause 
histologically and functionally identifiable changes. It does not, however, cause any 
clear changes in raphe-evoked responses. The lack of effect of 5-HT receptor 
antagonists on the important raphe-evoked bradycardia is confirmed, showing that 5- 
HT is not involved in this effect. Depletion with p-CPA has previously been shown 
to be effective in attenuating raphe-evoked responses both on cardiovascular 
variables (Smits et a l, 1978) and on serotonergic transmission in other brain areas 
(Chaput et al., 1990; Zhu & McNaughton, 1994). In the present experiments a very 
tight protocol was used to stimulate raphe areas sequentially, beginning rostrally. The 
control results obtained are comparable to those from the initial mapping study 
(which used sequential stimulation, beginning caudally), suggesting that the order in 
which the areas are stimulated (and any accompanying tissue damage) is not a 
confounding factor.
The maintenance of raphe-evoked effects despite severe 5-HT depletion may involve 
other transmitters, such as peptides. Thyrotropin-releasing hormone and substance P 
are examples of peptides found in the raphe (Chiba & Masuko, 1989). In the rat 
spinal cord, thyrotropin releasing hormone exerts a postsynaptic effect similar to that 
of 5-HT (Barbeau & Bedard, 1981; Hansen et al., 1983), whilst substance P enhances 
5-HT release, probably via terminal 5-HT autoreceptor blockade (Mitchell & 
Fleetwood-Walker, 1981). It is possible that an analogous situation is involved here 
to maintain serotonergic neurotransmission despite depletion. Another explanation 
could be receptor supersensitivity due to p-CPA, but this usually occurs after a 
longer period than the 48 hours of this protocol, and is more likely after destruction 
of serotonergic fibres with 5,7-DHT, as described previously (Ashby et a l, 1994; 
Sawynok & Reid, 1994).
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Some effects of raphe stimulation, however, were significantly different in the p- 
CPA group, but these are difficult to interpret. Stimulation of caudal raphe obscurus 
in depleted rats caused a hypotension that was not seen in control rats, but the 
sympathoinhibition was of a similar size. At a more rostral site, stimulation of raphe 
obscurus caused a small rise in MAP that was abolished in the depleted group, whilst 
stimulation of raphe pallidus caused a rise in MAP that was potentiated in the 
depleted group. The latter effect was associated with a potentiated 
sympathoinhibition. As seen in the methiothepin experiments, 5-HT depletion may 
be uncovering a previously eclipsed mechanism. If this is the case, it is most likely to 
cause the rise in MAP, the sympathoinhibition being reflexive, hence proportional to 
the MAP change. The lack of concurrent reflex bradycardia would be explained by 
the large increase in phrenic activity, which could easily swamp such an effect by 
respiratory modulation of CVPNs.
Surprisingly none of the main raphe-evoked effects were significantly changed by 
depletion. However, some effects are smaller in the depleted groups, for example the 
phrenic excitation at parts of raphe obscurus and pallidus, and the 
sympathoexcitation at raphe magnus/pallidus. Possibly the group sizes (n = 5) are too 
small to detect such differences, although more importantly the numbers seem 
sufficient to demonstrate the lack of effect on the bradycardia evoked by raphe 
magnus/pallidus.
4.4.5. Technical limitations
Microinjections have their limitations, even when not performed in cell groups as 
complex as the raphe. These include drug spread, limited reproducibility, and 
activation of a variety of neurones (including intemeurones). Similarly the additional 
methods used here (systemic drug pretreatment and global 5-HT depletion) have 
inherent problems due to the wide range of possible effects. Many of these problems 
have already been discussed, but suffice it to say that this study was intended to be 
merely a preliminary investigation of a possible mechanisms, and as such the 
techniques are appropriate.
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4.4.6. Conclusion
This study has not addressed the reflex role of the medullary raphe directly; previous 
researchers have found that extensive lesioning of the midline (in fact of any 
brainstem region other than NTS/DVN and RVLM) does not affect the 
cardiopulmonary or baroreflexes (Lee et al., 1972). Instead, these experiments tried 
to find functional evidence to support the anatomical connections between the 
medullary raphe and the NTS, DVN and nucleus ambiguus. The data very clearly 
demonstrate that a specific area of raphe magnus/pallidus exerts an excitatory 
influence on CVPNs. However, this does not seem to involve serotonergic 
transmission, as 5-HT receptor antagonists as well as depletion of 5-HT had no effect 
on this response. 5-HT depletion did, however, decrease the sensitivity of the 
bradycardic response to cardiopulmonary and baroreceptor stimulation, 
demonstrating that endogenous 5-HT is a necessary part of successful 
cardiopulmonary and baroreflex function.
4.4.7. Future experiments
The autonomic functions of the medullary raphe have been extensively mapped since 
the 1970s, however the effects of chemical stimulation of dorsal and medial raphe 
have not been characterised, although many reports of electrical stimulation exist. To 
conclude the present study, this needs to be done. The effect of chemically 
inactivating the raphe (with GABA or muscimol) is not expected to have much effect 
under a-chloralose anaesthesia, since raphe neurones usually have no spontaneous 
activity except under chloral hydrate or saffan anaesthesia. This could be tested to 
investigate any tonic roles. Furthermore, this would show unequivocally that the 
raphe are not involved in reflex bradycardias.
A more sensitive measure is neuronal recording from raphe, and testing the effects of 
selective 5 -HT7 receptor antagonists on these cells in vivo is an important 
experiment. Neurochemical assays in vitro suggest that SB-269970 reduces dorsal 
raphe neuronal activity (Roberts et al., 2004b), and this needs to be confirmed.
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The p-CPA findings of the present experiments require further investigation. This 
would best be done by comparing the effects firstly of different doses of p-CPA on 
baselines and reflexes; secondly of different doses of reflex stimulants (e.g. PBG, 
NaCN, phenylephrine) in the same animal; thirdly, and most importantly, the effects 
need to be observed in awake rats to exclude the effects of anaesthesia.
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5 . S e r o t o n e r g i c  a n d  g l u t a m a t e r g i c  m e c h a n i s m s  i n  
t h e  N u c l e u s  T r a c t u s  S o l i t a r i u s
5.1. Introduction
5.1.1. Background
The NTS is the site of termination of cardiopulmonary, baroreceptor and 
chemoreceptor afferents (see Jordan & Spyer, 1986). Integration of cardiovascular 
reflexes occurs within the complex microcircuitry of this nucleus, which distributes 
incoming stimuli to sympathetic, parasympathetic and respiratory neurones for 
generation of a motor response. Previous single-unit electrophysiological 
investigations have used iontophoretic application of drugs to characterise the role of 
glutamate receptors in reflex transmission (Wilson et al., 1996; Jeggo et al., 2001). 
Primary afferents release glutamate onto NTS second order neurones, which 
originally was thought to act via only AMPA receptors at this stage (see Andresen et 
al., 2004), although NMDA receptors are now also implicated (Jeggo, 2003; Jones & 
Jordan, unpublished data). Higher order neurones in the NTS (receiving 
polysynaptic inputs) also receive glutamatergic inputs via both AMPA and NMDA 
receptors (see Andresen et al., 2004). Additionally, 5 -HT3 receptors are thought to be 
located presynaptically on glutamatergic terminals in the NTS, where they cause 
excitation via NMDA receptors (Jeggo et al., 2001), although the role of AMPA 
receptors in this effect was not confirmed.
Other 5-HT receptors involved in reflex transmission have not been identified in the 
NTS. 5-HTia receptors participating in the cardiopulmonary reflex are found in the 
nucleus ambiguus in the cat (Wang & Ramage, 2001), but a previous study failed to 
find a clear role for 5-HTja receptors in the NTS of rats (Ramage & Mifflin, 1998). 
The reflex role of the 5 -HT7 receptor was characterised in Chapter 3 above, but the 
location of these receptors has not been elucidated. Theoretically they are likely to be 
either in the NTS or the nucleus ambiguus.
The NTS is known to be richly innervated by 5-HT containing fibres (e.g. 
Steinbusch, 1981). In the cat these make synaptic contact with NTS neurones (Maley
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& Elde, 1982), but whether this is the case in identified cardiovascular neurones of 
the rat NTS is not known.
5.1.2. Aims of the study
The aims of the present experiments are as follows: Firstly to confirm the role of 
AMPA/kainate receptors in the transmission of vagal afferent-evoked signals (and in 
particular the cardiopulmonary reflex) within the NTS, using the selective antagonist 
DNQX, applied iontophoretically, as previously described (Wang et al., 1998). 
Secondly, to confirm that the excitation of vagally-evoked NTS neurones by the 5- 
HT3 receptor agonist PBG, applied iontophoretically, is mediated via glutamate 
release onto AMPA as well as NMDA receptors. Thirdly, to test whether the 5-HT7 
receptor antagonist SB-269970 (at a dose known to attenuate cardiovascular reflexes) 
has any effect on vagally-evoked NTS neurones, DVN neurones, or gracile nucleus 
(touch-sensitive) neurones, when applied topically. Fourthly, to examine whether 
NTS neurones labelled by the juxtacellular method (Pinault, 1996) receive close 
appositions from 5-HT containing terminals. Lastly, in some of these experiments 
the effect of i.v. robalzotan was tested on the i.v. 8 -OH-DPAT evoked bradycardia, 
as additional supporting data for Chapter 3 (see 3.4.5)
5.2. Methods
5.2.1. Protocols
Characterisation
The firing of all neurones was tested for at least 1 min in the presence of 1 Hz vagal 
(or aortic nerve) stimulation (for construction of PSTHs and analysis of latency and 
jitter) and for at least 1 min in the absence of any stimuli to note ongoing activity. 
During vagal stimulation the threshold (lowest current required to evoke a spike) was 
noted. Subsequent vagal stimuli were presented at just above (approximately 1.5 
times) threshold. The effect of cardiopulmonary afferent activation with PBG ( 2 - 4  
pg) on neuronal firing was also recorded.
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Iontophoresis
Before the start of any iontophoretic protocol, anaesthesia was supplemented to 
prevent changes in neuronal activity due to anaesthetic wearing off during the 
protocol. Then the effect of various currents of AMPA, NMDA and PBG were tested 
until a currents were determined that caused a clear increase in neuronal activity 
within 10 s. Depending on the times taken for the neurone to begin firing and stop 
firing due to each drug, a time was selected for application of drugs and a time for 
recovery. Typically this consisted of 20 s on followed by 20 s off. The iontophoresis 
pumps were set to cycle automatically between drug ejection and drug retention, and 
between different drugs. Following at least 2 stable control applications, a continous 
current of DNQX was ejected* and agonist cycles continued in the presence of 
DNQX. After a maximum of 3 cycles, DNQX was switched off and agonist cycles 
continued until full recovery was observed. In some experiments several currents of 
DNQX were applied to determine its selectivity for the AMPA-evoked response
Once an AMPA-selective current was determined, the effects of DNQX were tested 
on vagally-evoked neuronal activity. Vagal stimulation was commenced at 1 Hz, and 
at least 3 min allowed to elapse as a control period. DNQX was switched on 
continuously until regular failures of the evoked spikes were observed. The time 
taken for this effect was recorded. Then DNQX was switched off and the neurone 
allowed to recover. The time to recovery was also noted.
Once the time for DNQX to affect vagus-evoked activity was estimated, the effect of 
DNQX on cardiopulmonary afferent-evoked neuronal activity was tested in some 
experiments. Control intra-atrial PBG injections were given every 5 min until at least 
2 stable controls were obtained. Several minutes were allowed to elapse, then DNQX 
was switched on continuously. After several minutes (typically 3 min) the reflex was 
retested, then DNQX switched off and the reflex tested 5 min later.
Topical applications
NTS neuronal activity was evoked by continuous stimulation (1 Hz) of the vagus. 
Periodically the stimulus was switched off for the last 10 s of a min to allow 
cardiopulmonary afferent stimulation. After at least 3 min stable control stimulation,
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either SB-269970 (100 |xg kg'1) or saline (10 pi) were applied topically, and 
stimulation continued up to a maximum of 25 min.
The ongoing activity of DVN neurones were recorded in the absence of any stimuli. 
After at least 3 min stable control activity, either SB-269970 (100 fig kg'1) or saline 
(10 pi) were applied topically, and neuronal activity followed for a maximum of 25 
min.
In neurones of the gracile nucleus, the receptive field was first mapped using gentle 
touch with the tip of a cotton bud, to establish the region of skin evoking the greatest 
burst firing of the neurone. Then, when spontanous activity had stabilised, stimuli 
were presented every 1 min, consisting of 10 touches of the receptive field. These 
touches were presented approximately once a second, and synchronised with the 
click of the ventilator pump (rate 60 -  70 min'1), so each stimulus corresponded to 
the peak of tracheal pressure (for subsequent analysis). After at least 3 stable control 
responses, either SB-269970 (100 fig kg'1) or saline (10 pi) was applied topically, 
and stimuli presented every minute thereafter (to a maximum of 15 mins).
When pharmacology was performed on more than one neurone in a given animal, at 
least 30 min were allowed to elapse between successive protocols. Drug and vehicle 
applications were alternated, and a maximum of 3 applications were made in each 
animal. Previous research on the micturition reflex in anaesthetised rats has 
demonstrated that SB-269970 can be given repeatedly, with no desensitisation of its 
inhibitory effect (Read, 2004).
Intravenous robalzotan 
To provide some information on the functional efficacy of systemic robalzotan in 
support of Chapter 3 data, in some experiments (n = 10) 8 -OH-DPAT (65 pg kg' 1 
i.v.) was given either alone or 2 min after robalzotan (100 pg kg' 1 i.v.). This was 
done shortly after induction of anaesthesia (approx 90 min before any single unit 
electrophysiology), allowing plenty of time for elimination of the drugs.
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5.3. Results
5.3.1. Glutamatergic study
Characterisation
A total of 22 neurones were recorded, all of which responded to electrical stimulation 
of the vagus, with a spike latency of between 22 and 35 ms, indicating activation by 
C-fibre afferents. 3 of 22 neurones were activated by a predominantly monosynaptic 
(Type 1) pathway, 8 by an intermediate (Type 2), and 11 by a polysynaptic (Type 3) 
pathway (Figures 5.1 and 5.2). Evoked spikes could not be cancelled by triggering 
the vagal stimulus from a spontanous spike (collision test) as can be done for DVN 
neurones (Figure 5.3) suggesting that they were orthodromically activated NTS 
neurones. They were recorded at a depth of 500 -  980 pm from the surface of the 
medulla, and between 100 pm caudal and 800 pm rostral to the calamus scriptorius.
Iontophoresis
Iontophoretic application of AMPA (20 -  120 nA) significantly increased the firing 
rate of all 13 neurones tested (0.3 ± 0.3 to 8.2 ± 0.8 spikes s'1, Table 9.43). NMDA 
(40 -  180 nA) also increased the firing rate of all 13 neurones tested (0.5 ± 0.2 to 6.4 
± 0.9 spikes s'1, Table 9.43). PBG (80 -  300 nA; n = 9) increased the firing rate of 7 
of 9 neurones (2.7 ± 1.4 to 4.2 ± 1.6 spikes s’1; Table 9.43), and had no effect on 2.
Iontophoretic application of DNQX (1 0 - 8 0  nA) significantly inhibited the AMPA- 
evoked firing in all 13 neurones tested (8.2 ± 0.8 to 2.6 ± 0.7 spikes s’1, Figures 5.4 
and 5.6, Table 9.44). It also produced a small, non-significant inhibition of the 
NMDA-evoked firing in 6 out of 13 neurones (6 .6  ± 0.9 to 4.4 ±1.2 spikes s'1), and a 
small, non-significant potentiation in the response in 3 neurones (5.3 ± 4.6 to 7 ± 2.2 
spikes s '1) and had no effect on 4 neurones (Figures 5.4 and 5.7, Table 9.45). Taken 
as a group, however, the NMDA-evoked response was not significantly inhibited by 
DNQX (6.4 ± 0.9 vs. 5.9 ± 1.1 spikes s’1, n = 13). Lastly, DNQX inhibited the PBG- 
evoked firing in 5 of 7 neurones (3.5 ±2.1 to 2.2 ±1.7 spikes s'1, Figures 5.5 and 5.6, 
Table 9.44) and had no effect in 2 further neurones.
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Iontophoresis of a similar current of DNQX (30 -  100 nA) significantly inhibited 
neuronal discharge evoked by electrical stimulation of the vagus (1 Hz) in all 12 
neurones tested (35.8 ± 7.5 spikes 20 s' 1 before DNQX vs. 15.3 ± 1.9 spikes 20 s' 1 
after DNQX; Figures 5.9 and 5.10, Table 9.47). Of these 12 neurones, 6 were Type 2 
(intermediate) and 6  were Type 3 (polysynaptic). The mean time taken for DNQX to 
cause the maximum inhibition was 3.5 ± 0.4 min, and the mean time to recovery of 
control values was 3.7 ± 0.3 min.
DNQX (30 -  80 nA) also attenuated the cardiopulmonary afferent-evoked firing in 5 
of 8 neurones (57 ± 25 to 33 ± 20 spikes, Figures 5.8 and 5.10, Table 9.46). Of these 
5 neurones, 2 were Type 2 (intermediate) and 3 were Type 3 (polysynaptic). DNQX 
had no effect in 2  neurones, and potentiated the firing in 1 .
Iontophoresis of the vehicle of DNQX (40 -  80 nA) potentiated the AMPA-evoked 
firing of all 4 neurones tested (7.3 ± 1.3 to 10.1 ± 1.9 spikes s'1, Figures 5.6).
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Figure 5.1 NTS neuronal characterisation (traces)
Sample experimental traces recorded extracellularly from NTS neurones in 
anaesthetised and neuromuscular blocked rats.
* vagal stimulus artefact
Type 1 (monosynaptic).
Type 2 (intermediate).
Type 3 (polysynaptic).
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Example of a neurone with very little variability of 
latency (jitter) over 5 sweeps. This is activated by a 
monosynaptic input.
Example of a neurone with moderate jitter over 5 
sweeps. This is probably activated by a mixture of 
mono- and polysynaptic inputs.
Example of a neurone with pronounced jitter over 5 
sweeps. This is activated by a presumed polysynaptic 
input.
5 sweepsType 1
Type 2
250 fiV
5 sweeps
20 ms
Type 5 sweeps
Figure 5.2 NTS neuronal characterisation (PSTHs)
Peri stimulus-time histograms (PSTHs) illustrating variability (jitter) of latency of 
the evoked spikes of NTS neurones over 50 sweeps of vagal stimulus (1 Hz). 
Number of spikes per bin (1 ms bins) is plotted against time after vagal stimulus.
Asterisks denote the bin reflecting the mean latency (i.e. mode).
A. Example of a Type 1 neurone with very low latency (monosynaptic).
B. Example of a Type 2 neurone with 3 ms jitter (intermediate).
C. Example of a Type 2 neurone firing a spike doublet. The first spike has a 2 
ms jitter.
D. Example of a Type 3 neurone with 10 ms jitter (polysynaptic).
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Figure 5.3 DVN neuronal characterisation
Sample experimental traces recorded extracellularly from a DVN neurone in an 
anaesthetised and neuromuscular blocked rat.
This neurone is antidromically activated, as shown by the following:
Top. The evoked spike has no jitter. (* vagal stimulus artefact)
Middle. The spontanous spikes occurring around the time of the vagal
stimulus collide with the antidromic impulse, causing a cancellation 
of the evoked spike (J).
Bottom. PSTH of 50 sweeps of 1 Hz vagal stimulus. Number of spikes per bin
(1 ms bins) is plotted against time after vagal stimulus.
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Figure 5.4 Iontophoresis trace: selectivity of DNQX
Experimental trace of an NTS extracellular recording with iontophoresis in an 
anaesthetised, neuromuscular blocked rat, illustrating selectivity of iontopho­
retically applied DNQX (80 nA) for the AMPA-evoked neuronal response, over the 
NMDA-evoked neuronal response.
Bars indicate duration and amplitude of iontophoretic currents.
Cell: raw extracellular signal.
Spikes s'1: rate meter ( I s  bins)
BP: blood pressure.
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Figure 5.5 Iontophoresis trace: effects o f DNQX on AMPA and PBG
Experimental trace of an NTS extracellular recording with iontophoresis in an 
anaesthetised, neuromuscular blocked rat, illustrating inhibitory effect of iontopho­
retically applied DNQX (10 nA) on both the PBG-evoked and AMPA-evoked 
neuronal responses, but not the NMDA-evoked neuronal response.
Bars indicate duration and amplitude of iontophoretic currents.
Cell: raw extracellular signal.
Spikes s'1: rate meter ( I s  bins)
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DNQX 1 0 nA
NMDA (nA) 40 40 40 40
AMPA (n A) 20 20 20 20
PBG (nA) 80 80 80 80
50'
Spikes s'1 
0
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Figure 5.6 Histograms: effects of DNQX on AMPA and PBG
A. Histogram of mean (± s.e.m.) NTS neuronal activity evoked by iontophoretic
application of AMPA (n = 13), AMPA in the presence of DNQX (n = 13), 
and recovery (REC; n = 11).
% P < 0.01 (Mann-Whitney Rank Sum test).
B. Histogram of mean (± s.e.m.) NTS neuronal activity evoked by iontophoretic
application of AMPA (n = 4), AMPA in the presence of the vehicle for 
DNQX (n = 4), and recovery (REC; n = 4).
NS: non-significant (paired Student’s t-test).
C. Histogram of mean (± s.e.m.) NTS neuronal activity evoked by iontophoretic
application of PBG (n = 5), PBG in the presence of DNQX (n = 5), and 
recovery (REC; n = 4).
NS: non-significant (Mann-Whitney Rank Sum test).
Boxed numbers show proportion of neurones in which the effect was observed.
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Figure 5.7 Histograms: effects o f DNQX on NMDA
Histograms illustrating the effects of DNQX on NMDA-evoked NTS neuronal 
activity, depending on whether firing was inhibited (by > 2 0  %), attenuated (by > 20  
%) or unaffected (< 2 0  % change).
A: Inhibition. Histogram of mean (± s.e.m.) NTS neuronal activity evoked
by iontophoretic application of NMDA (n = 6 ), AMPA in the 
presence of DNQX (n = 6), and recovery (REC; n = 6 ).
NS: non-significant (Mann-Whitney Rank Sum test).
B: No change. Histogram of mean (± s.e.m.) NTS neuronal activity evoked
by iontophoretic application of NMDA (n = 4), AMPA in the 
presence of DNQX (n = 4), and recovery (REC; n — 4).
NS: non-significant (Mann-Whitney Rank Sum test).
C: Potentiation. Histogram of mean (± s.e.m.) NTS neuronal activity evoked 
by iontophoretic application of NMDA (n = 3), AMPA in the 
presence of DNQX (n = 3), and recovery (REC; n = 2).
Boxed numbers show proportion of neurones in which the effect was observed.
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Figure 5.8 Trace of effects o f DNQX on cardiopulmonary reflex
Experimental trace from an anaesthetised rat illustrating effect of activating 
cardiopulmonary afferents with intra-atrial PBG (4 jig) on blood pressure (BP) and 
NTS neuronal discharge, before (control), 2 min after commencement of 
iontophoretically applied DNQX (80 nA), and 5 min after termination of the DNQX 
current (recovery). Heart rate is not shown because the animal is pretreated with the 
vagolytic neuromuscular blocker gallamine.
Spikes s'1: rate meter (1 s bins)
Numbers in circles indicate number of spikes per burst.
Insets: details of extracellular neuronal activity during reflex-evoked discharge 
before and during DNQX.
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Figure 5.9 Trace of effects of DNQX on vagus-evoked activity
Experimental trace from an anaesthetised rat illustrating effect of iontophoretically 
applied DNQX (20 and 40 nA) on vagally-evoked discharge of NTS neurones. The 
ipsilateral vagus nerve is being continuously stimulated (1 Hz, 1 ms pulse, 150 pA).
Spikes s'1: rate meter (1 s bins)
Insets: 5 superimposed sweeps of evoked extracellular neuronal activity before (left) 
and during (right) DNQX, illustrating failure of evoked spikes during 
antagonist application.
* stimulus artefact.
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Figure 5.10 Histograms o f effects of DNQX on evoked activity
A. Histogram of mean (± s.e.m.) NTS neuronal activity evoked by electrical 
stimulation (1 Hz) of the vagus (number of evoked spikes per 20 sweeps), 
both before (n = 12) and during iontophoretic application of DNQX (n = 12), 
and recovery (REC; n -  11).
X P  < 0.01 (Mann-Whitney Rank Sum test).
B. Histogram of mean (± s.e.m.) NTS neuronal activity evoked by activation of 
cardiopulmonary afferents with intra-atrial PBG (Reflex), both before (n = 5) 
and during iontophoretic application of DNQX (n = 5), and recovery (REC; 
n = 4). NS: non-significant (paired Student’s t-test).
Boxed numbers show proportion of neurones in which the effect was observed.
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5.3.2. Serotonergic study
Effects o f intravenous 8-OH-DPAT in the presence o f intravenous robalzotan
Intravenous administration of 8 -OH-DPAT (65 pg kg"1; n = 5) caused a fall in MAP 
of 18 ± 7 mmHg (from a baseline of 115 ± 9 mmHg) and a fall in HR of 48 ± 6 bpm 
(from a baseline of 370 ± 23 bpm). In a separate group, pretreatment with robalzotan 
(100 jig kg' 1 i.v.; n = 5) caused a rise in BP of 4 ± 4 mmHg (from a baseline of 117 ± 
2 mmHg) and a rise in HR of 34 ± 5 bpm (from a baseline of 384 ±20 bpm). 2 min 
after robalzotan pretreatment, 8 -OH-DPAT (65 jig kg"1 i.v.) caused a fall in MAP of 
5 ± 1 mmHg, and a fall in HR of 10 ± 2 bpm. This latter effect was significantly 
inhibited with respect to the non-pretreated group (P < 0.001, Student’s unpaired t- 
test).
Effect o f SB-269970 on NTS neurones 
A  total of 10 NTS neurones were recorded from 4 rats at a depth of 595 -  775 pm 
from the brain surface. All neurones responded to vagal stimulation with a latency of 
1 6 - 3 8  ms, suggesting activation by C-fibre afferents. Of these, 1 was Type 1 
(monosynaptic), 3 were Type 2 (intermediate) and the remaining 6  were Type 3 
(polysynaptic). 3 were excited by intra-atrial PBG, 2 were inhibited, and the 
remaining 5 unaffected. 6  neurones had no spontaneous activity, and 4 had a firing 
rate of 0.6 -  4.2 Hz.
Topically applied saline (10 pi, pH 5.8; n =5) had no significant effect on vagally- 
evoked activity (Figure 5.12, Table 9.48).
Topically applied SB-269970 (100 pg kg"1; n = 5) significantly inhibited vagally- 
evoked activity in the 5th minute after application (Figures 5.11 and 5.12, Table 
9.48), with the greatest effect in the 7th minute, compared to saline (23.6 ± 8 vs. 47 ± 
2 spikes 50 sweeps"1). Recovery was observed in the 25th minute.
Effect o f SB-269970 on DVN neurones
A total of 10 DVN neurones were recorded from 4 rats at a depth of 690 -  840 pm 
from the brain surface. All responded to antidromic stimulation of the vagus (as
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shown by the collision test; see methods) with a latency of 15 to 29 ms, indicating 
they had C-fibre axons. Also, 6  of 10 neurones received an additional inhibitory 
vagal input, as shown by the post-stimulus inhibition of baseline activity. 5 neurones 
were excited by intra-atrial PBG, 4 were inhibited, and 1 was unaffected. All 
neurones had spontaneous ongoing activity (mean 4.1 ±0.5 Hz).
Neither topically applied saline (10 jil, pH 5.8; n = 4) nor SB-269970 (100 pg kg'1; n 
= 6 ) had any significant effect on baseline neuronal activity (Figures 5.13 and 5.14, 
Table 9.49).
Effect o f SB-269970 on gracile neurones
A total of 14 gracile nucleus neurones were recorded in 4 rats, at a depth of 220 -  
575 pm. All responded to light touch of discrete parts of the hindquarters or flank; 
none responded to vagal stimulation. 2  neurones had no spontaneous activity, and the 
remaining 8 had a mean baseline firing rate of 3.7 ± 1 Hz.
Topically applied saline (10 pi, pH 5.8) had no significant effect on either baseline 
activity (real or normalised; n = 5), nor on touch-evoked activity (real or normalised; 
n = 7; Figures 5.16 and 5.17, Tables 9.50, 9.51, 9.52 and 9.53).
Topically applied SB-269970 (100 pg kg’1; n = 7) had no significant effect on either 
real or normalised baseline activity, or on real evoked activity (Figures 5.15, 5.16 
and 5.17, Tables 9.50, 9.52 and 9.53). However, when the evoked activity was 
normalised, evoked activity was significantly lower in the drug-treated group, at 1, 3, 
4, 7, 8 , 9 and 10 min post drug (Figure 5.17, Table 9.51).
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Figure 5.11 Trace of effects of SB-269970 on vagus-evoked activity
Experimental trace from an anaesthetised rat illustrating effect of topically (i.e.) 
applied SB-269970 (100 pg kg'1) on the vagally-evoked discharge of an NTS 
neurone. The ipsilateral vagus nerve is being continuously stimulated (1 Hz, 1 ms 
pulse, 100 pA).
Spikes s’1: rate meter ( I s  bins)
Insets: 5 superimposed sweeps of evoked extracellular neuronal activity before (left) 
and after (right) SB-269970, illustrating failure of evoked spikes during 
antagonist application.
* stimulus artefact.
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Figure 5.12 Graph o f effects o f SB-269970 on vagus-evoked activity
Graph illustrating mean (± s.e.m.) effects of topical saline (10 pi; n -  5) and SB- 
269970 (100 pg kg'1; n = 5) on vagally-evoked NTS neuronal activity in 
anaesthetised and neuromuscularly blocked rats. * P < 0.05, ** P < 0.01 (2-way 
ANOVA & least significant difference test).
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Figure 5.13 Trace of effects of SB-269970 on DVN activity
Experimental trace from an anaesthetised and neuromuscular blocked rat illustrating 
effect of topically (i.e.) applied SB-269970 (100 pg kg'1) on the ongoing discharge of 
a DVN neurone.
Spikes s'1: rate meter (1 s bins)
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Figure 5.14 Graph o f effects o f SB-269970 on DVN activity
Graph illustrating mean (± s.e.m.) effects of topical saline (10 pi; n = 4) and SB- 
269970 (100 pg kg'1; n — 6 ) on baseline DVfsl neuronal activity in anaesthetised and 
neuromuscularly blocked rats.
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Figure 5.15 Trace of effects of SB-269970 on evoked gracile activity
Experimental trace from an anaesthetised neuromuscular blocked rat illustrating 
effect of topically (i.e.) applied SB-269970 (100 jig kg'1) on the discharge of a 
gracile neurone evoked by lightly brushing the ipsilateral thigh with a cotton bud 
(arrows).
Spikes 0.1 s'1: rate meter (0.1 s bins)
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Figure 5.16 Graph o f effects o f SB-269970 on gracile activity
Graph illustrating mean (± s.e.m.) effects of topical saline (10 pi) and SB-269970 
(100 pg kg'1) on touch-evoked (n = 7) and baseline (n = 5) gracile neuronal activity 
in anaesthetised and neuromuscularly blocked rats.
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Figure 5.17 Normalised effects of SB-269970 on gracile activity
Graph illustrating normalised (% of control) mean (± s.e.m.) effects of topical saline 
(10 pi) and SB-269970 (100 pg kg"1) on touch-evoked (n = 7) and baseline (n = 5) 
gracile neuronal activity in anaesthetised and neuromuscularly blocked rats.
* P < 0.05, ** P < 0.01 (2-way ANOVA & least significant difference test).
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5.3.3. Juxtacellular labelling
5 juxtacellularly labelled neurones were histologically identified (4 or which are 
illustrated in Figure 5 .1 9 ,^ -  D). All were found within the NTS, at a depth of 440 -  
725 pm. 3 neurones (A, B, C) responded to electrical stimulation of the aortic nerve 
at a C-fibre latency, with a jitter suggesting Type 3 (polysynaptic). These neurones 
did not respond to vagal stimulation, but one of them responded to i.v. 
phenylephrine, confirming barosensitivity. The remaining 2 neurones (e.g. D) 
responded to electrical stimulation of the vagus, also at C-fibre (Type 3) latency, but 
had no spontaneous activity. Aortic nerve stimulation was not tested on those cells.
Light microscopic analysis showed that these neurones are surrounded by a dense 
network of 5-HT containing axons, but on closer inspection these rarely form close 
appositions. In Figure 5.19, the varicose terminals at A (asterisks) and E  are clearly 
not closely apposed, whereas those at F  and G may be forming proper synapses, but 
not clearly. The only convincing close appositions were at A (arrowheads).
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Figure 5.18 Juxtacellular labelling trace
Sample trace of a juxtacellular recording from an NTS neurone in an anaesthetised, 
neuromuscular blocked rat.
2 nA current pulses are being applied via the recording electrode, causing 
entrainment of neuronal firing to the current pulse (beginning at the arrow).
* current ejection stimulus artefacts (truncated for clarity).
Inset below: 5 superimposed sweeps of vagally-evoked NTS spikes taken
immediately before, and immediately after a 5 min period of 
entrainment, indicating that the same neurone is being recorded (spike 
amplitude has increased with time).
* vagal stimulus artefact.
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Figure 5.19 Micrographs of double-labelled neurones
Light micrographs of NTS coronal sections double labelled to show NTS neurones 
(juxtacellularly labelled with neurobiotin and visualised with DAB-imidazole) in 
brown, and 5-HT immunoreactive fibres (visualised with nickel-DAB) in black.
A, B, C: NTS neurones activated by electrical stimulation of the ipsilateral
aortic depressor nerve (ADN).
Arrowheads (A, A) indicate possible close appositions of 5-HT 
immunoreactive varicosities.
Arrows (4^) indicate probable lack of close apposition (asterisks in A, 
letters in C, shown at higher magnification in E).
D An NTS neurone activated by electrical stimulation of the ipsilateral
vagus nerve.
Arrows (4^) indicate probable lack of close apposition of 5-HT 
immunoreactive terminals (shown at higher magnification in F  and
G)-
Scale bars: 20 pm
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5.4. Discussion
5.4.1. Main findings
The above data demonstrate that both AMPA (i.e AMPA/kainate) receptors, and 5- 
HT7 receptors, are involved in the activation of NTS neurones by vagal afferents. 
Firstly, blockade of AMPA receptors with iontophoretically applied DNQX (at 
currents selective for the AMPA-evoked response) inhibited the activation of NTS 
neurones by electrical stimulation of the vagus, as well as inhibiting the 
cardiopulmonary afferent-evoked response in the majority of neurones tested, 
suggesting that glutamate, acting via AMPA receptors is a neurotransmitter at a 
number of sites within the cardiopulmonary reflex pathway in the NTS. Secondly, 
iontophoretic PBG excited NTS neurones, and this effect was also attenuated by 
iontophoretic DNQX, suggesting that 5 -HT3 receptors facilitate glutamate release 
onto AMPA receptors via a presynaptic action. These data complete previous results 
from this laboratory, which observed the same effects using the NMDA receptor 
antagonist AP-5 (Jeggo et al., 2001), demonstrating that both AMPA and NMDA 
receptors are recruited within these pathways. Thirdly, these data show that the 5- 
HT7 receptor antagonist SB-269970, given topically at the dose used to attenuate 
reflex bradycardias, inhibited the excitation of NTS neurones by vagal afferents, 
suggesting that the blockade of 5 -HT7 receptors by topical or intracistemal SB- 
269970 is occurring at the level of the NTS. The time course of SB-269970 in this 
respect was very similar to that observed in the reflex pharmacology of Chapter 3. 
Furthermore, SB-269970 did not affect the ongoing activity of DVN or gracile 
neurones, and did not have any clear effect on the ongoing or afferent-evoked 
excitation of gracile neurones, suggesting that the drug does not interfere with 
neuronal firing per se, and does not have other (e.g. local anaesthetic) actions. With 
respect to the systems tested, 5 -HT7 receptor activation would appear to be specific 
to neurones activated by vagal afferents, rather than neurones activated by 
discriminative touch (skin) afferents. Lastly, juxtacellularly labelled NTS neurones 
receiving vagal and aortic nerve afferent input were surrounded by a dense network 
of 5-HT immunoreactive fibres, but closely apposed terminals were very rare, whilst 
non-apposed terminals were more frequent. This suggests that there is no direct 
serotonergic innervation of these neurones.
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5.4.2. Single unit electrophysiology
Single unit extracellular recordings were make from NTS, DVN and gracile neurones 
based on their depth from the brain surface and their physiological characteristics. 
NTS neurones were identified as previously described in this laboratory (Wang et al., 
1997), based on their orthodromic activation by vagal afferents. The majority of 
these neurones had no spontaneous ongoing activity, which is what previous studies 
using pentobarbitone-anaesthetised rats have reported (Wang et a l, 1997; Sevoz- 
Couche et al., 2000a). Their synaptic position within the NTS (i.e. whether they are 
second order or higher order neurones) was assessed on the basis of the variability of 
their evoked latencies (also called synaptic jitter), which is considered the most 
reliable way of discriminating monosynaptically activated from polysynaptically 
activated NTS neurones (Doyle & Andresen, 2001). Recorded neurones were 
separated into 3 groups (Type 1, 2 and 3) based on the criteria of Sevoz-Couche et al. 
(2000a), who found that the intermediate (Type 2) neurones were pharmacologically 
distinct. For the purpose of this study, however, they can be seen as monosynaptic 
(Type 1) and polysynaptic (Types 2 and 3). All the NTS neurones recorded in this 
study had latencies in the C-fibre range (20 -  35 ms), suggesting activation by 
unmyelinated primary afferents. They tended to be found in the medial and 
commisural parts of the NTS, where unmyelinated pulmonary, bronchial and 
chemoreceptors terminated (see Loewy & Burton, 1978; Kalia & Mesulam, 1980; 
Jordan & Spyer, 1986).
DVN neurones were identified by the collision test, and by their regular ongoing 
discharge (Wang et al., 1995). All DVN neurones recorded had latencies suggesting 
unmyelinated efferents. Gracile neurones, which are part of a completely different 
system from NTS and DVN (the dorsal columns, mediating the sense of 
discriminative touch) were identified by their superficial position within the brain, 
their biophysical property of tending to fire in spike doublets, and their response to 
touch of the skin (i.e. fur) but not to stimulation of the vagus.
Therefore the present experiments have investigated 3 different types of neurone: 
firstly the autonomic sensory neurones of the NTS activated by primary afferents; 
secondly the parasympathetic preganglionic neurones of the DVN controlled by
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integrative autonomic centres such as the NTS; thirdly (as a non-autonomic control) 
the sensory neurones in the gracile nucleus, activated by skin afferents via the dorsal 
horn of the spinal cord (Tomasulo & Emmers, 1972).
5.4.3. Role of glutamate receptors
As would be expected, iontophoresis of AMPA and NMDA excited all NTS 
neurones tested. The AMPA/kainate receptor antagonist DNQX very effectively 
inhibited the excitation of NTS neurones by AMPA, and was reasonably selective for 
the AMPA-evoked response at currents of up to 80 nA. Although it inhibited the 
NMDA-evoked response in some neurones, taken as a group there were no 
significant effects, suggesting that for the purpose of this study the currents of 
DNQX used were selective for AMPA receptors. DNQX has a pKx of 6.3 at AMPA 
receptors, and of 4.4 at NMDA receptors, but this NMDA receptor antagonism at 
higher doses is non-competitive, via the glycine site at that receptor (see Watkins et 
al., 1990).
The DNQX solution used in the present experiments contained a small amount of 
DMSO to aid solubility, as used previously in this laboratory (Jones et a l, 2002). 
DMSO has direct neuronal effects even at these concentrations, as shown by the fact 
that the vehicle potentiated the AMPA-evoked excitation. This confirms, however, 
that the inhibitory effects of DNQX are drug-related, not vehicle-related.
AMPA-selective currents of DNQX inhibited the activation of NTS neurones by 
vagal afferents. All the neurones tested were Type 2 or 3 (presumed higher order). 
The evoked spikes began to fail within 2 min of current application, and the greatest 
response was typically at around 3.5 min. This may seem a long time, but is similar 
to previous iontophoretic studies in the NTS (Jeggo et al., 2000b). The location of 
the synapse(s) in question may be at some distance from the iontophoresis barrel, so 
it may take some time for enough DNQX to accumulate at sufficient synaptic 
concentrations. Since a retaining current is placed on the DNQX barrel between 
ejections, the charged moiety of the drug may not be at the tip of the barrel at the 
time that ejection current commences. This can cause further delays.
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DNQX also attenuated the cardiopulmonary afferent-evoked burst firing of the 
majority of NTS neurones tested. Whilst the group data was not statistically 
significant, the attenuation in the majority was > 2 0  %, which is a conservative 
criterion previously established to show change in these experiments, as NTS 
neuronal firing is relatively stable during pentobarbitone anaesthesia (Wang et a l, 
1996).
Together these data suggest that glutamate acting at AMPA receptors (as well as at 
NMDA receptors, as previously shown by Jeggo et al., 2001) is a major 
neurotransmitter within the NTS. A wealth of information implicates glutamate as 
the chief transmitter of primary vagal afferents (see Lawrence & Jarrott, 1996). 
Iontophoresis has previously shown that cardiopulmonary afferents activate second 
order NTS neurones via AMPA (but not NMDA) receptors (Wilson et al., 1996), and 
subsequent work in vivo and in vitro suggested that NMDA receptors are found on 
higher order but not second order NTS neurones (see Andresen et al., 2004). Whilst 
the present experiments support the view that glutamate is a transmitter within the 
NTS (i.e. between second and higher order neurones), recent work in this laboratory 
also suggests that NMDA receptors are found at second order as well as higher order 
neurones (Jeggo, 2003; Jones & Jordan, unpublished data). In the present 
experiments it cannot be ruled out that DNQX is diffusing as far as the synapse of 
primary afferents with second order neurones, but it is unlikely to have effects here 
for the following reason: the effect of DNQX on the AMPA-evoked response was 
one of inhibition not total blockade, indicating only partial receptor occupancy at this 
relatively proximal site. Therefore at a site as distant as several synapses away, the 
concentration of DNQX would probably be too low to antagonise synaptic events.
5.4.4. Role of 5-HT3 receptors
Iontophoretic PBG excited the majority of neurones tested, which confirms previous 
data (Jeggo et a l, 2001), although in the present study the excitation was not as 
great. This may be because the recording barrel was positioned further from the 
iontophoresis barrel in the compound electrode construction, so PBG has to diffuse 
further. Iontophoretic PBG-evoked excitation has previously been shown to be 
inhibited both by 5 -HT3 and NMDA receptor antagonists in the NTS (Jeggo et al.,
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2001) and by 5-HT3, NMDA and AMPA receptor antagonists in the DVN (Wang et 
al., 1998), suggesting that in both areas 5 -HT3 receptors are facilitating glutamate 
release by a presynaptic mechanism. This facilitation had already been reported in 
the NTS using microdialysis (Ashworth-Preece et al., 1995). The glutamatergic 
fibres involved may be primary afferents, or the axons connecting second order and 
higher order neurones within the NTS. In the both these and the present experiments, 
a mixture of presumed second and higher order neurones were tested, and 
pharmacological differences were not identified.
An opposing role for 5 -HT3 receptors in the NTS has also been proposed by studies 
using microinjection. NMDA-induced bradycardia in awake rats was prevented by 
prior micro injection of a 5 -HT3 receptor agonist (Bonagamba et a l, 2000), 
suggesting that 5 -HT3 receptors can inhibit glutamate release, presumably by 
activating an inhibitory pathway. Indeed in earlier studies, microinjection of 5 -HT3 
agonists into the NTS attenuated cardiopulmonary and chemoreflex bradycardias, the 
latter shown to be mediated by GABAa receptors (Sevoz et al. 1996, 1997). 
Although the larger-scale nature of these experiments (i.e. micro injection) is difficult 
to compare to the single unit iontophoretic studies of this laboratory, this 
disagreement might also imply two functional populations of 5 -HT3 receptors in the 
NTS, but this remains to be determined. Indeed, Jeggo (2003) found that less than 1 
% of vagally-activated NTS neurones were inhibited by iontophoretic PBG, at least 
in this caudal/commisural part of the NTS.
5.4.5. Role of 5-HT7 receptors
The intracistemal experiments of Chapter 3 have clearly defined the effective doses 
and time course over which the 5-HT7 receptor antagonist SB-269970 attenuates 
reflex bradycardias. The NTS seemed the most likely location of the 5-HT7 receptors 
involved, for the following reasons: firstly, it is within easiest reach of i.e. injections; 
secondly, it is the site of the greatest complexity in terms of neurochemical 
integration of cardiovascular reflexes; thirdly, it is very rich in 5-HT containing 
fibres. SB-269970 was administered topically because the effective dose was known. 
Possible negative iontophoretic data would be more difficult to interpret. Another 
speculation was that the 5-HT7 receptors mediating bradycardia are located in the
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nucleus ambiguus, as are 5-HTja receptors in the cat (Wang & Ramage, 2001). If 
this were the case, topical SB-269970 would have no effect on NTS neurones.
For the first few minutes, topical SB-269970 had little effect on vagus-evoked NTS 
activity. At around 5 min the evoked spikes began to fail, as they did during 
iontophoretic DNQX. In one experiment evoked activity was virtually abolished for 
several minutes. Such an effect suggests that a major neurotransmitter pathway is 
blocked, and would support the view that 5-HT is released from primary afferents. 
Some afferents with cell bodies in the nodose ganglia (i.e. cardiopulmonary and 
aortic baroreceptor fibres) contain 5-HT (Gaudin-Chazal et al., 1982; Nosjean et 
al., 1990; Sykes et al, 1994), but little is known of their function. Ablation of 5-HT 
containing fibres with 5,7-DHT microinjected into the nodose ganglia, or into the 
NTS, did not noticeably affect the baroreflex (Orer et al., 1991, but see also 4.4.3 for 
discussion). Otherwise there is no further functional data on these putative fibres. 
However, the strength of the effect of SB-269970 in the present experiments would 
suggest more than a neuromodulatory role for 5-HT in the NTS.
In the drug-treated group, only 1 neurone was presumed second order, and this was 
inhibited in a similar way to the remaining presumed higher order neurones. Topical 
application will certainly reach all neurones in the NTS, even more so than 
microinjections. Hence this technique cannot unequivocally identify the synaptic 
localisation of the 5 -HT7 receptors. At the very least many more second order 
neurones need to be tested, but at this stage it is unclear whether the receptor is 
located on second order or higher order neurones, or both.
'i
It was considered that topical SB-269970 might be interfering directly with neuronal 
activity. As the NTS neurones recorded had little if any ongoing activity, the drug 
was tested on DVN neurones. These have a regular ongoing discharge, which was 
unaffected by the drug, suggesting it has no serious non-serotonergic effects (e.g. 
blockade of Na+ or activation of K+ channels). A possiblity for the lack of effect, 
however, is that concentrations of the drug are insufficient once it has diffused as far 
as the DVN. To eliminate this possiblity, and to examine the effect on a non- 
autonomic system, SB-269970 was tested on gracile neurones.
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Gracile neurones typically have ongoing discharge, though not as regular as DVN 
neurones, and are highly excited by light touch of their receptive field (usually the 
hindlimbs and surrounding areas). Touch with a cotton bud or paint brush is a 
reproducible non-noxious stimulus frequently used in the study of A(3 vs. A8 and C- 
fibre inputs to the spinal cord (Dickenson & Sullivan, 1986), and in the present 
experiments produced consistent responses. SB-269970 had no effect on baseline 
neuronal activity, confirming the lack of effect on DVN neurones. On the evoked 
response there was no significant difference, but the considerable variability of the 
saline group led to the results being normalised in case this revealed any differences. 
There were indeed differences at some time points (1, 3, 4, 7, 8 , 9 and 10 min post 
drug), which is difficult to interpret. Taken individually, of the 7 neurones in the 
drug-treated group, 6  were not affected by more than 2 0  %, whereas 1 was strongly 
and irreversibly inhibited. Possibly this neurone represents a separate population, but 
it is more likely that a change in responsiveness took place (perhaps at the level of 
the receptive field, as its spontaneous activity was unchanged). It is therefore 
unlikely that 5 -HT7 receptors have any role in the transmission of touch, at least at 
this level of the brain. Therefore SB-269970 seems to be specific in reducing the 
excitability of NTS neurones in response to vagal stimuli. This demonstrates, for the 
first time, the effects of SB-269970 on neuronal activity in vivo.
5.4.6. Juxtacellular labelling
The method of Pinault (1996) is a useful way of revealing the soma, dendritic field 
and even axonal projections of an extracellularly recorded neurone, and has 
previously been used in this laboratory to characterise NTS neurones physiologically, 
pharmacologically, and immunocytochemically (Jones et a l, 2002). In the present 
experiments no pharmacological characterisation was performed, and only basic 
physiology. All neurones were activated by either the vagus or aortic nerve, at C- 
fibre latency. Immunocytochemistry for 5-HT showed a dense network of 5-HT 
containing fibres surrounding the somata and dendrites of these NTS neurones. In 
some instances there appeared to be close appositions between varicosities and NTS 
neurones, but closer inspection found that these tended not to touch. This brings to 
mind the original reticularist view of Golgi in the late 19th century, that axon 
terminals are fused to dendrites (based on light microscopic appearance), whereas
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Ramon y Cajal’s Neurone Doctrine insisted they were touching, not fused. The 
examples in Figure 5.19 certainly look neither touching, nor fused, suggesting that 
they are not conventional synapses.
The lack of specialised synapses would support the original idea of monoaminergic 
transmission being diffuse and non-specific (e.g. Descarries et al., 1975) -  that 
monoamines are required to diffuse to nearby targets, like a neural aerosol. This idea 
was based more on endocrinological ideas than on hard neurophysiology, and was 
discredited by the finding of conventional specialised synapses (see Pamavelas & 
Papadopoulos, 1989). Electron microscopic analysis of the feline NTS also found 5- 
HT containing terminals making synaptic contacts with NTS neurones (Maley & 
Elde, 1982). However, the function of these NTS neurones was not known, so 
whether this extends to cardiovascular neurones was uncertain. A recent study, 
however, examined the ultrastructure of barosensitive NTS neurones (expressing c- 
fos in response to elevated MAP), and reported that out of 53 synaptic inputs to c-fos 
positive neuronal cell bodies, not a single one contained 5-HT (Llewellyn-Smith et 
a l, 2004). Even c-fos negative NTS neurones received very few (~2 %) 5-HT 
containing synapses, compared to non-5-HT ones. Staining with an antibody for 
SERT revealed similar results. This suggests that on barosensitive NTS neurones, 
serotonergic innervation is sparse and, if present, targetted mainly to distal dendrites. 
However, the researchers noticed that thin astroglial leaflets usually separated NTS 
neurones from 5-HT containing terminals. This could account for the lack of close 
appositions seen with light microscopy, and could represent an entirely new 
dimension of monoaminergic transmission.
Astrocytes were originally believed to have a supportive, relatively passive role. 
More recent observations, almost exclusively in vitro, show that astrocytes also 
behave like additional targets of neuronal signals (see Fellin & Carmignoto, 2004). 
One role of astrocytes was to sequester glutamate, and they can also release 
glutamate. The crucial observation was that elevating intracellular calcium ([Ca2+]j) 
in cultured astrocytes causes release of glutamate, which activates ionotropic 
glutamate receptors on neighbouring neurones, increasing their [Ca2+]j (Parpura et 
al., 1994). Similar effects have been recently reported in the cortex of the 
anaesthetised rat (Hirase et al., 2004). Hence the emerging theory of
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gliotransmission proposes that astrocytes can release neurotransmitter onto neurones 
to transmit information in the CNS. This release is likely to be vesicular (Calegari et 
al., 1999; Araque et al., 2000), at least in the hippocampus. Astrocytes can respond 
to various neurotransmitters including glutamate, GABA, noradrenaline and 
acetylcholine (see Fellin & Carmignoto, 2004), and recent research proposes that 
astrocyte processes alongside a synapse respond to the transmitters within it, and 
then release their own transmitters as part of a feedback or feed-forward mechanism. 
The speculation from the present experiments and the findings of Llewellyn-Smith et 
al. (2004) is that 5-HT released from a serotonergic terminal onto an astrocyte 
process causes release of glutamate onto an NTS neurone. This could help explain 
the interaction between serotonergic and glutamatergic mechanisms in 
cardiovascular reflexes. Such an arrangement of terminal-astrocyte-dendrite (i.e. 
lacking any synaptic specialisation) has not previously been described, and remains 
hypothetical. Astrocytes do express a variety of receptors, however, and 5-htsA 
receptor mRNA is particularly prominent in rat glia (Carson et al., 1996) at least 
during development.
332
NTS Cell Body
Glial Coat
□ Synaptic terminals
5-HT terminals
Figure 5.20 Diagram of NTS ultrastructure
Diagram of a barosensitive NTS neurone (adapted from Llewellyn-Smith et al., 
2004) as seen by electron microscopy, illustrating non-5-HT axon terminals (light 
grey) making conventional synaptic contact, whereas 5-HT containing axons 
terminals (black) are separated from the neurone by a glial coat (grey).
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5.4.7. Limitations
Iontophoresis
In this study, care was taken to demonstrate that the currents of DNQX used were 
indeed selective for AMPA receptors, and this was done by showing inhibition of the 
effects of iontophoretic AMPA, but not of NMDA. This poses the following 
problem: iontophoretic agonists will act at receptors closest to the multibarrel 
aperture, and thus selectivity is true for the concentration of antagonist found at this 
site. However, the effects of the antagonist on synaptic actions (e.g. vagus-evoked 
activity) are likely to be at some distance from the iontophoresis barrels. It cannot be 
known how far away on a dendrite the synapse or synapses in question are located. 
The concentration of antagonist needed to inhibit synaptic actions also tends to be 
higher than that needed to inhibit exogenous agonists. Therefore this method of 
showing selectivity can be a problem, particularly when there is negative data (i.e. if 
the drug is not selective for agonists, it does not mean it will not be selective at 
synapses; conversely if it is selective for agonists, it may not be sufficiently 
concentrated at synapses). Here, however, DNQX is selective for AMPA, and 
inhibits synaptic events, therefore there should not be a problem.
In this study no controls were performed to monitor the effect of iontophoretic 
current ejection on neuronal activity (i.e. the effect of passing a negative 
iontophoretic current through saline at pH 8.5 -  10.5). However, the Neurophore 
system used in this study does use automatic current balancing. Previous studies in 
this laboratory indicated that iontophoresis of saline at this pH has no effect on 
neuronal activity (Wang et al., 1998; Jeggo, 2003).
Topical application
As comparison is being made between these results and those of Chapter 3, the 
topical drug was not applied to the dry surface of the medulla, but to the layer of CSF 
covering it. As such it was as close to an i.e. injection as possible. However, it is 
possible that the final concentration of the solution on the surface is higher than that 
in Chapter 3, and that the diffusion characteristics are altered by the exposure and
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partial drainage of the cistema magna. Therefore some selectivity problems with the 
drug cannot be ruled out.
Juxtacellular labelling 
The juxtacellular technique is becoming an increasingly popular way of identifying 
recorded neurones. It is technically easier than directly filling a neurone with HRP, 
which requires stable intracellular recording. However, unlike intracellular filling, 
there is less certainty that the recorded neurone has been filled with the juxtacellular 
technique. There is always the possibility that between recording and filling (or 
during the filling process) some movement of the electrode has occurred. However, 
the shape and amplitude of spikes are always compared during the entire recording- 
filling protocol to minimise this possibility. For example, in Figure 5.18 the shape of 
the spike is identical before and after filling, although the amplitude has increased 
(presumably due to increased impedance of the electrode), suggesting it is the same 
neurone. Using the technique of juxtacellular labelling, only the neurone that is 
entrained to fire by current pulses is labelled. If the current pulses are comparatively 
small (< 10 nA, as in the present experiments) the chance of entraining multiple 
neurones is very low.
5.4.8. Conclusion
The data support the view that glutamate is the major transmitter between vagal 
afferents and NTS neurones, and between second order and higher order NTS 
neurones. Furthermore, this release of glutamate is aided by 5 -HT3 receptors located 
presynpatically on glutamatergic terminals. However, 5 -HT7 receptors must now be 
included as major players in the NTS. A variety of reflex bradycardias have been 
shown to involve 5 -HT7 receptor activation, and the present experiments have 
provided compelling preliminary evidence that they are located in the NTS. Indeed, 
the inhibitory effect of SB-269970 on vagus-activated NTS neurones was so great 
that the possibility must be considered that serotonergic and glutamatergic primary 
afferents are working in tandem. From histological examination, however, the 
synaptic arrangment of 5-HT containing fibres in the NTS has been given an added 
complexity. Either the dated but long-held dogma of serotonergic transmission as 
diffuse (like an aerosol) is resurfacing in the present data, or another mechanism is
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emerging. This latter possibility might be the increasingly popular theory that 
astrocytes participate in neurotransmission.
5.4.9. Future experiments
The effects of SB-269970 and of another antagonist (i.e. SB-656104) need to be 
confirmed topically using a lower dose, and also iontophoretically. It is vital to 
elucidate whether the effects are occuring at second order or higher order neurones. 
Whether WAY-10063 5 (and other 5-HTjA receptor antagonists) have similar effects 
at the NTS must also be addressed, as this would imply a dual location of the 
receptors at NTS and nucleus ambiguus (comparable to the supraspinal and spinal 
location of micturition-controlling 5-HTja receptors).
The idea of glial roles in the NTS is certainly worth following. A simple double stain 
of glial cells and 5-HT containing terminals would yield clues to how these might 
interact. Further juxtacellular labelling experiments are currently underway to look at 
the nature of 5-HT appositions in the NTS with the DVN, and compare these with 
substance P and other peptide-containing fibres.
Finally the role of serotonergic vagal afferents needs to be addressed, and this might 
be done by application of 5,7-DHT to the nodose ganglia. If the 5 -HT7 receptor 
mediated effect is transmitted from primary afferents, one would expect topical 
antagonists to have no effect in such animals.
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6. R o l e  o f  c e n t r a l  5 -H T 7 r e c e p t o r s  in  c a r d io v a s c u l a r
REFLEX INTEGRATION IN AWAKE RATS
6.1. Introduction
6.1.1. Background
The physiology and pharmacology o f cardiovascular reflexes has been most widely 
studied in anaesthetised animals, where a wider range o f variables can be monitored and 
controlled with moderate technical ease. However, cardiovascular reflexes serve to 
maintain the physiological functions of the awake animal, and it is in this state that they 
function normally, since anaesthetics can have a number o f modulatory effects 
principally through their depressant mechanisms. Fewer studies have concentrated on 
reflexes in awake animals due to technical difficulty and limitations. The technique 
developed by Michelini & Bonagamba (1988) allows microinjections to be made into 
the NTS o f awake, freely moving and unrestrained rats, whilst simultaneously 
stimulating cardiovascular reflexes. Using this technique, it was found that 
microinjection o f glutamate into the NTS evoked a pressor response (Machado & 
Bonagamba, 1992), whilst previous studies in anaesthetised rats reported a depressor 
response (Talman et al., 1980), mimicking baroreceptor activation. When these awake 
rats were anaesthetised with urethane, however, the hypertension evoked by glutamate 
reversed to a hypotension (Machado & Bonagamba, 1992). Furthermore, when rats were 
anaesthetised with a-chloralose, the depressor response was even greater than in the 
urethane group. This demonstrates the potential influence o f anaesthesia on NTS 
cardiovascular mechanisms. There are several possible explanations: firstly, under 
anaesthesia glutamate receptors in the NTS may not be under the influence o f other 
neuromodulatory mechanisms; secondly, the CVLM may be more active in the 
anaesthetised animal, where glutamate causes hypertension when muscimol is 
microinjected into CVLM (Urbanski & Sapru, 1988); thirdly, that the chemoreflex 
pathway is more important and easily activated in awake animals, leading to a 
chemoreflex hypertension. Consequently it is possible that reflex mechanisms (such as a
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pharmacological effect) observed under anaesthesia may be quite different in the 
absence o f this physiological and pharmacological complication.
6.1.2. Aims of the study
To date there are no reports o f a serotonergic mechanism contributing to cardiovascular 
reflex transmission in awake animals. The present experiments were performed to re­
examine the modulatory effects o f the 5 -HT7 receptor antagonist SB-269970 on the 
cardiopulmonary and chemoreflex, as described in Chapter 3. The same dose (100 pg 
kg '1) and route (i.e.) were used. Furthermore the effect o f the antagonist on baseline 
MAP and HR, as well as any gross observable behavioural effects, were monitored.
6.2. Methods
This study was carried out at the Faculty o f Medicine o f Ribeirao Preto, University of 
Sao Paulo, Ribeirao Preto, Brazil, following approval by the Ethical Committee o f the 
University o f Sao Paulo. All experiments were performed on adult male Wistar rats (280 
-  330 g) obtained from a colony at the Faculty o f Medicine o f Ribeirao Preto. Animals 
were housed in groups o f 2 -  4 at ambient temperature and humidity, with food and 
water ad libitum. After vascular cannulation, animals were housed singly (to prevent 
interference with the cannulae) and kept overnight in the room where experiments 
would be performed the next day, to avoid moving and disturbing the animals on the day 
o f the experiment.
6.2.1. Implantation of intracisternal cannulae
Four days before the experiment, rats were anaesthetised with tribromoethanol (250 mg 
kg ' 1 i.p.) and placed in a stereotaxic frame (David Kopf) using atraumatic ear bars. 
Supplementary doses o f anaesthetic (25 mg i.p.) were given if  required during surgery. 
The scalp and nuchal muscles were injected with 0.2 ml Lidostesin (3 % lignocaine and 
1:50 000 noradrenaline). The scalp was incised and the underlying connective tissue and
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periosteum removed. The bregmoid and lamdoid sutures were located, and the incisor 
bar adjusted to achieve a flat skull position. The nuchal muscles were retracted from the 
occipital bone by blunt dissection. To allow placement o f a vertical guide cannula into 
the cistema magna, a small craniotomy was performed from the occipital notch to within 
1 mm of the atlanto-occipital membrane using a dental drill. Also, 2 burr holes were 
made in the parietal bones several millimeters lateral to the midline for the placement of 
watch screws.
A guide cannula (22 gauge, 15 mm) was placed in the cistema magna using stereotaxic 
coordinates (from Paxinos & Watson, 1998) relative to bregma (AP -14.5, L 0.0, DV -  
7.9), and bonded to the skull and watch screws using dental acrylic. Postoperatively, rats 
were treated with a compound antibiotic preparation (Pentabiotico Veterinario; 0.2 ml 
intramuscular).
6.2.2. Cannulation of femoral artery and vein
On the day before experiment, rats were again anaesthetised with tribromoethanol (250 
mg kg ' 1 i.p. followed by 25 mg i.p. when required) and a 0.5 cm incision made to isolate 
the femoral artery and vein. The femoral artery and vein was tied distally. This is 
thought to aid the opening o f collateral circulation to the leg to prevent ischaemia. Care 
was taken not to damage the femoral nerve. Polyethylene cannulae were constructed 
using 18 cm o f PE50 tubing (Clay Adams, USA, ID 0.58 mm, OD 0.965 mm) attached 
to 2.5 cm (for vein) or 5 cm (for artery) PE 10 tubing (ID 0.28 mm, OD 0.61 mm). The
'i
cannulae were pre-filled with saline, sealed distally, and inserted into the femoral vein 
and artery so the tips lay within the inferior vena cava and abdominal aorta, respectively. 
The distal ends o f the cannulae were tunneled subcutaneously, exteriorised through the 
back o f the neck, and sutured to the skin. The incision was closed with a single suture.
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6.2.3. Recording of arterial pressure and heart rate
On the day o f the experiment, the cannulae were flushed with saline and the arterial 
cannula connected to a pressure transducer via a length o f PE50 tubing under conscious, 
freely moving conditions. Pulsatile arterial pressure and mean arterial pressure were 
measured by a transducer (Model CDX III, Cobe Labs, USA) connected to a 
physiological recorder (Narcotrace 80, Narco Bio-Systems, USA). Heart rate was 
derived from the pulsatile arterial pressure with a biotachometer coupler (Narco, Model 
7302). Variables were displayed on a chart recorder, and calibrated at the beginning o f 
each experiment. The venous cannula was connected to a length o f saline-filled PE50 
tubing for intravenous injection under freely moving conditions.
6.2.4. Stimulation of cardiovascular reflexes
Once baseline variables had stabilized, intravenous injections were given to stimulate a 
variety o f afferents. Chemoreceptor afferents were stimulated by injecting potassium 
cyanide (KCN; 10 -  80 pg per animal in a volume o f 100 pi; see Franchini & Kreiger, 
1993). The dose was adjusted to produce a bradycardia o f 100 -  200 bpm. 
Cardiopulmonary afferents were stimulated by injecting 5-HT (0.1 %; 1 -  3 pg per 
animal). The dose was adjusted to produce a bradycardia o f 200 -  300 bpm. Afer drug 
injection, the cannula was flushed with 0.3 ml saline and the time marked with an event 
marker on the chart recorder. 5 min was allowed to elapse between reflex stimulations to 
prevent tachyphylaxis.
6.2.5. Intracisternal injection
Drug or vehicle was injected once at least 2 stable control bradycardias had been 
recorded. When variables returned to baseline and the animal was calm, an injector 
constructed from a 30 gauge gingival needle (length 15.8 mm), and attached via a length 
o f PE 10 tubing to a 10 pi syringe (Hamilton, USA), was carefully inserted into the guide 
cannula. This was done without restraining or cornering the animal in any way. Drug or 
vehicle (saline) was injected in a volume o f 5 pi over 20 s, and the injector left in place
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for 1 min to ensure diffusion. Reflexes were elicited at 5, 10, 15, 20, 25 and 30 min post 
drug.
At the end o f the experiments, 5 pi o f dye (2 % Evans blue) was injected i.e. for 
verification o f drug delivery. The animal was then immediately anaesthetised with 
thiopentone sodium (50 mg kg ' 1 i.v.) and perfused transcardially with saline followed by 
10 % buffered formaldehyde. The brain was removed and examined for staining. Data 
was only used from animals that showed good staining on all medullary surfaces.
6.2.6. Data analysis
Mean arterial pressure (MAP) and heart rate (HR; derived from the pulsatile arterial 
pressure wave) were measured directly from the polygraph printout, using the 
calibration points inserted at the beginning o f each experiment. Baseline MAP and HR 
were calculated by taking the best-fit average from the 30 s prior to each reflex 
stimulation. Readings were only taken if  the baseline was stable (± 5 mmHg for MAP, ± 
10 bpm for HR). Reflex-evoked changes were calculated as the absolute changes in 
baseline variables following an intravenous injection.
Baseline and reflex-evoked changes in drug-treated animals were compared with time- 
matched saline controls using 2-way ANOVA followed by the LSD test, as in Chapter 3. 
Similarly, data in saline-treated animals were themselves compared to averaged pre­
saline controls using 1-way ANOVA followed by the Tukey test (and this test was also 
used to analyse the effect o f SB-269970 on the chemoreflex, where no saline controls 
were available). Values of P < 0.05 were considered significant.
6.2.7. Drugs and solutions
See 2.9 above.
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6.3. Results
6.3.1. Effect of SB-269970 on baseline variables
Intracistemal injection of SB-269970 (100 pg kg'1, n = 5) had no significant effect on 
baseline MAP or HR when compared to i.e. saline (Figure 6.1, Table 9.56). 
Intracistemal saline (5 pi, n -  5) also had no effect on baselines (Figure 6.1, Table 
9.54). SB-269970 had no noticeable effects on locomotor or exploratory activity.
6.3.2. Effect of SB-269970 on cardiopulmonary reflex
Injection of 5-HT (1 -  3 pg i.v., n = 10) caused an immediate bradycardia of -278 ±
14 bpm (from a baseline of 376 ± 1 7  bpm) and a hypotension of -56 ± 6  mmHg 
(from a baseline of 104 ± 4 mmHg). Intracistemal injection of SB-269970 (100 pg 
kg'1, n = 5) significantly attenuated both the bradycardia (-142 ± 54 bpm) and the 
hypotension (-22 ± 7 mmHg) 5 min after injection, compared to i.e. saline. At 15 min 
the difference was no longer significant, and at 30 min full recovery was observed 
(Figures 6.2 and 6.3, Table 9.57). Saline (5 pi i.e.; n = 5) had no significant effect on 
reflex-evoked changes (Figure 6.3, Table 9.55).
6.3.3. Effect of SB-269970 on chemoreflex
Injection of KCN (20 -  40 pg i.v., n = 5) caused an immediate bradycardia of -188 ± 
23 bpm (from a baseline of 343 ± 11  bpm) and a hypertension of 41 ± 4 mmHg 
(from a baseline of 103 ± 4 mmHg). Intracistemal injection of SB-269970 (100 pg 
kg'1, n = 5) did not significantly affect the chemoreflex (Figure 6.5, Table 9.58), 
although in 3 out of 5 animals the bradycardia was strongly attenuated, and in 2 out 
of 5 the hypertension was attenuated (Figure 6.4). No vehicle controls were 
performed.
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Figure 6.1 Baseline graph: SB-269970
Graph showing the effects (mean ± s.e.m.) of 5 pi saline i.e. (□, n = 5) and SB-269970, 
100 pg kg ' 1 i.e. ( • ,  n = 5) on baseline mean heart rate (HR) and mean arterial pressure 
(MAP) in awake rats.
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Figure 6.2 Cardiopulmonary reflex trace: SB-269970
Sample trace showing effect o f SB-269970 (100 pg kg ' 1 i.e.) on heart rate (HR), 
pulsatile blood pressure (BP), and mean arterial pressure (MAP) responses evoked by 
stimulation o f cardiopulmonary afferents with 5-HT (3 pg i.v.) in an awake rat.
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Figure 6.3 Cardiopulmonary reflex graph: SB-269970
Graph showing the effects (mean ± s.e.m.) o f 5 pi saline i.e. (□, n = 5) and SB-269970, 
100 pg kg ' 1 i.e. ( • ,  n — 5) on changes (A) in heart rate (HR) and mean arterial pressure 
(MAP) evoked by cardiopulmonary afferent stimulation with 5-HT in awake rats.
* P <  0.05, ** P  < 0.01, 2-way ANOVA followed by LSD test.
346
Figure 6.4 Chemoreflex trace: SB-269970
Sample trace showing effect o f SB-269970 (100 pg kg ' 1 i.e.) on heart rate (HR), 
pulsatile blood pressure (BP), and mean arterial pressure (MAP) responses evoked by 
stimulation o f chemoreceptor afferents with potassium cyanide (KCN; 20 pg i.v.) in an 
awake rat.
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Figure 6.5 Chemoreflex graph: SB-269970
Graph showing the effects (mean ± s.e.m.) o f SB-269970, 100 jig kg ' 1 i.e. ( • ,  n = 5) 
on changes (A) in heart rate (HR) and mean arterial pressure (MAP) evoked by 
chemoreceptor afferent stimulation with potassium cyanide (KCN) in awake rats.
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6.4. Discussion
6.4.1. General findings
The data demonstrate that blockade of 5 -HT7 receptors located in the brainstem 
significantly attenuates cardiopulmonary reflex bradycardia and hypotension in 
awake rats. This is in agreement with the findings of Chapter 3, and confirms that the 
cardiac vagal component of the cardiopulmonary reflex involves activation of central 
5 -HT7 receptors, both in the anaesthetised and awake animal. It should be noted that 
in the awake rat, the cardiopulmonary reflex hypotension is atropine-sensitive 
(Chianca & Machado, 1996) and does not reflect a withdrawal of sympathetic tone, 
as is seen in the anaesthetised animal. In the present experiments no atenolol 
pretreatment was given, demonstrating that similar responses can be observed in the 
absence of cardiac sympathoadrenal blockade.
The present data also confirm that the antagonist has no effect on baseline HR and 
BP, which is also in agreement with the previous data from the anaesthetised animal. 
However, these preliminary experiments failed to demonstrate a significant effect of 
SB-269970 on the chemoreflex.
6.4.2. Technical considerations
In this study the antagonist was given in a lower volume than in the anaesthetised 
study (5  pi instead of 10  pi) to minimise subsequent pressure changes in the cistema 
magna which could either have an effect on medullary activity, or facilitate the 
escape of drug through the guide cannula. Consequently the concentration of the 
antagonist is higher than in the anaesthetised study, but this is unlikely to be a 
problem since it rapidly disperses into the cerebrospinal fluid.
The standard method of activating cardiopulmonary afferents is intra-atrial PBG 
(Kay & Armstrong, 1990) which acts on 5 -HT3 receptors located on vagal sensory 
endings. In this awake rat preparation (Michelini & Bonagamba, 1988) it is not 
possible to inject directly into the right atrium, hence 5-HT was selected for injection 
into the femoral vein. 5-HT is rapidly cleared by pulmonary monoamine oxidase, so
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it is unlikely to activate receptors downstream of the cardiopulmonary circulation. It 
may, however, have direct tachycardic effects on the heart, but since the results are 
similar to those using PBG in anaesthetised rats, this is unlikely to be an important 
complication.
The bradycardias evoked in this study are much larger than in the anaesthetised 
series (200 -  300 bpm compared with 40 -  100 bpm). However, seeing that these 
bradycardias are attenuated in a way comparable to the anaesthetised experiments 
(55 ± 17 % attenuation compared to 63 ± 7 % in anaesthetised rats) it would appear 
that 5 -HT7 receptors contribute to a wide range of reflex vagal tones to the heart, and 
are not just involved in submaximal bradycardias.
6.4.3. Limitations
The main difficulty in working with awake animals is the greater variability of data, 
which can eclipse subtle changes. Even in the very controlled system of the 
anaesthetised animal, both baselines and reflexes have a certain natural variability. In 
an awake animal that may be resting, exploring or grooming at different points in the 
experiment, and which may have a behavioural response to a reflex challenge, there 
are many factors influencing both baselines and reflexes, and the general noise in the 
system is thus amplified.
The present chemoreflex data are very variable and not significant in this small group 
size, although the antagonist was having some effect in the majority of animals. This 
is likely to be clarified by a few more experiments, and by a separate vehicle control 
group. What is apparent, however, is that the chemoreflex is more complex in its 
central integration and circuitry than the cardiopulmonary reflex, and as such is 
subject to more perturbations and variations. This is especially true in the conscious 
animal, where the reflex is accompanied by a marked behavioral response. The 
chemoreflex is augmented by the hypothalamic defence area, whereas the baroreflex 
is attenuated (Coote et al., 1979). The hypothalamic defence area is quite sensitive to 
anaesthetics, so in an anaesthetised animal it is not expected to have an active role in 
these reflexes. In the awake animal, however, behavioural alerting will have the 
effect of increasing the size of the chemoreflex, which may mask any changes caused
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by the 5 -HT7 receptor antagonist. Behavioural alerting is caused by the chemoreflex 
itself, and also by anxiety. Suffice it to say that the chemoreflex is technically more 
difficult and more variable, hence negative data based on a sample size of 5 should 
be interpreted cautiously.
6.4.4. Conclusion
From the close similarities between the present data, and the findings in Chapter 3, it 
is clear that the samed presumed 5 -HT7 receptor mechanism is involved in the 
cardiopulmonary reflex arc both in anaesthetised and awake rats.
6.4.5. Future experiments
As this was only a preliminary set of experiments, a full investigation of the role of 
5 -HT7 as well as 5-HT\A receptors would be useful in confirming both the very clear- 
cut and more surprising results discussed in Chapter 3 (particularly with respect to 5- 
HTja receptors). Any findings could then be retested further using bilateral 
microinjection of the antagonist into various NTS regions.
This model would also be a very useful way of confirming the effects of 5-HT 
depletion with p-CPA on cardiovascular reflex sensitivity and baseline MAP, as 
described in Chapter 4.
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7. G e n e r a l  D isc u ssio n
7.1. Conclusions
The present experiments have investigated the neuropharmacology of three 
cardiovascular reflexes in anaesthetised rats (and began to re-examine two of these in 
awake rats). Furthermore, the roles of some of the cell groups associated with the 
serotonergic system were examined, and the physiology, pharmacology, and 
anatomy of these reflex pathways was taken to the single cell level in the NTS. 
Based on these data, the following conclusions can be made:
1. Central 5-HT receptors facilitate neurotransmission of reflex bradycardias. 
The 5 -HT7 receptor is involved in all reflex bradycardias here tested. This 
suggests that the 5 -HT7 receptor is the chief mediator of the serotonergic 
contribution to reflex bradycardias, at least in the rat. Preliminary evidence 
suggests that this role extends to the awake as well as the anaesthetised rat.
2 . The 5-HTia receptor also facilitates reflex bradycardias, but the effect is not 
as clear in the rat as in the rabbit. The effect depends on the antagonist used, 
as well as which reflex is stimulated. Using WAY-100635, the 
cardiopulmonary reflex bradycardia is the most sensitive, the chemoreflex 
second and the baroreflex bradycardia least sensitive.
3. At least in the anaesthetised rat, central and peripheral 5-HT receptors are not 
tonically involved in controlling cardiovascular variables, although depletion 
of endogenous 5-HT lowers blood pressure. 5-HT depletion also 
demonstrates that endogenous 5-HT is required for successful reflex 
bradycardias
4. Chemical stimulation of various parts of the medullary raphe revealed that the 
rostral and caudal parts of these nuclei have opposing influences on 
sympathetic and respiratory drive. The cardiac vagal effects of raphe 
stimulation do not involve serotonergic mechanisms, and there is no evidence 
that these nuclei tonically contribute to reflex bradycardias.
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5. Within the NTS, glutamate is a major neurotransmitter both at second and 
higher order neurones, acting at AMPA and NMDA receptors, and 
presynaptic 5 -HT3 receptors facilitate its release. 5 -HT7 receptors at this level 
also facilitate transmission of vagal afferent signals, raising the possibility 
that 5-HT is released from primary afferent fibres.
6 . The cell bodies and proximal dendrites of NTS neurones activated by vagal 
afferents are rarely contacted by serotonergic terminals, therefore this 
interaction is either diffuse and non-specific, or another mechanism is 
involved. Astrocytes could be the intermediary, activated by 5-HT and 
releasing glutamate onto NTS neurones.
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Figure 7.1 Central serotonergic control of cardiovascular reflexes
Schematic diagram illustrating some possible synaptic arrangements of 5-HT (and 
amino acid) receptors involved in cardiovascular reflex control in mammals, based 
on present and previous data. Two NTS neurones (one second order and one higher 
order) and one cardiac vagal preganglionic neurone (CVPN) are shown. Additionally 
an NTS astrocyte is shown (grey).
Dotted lines represent serotonergic fibres either from identified (e.g. raphe pallidus: 
RPa) or unknown sources (?). Unbroken lines are glutamatergic (or GABAergic) 
axons. Axon terminals are shown in terms of excitatory (•)  or inhibitory (o) synaptic 
inputs.
References
© Wang & Ramage (2001)
© Wang et al. (1996)
© Sevoz-Couche et al. (2000a)
© Jeggo et al. (2000a)
© Jeggo et al. (2000b, 2001)
© Edwards & Paton (1999, 2000)
© Sevoz et al. (1996, 1997)
© Present experiments
355
? RPa
5 -H T , - C .
d ) © / '
5-HT.
G A B A , 5 -H T £D
t ' S - H T ©
t o ra m p a ®
N M D A
°j A M PA  
N M D A
AM PA
NM D A
© 5 - H T S  
© 5 - H T .
6 - ^  /
®(D /
5 -H T
©
2A2S
? >  A M PA
Nodose 7 
ganglion
NTS
CVPN
356
7.2. Roles of the serotonergic system
From an overview o f the literature as well as the present experiments, the role of the 
serotonergic system in cardiovascular reflexes is a particularly complex picture, due 
to numerous different receptors being involved, as well as the receptors being located 
in different brain areas. The precise synaptic arrangment of 5-HT receptors (and the 
axons innervating them) remains quite poorly understood. There are many 
possibilities (as summarised in Figure 7.1), some based on established and 
compelling evidence, and some on relatively preliminary data.
Central 5-HTia receptors, whose activation causes bradycardia, are located in the 
nucleus ambiguus. Since these are inhibitory receptors causing increased activity in 
CVPNs, they are thought to be presynaptic on an inhibitory terminal, probably 
inhibiting a tonic GABAergic brake. In terms of the cardiopulmonary reflex, this has 
been shown in the cat, and may well be the target of 5-HT]A receptor antagonists in 
the rabbit. In the DVN, 5 -HT3 receptors potentiate glutamate release, therefore are 
probably on glutamatergic terminals. Hence it is possible that such 5 -HT3 receptors 
are also located in the nucleus ambiguus. The origin o f the 5-HT containing fibres, 
however, is uknown.
In the NTS, 5-H T ia receptors involved in cardiovascular reflexes have not been 
demonstrated, but again 5 -HT3 receptors are thought to be presynaptic on 
glutamatergic terminals contacting both second and higher order neurones. The 
innervation may come from serotonergic vagal afferents, or from elsewhere. The 
glutamatergic transmission is now thought to be via AMPA and NMDA receptors at 
both second and higher order neurones. Furthermore, 5 -HT7 receptors contributing to 
reflex bradycardias are probably in the NTS, though whether second or higher order 
neurones express them remains to be seen. 5 -HT7 receptors could be located on NTS 
neurones receiving serotonergic primary afferents, or fibres from elsewhere. They 
could also be found on astrocytes, which are then releasing glutamate onto NTS 
neurones. Alternatively, the 5 -HT3 receptor could be located on astrocytes instead of, 
or in addition to, glutamatergic terminals.
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Several 5-HT receptors are also found in the NTS without being tonically involved in 
reflexes. The 5 -HT4 receptor inhibits reflexes, and is thought to be innervated by 
raphe pallidus neurones. Since it is an excitatory receptor, it is likely to involve 
activation of a GABAergic brake. Likewise 5 -HT3 receptors can also inhibit reflexes 
via GABAergic mechanisms in the NTS. Whether this is part of a physiological 
pathway is not known. Similarly, the 5-H T ib receptor increases NTS neuronal and 
reflex-evoked activity, whilst the 5-HTm receptor decreases it. Also the 5-HT2c 
receptor inhibits second order NTS neurones, and the 5-HT2a and 5-HT2B receptors 
excite higher order NTS neurones. None of these receptors, however, is involved in 
tonic reflex pathways. ■
One possibility that has received little attention is that blocking 5-HT 1 a and 5 -HT7 
receptors simply increases raphe neuronal firing, and activates inhibitory pathways 
(for example the 5 -HT4 receptor pathway described above). In this case, the 
serotonergic system would not be involved in reflexes at all, except when its activity 
were modulated by blockade of somatodendritic autoreceptors. Whilst this effect has 
been demonstrated using 5-HTiA receptor antagonists (e.g. Wang et al, 1995), the 
effect of 5 -HT7 receptor antagonists on raphe neuronal firing is unclear, but an 
inhibition rather than excitation has been suggested (Roberts et al., 2004b). The 
present experiments have demonstrated that rats depleted of 5-HT have poor reflex 
bradycardias. This supports the role of 5-HT per se in reflexes, rather than the effects 
being secondary to modulation of serotonergic neurones.
7.3. Clinical implications
These findings have a variety of clinical implications. The serotonergic system has a 
variety of important influences, most noteably in higher brain functions such as 
mood. The autonomic system is critically associated with mood and affective states 
(see Jordan, 1990), and the most widespread use of drugs acting on serotonergic 
neurones is in the treatment of affective disorders, such as unipolar depression. 
Whether depression is caused by a functional deficit of serotonergic transmission 
remains contentious, but the efficacy of 5-HT reuptake inhibitors in treating 
depression is clear. Additionally, drugs acting at 5-HT receptors are used for various 
clinical conditions including migraine, anxiety, nausea, and schizophrenia.
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Antidepressants have various cardiovascular side-effects. This is most prominent in 
the older tricyclics, which are especially dangerous in overdose, typically causing 
arrhythmias and heart block due to various non-selective actions (Glassman et al., 
1987). In addition to antagonising muscarinic and a adrenoceptors, tricyclic 
antidepressants are also classified as Type 1A antiarrhythmic drugs, hence their 
particular danger after myocardial infarction (Roose & Glassman, 1994). However, 
the use of imipramine as an antiarrhythmic yielded an interesting result: that non­
depressed patients tend not to develop orthostatic hypotension, which is a common 
intolerable side effect in depressed patients treated with imipramine or similar 
(Glassman et al., 1987). The obvious cause of such orthostatic hypotension would be 
baroreflex dysfunction in the depressed state, aggravated by the peripheral ai 
adrenoceptor blockade caused by the drug, leading to a failure of the system to adapt 
sufficiently to postural changes in blood pressure. This remains to be confirmed.
Unipolar depression has not been associated with cardiovascular risk factors such as 
hypertension, although bipolar affective disorder has been (Yates & Wallace, 1987). 
However, there is a growing body of evidence that unipolar depression carries a 
greater risk of mortality after coronary artery bypass surgery (Baker et al., 2001; 
Blumenthal et al., 2003). The depression in these cases was considered independent 
of the heart disease. Depressed patients with coronary heart disease have markedly 
lower heart rate variability than those without depression (Stein et al., 2000). Indeed 
this is also seen in otherwise healthy depressed patients (Tulen et al., 1996). In both 
cases this was observed in the absence of antidepressant medication, and suggests 
depression (rather than its treatment) alters cardiac autonomic modulation. Patients 
with cardiovascular disease frequently have at least one psychiatric diagnosis, such 
as depression (~30 %) or anxiety (24 %) (Bankier et al., 2004).
Whether 5-HT is involved is far from clear. Many other factors and neurochemical 
phenomena are involved with depression, including inflammatory mediators (Joynt 
et a l, 2003). Treatment with SSRIs can protect against myocardial infarction (Sauer 
et al., 2 0 0 1 ), but whether this is due to amelioration of depression or other effects is 
uncertain. The SSRI sertraline can prolong bleeding time (Calhoun & Calhoun, 
1996), so the protective effect might be to inhibit 5-HT mediated platelet activation.
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In themselves, SSRIs have few cardiovascular side effects. Fluoxetine has been 
shown to reverse the decreased heart rate variability in post traumatic stress disorder 
patients (Cohen et al., 2000). As this is a comparatively selective drug, it suggests 
that the altered heart rate variability (seen also in depression) is due to a serotonergic 
mechanism. Short-term fluoxetine treatment enhances baroreflex control of 
sympathetic nerves in rats (Moffitt & Johnson, 2004), possibly by temporarily 
reducing raphe neuronal firing, which takes a few weeks of SSRI treatment to 
recover (de Montigny et a l, 1990). This illustrates again how 5-HT receptors and 
serotonergic neurones can positively or negatively influence aspects of the 
cardiovascular system. As such, the influence of serotonergic drugs, and the 
relationship between serotonergic higher brain and autonomic functions, remain very 
complex questions, with many mechanisms and roles remaining to be elucidated.
7.4. Future studies
The present experiments have begun to investigate the origin of the endogenous 5- 
HT that facilitates cardiovascular reflexes, but this needs to be conclusively 
identified. The possibilities that vagal afferents release 5-HT, or that the antagonists 
are modulating raphe firing and thus causing the effect, can be investigated by 
various comparatively simple techniques, such as single unit recording (raphe) and 
microdialysis from the NTS (vagal afferents).
The exact mechanisms of the interactions between glutamate and 5-HT in the NTS 
need to be verified, as these could possibly extend to other brain areas. A 
combination of in vivo and in vitro electrophysiology would be useful in detecting 
synaptic mechanisms. Combined with further light and electron microsopic analysis, 
the possible and exciting role of astrocytes might be confirmed.
The role of 5-HT7 receptors in other species needs to be confirmed, and in this 
respect similar experiments in the guinea pig and rabbit are important. This would 
verify any species differences, and begin to address whether these effects apply to 
mammals in general, and to man in particular. Further information on the 5-HT7
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receptor is also needed to characterise its role in other systems, especially mood and 
depression, in which it has been implicated.
Further scientific and clinical studies are also required to investigate links between 
depression and cardiovascular disease. These are both enormous health problems, 
and the identification of a common neuropharmacological factor is of great potential 
benefit.
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9. A p p e n d ix
9.1 Chapter 3 data
9.1.1 Baselines
Mean (± s.e.m.) baseline MAP, R-R interval, integrated renal (IRNA) and integrated 
phrenic (IPNA) nerve activity before and after 10 pi i.e. test solution in 
anaesthetised, neuromuscular blocked and mechanically ventilated rats. |  P < 0.05, J 
P < 0.01 (compared to control), * P < 0.05, ** P  < 0.01 (compared to i.e. saline). 
Numbers in parentheses show differences relative to the appropriate saline control.
Table 9.1 Saline (pH 5.8; n = 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 112 ± 3 180 ± 7 100  ± 0 100  ± 0
5 116 ± 5 175 ± 7 96 ± 15 116 ± 13
15 118 ± 5 173 ± 7 t 99 ± 18 121 ± 10
25 119 ± 5 171 ± 6 t 95 ± 16 141 ± 19
35 120 ± 4 167 ± 5 t 100 ± 15 140 ± 16
Table 9.2 SB-269970 (30 |4g kg'1 i.e.; n = 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 113 ± 10 
( + 2  ± 1 2 )
177 ± 4  
(-2 ± 9)
100  ± 0 100  ± 0
5 11 0  ± 11 
( -6  ± 16)
175 ± 5  
(0  ± 1 1 )
99 ± 2  
(+3 ±15)
131 ± 18 
(+3 ± 19)
15 1 14 db 10 
(-4 ± 14)
173 ± 5  
(+1  ± 1 0 )
103 ± 4  
(+4 ± 21)
123 ±21 
(-26 ± 2 0 )
25 115 ± 9 
(-4 ± 14)
167 ± 6  
(-3 ±11)
106 ±3 
(+11 ± 19)
144 ± 34 
(-32 ± 16)
35 115 ± 10 
(-5 ± 14)
165 ± 6  
(-2 ± 9)
107 ± 5  
(+7 ± 19)
161 ± 18 
(+28 ± 29)
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Table 9.3 SB-269970 (100 jag kg'1 i.e.; n = 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 120  ± 6  
( + 8  ± 9)
182 ± 3  
(+ 2  ± 8 )
100  + 0 100  + 0
5 119+10 
(+3 ± 14)
179 ± 3  
(+4 ± 8 )
102 + 4 
(+5 ± 17)
143 ± 18 
(+15 ± 24)
15 126 ± 6  
( + 1 0  ± 1 1 )
175 + 3 
(+3 ± 8 )
103 + 5 
(+5 ± 20)
8 8 + 18* 
(-61 ± 24*)
25 128 ± 7  
( + 1 0  ± 1 0 )
175 + 5 
(+4 ± 10)
100 + 5 
(+5 ± 17)
101 + 56* 
(-75 ± 42*)
35 133 ± 6  
(+13 ± 9)
173 + 5 
(+5 + 9)
1 0 1 + 6  
(+1 ± 14)
119+ 19 
(-14 + 31)
Table 9.4 SB-269970 (300 gg kg'1 i.e.; n = 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 111 + 9 
(-1 ± 7)
187 + 5 
( + 8  + 1 1 )
100  + 0 100  + 0
5 116+14 
(0  ± 1 0 )
183 + 3 
(+ 8  ± 7)
104 + 4 
( + 8  ± 18)
56 ± 29* 
(-72 ± 37*)
15 131 ± 16 
(+14 ± 17)
175 + 2 
(+2 ± 7)
115 + 7 
(+16 ± 23)
24+ 12** 
(-124 ± 18**)
25 126+11 
(+7 ± 7)
173 + 4 
(+2 ± 9)
119 + 8 
(+24 ± 17)
42 ± 18** 
(-133 ± 35**)
35 138+ 11 
(+19 ± 9)
169 + 3 
(+1 ± 7)
119 + 8 
(+19 ± 15)
60 + 23* 
(-74 ± 33*)
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Table 9.5 SB-269970 (100 ng kg ' i.v.; n = 3)
(Compared to i.e. control)
time after baseline baseline baseline
injection (min) MAP (mmHg) R-R int (ms) IRNA (%)
Control 107 ± 3 180 ± 7 1 0 0 ± 0
( -6  ±9) (+9 ± 4)
5 111 ± 6 179 ± 5 113+4
(-4 ± 12) (+10 ± 4) (+7 ± 9)
Table 9.6 Vehicle for SB-656104 (10 jil i.e.; n — 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 107 + 2 190 + 4 100  + 0 100 + 0
5 117+ If 186 + 5 1 0 0 + 1 0 8 8 + 10
15 118 + 2 1 184 + 5 129 + 29 114 + 23
25 121 ± I f 183 + 5 116+19 148 + 41
Table 9.7 SB-656104 (100 ng kg ' 1 i.e.; n =  5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 105 + 6 
(-1 ± 7)
187 + 4 
(+4 + 3)
100  + 0 100  + 0
5 115 + 9 
( -2  ± 8 )
185 + 4 
(-1 + 3)
145 ± 40 
(+46 ± 37)
77 + 8 
(-1 1 + 6)
15 128 + 8 
( + 1 0  ± 8 )
180 + 4 
(-4 + 5)
139 + 49 
(+10 + 63)
144 + 38 
(+30 ± 19)
25 137 + 6 
(+13 ± 6 )
177 + 3 
( -6  + 5)
164 + 55 
(+48 ± 62)
153 + 21 
(+5 ± 17)
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Table 9.8 WAY-100635 (100 \ig kg'1 i.e.; n = 5)
time after baseline baseline baseline baseline
injection (min) MAP (mmHg) R-R int (ms) IRNA (%) IPNA (%)
Control 115 + 3 
(+3 ± 5)
170 ± 2  
(-9 ± 8 )
100 ± 0 100  + 0
5 118 + 4 170 ± 2 95 ± 4 93 + 26
(+2 ± 7) (-5 ±7) (-1 ± 15) (-35 ± 30)
15 118 + 3 165 ± 2 107 ± 5 87 + 29
(+2 ±5) (-7 ±7) (+9 ± 15) (-62 ± 14)
25 119 + 3 164 ±3 116 + 5 103 + 30
(+1  ± 6 ) (-7 ±7) (+ 2 1  ± 16) (-73 ± 21)
Table 9.9 Robalzotan (100 jxg kg'1 i.e.; n — 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 100 + 4 
(-12 + 4)
177 + 6 
(-2 ± 7)
100  + 0 100  + 0
5 100 + 7 
(-16 ± 8 )
177 + 7 
(+3 + 7)
1 0 1 + 2  
( + 6  ± 13)
86  + 9 
(-27 ± 14)
15 102  + 6 
(-15 + 7)
176 + 6 
(+3 ± 6 )
110 + 7 
(+ 1 1  + 12)
96+16 
(-40 ± 29)
25 102  + 6 
(-16 ± 9)
174 + 5 
(+3 ± 5)
115 + 9 
(+ 2 1  ± 10)
93 + 13 
(-33 ± 17)
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Table 9.10 (-)-Pindolol (100 jig kg'1 i.e.; n -  5)
time after baseline baseline baseline
injection (min) MAP (mmHg) R-R int (ms) IRNA (%)
Control 103 ± 2 170 ± 3 100  ± 0
(-8  ± 2 ) (-9 ±9)
5 110 ± 9 157 ±4* 83 ± 15
( -6  ± 8 ) (-18 ± 1 0 *) (-13 ± 15)
15 111 ± 9 149 ± 4** 123 ±47
(-7 ± 8 ) (-23 ± 10**) (+25 ± 37)
25 117 ± 5 145 ±4** 159 ±63
( -2  ± 6 ) (-26 ± 9**) (+64 ± 61)
Table 9.11 Cinanserin (100 jig  kg'1 i.e.; n = 5)
time after 
injection (min)
baseline 
MAP (mmHg)
baseline 
R-R int (ms)
baseline 
IRNA (%)
baseline 
IPNA (%)
Control 113 d= 3 
(+2 ± 5)
192 ± 3  
(+13 ±5)
100  ± 0 100  ± 0
5 120 ± 5  
(+4 ± 7)
194 ±4* 
(+19 ± 3*)
99 ± 2  
(+3 ± 14)
141 ± 19 
(+13 ± 24)
15 119 ± 3 
(+2 ± 7)
186 ± 5 
(+14 ± 2)
109 ±3 
(+10 ± 19)
150 ±27 
(+1 ± 37)
25 119 ± 3 
(0 ± 7)
181 ± 4  
(+ 1 0  ± 2 )
131± 18* 
(+36 ± 20*)
150 ±27 
(-26 ± 49)
441
Table 9.12 SB-204070 (100 gg kg'1 i.e.; n =  5)
time after baseline baseline baseline baseline
injection (min) MAP (mmHg) R-R int (ms) IRNA (%) IPNA (%)
Control 113 + 3 
(+2 ± 5)
187 ± 5  
(+ 8  ± 7 )
100 ± 0 100 + 0
5 114 + 4 181 ± 8 112 ± 6 211 ± 14**
(-2  ± 6 ) (+7 ± 10) (+15 ± 14) (+83 ± 23**)
15 109 ± 4 182 ± 8 130 ± 14 168 + 27
(-9 ± 6 ) (+9 ±11) (+31 ± 14) (+19 ± 35)
25 112 + 3 180 ± 7 126 + 9 203 + 18
(-7 ± 6 ) (+10 ± 9) (+31 ± 16) (+28 ± 49)
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9.1.2 Cardiopulmonary reflex
Mean (± s.e.m.) effects of 10 pi saline i.e. on changes (A) in MAP, R-R interval, and 
integrated renal nerve activity (IRNA) in response to cardiopulmonary afferent 
stimulation with phenylbiguanide in anaesthetised, neuromuscular blocked and 
atenolol pretreated rats, f  P < 0.05 (compared to control), * P < 0.05, ** P < 0.01 
(compared to i.e. saline). Numbers in parentheses show differences relative to the 
appropriate saline control.
Table 9.13 Saline (10 pi pH 5.8 i.e.; n = 5)
time after 
injection (min)
reflex AMAP 
(mmHg)
reflex AR-R interval 
(ms)
reflex AIRNA
(%)
Control -33 ± 5 41 ± 4 100 ± 0
5 -34 ± 5 40 ± 4 122 ± 7
15 -34 ± 6 39 ± 3 119 ± 8
25 -35 ± 6 39 ± 3 131± 11 t
35 -37 ± 6 37 ± 3 134 ± 9 f
Table 9.14 SB-269970 (30 ng k g 1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -29 ± 3 43 ± 7 100 + 0
(+3 ± 3) (+1  + 11)
5 -25 ± 2 27 ±3* 83+4**
(+9 ± 6 ) (-13 ± 3*) (-39 ± 10**)
15 -24 ±3 24 ±3* 84 + 9*
( + 1 0  ± 6 ) (-15 ± 5*) (-35 ± 14*)
25 -27 ± 4 24 ±6* 106+ 17
(+9 ± 4) (-15 ± 8 ) (-25 ± 18)
35 -34 ± 5 35 + 5 85+ 15**
( + 2  ± 2 ) (-2  + 8 ) ( .4 9  ± 14**)
443
Table 9.15 SB-269970 (100 gg kg'1 i.e.; n =  5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -35 ± 3 41 ± 7 100 ± 0
(-2 ± 5) (-1 ± 8)
5 -30 ± 5 23 ± 7* 94 ± 14
(+4 ± 8) (-17 ± 7*) (-27 ± 12)
15 -26 ± 4 12 ± 3** 91 ± 18
(+9 ± 7) (-27 ± 2**) (-28 ± 19)
25 -31 ± 4 17±4** 90 ± 27*
(+5 ± 7) (-22 ± 4**) (-40 ± 19*)
35 -38 ± 5 23 ±4* 76 ±22**
(-1 ± 7) (-14 ± 4) (-58 ±21**)
Table 9.16 SB-269970 (300 gg kg'1 i.e.; n = 5)
time after 
injection (min)
reflex AMAP 
(mmHg)
reflex AR-R interval 
(ms)
reflex AIRNA 
(%)
Control -28 ± 3  
(+5 ±  5)
52 ± 11 
(+10 ±  12)
100  ± 0
5 -6  ± 2 ** 
(+30 ±  7**)
7 ±2** 
(-33 ±  4**)
31± 16** 
(-91 ±  15**)
15 -1 ± 2 ** 
(+36 ±  7**)
4 ±2** 
(-35 ±  4**)
5 ± 2** 
(-114 ± 7 * * )
25 -3 ±5** 
(+35 ±  9**)
5 ± 3** 
(-34 ±  5**)
18 ± 7** 
(-112 ± 17**)
35 -13 ± 3** 
(+24 ± 5**)
8 ± 3** 
(-29 ± 5**)
6 9 ± 18** 
(-65 ± 23**)
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Table 9.17 SB-269970 (100 gg kg'1 i.v..; n = 3)
(differences relative to i.e. control)
rime after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -32 ± 4 48 ± 14 100  + 0
(+3 ± 6) (+10 +8)
5 -37 ± 2 43 ± 13 115 + 5
(-2 ± 9) (+9 ± 10) (-3 ± 8)
Table 9.18 Vehicle for SB-656104 (10 gl i.e.; n = 5)
time after 
injection (min)
reflex AMAP 
(mmHg)
reflex AR-R interval 
(ms)
reflex AIRNA 
(%)
Control -31 ± 7 6 1 + 9 100  + 0
5 -35 + 12 55 + 8 83 + 16
15 -37+12 52 + 8 94 + 25
25 -34+ 12 50 + 5 109 + 23
Table 9.19 SB-656104 (100 gg kg' i.e.; n = 5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -46 ± 8 56 + 8 100  + 0
(-14 + 8) (-5 + 11)
5 -15 + 5* 9 ± 5** 70+15
(+20 + 11*) (-46 ± 8**) (-13 ±16)
15 -18 + 5* 9 ± 5** 64+18
(+20 + 11*) (-42 ± 10**) (-30 ± 25)
25 -19+ 4 9 ± 6 ** 78+14
(+14 ± 12) (-41 ± 7**) (-31 ± 23)
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Table 9.20 WAY-100635 (100 \ig k g 1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -36 ± 2 48 + 7 100  + 0
(-3 ± 5) (+7 ± 8)
5 -22 ± 3 20 ± 3** 87+12
(+11 ±4) (-20 ± 6**) (-35 ± 13)
15 -30 ± 5 30 + 4 125 + 28
(+5 + 7) (-9 + 5) (+6 ± 32)
25 -40 + 4 43 + 4 123 ± 10
(-4 + 8) (+4 ± 4) (-8 ± 18)
Table 9.21 Robalzotan (100 jig kg'1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -28 + 4 57 + 14 100  + 0
(+5 ± 4) (+15 ± 16)
5 -29 + 5 47 + 8 99 + 5
(+5 ± 6) (+7 + 11) (-23 ± 8)
15 -30 + 4 61 ± 14 1 1 1 + 6
(+4 ± 6) (+22 ± 13) (-7 ± 7)
25 -31 + 5 60+ 12 114+11
(+5 ± 4) (+21 + 11) (-16+16)
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Table 9.22 Cinanserin (100 |ig kg'1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -34 ± 1 51 ± 5 100  + 0
(-1± 5) (+9 ± 4)
5 -28 ± 2 45 ± 5 90 + 7*
(+5 ± 6) (+5 ± 4) (-32 ± 14*)
15 -34 ± 2 50 ± 8 128 + 8
(0 ± 7 ) (+11 ±7) (+9 ± 8)
25 -36 ± 1 56 ± 8 * 131 ± 14
(-1 ± 6) (+17 ± 8*) (0 + 11)
Table 9.23 SB-204070 (100 gg kg'1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval reflex AIRNA
injection (min) (mmHg) (ms) (%)
Control -39 + 3 62+ 12 100  + 0
(-6 + 8) (+21± 12)
5 -32 + 5 42+  10 101 ± 17
(+2 ± 9) (+2 + 11) (-21 ± 23)
15 -39 + 4 54+13 126 + 8
(-5 ± 9) (+15 ± 14) (+7 ± 13)
25 -42 + 3 56+11 130+ 10
(-6 + 7) (+17 ± 12) (-1 ± 9)
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9.1.3 Chemoreflex
Mean (± s.e.m.) effects of test solutions (10 jal i.e.) on changes (A) in MAP, R-R 
interval,, integrated renal nerve activity (IRNA) and integrated phrenic nerve activity 
(IPNA) in response to chemoreceptor stimulation with sodium cyanide in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats, t  P < 0.05, J P < 
0.01 (compared to control), * P < 0.05, ** P  < 0.01 (compared to i.e. saline). 
Numbers in parentheses show differences relative to the appropriate saline control.
Table 9.24 10 pi saline (pH 5.8 i.e.; n = 5)
time after 
injection (min)
reflex AMAP 
(mmHg)
reflex AR-R 
interval (ms)
reflex 
AIRNA (%)
reflex 
AIPNA (%)
Control -30 ± 2 22 ± 2 100 ± 0 100 ± 0
10 -25 ± 4 29 ± 3f 159 ± 21 92 ±30
20 -23 ± 3 2 9 ± 4 f 113 ± 31 96 ± 10
30 -26 ± 5 27 ± 2 152 ±43 84 ± 18
Table 9.25 SB-269970 (100 gg  kg' i.e.; n = 5)
time after reflex AMAP reflex AR-R reflex reflex
injection (min) (mmHg) interval (ms) AIRNA (%) AIPNA (%)
Control -31 ± 5 30 ± 4 100 ± 0 100 ± 0
(-1 ± 7) (8 ±5)
10 -32 ± 7 11 ± 2** 42 ± 6** 103 ±21
(-7 ±8) (-19 ± 5**) (-118 ± 16**) (+10 ±41)
20 -33 ± 6 11 ± 3** 54 ± 10 93 ± 15
(-10 ± 7) (-18 ± 3**) (-59 ± 29) (-4 ± 15)
30 -26 ± 3 20 ± 7 90 ± 13 84 ± 18
(0 ± 3) (-7 ± 6) (-63 ± 40) (0 ± 20)
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Table 9.26 WAY-100635 (100 jig kg'1 i.e.; n — 5)
time after reflex AMAP reflex AR-R reflex reflex
injection (min) (mmHg) interval (ms) AIRNA (%) AIPNA (%)
Control -34 ± 4  
(-4 ± 4)
33 + 4 
(+11 ±2)
100 + 0 100 + 0
10 -34 ± 5 36 ± 5 93 ± 9* 141+47
(-7 ±8) (+6 ± 8) (-55 ± 26*) (+67 ± 27)
20 -32 ± 5 34 ± 5 127+ 12 167 + 64
(-9 ± 6) (+3 ± 7) (+17 + 35) (+96 ± 56)
30 -31 ± 5 38 ± 7 137+ 14 143 + 49
(-3 ±5) (+9 ± 3) (-42 ± 31) (+70 ± 33)
Table 9.27 Saline: Protocol 3 (10 jil i.e.; n = 5)
time after 
injection (min)
reflex AMAP 
(mmHg)
reflex AR-R 
interval (ms)
reflex 
AIRNA (%)
reflex 
AIPNA (%)
Control -38 + 4 37 + 7 100 + 0 100 + 0
2 -41+3 43 ± 10 193 + 40 120+16
5 -43 + 4 40 + 9 182 + 60 113 + 25
Table 9.28 WAY-100635: Protocol 3 (100 jig k g 1 i.e.; n = 5)
time after reflex AMAP reflex AR-R reflex reflex
injection (min) (mmHg) interval (ms) AIRNA (%) AIPNA (%)
Control -41+ 3 35 + 8 100 + 0 100 + 0
(-3 + 7) (-1 ± 5)
2 -38 + 2 18 ± 7* 101 + 8* 126+ 17
(+3 ± 5) (-24 ± 5*) (-92 + 41*) (+4 + 11)
5 -4 1 + 4 3 1 + 7 133 + 27 110+ 15
(+2 ± 6) (-9 ± 5) (-49 ± 80) (-3 ± 18)
449
9.1.4 Aortic nerve stimulation
Mean (± s.e.m.) effects of test solutions (10 p.1 i.e.) on changes (A) in MAP and R-R 
interval in response to electrical stimulation of the right aortic depressor nerve in 
anaesthetised, neuromuscular blocked and atenolol pretreated rats, t  P < 0.05 
(compared to control), * P < 0.05, ** P < 0.01 (compared to i.e. saline). Numbers in 
parentheses show differences relative to the appropriate saline control.
Table 9.29 10 pi saline i.e. (pH 5.8; n = 5)
time after reflex AMAP reflex AR-R interval
injection (min) (mmHg) (ms)
Control -33 ± 3 50 ± 4
(-10 ± 4) (-3 ± 15)
5 -23 ± 5 24 ±6*
(+2 ± 10) (-29 ± 18*)
15 -20 ± 4 23 ± 7
(+7 ± 8) (-22 ± 13)
25 -24 ± 4 24 ± 8
(+2 ± 8) (-14 ± 13)
Table 9.30 SB-269970 (100 ng kg'1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval
injection (min) (mmHg) (ms)
Control -33 ± 3 50 ± 4
(-10 ±4) (-3 ± 15)
5 -23 ± 5 24 ±6*
(+2 ± 10) (-29 ± 18*)
15 -20 ± 4 23 ± 7
(+7 ± 8) (-22 ± 13)
25 -24 ± 4 24 ± 8
(+2 ± 8) (-14 ± 13)
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Table 9.31 WAY-100635 (100 \ig  kg'1 i.e.; n =  5)
time after reflex AMAP reflex AR-R interval
injection (min) (mmHg) (ms)
Control -30 ± 7 78 ±21
(-8 ± 8) (±25 ± 11)
5 -27 ± 8 68 ± 18
(-2 ± 8) (±15 ± 10)
15 -31 ± 8 62 ± 13
(-4 ± 10) (±17 ± 10)
25 -35 ± 6 76 ± 16
(-9 ± 9) (±38 ± 13)
Table 9.32 WAY-100635 (100 followed by 200 |.ig kg'; n =  6)
Time after 
injection (min)
reflex 
A MAP (mmHg)
reflex 
A R-R interval (ms)
Control -35 ± 5 59 ± 7
100 fig kg1 2 -25 ± 6 42 ± 9
5 -27 ± 5 45 ± 8
200 fig kg1 2 -16 ± 4 t 25 ± 8  t
3 -17 ± 5 f 37± 11
4 -20 ± 8 t 45 ± 12
5 -26 ± 7 57 ± 15
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Table 9. 33 (-)-Pindolol (100 gg kg'1 i.e.; n = 5)
time after reflex AMAP reflex AR-R interval
injection (min) (mmHg) (ms)
Control -22 ± 5 50 ± 11
(0 ± 4 ) (-2 ± 19)
5 -18 ± 4 32 ± 7
(+6 ± 3) (-22 ± 18)
15 -25 ± 7 44 ± 6
(+2 ±4) (-1 ± H )
25 -37 ± 4 55 ± 6
(-10 ± 5) (+17 ± 7)
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9.1.5 Baroreflex (phenylephrine)
Mean (± s.e.m.) effects of i.e. saline on changes (A) in MAP, R-R interval, reflex 
gain, and reflex changes in integrated renal nerve activity (IRNA), in response to 
intravenous phenylephrine in anaesthetised, neuromuscular blocked and atenolol 
pretreated rats, f  P <  0.05 (compared to control), * P < 0.05, ** P < 0.01 (compared 
to saline). Numbers in parentheses show differences relative to the appropriate saline 
control.
Table 9.34 10 pi saline i.e. (pH 5.8; n -  5)
time after 
injection (min)
AMAP
(mmHg)
reflex AR-R 
interval (ms)
reflex gain 
(ms mmHg1)
reflex 
AIRNA (%)
Control 77 ± 4 26 ± 4 0.25 ± 0.04 100 ± 0
5 73 ± 5 28 ± 3 0.34 ± 0.06f 114 ± 12
15 75 ± 6 27 ± 5 0.27 ±0.05 130 ± 23
25 64 ± 4 21 ± 5 0.23 ± 0.04 135 ± 33
Table 9.35 SB-269970 (100 ng kg'1 i.e.; n =  5)
time after AMAP reflex AR-R reflex gain reflex
injection (min) (mmHg) interval (ms) (ms mmHg1) AIRNA (%)
Control 78 ±3 19 ± 4 0.22 ± 0.04 100 ± 0
(0 ± 5 ) (-4 ± 6) (-0.04 ± 0.07)
5 77 ± 6 10 ± 3** 0.15 ±0.06** 96 ± 9
(+4 ± 6) (-18 ± 4**) (-0.2 ± 0.1**) (-17 ± 15)
15 73 ± 7 g _l_ | ** 0.1 ±0.03* 87 ± 10
(-2 ± 10) (-17 ± 4**) (-0.17 ± 0.06*) (-42 ± 21)
25 1 62 ± 5 13 ±3 0.11 ±0.04 87 ± 10
(-2 ± 7) (-9 ± 3) (-0.12 ±0.05) (-48 ± 32)
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9.2 Chapter 4 data
9.2.1 Raphe stimulation
Mean (± s.e.m.) changes (A) evoked by micro injection of DL-homocysteic acid 
(DLH; 2.5 nmol) into raphe at various depths from the brain surface, and 1 mm 
lateral to the midline (lateral), in anaesthetised, neuromuscular blocked and atenolol 
pretreated rats. Rostral location is relative to the calamus scriptorius. * P < 0.05, ** P 
0.01 (relative to baseline, Student’s paired t-test). ROb: raphe obscurus, RPa: raphe 
pallidus, RMg: raphe magnus, Gi: gigantocellular reticular nucleus, pontam.: 
pontamine.
Table 9.36 1.5 mm rostral
Depth
(mm)
Nucleus n AMAP
(mmHg)
A HR 
(bpm)
A IRNA 
(%)
AIPNA
(%)
2.0 ROb 6 4 ± 2 2 ± 2 -45 ± 8 ** 116 ± 21 **
2.5 RPa 5 3 ± 3 3 ± 1 -40 ± 8 ** 123 ± 4 6 *
lateral Gi 3 -2 ± 8 0 -6 ± 6 20 ±48
saline RPa 3 0 0 0 0
Table 9.37 2.5 mm rostral
Depth
(mm)
Nucleus n AMAP
(mmHg)
A HR 
(bpm)
AIRNA
(%)
AIPNA
(%)
1.5 ROb 9 7 ± 4 1 ± 3 -35 ± 3** 38 ±20
2.0 ROb 1 11 ± 1 7 ± 1 -29 ± 8** 15 ± 15
2.5 RPa 8 12 ± 1 8 ± 1 -20 ± 9* 41 ± 18
lateral Gi 4 22 ± 3** 0 ± 7 36 ±3** -
Table 9.3 8 3.5 mm rostral
Depth
(mm)
Nucleus n AMAP
(mmHg)
A HR 
(bpm)
A IRNA (%) A IPNA (%)
2.0 RMg 6 8 ± 3 -30 ± 7** 31 ± 6** -53 ±7**
2.5 RMg/Pa 7 9 ± 1 -42 ± 6** 46 ± 6** -60 ± 6**
lateral Gi 5 13 ± 1* -8 ± 5 33 ± 10 -47 ± 8**
pontam. RMg/Pa 7 0 ±  1 0 ±  1 -1 ± 4 -3 ±3
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9.2.2 Pharmacology
Table 9.39 5-HT receptor antagonists: effects on baselines
Mean (± s.e.m.) baseline MAP, HR, IRNA and IPNA before (control) and 5 min after intravenous injection of saline or various 5-HT receptor 
antagonists in anaesthetised, neuromuscular blocked and atenolol pretreated rats. :i: P  < 0.05. P 0.01 (relative to saline. 2-way ANOVA 
followed by LSD test), t  no statistical comparison.
i MAP (nimHg) HR (bpm) ; IRNA (%) ■ j IPNA (%)
DRUG n control 5  min control ! 5  min[ \ control 5  min \ control
^....................................... J
; 5  min
Saline 5 122 ± 5 \ 124 ± 6 \ 345 ± 4 352 ± 6 100 ± 0 137 ± 15 \ 100 ±0 \ 154 ±29 j
1 ml kg 1 i.v.
1
;
Methiothepin 5 128 ± 0 T  118 ± 8 ' 348 ± 10 " T  347 ± 9 100 ± 0 103 ±  19 100 ± 0 I  124 ± 43 ...... j
i i 1 •1 mg kg i.v. j 1
Methiothepin
• 4  ...
123 ±  2 120 ±5 320 ±  10 : 3 14 ±  0 : - 100 ± 0 93 ±  7 100 ± 0 229 ±  63.. . i
3 mg kg"1 i.v. 1
i  !
Granisetron t 1 10 ±  1 118 ± 4 ' 341 ±  7 340 ±  12 100 ±  0 132 ±  9 : 100 ±  0 122 ± 39 i
0.3 mg kg 1 i.v. 1
SB-204070 v : 126 ± 6 130 ± 2 351 ± 5 329 ± 0 100 ± 0 67 ± 34 100 ± 0 ! 117 ± 23 ...... ;
3 mg kg"1 i.v. ! ! i i
Table 9.40 5-HT receptor antagonists: effects on raphe stimulation
Mean (± s.e.m.) changes (A) in MAP. HR. IRNA and IPNA evoked by microinjection of DLH (2.5 nmol) into raphe magnus/pallidus. both 
before (control) and 5 min after intravenous injection of saline or various 5-HT receptor antagonists in anaesthetised, neuromuscular blocked and 
atenolol pretreated rats. : P  < 0.05, :::i: P  0.01 (relative to saline, 2-way ANOVA followed by LSD test), f  no statistical comparison.
| A MAP (mmHg) A HR (bpm) I A IRNA ( %)
i
| A IPNA (%)
i
i1... .........4
DRUG I 11I control 5 min j control \ 5 min! i control 5 min control | 5 min
Saline 5 5 ± 4 4 ± 4 -20 ± 5 [-28 + 5 K)1 ± 20 80 ± 20 •81 -  5 ..~ ” T -78 ± 5  ;
1 ml kg"1 j j | ; i i
Methiothepin 5 2 ± 5 ' -2 ± 3 -16 ±1 ~~~ -22 ± 3 ! 120 ±20 155 ± 55 [ -88 ± 6 ‘ [ -65 ±  7 ;
1 mg kg 1 i.v. ' 1 i
!
Methiothepin ! 4 - 0  ±  1 : -4 ± 2 -25 ±  7 ! -IS ±  6 107 ±50 355 ±  100 :: -93 ± 4 -66 ± 1 7
3 mg kg ! i.v. : ! ;
Granisetron f i -3 ± 1 1 ±5 -25 ± 6 -20 ± 6 77 ± 37 37 ± 37 -67 ± 0 -59 ± 1
j SB-204070 t -> -5 ± 2 : -7 ± l -46 ± 14 1 -30 ± 5 175 ± 10 275 ±108 : -72  ± 9 ; - 7 0 ± 10
3 mg kg 1 i.v. !
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9.2.3. 5-HT depletion
Table 9.41 p-CPA: effect of raphe stimulation
Mean (± s.e.m.) changes (A) in MAP, HR. IRNA and IPNA in response to microinjection of DLH (2.5 nmol) into parts of the raphe at various 
points relative to the calamus scriptorius (rostral) and brain surface (depth) in anaesthetised, neuromuscular blocked and atenolol pretreated rats, 
treated with either saline or p-CPA. * P  < 0.05, P  0.01 (relative to control, Student's paired t-test).
Rostral Depth ft
A M AP (mmHg) A HR (bpm) A IRNA (%) A IPNA (%)
_ „.i .... ........
saline p-CPA saline p-CPA saline p-CPA
i
saline p-CPA
1.5 1.5 5 0 ± 2 -10 ± 3 : 10 ± 2 6 ± 1 -2b ± 21 -40 ± 7 220 ± 75 2b3 ± 43
2.5 ; 5 2 ± 2 1 ± 5 10 ± 2 9 ± 2 20 ± 37 ' 1 -24 ± 12 ; 227 ± b8 75 ± 19
7 5 1.5 5 11 ±2 -3 ± 4 ; -j i+ 3 ± 1 -41 ± 7 -39 ± 8 120 ± 3b b3 ± 30
2.5 5 7 ±3 1 tS ± :: 8 ± 2 13 ± 2 -8 ± 11 -54 ± 5:;::;: 182 ±31 123 ±34
4 c -------0.7 1.5 ■■ 5
_____
-4 ± (S ' - 7 ± 2
— ________
' -13 ± 12 -5 ± 8
|
' -18 ± 2 3 .. -19 ±12
2.5 5
l
+i 
r) - ! ± 1 -29 ± 6 -27 ± 8 113 ± lb j  59 ± 3b
t
-51 ± 13 -54 ± 8
Table 9.42 p-CPA: effect on baselines and reflexes
Mean (± s.e.m.) baseline MAP and HR, changes (A) in MAP and R-R interval, and 
baroreflex slope and correlation, evoked by cardiopulmonary reflex activation with 
intra-atrial phenylbiguanide (2.5 pg) or baroreflex activation with intravenous 
phenylephrine (10 pg), in anaesthetised, neuromuscular blocked and atenolol 
pretreated rats, treated with either saline or p-CPA.
* P < 0.05, ** P  < 0.01 (relative to control, Student’s paired t-test).
n Saline p-CPA
Baseline MAP (mmHg) 7 107 ± 5 86 ±7*
Baseline HR (bpm) 7 311 ± 5 321 ± 6
Cardiopulmonary reflex
A R-R interval (ms) 7 130 ±31 38 ±7**
A MAP (mmHg) 7 -31 ± 6 -27 ± 4
Baroreflex (phenylephrine)
A MAP (mmHg) 5 72 ± 6 77 ± 7
A R-R interval (ms) 5 82 ± 12 55 ± 12
Slope (ms m m H g') 5 0.66 ±0.07 0.19 ±0.05**
AP/At (mmHg s '1) 5 28 ± 2 27 ±3
Correlation (r) 5 0.82 ±0.02 0.76 ±0.08
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9.3 Chapter 5 data
9.3.1 Iontophoresis
Table 9.43 Effects o f agonists
Effects of AMPA (20 -  120 nA), NMDA (40 -  180 nA) and PBG (80 -  300 nA) on 
baseline firing rate (spikes s'1) of vagally-evoked NTS neurones. J P < 0.01 (Mann- 
Whitney Rank Sum test: before cf. after)
Drug n Before During
AMPA 13 0.6 ±0.3 8.2 ±0.8 %
NMDA 13 0.5 ±0.2 6.4 ±0.9 t
PBG 7 2.7 ± 1.4 4.2 ± 1.6
Table 9.44 Effects o f DNQX on AMPA & PBG
Effects of DNQX (10 -  80 nA) on baseline and agonist-evoked neuronal firing 
(spikes s'1). Rec: recovery. X P < 0.01 (Mann-Whitney Rank Sum test: agonist cf. 
agonist + DNQX)
Agonist n baseline agonist baseline 
+ DNQX
agonist + 
DNQX
agonist
(rec)
n
(rec)
AMPA 13 0.3 ±0.1 8.2 ±0.8 0.3 ±0.1 2.6 ± 0.7 X 6.4 ±0.7 11
PBG 5 2.4 ± 1.9 3.5 ±2.1 2.3 ± 1.6 2.2 ± 1.7 3.4 ±2.1 4
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Table 9.45 Effects of DNQX on NMDA
Different effects of DNQX (10 -  80 nA) on baseline and NMDA-evoked neuronal 
firing (spikes s -1)- I > 20 /o inhibition, |  20 /o potentiation, NE. no change. R.ec.
recovery. Bottom row shows mean of whole group (Total).
Effect n baseline NMDA baseline 
± DNQX
NMDA ± 
DNQX
NMDA
(rec)
n
(rec)
1 6 0.7 ±0.4 6.6 ±0.9 0.4 ±0.1 4.4 ± 1.2 9.3 ± 1.6 6
t 3 0.3 ±0.2 5.3 ± 1.6 0.5 ±0.4 7 ±2.2 4.9 ±0.1 2
NE 4 0.3 ±0.3 7 ± 2.7 0.3 ±0.3 7.3 ±2.9 11.2 ± 4.7 4
Total 13 0.5 ±0.2 6.4 ±0.9 0.4 ±0.1 5.9 ±1.1 9.2 ± 1.7 12
Table 9.46 Effects o f DNQX on cardiopulmonary reflex
Effects of iontophoretically applied DNQX (30 -  80 nA) on cardiopulmonary 
afferent-evoked discharge of NTS neurones evoked by intra-atrial (i.a.) PBG. Rec: 
recovery.
n Reflex Reflex
±DNQX
Reflex
(rec)
n
(rec)
PBG i.a. 5 57 ±25 33 ±20 51 ±24 4
Table 9.47 Effects o f DNQX on vagus-evoked activity
Effects of iontophoretically applied DNQX (30 -  100 nA) on discharge of NTS 
neurones evoked by electrical stimulation of the vagus (number of spikes per 20 s). J 
P < 0.01 (Mann Whitney Rank Sum test: Vagus cf. DNQX).
n Vagus Vagus 
± DNQX
Vagus
(rec)
n
(rec)
Vagus 1 Hz 12 35.8 ±7.5 15.3 ± 1.9J 34 ±9.8 11
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9.3.2 Topical SB-269970
Mean (± s.e.m.) effects of topically applied saline (10 pi) and SB-269970 (100 pg kg'1) on neuronal activity in anaesthetised and neuromuscular 
blocked rats. Time is relative to administration (data after 10 min not shown). * P < 0.05, P < 0.01 (compared to saline).
Table 9.48 Vagally-evoked NTS neuronal activity (evoked spikes 50 sweeps"1; n = 5)
Time (min) -2 -1 0 ! 1
1
2 3 4 5 6 7 8 9 | i °
Saline 51 + 1 49± 1 48±2 ! 49±2 47±2 48±1 46±22 48±2 47±1 47±2 47+3 47±2 46±2
SB-269970 48± 1 48± 1 48± 1 1 46±2
L..............
36±9 3 5 ±9 32±9 33±9;: 28±8:;::i: 24±8* 25±8** 25 ±9*:!: ; 25±7:--
Table 9.49 Baseline DVN neuronal activity (spikes s"1; n -  6 (drug) and n -  4 (saline))
Time (min) • - 2 ...
i . . ;
-1 01
1 ...“ ‘ 2... v .... '..... ' 4 T ...... - 6 7 8 9 10 “
Saline j4.3±0.4 ; 4±0.4 4.3±0.7 3.6±0.6 3.7±0.9 3.9±0.8 4.4± 1.2 4.4± 1.6 4.3± 1.5 4.5± 1.5 3.8±0.9 3.7±0.8
.
SB-269970 | 3.9+0.7 ;
i
3.9±0.7 | 4±0.9
1
3.1 ±0.8 3.6±0.7
.
3.5±0.7 3.2+0.8 l~T6±().8 3.8±0.9
.
4±0.8 3.6±0.8 3.6±0.8 3.6±1.1
_____
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Table 9.50 Touch-evoked Gracile neuronal activity (evoked spikes 10 stimuli'1; n = 7)
Time (min) -2 -1 0 1 2 3 4 5 6 7 8 9 10
Saline 318±99 295±85 3 16±102 334±108 320±101 333+109 r 300+103 298±98 302±109 327±109 332+116
. .
3 41 ± 115 306±98
SB-269970 237±48 236±44 224±43 203±37 184±42 166±38 164±46 179±50 176±48 187±50 171±50 174±46 161±43
Table 9.51 Touch-evoked Gracile neuronal activity (% of control; n -  7)
Time (min) Control
Saline 100±0
1 | 2 3 {4
12()± 14 ! 113115 1 114± 14 1 110± 18
! 1 i
5 i 6
!
105+13 ! 105± 13
7 | 8
j
117±18 j 109+10
9 10
126±8 ’ 115±9
SB-269970 100±0 89±6:; j 89±6 ! 80±12 :; ! 78±13:;:
............... ................ -  J. . .  . 2 . ..........
82±13 | 82±14 86114- | 7 7 i 14* 8 0 i 13** | 7 2 il l* *
Table 9.52 Baseline gracile neuronal activity (spikes s’1; n = 7 (drug) and n = 5 (saline))
Time (min)
1
-2 -1 0 1 2 3 4 5 6 7 8 9 10
| Saline
1
3.4± 1.7 ! 3.8±1.7 4.711.8 5.512 ; 5.4i 1.8 5.612.2 5.812.5 5.412.5 4.511.9 4.511.9 4.912 : 3.612.2 412.2
SB-269970 3.611.4 ; 3.211.1 3.611.2 2.710.8 ' 2.610.5 3.711.3 2.9l 1 2.110.5 ^2.710.9 2.810.9 2.610.7 ; 2.310.8
:
^ i l
Table 9.53 Baseline gracile neuronal activity (% of control; n -  7 (drug) and n = 5 (saline))
Time (min) Control 1 2 3
I
S 4
j
! 5 6 7 8
|
9 ! 10
Saline ! lOOK) 150135 153116 ' 151137 ! 174146 ! 132116 i 135129 139131 134121 132126 ' 155133
SB-269970 j 100K) 99117 126139 140132 ' 128135 ' 102135 118144 131148 110136 103142 j 13415 f
9.4 Chapter 6 data
Mean (± s.e.m.) baseline or reflex-evoked changes (A) in MAP and HR before 
(control) and after 5 p.1 i.e. test solution in awake unrestrained rats.
P < 0.05, ** P  < 0.01 (compared to saline).
Numbers in parentheses show differences relative to the appropriate saline control. 
Table 9.54 5 ptl i.e. saline {n = 5)
Effects on baselines
time after injection 
(min)
baseline 
MAP (mmHg)
baseline 
HR (bpm)
Control 97 ± 6 352 ± 18
5 101 ± 5 370 ± 20
10 102 ± 7 360 ± 27
15 100 ± 6 354 ± 19
20 99 ± 7 360 ± 23
25 100 ± 6 344 ± 19
30 101 ± 5 358 ± 17
Table 9.55 Saline (5 pi i.e.; n = 5)
Effects on cardiopulmonary reflex
time after injection 
(min)
reflex A 
MAP (mmHg)
reflex A 
HR (bpm)
Control -56 ± 8 -265 ± 52
5 -64 ± 9 -296 ± 68
10 -59 ± 12 -288 ±71
15 -57 ± 12 -268 ± 64
20 -60 ± 14 -278 ± 64
25 -57 ± 12 -260 ± 59
30 -60 ± 9 -266 ± 60
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Table 9.56 SB-269970 (100 gg kg' i.e.; n =  5)
Effects on baselines
time after injection baseline baseline
(min) MAP (mmHg) HR (bpm)
Control 112 ± 5 399 + 27
(+15 ± 5) (+47 ± 25)
5 111+ 8 386 + 9
(+10 ± 3) (+16 ± 26)
10 112 + 8 400 ± 26
(+10 + 5) (+40 ± 28)
15 111 + 8 394 ± 25
(+11+4) (+40 ± 26)
20 107 + 6 370+  15
(+8 ± 7) (+10 ± 25)
25 109 + 4 378 + 17
(+9 ± 4) (+34 ± 21)
30 106 + 4 358 + 15
(+5 + 2) (0 ± 21)
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Table 9.57 SB-269970 (100 gg kg'1 i.e.; n =  5)
Effects on cardiopulmonary reflex
time after injection reflex A reflex A
(min) MAP (mmHg) HR (bpm)
Control -56 ± 8 -290 ± 22
(+1 ± 7) (-25 ± 20)
5 -22 ± 7** -142 + 54**
(+42 ± 15**) (+154 + 61**)
10 -33^ 5* -184 + 37*
(+26 ± 15*) (+104 ± 46*)
15 -39 ± 5 -226 ± 28
(+18 ± 15) (+42 ± 50)
20 -39 ± 7 -238+ 18
(+21 ± 14) (+40 ± 19)
25 -46 ± 7 -238+ 18
(+11 ±9) (+22 ± 18)
30 -55 ± 7 -272 + 21
(+5 ±7) (-6 ± 27)
Table 9.58 SB-269970 (100 gg kg'1 i.e.; n = 5)
Effects on chemoreflex
time after injection 
(min)
reflex A 
MAP (mmHg)
reflex A 
HR (bpm)
Control 4 1 + 4 -188 + 23
5 9 + 1 8 -88 + 51
10 16 + 26 126 + 44
15 21 + 2 3 -124 + 45
20 4 1 + 4 -193 + 28
25 25 + 15 -118 + 52
30 23 + 14 -124 + 50
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9.5 Baroreflex gain script
Spike2 script to measure beat-by-beat arterial pressure and R-R interval from a one 
channel of BP and one channel of discriminated R waves (from ECG). The script 
plots peak and trough (systolic and diastolic) arterial pressure pressure and 
corresponding heart rate, also time of each systolic and diastolic peak, and time of 
each R wave peak (from which R-R interval is calculated). Data are plotted to a Log 
file.
var vl2%; 
var vl9%;
’ t.
var vlO%; 
var v20%; 
var v21%;
var tv%,sTime,eTime;
vl2%:=ViewFind("*.SMR");
vlO%:=ViewFind("Logl");
FrontView(vl2%);
CursorSet(O);
Cursor Label (2);
CursorVisible(0,l);
CursorActive(O);', 14,trig%,0 . 4 , 0 , 0 , 0 ) ;  
Interact("Select analysis start position, press 
'control + O' for cursor", 128);
CursorSearch(O); 
sTime := Cursor(O); 
eTime := Cursor(l);
'CursorCheck();
v l 9%:=MeasureToXY(4,2,0,10,0,0); 
MeasureX(102,l,"Cursor(0)","0",0); 
MeasureY(100,2,"Cursor(0)","0",0); 
MeasureChan(l,"Systolic",0);
WindowV isible( 1);
Process(sTime,eTime,0,1);
EditCopy(4);
Front View(v 10%);
Window(0,0,65.25,40.5405);
EditPasteQ;
WindowVisible(2);
FrontView(vl9%);
WindowV isible(2);
FrontView(vl 2%); 
v20%:=MeasureT oXY (5,2,0,10,0,0); 
MeasureX( 102,1 ,"Cursor(0)","0",0); 
MeasureY (100,2,"Cursor(0)","0",0); 
MeasureChan( 1 /'Diastolic", 0); 
WindowVisible(l); 
Process(sTime,eTime,0,l); 
EditCopy(4);
FrontView(vl0%);
Window(0,0,65.25,40.5405); 
EditPaste();
W indo w V i sible(2);
Front V iew( v20%);
WindowVisible(2);
FrontView(vl 2%);
v21 %:=MeasureT oX Y (14,10,0,10,0,0); 
MeasureX(102,l,"Cursor(0)","0",0); 
MeasureY (100,10,"Cursor(0)","0",0); 
MeasureChan(l,"Heart rate",0);
W indow Visible( 1);
Process(sTime,eTime,0,l);
EditCopy(4);
Front V iew( v 10%);
Window(0,0,65.25,40.5405); 
EditPaste();
WindowVisible(2);
FrontView(v21%);
WindowVisible(2);
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